<?xml version="1.0" encoding="UTF-8" standalone="yes"?><Rowset rowCount='1362'><Row><Action id="14323">Angiopoietin ligand-2 inhibitor</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="US">US</Country><Drug id="71794">adalimumab + anti-Ang2 Zybody (inflammatory disease), Zyngenia</Drug><DrugRelationship>Product</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Priority</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PRI</HighestPatStatusIdForCnty><Indication id="1781">Psoriatic arthritis</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA6726805">WO-2012009705</Patent><Status id="PRI">First Priority</Status><StatusDate>2010-07-15 00:00:00</StatusDate><StatusSortCode>1</StatusSortCode><TherapyArea id="185">Immune disorder</TherapyArea></Row><Row><Action id="14323">Angiopoietin ligand-2 inhibitor</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="US">US</Country><Drug id="71794">adalimumab + anti-Ang2 Zybody (inflammatory disease), Zyngenia</Drug><DrugRelationship>Product</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Priority</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PRI</HighestPatStatusIdForCnty><Indication id="188">Inflammatory disease</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA6726805">WO-2012009705</Patent><Status id="PRI">First Priority</Status><StatusDate>2010-07-15 00:00:00</StatusDate><StatusSortCode>1</StatusSortCode><TherapyArea id="188">Inflammatory disease</TherapyArea></Row><Row><Action id="14323">Angiopoietin ligand-2 inhibitor</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="US">US</Country><Drug id="71794">adalimumab + anti-Ang2 Zybody (inflammatory disease), Zyngenia</Drug><DrugRelationship>Product</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Priority</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PRI</HighestPatStatusIdForCnty><Indication id="189">Inflammatory bowel disease</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA6726805">WO-2012009705</Patent><Status id="PRI">First Priority</Status><StatusDate>2010-07-15 00:00:00</StatusDate><StatusSortCode>1</StatusSortCode><TherapyArea id="188">Inflammatory disease</TherapyArea></Row><Row><Action id="14323">Angiopoietin ligand-2 inhibitor</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="US">US</Country><Drug id="71794">adalimumab + anti-Ang2 Zybody (inflammatory disease), Zyngenia</Drug><DrugRelationship>Product</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Priority</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PRI</HighestPatStatusIdForCnty><Indication id="291">Rheumatoid arthritis</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA6726805">WO-2012009705</Patent><Status id="PRI">First Priority</Status><StatusDate>2010-07-15 00:00:00</StatusDate><StatusSortCode>1</StatusSortCode><TherapyArea id="185">Immune disorder</TherapyArea></Row><Row><Action id="14323">Angiopoietin ligand-2 inhibitor</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="US">US</Country><Drug id="71794">adalimumab + anti-Ang2 Zybody (inflammatory disease), Zyngenia</Drug><DrugRelationship>Product</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Priority</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PRI</HighestPatStatusIdForCnty><Indication id="3003">Juvenile rheumatoid arthritis</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA6726805">WO-2012009705</Patent><Status id="PRI">First Priority</Status><StatusDate>2010-07-15 00:00:00</StatusDate><StatusSortCode>1</StatusSortCode><TherapyArea id="185">Immune disorder</TherapyArea></Row><Row><Action id="14323">Angiopoietin ligand-2 inhibitor</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="US">US</Country><Drug id="71794">adalimumab + anti-Ang2 Zybody (inflammatory disease), Zyngenia</Drug><DrugRelationship>Product</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Priority</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PRI</HighestPatStatusIdForCnty><Indication id="36">Autoimmune disease</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA6726805">WO-2012009705</Patent><Status id="PRI">First Priority</Status><StatusDate>2010-07-15 00:00:00</StatusDate><StatusSortCode>1</StatusSortCode><TherapyArea id="185">Immune disorder</TherapyArea></Row><Row><Action id="14323">Angiopoietin ligand-2 inhibitor</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="US">US</Country><Drug id="71794">adalimumab + anti-Ang2 Zybody (inflammatory disease), Zyngenia</Drug><DrugRelationship>Product</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Priority</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PRI</HighestPatStatusIdForCnty><Indication id="651">Cancer</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA6726805">WO-2012009705</Patent><Status id="PRI">First Priority</Status><StatusDate>2010-07-15 00:00:00</StatusDate><StatusSortCode>1</StatusSortCode><TherapyArea id="230">Neoplasm</TherapyArea></Row><Row><Action id="14323">Angiopoietin ligand-2 inhibitor</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="US">US</Country><Drug id="71794">adalimumab + anti-Ang2 Zybody (inflammatory disease), Zyngenia</Drug><DrugRelationship>Product</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Priority</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PRI</HighestPatStatusIdForCnty><Indication id="84">Crohns disease</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA6726805">WO-2012009705</Patent><Status id="PRI">First Priority</Status><StatusDate>2010-07-15 00:00:00</StatusDate><StatusSortCode>1</StatusSortCode><TherapyArea id="185">Immune disorder</TherapyArea></Row><Row><Action id="14323">Angiopoietin ligand-2 inhibitor</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="US">US</Country><Drug id="71794">adalimumab + anti-Ang2 Zybody (inflammatory disease), Zyngenia</Drug><DrugRelationship>Product</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Priority</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PRI</HighestPatStatusIdForCnty><Indication id="989">Colorectal tumor</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA6726805">WO-2012009705</Patent><Status id="PRI">First Priority</Status><StatusDate>2010-07-15 00:00:00</StatusDate><StatusSortCode>1</StatusSortCode><TherapyArea id="129">Gastrointestinal disease</TherapyArea></Row><Row><Action id="3756">Erbb2 tyrosine kinase receptor inhibitor</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="US">US</Country><Drug id="71794">adalimumab + anti-Ang2 Zybody (inflammatory disease), Zyngenia</Drug><DrugRelationship>Product</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Priority</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PRI</HighestPatStatusIdForCnty><Indication id="1781">Psoriatic arthritis</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA6726805">WO-2012009705</Patent><Status id="PRI">First Priority</Status><StatusDate>2010-07-15 00:00:00</StatusDate><StatusSortCode>1</StatusSortCode><TherapyArea id="185">Immune disorder</TherapyArea></Row><Row><Action id="3756">Erbb2 tyrosine kinase receptor inhibitor</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="US">US</Country><Drug id="71794">adalimumab + anti-Ang2 Zybody (inflammatory disease), Zyngenia</Drug><DrugRelationship>Product</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Priority</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PRI</HighestPatStatusIdForCnty><Indication id="188">Inflammatory disease</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA6726805">WO-2012009705</Patent><Status id="PRI">First Priority</Status><StatusDate>2010-07-15 00:00:00</StatusDate><StatusSortCode>1</StatusSortCode><TherapyArea id="188">Inflammatory disease</TherapyArea></Row><Row><Action id="3756">Erbb2 tyrosine kinase receptor inhibitor</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="US">US</Country><Drug id="71794">adalimumab + anti-Ang2 Zybody (inflammatory disease), Zyngenia</Drug><DrugRelationship>Product</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Priority</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PRI</HighestPatStatusIdForCnty><Indication id="189">Inflammatory bowel disease</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA6726805">WO-2012009705</Patent><Status id="PRI">First Priority</Status><StatusDate>2010-07-15 00:00:00</StatusDate><StatusSortCode>1</StatusSortCode><TherapyArea id="188">Inflammatory disease</TherapyArea></Row><Row><Action id="3756">Erbb2 tyrosine kinase receptor inhibitor</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="US">US</Country><Drug id="71794">adalimumab + anti-Ang2 Zybody (inflammatory disease), Zyngenia</Drug><DrugRelationship>Product</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Priority</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PRI</HighestPatStatusIdForCnty><Indication id="291">Rheumatoid arthritis</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA6726805">WO-2012009705</Patent><Status id="PRI">First Priority</Status><StatusDate>2010-07-15 00:00:00</StatusDate><StatusSortCode>1</StatusSortCode><TherapyArea id="185">Immune disorder</TherapyArea></Row><Row><Action id="3756">Erbb2 tyrosine kinase receptor inhibitor</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="US">US</Country><Drug id="71794">adalimumab + anti-Ang2 Zybody (inflammatory disease), Zyngenia</Drug><DrugRelationship>Product</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Priority</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PRI</HighestPatStatusIdForCnty><Indication id="3003">Juvenile rheumatoid arthritis</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA6726805">WO-2012009705</Patent><Status id="PRI">First Priority</Status><StatusDate>2010-07-15 00:00:00</StatusDate><StatusSortCode>1</StatusSortCode><TherapyArea id="185">Immune disorder</TherapyArea></Row><Row><Action id="3756">Erbb2 tyrosine kinase receptor inhibitor</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="US">US</Country><Drug id="71794">adalimumab + anti-Ang2 Zybody (inflammatory disease), Zyngenia</Drug><DrugRelationship>Product</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Priority</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PRI</HighestPatStatusIdForCnty><Indication id="36">Autoimmune disease</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA6726805">WO-2012009705</Patent><Status id="PRI">First Priority</Status><StatusDate>2010-07-15 00:00:00</StatusDate><StatusSortCode>1</StatusSortCode><TherapyArea id="185">Immune disorder</TherapyArea></Row><Row><Action id="3756">Erbb2 tyrosine kinase receptor inhibitor</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="US">US</Country><Drug id="71794">adalimumab + anti-Ang2 Zybody (inflammatory disease), Zyngenia</Drug><DrugRelationship>Product</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Priority</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PRI</HighestPatStatusIdForCnty><Indication id="651">Cancer</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA6726805">WO-2012009705</Patent><Status id="PRI">First Priority</Status><StatusDate>2010-07-15 00:00:00</StatusDate><StatusSortCode>1</StatusSortCode><TherapyArea id="230">Neoplasm</TherapyArea></Row><Row><Action id="3756">Erbb2 tyrosine kinase receptor inhibitor</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="US">US</Country><Drug id="71794">adalimumab + anti-Ang2 Zybody (inflammatory disease), Zyngenia</Drug><DrugRelationship>Product</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Priority</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PRI</HighestPatStatusIdForCnty><Indication id="84">Crohns disease</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA6726805">WO-2012009705</Patent><Status id="PRI">First Priority</Status><StatusDate>2010-07-15 00:00:00</StatusDate><StatusSortCode>1</StatusSortCode><TherapyArea id="185">Immune disorder</TherapyArea></Row><Row><Action id="3756">Erbb2 tyrosine kinase receptor inhibitor</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="US">US</Country><Drug id="71794">adalimumab + anti-Ang2 Zybody (inflammatory disease), Zyngenia</Drug><DrugRelationship>Product</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Priority</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PRI</HighestPatStatusIdForCnty><Indication id="989">Colorectal tumor</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA6726805">WO-2012009705</Patent><Status id="PRI">First Priority</Status><StatusDate>2010-07-15 00:00:00</StatusDate><StatusSortCode>1</StatusSortCode><TherapyArea id="129">Gastrointestinal disease</TherapyArea></Row><Row><Action id="381">TNF alpha ligand inhibitor</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="US">US</Country><Drug id="71794">adalimumab + anti-Ang2 Zybody (inflammatory disease), Zyngenia</Drug><DrugRelationship>Product</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Priority</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PRI</HighestPatStatusIdForCnty><Indication id="1781">Psoriatic arthritis</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA6726805">WO-2012009705</Patent><Status id="PRI">First Priority</Status><StatusDate>2010-07-15 00:00:00</StatusDate><StatusSortCode>1</StatusSortCode><TherapyArea id="185">Immune disorder</TherapyArea></Row><Row><Action id="381">TNF alpha ligand inhibitor</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="US">US</Country><Drug id="71794">adalimumab + anti-Ang2 Zybody (inflammatory disease), Zyngenia</Drug><DrugRelationship>Product</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Priority</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PRI</HighestPatStatusIdForCnty><Indication id="188">Inflammatory disease</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA6726805">WO-2012009705</Patent><Status id="PRI">First Priority</Status><StatusDate>2010-07-15 00:00:00</StatusDate><StatusSortCode>1</StatusSortCode><TherapyArea id="188">Inflammatory disease</TherapyArea></Row><Row><Action id="381">TNF alpha ligand inhibitor</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="US">US</Country><Drug id="71794">adalimumab + anti-Ang2 Zybody (inflammatory disease), Zyngenia</Drug><DrugRelationship>Product</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Priority</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PRI</HighestPatStatusIdForCnty><Indication id="189">Inflammatory bowel disease</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA6726805">WO-2012009705</Patent><Status id="PRI">First Priority</Status><StatusDate>2010-07-15 00:00:00</StatusDate><StatusSortCode>1</StatusSortCode><TherapyArea id="188">Inflammatory disease</TherapyArea></Row><Row><Action id="381">TNF alpha ligand inhibitor</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="US">US</Country><Drug id="71794">adalimumab + anti-Ang2 Zybody (inflammatory disease), Zyngenia</Drug><DrugRelationship>Product</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Priority</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PRI</HighestPatStatusIdForCnty><Indication id="291">Rheumatoid arthritis</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA6726805">WO-2012009705</Patent><Status id="PRI">First Priority</Status><StatusDate>2010-07-15 00:00:00</StatusDate><StatusSortCode>1</StatusSortCode><TherapyArea id="185">Immune disorder</TherapyArea></Row><Row><Action id="381">TNF alpha ligand inhibitor</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="US">US</Country><Drug id="71794">adalimumab + anti-Ang2 Zybody (inflammatory disease), Zyngenia</Drug><DrugRelationship>Product</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Priority</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PRI</HighestPatStatusIdForCnty><Indication id="3003">Juvenile rheumatoid arthritis</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA6726805">WO-2012009705</Patent><Status id="PRI">First Priority</Status><StatusDate>2010-07-15 00:00:00</StatusDate><StatusSortCode>1</StatusSortCode><TherapyArea id="185">Immune disorder</TherapyArea></Row><Row><Action id="381">TNF alpha ligand inhibitor</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="US">US</Country><Drug id="71794">adalimumab + anti-Ang2 Zybody (inflammatory disease), Zyngenia</Drug><DrugRelationship>Product</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Priority</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PRI</HighestPatStatusIdForCnty><Indication id="36">Autoimmune disease</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA6726805">WO-2012009705</Patent><Status id="PRI">First Priority</Status><StatusDate>2010-07-15 00:00:00</StatusDate><StatusSortCode>1</StatusSortCode><TherapyArea id="185">Immune disorder</TherapyArea></Row><Row><Action id="381">TNF alpha ligand inhibitor</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="US">US</Country><Drug id="71794">adalimumab + anti-Ang2 Zybody (inflammatory disease), Zyngenia</Drug><DrugRelationship>Product</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Priority</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PRI</HighestPatStatusIdForCnty><Indication id="651">Cancer</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA6726805">WO-2012009705</Patent><Status id="PRI">First Priority</Status><StatusDate>2010-07-15 00:00:00</StatusDate><StatusSortCode>1</StatusSortCode><TherapyArea id="230">Neoplasm</TherapyArea></Row><Row><Action id="381">TNF alpha ligand inhibitor</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="US">US</Country><Drug id="71794">adalimumab + anti-Ang2 Zybody (inflammatory disease), Zyngenia</Drug><DrugRelationship>Product</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Priority</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PRI</HighestPatStatusIdForCnty><Indication id="84">Crohns disease</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA6726805">WO-2012009705</Patent><Status id="PRI">First Priority</Status><StatusDate>2010-07-15 00:00:00</StatusDate><StatusSortCode>1</StatusSortCode><TherapyArea id="185">Immune disorder</TherapyArea></Row><Row><Action id="381">TNF alpha ligand inhibitor</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="US">US</Country><Drug id="71794">adalimumab + anti-Ang2 Zybody (inflammatory disease), Zyngenia</Drug><DrugRelationship>Product</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Priority</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PRI</HighestPatStatusIdForCnty><Indication id="989">Colorectal tumor</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA6726805">WO-2012009705</Patent><Status id="PRI">First Priority</Status><StatusDate>2010-07-15 00:00:00</StatusDate><StatusSortCode>1</StatusSortCode><TherapyArea id="129">Gastrointestinal disease</TherapyArea></Row><Row><Action id="14323">Angiopoietin ligand-2 inhibitor</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="US">US</Country><Drug id="71795">anti-Her-2/anti-Ang2 mAb (cancer), Zyngenia</Drug><DrugRelationship>Product</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Priority</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PRI</HighestPatStatusIdForCnty><Indication id="1781">Psoriatic arthritis</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA6726805">WO-2012009705</Patent><Status id="PRI">First Priority</Status><StatusDate>2010-07-15 00:00:00</StatusDate><StatusSortCode>1</StatusSortCode><TherapyArea id="185">Immune disorder</TherapyArea></Row><Row><Action id="14323">Angiopoietin ligand-2 inhibitor</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="US">US</Country><Drug id="71795">anti-Her-2/anti-Ang2 mAb (cancer), Zyngenia</Drug><DrugRelationship>Product</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Priority</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PRI</HighestPatStatusIdForCnty><Indication id="188">Inflammatory disease</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA6726805">WO-2012009705</Patent><Status id="PRI">First Priority</Status><StatusDate>2010-07-15 00:00:00</StatusDate><StatusSortCode>1</StatusSortCode><TherapyArea id="188">Inflammatory disease</TherapyArea></Row><Row><Action id="14323">Angiopoietin ligand-2 inhibitor</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="US">US</Country><Drug id="71795">anti-Her-2/anti-Ang2 mAb (cancer), Zyngenia</Drug><DrugRelationship>Product</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Priority</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PRI</HighestPatStatusIdForCnty><Indication id="189">Inflammatory bowel disease</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA6726805">WO-2012009705</Patent><Status id="PRI">First Priority</Status><StatusDate>2010-07-15 00:00:00</StatusDate><StatusSortCode>1</StatusSortCode><TherapyArea id="188">Inflammatory disease</TherapyArea></Row><Row><Action id="14323">Angiopoietin ligand-2 inhibitor</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="US">US</Country><Drug id="71795">anti-Her-2/anti-Ang2 mAb (cancer), Zyngenia</Drug><DrugRelationship>Product</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Priority</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PRI</HighestPatStatusIdForCnty><Indication id="291">Rheumatoid arthritis</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA6726805">WO-2012009705</Patent><Status id="PRI">First Priority</Status><StatusDate>2010-07-15 00:00:00</StatusDate><StatusSortCode>1</StatusSortCode><TherapyArea id="185">Immune disorder</TherapyArea></Row><Row><Action id="14323">Angiopoietin ligand-2 inhibitor</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="US">US</Country><Drug id="71795">anti-Her-2/anti-Ang2 mAb (cancer), Zyngenia</Drug><DrugRelationship>Product</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Priority</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PRI</HighestPatStatusIdForCnty><Indication id="3003">Juvenile rheumatoid arthritis</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA6726805">WO-2012009705</Patent><Status id="PRI">First Priority</Status><StatusDate>2010-07-15 00:00:00</StatusDate><StatusSortCode>1</StatusSortCode><TherapyArea id="185">Immune disorder</TherapyArea></Row><Row><Action id="14323">Angiopoietin ligand-2 inhibitor</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="US">US</Country><Drug id="71795">anti-Her-2/anti-Ang2 mAb (cancer), Zyngenia</Drug><DrugRelationship>Product</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Priority</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PRI</HighestPatStatusIdForCnty><Indication id="36">Autoimmune disease</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA6726805">WO-2012009705</Patent><Status id="PRI">First Priority</Status><StatusDate>2010-07-15 00:00:00</StatusDate><StatusSortCode>1</StatusSortCode><TherapyArea id="185">Immune disorder</TherapyArea></Row><Row><Action id="14323">Angiopoietin ligand-2 inhibitor</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="US">US</Country><Drug id="71795">anti-Her-2/anti-Ang2 mAb (cancer), Zyngenia</Drug><DrugRelationship>Product</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Priority</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PRI</HighestPatStatusIdForCnty><Indication id="651">Cancer</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA6726805">WO-2012009705</Patent><Status id="PRI">First Priority</Status><StatusDate>2010-07-15 00:00:00</StatusDate><StatusSortCode>1</StatusSortCode><TherapyArea id="230">Neoplasm</TherapyArea></Row><Row><Action id="14323">Angiopoietin ligand-2 inhibitor</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="US">US</Country><Drug id="71795">anti-Her-2/anti-Ang2 mAb (cancer), Zyngenia</Drug><DrugRelationship>Product</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Priority</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PRI</HighestPatStatusIdForCnty><Indication id="84">Crohns disease</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA6726805">WO-2012009705</Patent><Status id="PRI">First Priority</Status><StatusDate>2010-07-15 00:00:00</StatusDate><StatusSortCode>1</StatusSortCode><TherapyArea id="185">Immune disorder</TherapyArea></Row><Row><Action id="14323">Angiopoietin ligand-2 inhibitor</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="US">US</Country><Drug id="71795">anti-Her-2/anti-Ang2 mAb (cancer), Zyngenia</Drug><DrugRelationship>Product</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Priority</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PRI</HighestPatStatusIdForCnty><Indication id="989">Colorectal tumor</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA6726805">WO-2012009705</Patent><Status id="PRI">First Priority</Status><StatusDate>2010-07-15 00:00:00</StatusDate><StatusSortCode>1</StatusSortCode><TherapyArea id="129">Gastrointestinal disease</TherapyArea></Row><Row><Action id="3756">Erbb2 tyrosine kinase receptor inhibitor</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="US">US</Country><Drug id="71795">anti-Her-2/anti-Ang2 mAb (cancer), Zyngenia</Drug><DrugRelationship>Product</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Priority</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PRI</HighestPatStatusIdForCnty><Indication id="1781">Psoriatic arthritis</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA6726805">WO-2012009705</Patent><Status id="PRI">First Priority</Status><StatusDate>2010-07-15 00:00:00</StatusDate><StatusSortCode>1</StatusSortCode><TherapyArea id="185">Immune disorder</TherapyArea></Row><Row><Action id="3756">Erbb2 tyrosine kinase receptor inhibitor</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="US">US</Country><Drug id="71795">anti-Her-2/anti-Ang2 mAb (cancer), Zyngenia</Drug><DrugRelationship>Product</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Priority</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PRI</HighestPatStatusIdForCnty><Indication id="188">Inflammatory disease</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA6726805">WO-2012009705</Patent><Status id="PRI">First Priority</Status><StatusDate>2010-07-15 00:00:00</StatusDate><StatusSortCode>1</StatusSortCode><TherapyArea id="188">Inflammatory disease</TherapyArea></Row><Row><Action id="3756">Erbb2 tyrosine kinase receptor inhibitor</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="US">US</Country><Drug id="71795">anti-Her-2/anti-Ang2 mAb (cancer), Zyngenia</Drug><DrugRelationship>Product</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Priority</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PRI</HighestPatStatusIdForCnty><Indication id="189">Inflammatory bowel disease</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA6726805">WO-2012009705</Patent><Status id="PRI">First Priority</Status><StatusDate>2010-07-15 00:00:00</StatusDate><StatusSortCode>1</StatusSortCode><TherapyArea id="188">Inflammatory disease</TherapyArea></Row><Row><Action id="3756">Erbb2 tyrosine kinase receptor inhibitor</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="US">US</Country><Drug id="71795">anti-Her-2/anti-Ang2 mAb (cancer), Zyngenia</Drug><DrugRelationship>Product</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Priority</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PRI</HighestPatStatusIdForCnty><Indication id="291">Rheumatoid arthritis</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA6726805">WO-2012009705</Patent><Status id="PRI">First Priority</Status><StatusDate>2010-07-15 00:00:00</StatusDate><StatusSortCode>1</StatusSortCode><TherapyArea id="185">Immune disorder</TherapyArea></Row><Row><Action id="3756">Erbb2 tyrosine kinase receptor inhibitor</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="US">US</Country><Drug id="71795">anti-Her-2/anti-Ang2 mAb (cancer), Zyngenia</Drug><DrugRelationship>Product</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Priority</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PRI</HighestPatStatusIdForCnty><Indication id="3003">Juvenile rheumatoid arthritis</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA6726805">WO-2012009705</Patent><Status id="PRI">First Priority</Status><StatusDate>2010-07-15 00:00:00</StatusDate><StatusSortCode>1</StatusSortCode><TherapyArea id="185">Immune disorder</TherapyArea></Row><Row><Action id="3756">Erbb2 tyrosine kinase receptor inhibitor</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="US">US</Country><Drug id="71795">anti-Her-2/anti-Ang2 mAb (cancer), Zyngenia</Drug><DrugRelationship>Product</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Priority</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PRI</HighestPatStatusIdForCnty><Indication id="36">Autoimmune disease</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA6726805">WO-2012009705</Patent><Status id="PRI">First Priority</Status><StatusDate>2010-07-15 00:00:00</StatusDate><StatusSortCode>1</StatusSortCode><TherapyArea id="185">Immune disorder</TherapyArea></Row><Row><Action id="3756">Erbb2 tyrosine kinase receptor inhibitor</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="US">US</Country><Drug id="71795">anti-Her-2/anti-Ang2 mAb (cancer), Zyngenia</Drug><DrugRelationship>Product</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Priority</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PRI</HighestPatStatusIdForCnty><Indication id="651">Cancer</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA6726805">WO-2012009705</Patent><Status id="PRI">First Priority</Status><StatusDate>2010-07-15 00:00:00</StatusDate><StatusSortCode>1</StatusSortCode><TherapyArea id="230">Neoplasm</TherapyArea></Row><Row><Action id="3756">Erbb2 tyrosine kinase receptor inhibitor</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="US">US</Country><Drug id="71795">anti-Her-2/anti-Ang2 mAb (cancer), Zyngenia</Drug><DrugRelationship>Product</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Priority</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PRI</HighestPatStatusIdForCnty><Indication id="84">Crohns disease</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA6726805">WO-2012009705</Patent><Status id="PRI">First Priority</Status><StatusDate>2010-07-15 00:00:00</StatusDate><StatusSortCode>1</StatusSortCode><TherapyArea id="185">Immune disorder</TherapyArea></Row><Row><Action id="3756">Erbb2 tyrosine kinase receptor inhibitor</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="US">US</Country><Drug id="71795">anti-Her-2/anti-Ang2 mAb (cancer), Zyngenia</Drug><DrugRelationship>Product</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Priority</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PRI</HighestPatStatusIdForCnty><Indication id="989">Colorectal tumor</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA6726805">WO-2012009705</Patent><Status id="PRI">First Priority</Status><StatusDate>2010-07-15 00:00:00</StatusDate><StatusSortCode>1</StatusSortCode><TherapyArea id="129">Gastrointestinal disease</TherapyArea></Row><Row><Action id="381">TNF alpha ligand inhibitor</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="US">US</Country><Drug id="71795">anti-Her-2/anti-Ang2 mAb (cancer), Zyngenia</Drug><DrugRelationship>Product</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Priority</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PRI</HighestPatStatusIdForCnty><Indication id="1781">Psoriatic arthritis</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA6726805">WO-2012009705</Patent><Status id="PRI">First Priority</Status><StatusDate>2010-07-15 00:00:00</StatusDate><StatusSortCode>1</StatusSortCode><TherapyArea id="185">Immune disorder</TherapyArea></Row><Row><Action id="381">TNF alpha ligand inhibitor</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="US">US</Country><Drug id="71795">anti-Her-2/anti-Ang2 mAb (cancer), Zyngenia</Drug><DrugRelationship>Product</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Priority</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PRI</HighestPatStatusIdForCnty><Indication id="188">Inflammatory disease</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA6726805">WO-2012009705</Patent><Status id="PRI">First Priority</Status><StatusDate>2010-07-15 00:00:00</StatusDate><StatusSortCode>1</StatusSortCode><TherapyArea id="188">Inflammatory disease</TherapyArea></Row><Row><Action id="381">TNF alpha ligand inhibitor</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="US">US</Country><Drug id="71795">anti-Her-2/anti-Ang2 mAb (cancer), Zyngenia</Drug><DrugRelationship>Product</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Priority</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PRI</HighestPatStatusIdForCnty><Indication id="189">Inflammatory bowel disease</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA6726805">WO-2012009705</Patent><Status id="PRI">First Priority</Status><StatusDate>2010-07-15 00:00:00</StatusDate><StatusSortCode>1</StatusSortCode><TherapyArea id="188">Inflammatory disease</TherapyArea></Row><Row><Action id="381">TNF alpha ligand inhibitor</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="US">US</Country><Drug id="71795">anti-Her-2/anti-Ang2 mAb (cancer), Zyngenia</Drug><DrugRelationship>Product</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Priority</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PRI</HighestPatStatusIdForCnty><Indication id="291">Rheumatoid arthritis</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA6726805">WO-2012009705</Patent><Status id="PRI">First Priority</Status><StatusDate>2010-07-15 00:00:00</StatusDate><StatusSortCode>1</StatusSortCode><TherapyArea id="185">Immune disorder</TherapyArea></Row><Row><Action id="381">TNF alpha ligand inhibitor</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="US">US</Country><Drug id="71795">anti-Her-2/anti-Ang2 mAb (cancer), Zyngenia</Drug><DrugRelationship>Product</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Priority</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PRI</HighestPatStatusIdForCnty><Indication id="3003">Juvenile rheumatoid arthritis</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA6726805">WO-2012009705</Patent><Status id="PRI">First Priority</Status><StatusDate>2010-07-15 00:00:00</StatusDate><StatusSortCode>1</StatusSortCode><TherapyArea id="185">Immune disorder</TherapyArea></Row><Row><Action id="381">TNF alpha ligand inhibitor</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="US">US</Country><Drug id="71795">anti-Her-2/anti-Ang2 mAb (cancer), Zyngenia</Drug><DrugRelationship>Product</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Priority</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PRI</HighestPatStatusIdForCnty><Indication id="36">Autoimmune disease</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA6726805">WO-2012009705</Patent><Status id="PRI">First Priority</Status><StatusDate>2010-07-15 00:00:00</StatusDate><StatusSortCode>1</StatusSortCode><TherapyArea id="185">Immune disorder</TherapyArea></Row><Row><Action id="381">TNF alpha ligand inhibitor</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="US">US</Country><Drug id="71795">anti-Her-2/anti-Ang2 mAb (cancer), Zyngenia</Drug><DrugRelationship>Product</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Priority</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PRI</HighestPatStatusIdForCnty><Indication id="651">Cancer</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA6726805">WO-2012009705</Patent><Status id="PRI">First Priority</Status><StatusDate>2010-07-15 00:00:00</StatusDate><StatusSortCode>1</StatusSortCode><TherapyArea id="230">Neoplasm</TherapyArea></Row><Row><Action id="381">TNF alpha ligand inhibitor</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="US">US</Country><Drug id="71795">anti-Her-2/anti-Ang2 mAb (cancer), Zyngenia</Drug><DrugRelationship>Product</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Priority</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PRI</HighestPatStatusIdForCnty><Indication id="84">Crohns disease</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA6726805">WO-2012009705</Patent><Status id="PRI">First Priority</Status><StatusDate>2010-07-15 00:00:00</StatusDate><StatusSortCode>1</StatusSortCode><TherapyArea id="185">Immune disorder</TherapyArea></Row><Row><Action id="381">TNF alpha ligand inhibitor</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="US">US</Country><Drug id="71795">anti-Her-2/anti-Ang2 mAb (cancer), Zyngenia</Drug><DrugRelationship>Product</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Priority</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PRI</HighestPatStatusIdForCnty><Indication id="989">Colorectal tumor</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA6726805">WO-2012009705</Patent><Status id="PRI">First Priority</Status><StatusDate>2010-07-15 00:00:00</StatusDate><StatusSortCode>1</StatusSortCode><TherapyArea id="129">Gastrointestinal disease</TherapyArea></Row><Row><Action id="14323">Angiopoietin ligand-2 inhibitor</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="US">US</Country><Drug id="71794">adalimumab + anti-Ang2 Zybody (inflammatory disease), Zyngenia</Drug><DrugRelationship>Product</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Priority</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PRI</HighestPatStatusIdForCnty><Indication id="1781">Psoriatic arthritis</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA6726805">WO-2012009705</Patent><Status id="PRI">First Priority</Status><StatusDate>2010-07-15 00:00:00</StatusDate><StatusSortCode>1</StatusSortCode><TherapyArea id="185">Immune disorder</TherapyArea></Row><Row><Action id="14323">Angiopoietin ligand-2 inhibitor</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="US">US</Country><Drug id="71794">adalimumab + anti-Ang2 Zybody (inflammatory disease), Zyngenia</Drug><DrugRelationship>Product</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Priority</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PRI</HighestPatStatusIdForCnty><Indication id="188">Inflammatory disease</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA6726805">WO-2012009705</Patent><Status id="PRI">First Priority</Status><StatusDate>2010-07-15 00:00:00</StatusDate><StatusSortCode>1</StatusSortCode><TherapyArea id="188">Inflammatory disease</TherapyArea></Row><Row><Action id="14323">Angiopoietin ligand-2 inhibitor</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="US">US</Country><Drug id="71794">adalimumab + anti-Ang2 Zybody (inflammatory disease), Zyngenia</Drug><DrugRelationship>Product</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Priority</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PRI</HighestPatStatusIdForCnty><Indication id="189">Inflammatory bowel disease</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA6726805">WO-2012009705</Patent><Status id="PRI">First Priority</Status><StatusDate>2010-07-15 00:00:00</StatusDate><StatusSortCode>1</StatusSortCode><TherapyArea id="188">Inflammatory disease</TherapyArea></Row><Row><Action id="14323">Angiopoietin ligand-2 inhibitor</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="US">US</Country><Drug id="71794">adalimumab + anti-Ang2 Zybody (inflammatory disease), Zyngenia</Drug><DrugRelationship>Product</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Priority</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PRI</HighestPatStatusIdForCnty><Indication id="291">Rheumatoid arthritis</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA6726805">WO-2012009705</Patent><Status id="PRI">First Priority</Status><StatusDate>2010-07-15 00:00:00</StatusDate><StatusSortCode>1</StatusSortCode><TherapyArea id="185">Immune disorder</TherapyArea></Row><Row><Action id="14323">Angiopoietin ligand-2 inhibitor</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="US">US</Country><Drug id="71794">adalimumab + anti-Ang2 Zybody (inflammatory disease), Zyngenia</Drug><DrugRelationship>Product</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Priority</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PRI</HighestPatStatusIdForCnty><Indication id="3003">Juvenile rheumatoid arthritis</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA6726805">WO-2012009705</Patent><Status id="PRI">First Priority</Status><StatusDate>2010-07-15 00:00:00</StatusDate><StatusSortCode>1</StatusSortCode><TherapyArea id="185">Immune disorder</TherapyArea></Row><Row><Action id="14323">Angiopoietin ligand-2 inhibitor</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="US">US</Country><Drug id="71794">adalimumab + anti-Ang2 Zybody (inflammatory disease), Zyngenia</Drug><DrugRelationship>Product</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Priority</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PRI</HighestPatStatusIdForCnty><Indication id="36">Autoimmune disease</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA6726805">WO-2012009705</Patent><Status id="PRI">First Priority</Status><StatusDate>2010-07-15 00:00:00</StatusDate><StatusSortCode>1</StatusSortCode><TherapyArea id="185">Immune disorder</TherapyArea></Row><Row><Action id="14323">Angiopoietin ligand-2 inhibitor</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="US">US</Country><Drug id="71794">adalimumab + anti-Ang2 Zybody (inflammatory disease), Zyngenia</Drug><DrugRelationship>Product</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Priority</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PRI</HighestPatStatusIdForCnty><Indication id="651">Cancer</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA6726805">WO-2012009705</Patent><Status id="PRI">First Priority</Status><StatusDate>2010-07-15 00:00:00</StatusDate><StatusSortCode>1</StatusSortCode><TherapyArea id="230">Neoplasm</TherapyArea></Row><Row><Action id="14323">Angiopoietin ligand-2 inhibitor</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="US">US</Country><Drug id="71794">adalimumab + anti-Ang2 Zybody (inflammatory disease), Zyngenia</Drug><DrugRelationship>Product</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Priority</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PRI</HighestPatStatusIdForCnty><Indication id="84">Crohns disease</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA6726805">WO-2012009705</Patent><Status id="PRI">First Priority</Status><StatusDate>2010-07-15 00:00:00</StatusDate><StatusSortCode>1</StatusSortCode><TherapyArea id="185">Immune disorder</TherapyArea></Row><Row><Action id="14323">Angiopoietin ligand-2 inhibitor</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="US">US</Country><Drug id="71794">adalimumab + anti-Ang2 Zybody (inflammatory disease), Zyngenia</Drug><DrugRelationship>Product</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Priority</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PRI</HighestPatStatusIdForCnty><Indication id="989">Colorectal tumor</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA6726805">WO-2012009705</Patent><Status id="PRI">First Priority</Status><StatusDate>2010-07-15 00:00:00</StatusDate><StatusSortCode>1</StatusSortCode><TherapyArea id="129">Gastrointestinal disease</TherapyArea></Row><Row><Action id="3756">Erbb2 tyrosine kinase receptor inhibitor</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="US">US</Country><Drug id="71794">adalimumab + anti-Ang2 Zybody (inflammatory disease), Zyngenia</Drug><DrugRelationship>Product</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Priority</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PRI</HighestPatStatusIdForCnty><Indication id="1781">Psoriatic arthritis</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA6726805">WO-2012009705</Patent><Status id="PRI">First Priority</Status><StatusDate>2010-07-15 00:00:00</StatusDate><StatusSortCode>1</StatusSortCode><TherapyArea id="185">Immune disorder</TherapyArea></Row><Row><Action id="3756">Erbb2 tyrosine kinase receptor inhibitor</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="US">US</Country><Drug id="71794">adalimumab + anti-Ang2 Zybody (inflammatory disease), Zyngenia</Drug><DrugRelationship>Product</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Priority</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PRI</HighestPatStatusIdForCnty><Indication id="188">Inflammatory disease</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA6726805">WO-2012009705</Patent><Status id="PRI">First Priority</Status><StatusDate>2010-07-15 00:00:00</StatusDate><StatusSortCode>1</StatusSortCode><TherapyArea id="188">Inflammatory disease</TherapyArea></Row><Row><Action id="3756">Erbb2 tyrosine kinase receptor inhibitor</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="US">US</Country><Drug id="71794">adalimumab + anti-Ang2 Zybody (inflammatory disease), Zyngenia</Drug><DrugRelationship>Product</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Priority</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PRI</HighestPatStatusIdForCnty><Indication id="189">Inflammatory bowel disease</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA6726805">WO-2012009705</Patent><Status id="PRI">First Priority</Status><StatusDate>2010-07-15 00:00:00</StatusDate><StatusSortCode>1</StatusSortCode><TherapyArea id="188">Inflammatory disease</TherapyArea></Row><Row><Action id="3756">Erbb2 tyrosine kinase receptor inhibitor</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="US">US</Country><Drug id="71794">adalimumab + anti-Ang2 Zybody (inflammatory disease), Zyngenia</Drug><DrugRelationship>Product</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Priority</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PRI</HighestPatStatusIdForCnty><Indication id="291">Rheumatoid arthritis</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA6726805">WO-2012009705</Patent><Status id="PRI">First Priority</Status><StatusDate>2010-07-15 00:00:00</StatusDate><StatusSortCode>1</StatusSortCode><TherapyArea id="185">Immune disorder</TherapyArea></Row><Row><Action id="3756">Erbb2 tyrosine kinase receptor inhibitor</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="US">US</Country><Drug id="71794">adalimumab + anti-Ang2 Zybody (inflammatory disease), Zyngenia</Drug><DrugRelationship>Product</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Priority</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PRI</HighestPatStatusIdForCnty><Indication id="3003">Juvenile rheumatoid arthritis</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA6726805">WO-2012009705</Patent><Status id="PRI">First Priority</Status><StatusDate>2010-07-15 00:00:00</StatusDate><StatusSortCode>1</StatusSortCode><TherapyArea id="185">Immune disorder</TherapyArea></Row><Row><Action id="3756">Erbb2 tyrosine kinase receptor inhibitor</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="US">US</Country><Drug id="71794">adalimumab + anti-Ang2 Zybody (inflammatory disease), Zyngenia</Drug><DrugRelationship>Product</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Priority</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PRI</HighestPatStatusIdForCnty><Indication id="36">Autoimmune disease</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA6726805">WO-2012009705</Patent><Status id="PRI">First Priority</Status><StatusDate>2010-07-15 00:00:00</StatusDate><StatusSortCode>1</StatusSortCode><TherapyArea id="185">Immune disorder</TherapyArea></Row><Row><Action id="3756">Erbb2 tyrosine kinase receptor inhibitor</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="US">US</Country><Drug id="71794">adalimumab + anti-Ang2 Zybody (inflammatory disease), Zyngenia</Drug><DrugRelationship>Product</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Priority</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PRI</HighestPatStatusIdForCnty><Indication id="651">Cancer</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA6726805">WO-2012009705</Patent><Status id="PRI">First Priority</Status><StatusDate>2010-07-15 00:00:00</StatusDate><StatusSortCode>1</StatusSortCode><TherapyArea id="230">Neoplasm</TherapyArea></Row><Row><Action id="3756">Erbb2 tyrosine kinase receptor inhibitor</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="US">US</Country><Drug id="71794">adalimumab + anti-Ang2 Zybody (inflammatory disease), Zyngenia</Drug><DrugRelationship>Product</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Priority</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PRI</HighestPatStatusIdForCnty><Indication id="84">Crohns disease</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA6726805">WO-2012009705</Patent><Status id="PRI">First Priority</Status><StatusDate>2010-07-15 00:00:00</StatusDate><StatusSortCode>1</StatusSortCode><TherapyArea id="185">Immune disorder</TherapyArea></Row><Row><Action id="3756">Erbb2 tyrosine kinase receptor inhibitor</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="US">US</Country><Drug id="71794">adalimumab + anti-Ang2 Zybody (inflammatory disease), Zyngenia</Drug><DrugRelationship>Product</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Priority</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PRI</HighestPatStatusIdForCnty><Indication id="989">Colorectal tumor</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA6726805">WO-2012009705</Patent><Status id="PRI">First Priority</Status><StatusDate>2010-07-15 00:00:00</StatusDate><StatusSortCode>1</StatusSortCode><TherapyArea id="129">Gastrointestinal disease</TherapyArea></Row><Row><Action id="381">TNF alpha ligand inhibitor</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="US">US</Country><Drug id="71794">adalimumab + anti-Ang2 Zybody (inflammatory disease), Zyngenia</Drug><DrugRelationship>Product</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Priority</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PRI</HighestPatStatusIdForCnty><Indication id="1781">Psoriatic arthritis</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA6726805">WO-2012009705</Patent><Status id="PRI">First Priority</Status><StatusDate>2010-07-15 00:00:00</StatusDate><StatusSortCode>1</StatusSortCode><TherapyArea id="185">Immune disorder</TherapyArea></Row><Row><Action id="381">TNF alpha ligand inhibitor</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="US">US</Country><Drug id="71794">adalimumab + anti-Ang2 Zybody (inflammatory disease), Zyngenia</Drug><DrugRelationship>Product</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Priority</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PRI</HighestPatStatusIdForCnty><Indication id="188">Inflammatory disease</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA6726805">WO-2012009705</Patent><Status id="PRI">First Priority</Status><StatusDate>2010-07-15 00:00:00</StatusDate><StatusSortCode>1</StatusSortCode><TherapyArea id="188">Inflammatory disease</TherapyArea></Row><Row><Action id="381">TNF alpha ligand inhibitor</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="US">US</Country><Drug id="71794">adalimumab + anti-Ang2 Zybody (inflammatory disease), Zyngenia</Drug><DrugRelationship>Product</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Priority</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PRI</HighestPatStatusIdForCnty><Indication id="189">Inflammatory bowel disease</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA6726805">WO-2012009705</Patent><Status id="PRI">First Priority</Status><StatusDate>2010-07-15 00:00:00</StatusDate><StatusSortCode>1</StatusSortCode><TherapyArea id="188">Inflammatory disease</TherapyArea></Row><Row><Action id="381">TNF alpha ligand inhibitor</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="US">US</Country><Drug id="71794">adalimumab + anti-Ang2 Zybody (inflammatory disease), Zyngenia</Drug><DrugRelationship>Product</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Priority</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PRI</HighestPatStatusIdForCnty><Indication id="291">Rheumatoid arthritis</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA6726805">WO-2012009705</Patent><Status id="PRI">First Priority</Status><StatusDate>2010-07-15 00:00:00</StatusDate><StatusSortCode>1</StatusSortCode><TherapyArea id="185">Immune disorder</TherapyArea></Row><Row><Action id="381">TNF alpha ligand inhibitor</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="US">US</Country><Drug id="71794">adalimumab + anti-Ang2 Zybody (inflammatory disease), Zyngenia</Drug><DrugRelationship>Product</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Priority</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PRI</HighestPatStatusIdForCnty><Indication id="3003">Juvenile rheumatoid arthritis</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA6726805">WO-2012009705</Patent><Status id="PRI">First Priority</Status><StatusDate>2010-07-15 00:00:00</StatusDate><StatusSortCode>1</StatusSortCode><TherapyArea id="185">Immune disorder</TherapyArea></Row><Row><Action id="381">TNF alpha ligand inhibitor</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="US">US</Country><Drug id="71794">adalimumab + anti-Ang2 Zybody (inflammatory disease), Zyngenia</Drug><DrugRelationship>Product</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Priority</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PRI</HighestPatStatusIdForCnty><Indication id="36">Autoimmune disease</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA6726805">WO-2012009705</Patent><Status id="PRI">First Priority</Status><StatusDate>2010-07-15 00:00:00</StatusDate><StatusSortCode>1</StatusSortCode><TherapyArea id="185">Immune disorder</TherapyArea></Row><Row><Action id="381">TNF alpha ligand inhibitor</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="US">US</Country><Drug id="71794">adalimumab + anti-Ang2 Zybody (inflammatory disease), Zyngenia</Drug><DrugRelationship>Product</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Priority</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PRI</HighestPatStatusIdForCnty><Indication id="651">Cancer</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA6726805">WO-2012009705</Patent><Status id="PRI">First Priority</Status><StatusDate>2010-07-15 00:00:00</StatusDate><StatusSortCode>1</StatusSortCode><TherapyArea id="230">Neoplasm</TherapyArea></Row><Row><Action id="381">TNF alpha ligand inhibitor</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="US">US</Country><Drug id="71794">adalimumab + anti-Ang2 Zybody (inflammatory disease), Zyngenia</Drug><DrugRelationship>Product</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Priority</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PRI</HighestPatStatusIdForCnty><Indication id="84">Crohns disease</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA6726805">WO-2012009705</Patent><Status id="PRI">First Priority</Status><StatusDate>2010-07-15 00:00:00</StatusDate><StatusSortCode>1</StatusSortCode><TherapyArea id="185">Immune disorder</TherapyArea></Row><Row><Action id="381">TNF alpha ligand inhibitor</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="US">US</Country><Drug id="71794">adalimumab + anti-Ang2 Zybody (inflammatory disease), Zyngenia</Drug><DrugRelationship>Product</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Priority</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PRI</HighestPatStatusIdForCnty><Indication id="989">Colorectal tumor</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA6726805">WO-2012009705</Patent><Status id="PRI">First Priority</Status><StatusDate>2010-07-15 00:00:00</StatusDate><StatusSortCode>1</StatusSortCode><TherapyArea id="129">Gastrointestinal disease</TherapyArea></Row><Row><Action id="14323">Angiopoietin ligand-2 inhibitor</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="US">US</Country><Drug id="71795">anti-Her-2/anti-Ang2 mAb (cancer), Zyngenia</Drug><DrugRelationship>Product</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Priority</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PRI</HighestPatStatusIdForCnty><Indication id="1781">Psoriatic arthritis</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA6726805">WO-2012009705</Patent><Status id="PRI">First Priority</Status><StatusDate>2010-07-15 00:00:00</StatusDate><StatusSortCode>1</StatusSortCode><TherapyArea id="185">Immune disorder</TherapyArea></Row><Row><Action id="14323">Angiopoietin ligand-2 inhibitor</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="US">US</Country><Drug id="71795">anti-Her-2/anti-Ang2 mAb (cancer), Zyngenia</Drug><DrugRelationship>Product</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Priority</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PRI</HighestPatStatusIdForCnty><Indication id="188">Inflammatory disease</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA6726805">WO-2012009705</Patent><Status id="PRI">First Priority</Status><StatusDate>2010-07-15 00:00:00</StatusDate><StatusSortCode>1</StatusSortCode><TherapyArea id="188">Inflammatory disease</TherapyArea></Row><Row><Action id="14323">Angiopoietin ligand-2 inhibitor</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="US">US</Country><Drug id="71795">anti-Her-2/anti-Ang2 mAb (cancer), Zyngenia</Drug><DrugRelationship>Product</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Priority</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PRI</HighestPatStatusIdForCnty><Indication id="189">Inflammatory bowel disease</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA6726805">WO-2012009705</Patent><Status id="PRI">First Priority</Status><StatusDate>2010-07-15 00:00:00</StatusDate><StatusSortCode>1</StatusSortCode><TherapyArea id="188">Inflammatory disease</TherapyArea></Row><Row><Action id="14323">Angiopoietin ligand-2 inhibitor</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="US">US</Country><Drug id="71795">anti-Her-2/anti-Ang2 mAb (cancer), Zyngenia</Drug><DrugRelationship>Product</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Priority</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PRI</HighestPatStatusIdForCnty><Indication id="291">Rheumatoid arthritis</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA6726805">WO-2012009705</Patent><Status id="PRI">First Priority</Status><StatusDate>2010-07-15 00:00:00</StatusDate><StatusSortCode>1</StatusSortCode><TherapyArea id="185">Immune disorder</TherapyArea></Row><Row><Action id="14323">Angiopoietin ligand-2 inhibitor</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="US">US</Country><Drug id="71795">anti-Her-2/anti-Ang2 mAb (cancer), Zyngenia</Drug><DrugRelationship>Product</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Priority</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PRI</HighestPatStatusIdForCnty><Indication id="3003">Juvenile rheumatoid arthritis</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA6726805">WO-2012009705</Patent><Status id="PRI">First Priority</Status><StatusDate>2010-07-15 00:00:00</StatusDate><StatusSortCode>1</StatusSortCode><TherapyArea id="185">Immune disorder</TherapyArea></Row><Row><Action id="14323">Angiopoietin ligand-2 inhibitor</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="US">US</Country><Drug id="71795">anti-Her-2/anti-Ang2 mAb (cancer), Zyngenia</Drug><DrugRelationship>Product</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Priority</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PRI</HighestPatStatusIdForCnty><Indication id="36">Autoimmune disease</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA6726805">WO-2012009705</Patent><Status id="PRI">First Priority</Status><StatusDate>2010-07-15 00:00:00</StatusDate><StatusSortCode>1</StatusSortCode><TherapyArea id="185">Immune disorder</TherapyArea></Row><Row><Action id="14323">Angiopoietin ligand-2 inhibitor</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="US">US</Country><Drug id="71795">anti-Her-2/anti-Ang2 mAb (cancer), Zyngenia</Drug><DrugRelationship>Product</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Priority</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PRI</HighestPatStatusIdForCnty><Indication id="651">Cancer</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA6726805">WO-2012009705</Patent><Status id="PRI">First Priority</Status><StatusDate>2010-07-15 00:00:00</StatusDate><StatusSortCode>1</StatusSortCode><TherapyArea id="230">Neoplasm</TherapyArea></Row><Row><Action id="14323">Angiopoietin ligand-2 inhibitor</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="US">US</Country><Drug id="71795">anti-Her-2/anti-Ang2 mAb (cancer), Zyngenia</Drug><DrugRelationship>Product</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Priority</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PRI</HighestPatStatusIdForCnty><Indication id="84">Crohns disease</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA6726805">WO-2012009705</Patent><Status id="PRI">First Priority</Status><StatusDate>2010-07-15 00:00:00</StatusDate><StatusSortCode>1</StatusSortCode><TherapyArea id="185">Immune disorder</TherapyArea></Row><Row><Action id="14323">Angiopoietin ligand-2 inhibitor</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="US">US</Country><Drug id="71795">anti-Her-2/anti-Ang2 mAb (cancer), Zyngenia</Drug><DrugRelationship>Product</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Priority</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PRI</HighestPatStatusIdForCnty><Indication id="989">Colorectal tumor</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA6726805">WO-2012009705</Patent><Status id="PRI">First Priority</Status><StatusDate>2010-07-15 00:00:00</StatusDate><StatusSortCode>1</StatusSortCode><TherapyArea id="129">Gastrointestinal disease</TherapyArea></Row><Row><Action id="3756">Erbb2 tyrosine kinase receptor inhibitor</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="US">US</Country><Drug id="71795">anti-Her-2/anti-Ang2 mAb (cancer), Zyngenia</Drug><DrugRelationship>Product</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Priority</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PRI</HighestPatStatusIdForCnty><Indication id="1781">Psoriatic arthritis</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA6726805">WO-2012009705</Patent><Status id="PRI">First Priority</Status><StatusDate>2010-07-15 00:00:00</StatusDate><StatusSortCode>1</StatusSortCode><TherapyArea id="185">Immune disorder</TherapyArea></Row><Row><Action id="3756">Erbb2 tyrosine kinase receptor inhibitor</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="US">US</Country><Drug id="71795">anti-Her-2/anti-Ang2 mAb (cancer), Zyngenia</Drug><DrugRelationship>Product</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Priority</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PRI</HighestPatStatusIdForCnty><Indication id="188">Inflammatory disease</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA6726805">WO-2012009705</Patent><Status id="PRI">First Priority</Status><StatusDate>2010-07-15 00:00:00</StatusDate><StatusSortCode>1</StatusSortCode><TherapyArea id="188">Inflammatory disease</TherapyArea></Row><Row><Action id="3756">Erbb2 tyrosine kinase receptor inhibitor</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="US">US</Country><Drug id="71795">anti-Her-2/anti-Ang2 mAb (cancer), Zyngenia</Drug><DrugRelationship>Product</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Priority</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PRI</HighestPatStatusIdForCnty><Indication id="189">Inflammatory bowel disease</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA6726805">WO-2012009705</Patent><Status id="PRI">First Priority</Status><StatusDate>2010-07-15 00:00:00</StatusDate><StatusSortCode>1</StatusSortCode><TherapyArea id="188">Inflammatory disease</TherapyArea></Row><Row><Action id="3756">Erbb2 tyrosine kinase receptor inhibitor</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="US">US</Country><Drug id="71795">anti-Her-2/anti-Ang2 mAb (cancer), Zyngenia</Drug><DrugRelationship>Product</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Priority</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PRI</HighestPatStatusIdForCnty><Indication id="291">Rheumatoid arthritis</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA6726805">WO-2012009705</Patent><Status id="PRI">First Priority</Status><StatusDate>2010-07-15 00:00:00</StatusDate><StatusSortCode>1</StatusSortCode><TherapyArea id="185">Immune disorder</TherapyArea></Row><Row><Action id="3756">Erbb2 tyrosine kinase receptor inhibitor</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="US">US</Country><Drug id="71795">anti-Her-2/anti-Ang2 mAb (cancer), Zyngenia</Drug><DrugRelationship>Product</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Priority</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PRI</HighestPatStatusIdForCnty><Indication id="3003">Juvenile rheumatoid arthritis</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA6726805">WO-2012009705</Patent><Status id="PRI">First Priority</Status><StatusDate>2010-07-15 00:00:00</StatusDate><StatusSortCode>1</StatusSortCode><TherapyArea id="185">Immune disorder</TherapyArea></Row><Row><Action id="3756">Erbb2 tyrosine kinase receptor inhibitor</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="US">US</Country><Drug id="71795">anti-Her-2/anti-Ang2 mAb (cancer), Zyngenia</Drug><DrugRelationship>Product</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Priority</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PRI</HighestPatStatusIdForCnty><Indication id="36">Autoimmune disease</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA6726805">WO-2012009705</Patent><Status id="PRI">First Priority</Status><StatusDate>2010-07-15 00:00:00</StatusDate><StatusSortCode>1</StatusSortCode><TherapyArea id="185">Immune disorder</TherapyArea></Row><Row><Action id="3756">Erbb2 tyrosine kinase receptor inhibitor</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="US">US</Country><Drug id="71795">anti-Her-2/anti-Ang2 mAb (cancer), Zyngenia</Drug><DrugRelationship>Product</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Priority</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PRI</HighestPatStatusIdForCnty><Indication id="651">Cancer</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA6726805">WO-2012009705</Patent><Status id="PRI">First Priority</Status><StatusDate>2010-07-15 00:00:00</StatusDate><StatusSortCode>1</StatusSortCode><TherapyArea id="230">Neoplasm</TherapyArea></Row><Row><Action id="3756">Erbb2 tyrosine kinase receptor inhibitor</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="US">US</Country><Drug id="71795">anti-Her-2/anti-Ang2 mAb (cancer), Zyngenia</Drug><DrugRelationship>Product</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Priority</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PRI</HighestPatStatusIdForCnty><Indication id="84">Crohns disease</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA6726805">WO-2012009705</Patent><Status id="PRI">First Priority</Status><StatusDate>2010-07-15 00:00:00</StatusDate><StatusSortCode>1</StatusSortCode><TherapyArea id="185">Immune disorder</TherapyArea></Row><Row><Action id="3756">Erbb2 tyrosine kinase receptor inhibitor</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="US">US</Country><Drug id="71795">anti-Her-2/anti-Ang2 mAb (cancer), Zyngenia</Drug><DrugRelationship>Product</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Priority</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PRI</HighestPatStatusIdForCnty><Indication id="989">Colorectal tumor</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA6726805">WO-2012009705</Patent><Status id="PRI">First Priority</Status><StatusDate>2010-07-15 00:00:00</StatusDate><StatusSortCode>1</StatusSortCode><TherapyArea id="129">Gastrointestinal disease</TherapyArea></Row><Row><Action id="381">TNF alpha ligand inhibitor</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="US">US</Country><Drug id="71795">anti-Her-2/anti-Ang2 mAb (cancer), Zyngenia</Drug><DrugRelationship>Product</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Priority</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PRI</HighestPatStatusIdForCnty><Indication id="1781">Psoriatic arthritis</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA6726805">WO-2012009705</Patent><Status id="PRI">First Priority</Status><StatusDate>2010-07-15 00:00:00</StatusDate><StatusSortCode>1</StatusSortCode><TherapyArea id="185">Immune disorder</TherapyArea></Row><Row><Action id="381">TNF alpha ligand inhibitor</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="US">US</Country><Drug id="71795">anti-Her-2/anti-Ang2 mAb (cancer), Zyngenia</Drug><DrugRelationship>Product</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Priority</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PRI</HighestPatStatusIdForCnty><Indication id="188">Inflammatory disease</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA6726805">WO-2012009705</Patent><Status id="PRI">First Priority</Status><StatusDate>2010-07-15 00:00:00</StatusDate><StatusSortCode>1</StatusSortCode><TherapyArea id="188">Inflammatory disease</TherapyArea></Row><Row><Action id="381">TNF alpha ligand inhibitor</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="US">US</Country><Drug id="71795">anti-Her-2/anti-Ang2 mAb (cancer), Zyngenia</Drug><DrugRelationship>Product</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Priority</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PRI</HighestPatStatusIdForCnty><Indication id="189">Inflammatory bowel disease</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA6726805">WO-2012009705</Patent><Status id="PRI">First Priority</Status><StatusDate>2010-07-15 00:00:00</StatusDate><StatusSortCode>1</StatusSortCode><TherapyArea id="188">Inflammatory disease</TherapyArea></Row><Row><Action id="381">TNF alpha ligand inhibitor</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="US">US</Country><Drug id="71795">anti-Her-2/anti-Ang2 mAb (cancer), Zyngenia</Drug><DrugRelationship>Product</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Priority</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PRI</HighestPatStatusIdForCnty><Indication id="291">Rheumatoid arthritis</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA6726805">WO-2012009705</Patent><Status id="PRI">First Priority</Status><StatusDate>2010-07-15 00:00:00</StatusDate><StatusSortCode>1</StatusSortCode><TherapyArea id="185">Immune disorder</TherapyArea></Row><Row><Action id="381">TNF alpha ligand inhibitor</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="US">US</Country><Drug id="71795">anti-Her-2/anti-Ang2 mAb (cancer), Zyngenia</Drug><DrugRelationship>Product</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Priority</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PRI</HighestPatStatusIdForCnty><Indication id="3003">Juvenile rheumatoid arthritis</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA6726805">WO-2012009705</Patent><Status id="PRI">First Priority</Status><StatusDate>2010-07-15 00:00:00</StatusDate><StatusSortCode>1</StatusSortCode><TherapyArea id="185">Immune disorder</TherapyArea></Row><Row><Action id="381">TNF alpha ligand inhibitor</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="US">US</Country><Drug id="71795">anti-Her-2/anti-Ang2 mAb (cancer), Zyngenia</Drug><DrugRelationship>Product</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Priority</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PRI</HighestPatStatusIdForCnty><Indication id="36">Autoimmune disease</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA6726805">WO-2012009705</Patent><Status id="PRI">First Priority</Status><StatusDate>2010-07-15 00:00:00</StatusDate><StatusSortCode>1</StatusSortCode><TherapyArea id="185">Immune disorder</TherapyArea></Row><Row><Action id="381">TNF alpha ligand inhibitor</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="US">US</Country><Drug id="71795">anti-Her-2/anti-Ang2 mAb (cancer), Zyngenia</Drug><DrugRelationship>Product</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Priority</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PRI</HighestPatStatusIdForCnty><Indication id="651">Cancer</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA6726805">WO-2012009705</Patent><Status id="PRI">First Priority</Status><StatusDate>2010-07-15 00:00:00</StatusDate><StatusSortCode>1</StatusSortCode><TherapyArea id="230">Neoplasm</TherapyArea></Row><Row><Action id="381">TNF alpha ligand inhibitor</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="US">US</Country><Drug id="71795">anti-Her-2/anti-Ang2 mAb (cancer), Zyngenia</Drug><DrugRelationship>Product</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Priority</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PRI</HighestPatStatusIdForCnty><Indication id="84">Crohns disease</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA6726805">WO-2012009705</Patent><Status id="PRI">First Priority</Status><StatusDate>2010-07-15 00:00:00</StatusDate><StatusSortCode>1</StatusSortCode><TherapyArea id="185">Immune disorder</TherapyArea></Row><Row><Action id="381">TNF alpha ligand inhibitor</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="US">US</Country><Drug id="71795">anti-Her-2/anti-Ang2 mAb (cancer), Zyngenia</Drug><DrugRelationship>Product</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Priority</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PRI</HighestPatStatusIdForCnty><Indication id="989">Colorectal tumor</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA6726805">WO-2012009705</Patent><Status id="PRI">First Priority</Status><StatusDate>2010-07-15 00:00:00</StatusDate><StatusSortCode>1</StatusSortCode><TherapyArea id="129">Gastrointestinal disease</TherapyArea></Row><Row><Action id="14323">Angiopoietin ligand-2 inhibitor</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="US">US</Country><Drug id="71794">adalimumab + anti-Ang2 Zybody (inflammatory disease), Zyngenia</Drug><DrugRelationship>Product</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Priority</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PRI</HighestPatStatusIdForCnty><Indication id="1781">Psoriatic arthritis</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA6726805">WO-2012009705</Patent><Status id="PRI">First Priority</Status><StatusDate>2010-07-15 00:00:00</StatusDate><StatusSortCode>1</StatusSortCode><TherapyArea id="185">Immune disorder</TherapyArea></Row><Row><Action id="14323">Angiopoietin ligand-2 inhibitor</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="US">US</Country><Drug id="71794">adalimumab + anti-Ang2 Zybody (inflammatory disease), Zyngenia</Drug><DrugRelationship>Product</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Priority</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PRI</HighestPatStatusIdForCnty><Indication id="188">Inflammatory disease</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA6726805">WO-2012009705</Patent><Status id="PRI">First Priority</Status><StatusDate>2010-07-15 00:00:00</StatusDate><StatusSortCode>1</StatusSortCode><TherapyArea id="188">Inflammatory disease</TherapyArea></Row><Row><Action id="14323">Angiopoietin ligand-2 inhibitor</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="US">US</Country><Drug id="71794">adalimumab + anti-Ang2 Zybody (inflammatory disease), Zyngenia</Drug><DrugRelationship>Product</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Priority</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PRI</HighestPatStatusIdForCnty><Indication id="189">Inflammatory bowel disease</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA6726805">WO-2012009705</Patent><Status id="PRI">First Priority</Status><StatusDate>2010-07-15 00:00:00</StatusDate><StatusSortCode>1</StatusSortCode><TherapyArea id="188">Inflammatory disease</TherapyArea></Row><Row><Action id="14323">Angiopoietin ligand-2 inhibitor</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="US">US</Country><Drug id="71794">adalimumab + anti-Ang2 Zybody (inflammatory disease), Zyngenia</Drug><DrugRelationship>Product</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Priority</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PRI</HighestPatStatusIdForCnty><Indication id="291">Rheumatoid arthritis</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA6726805">WO-2012009705</Patent><Status id="PRI">First Priority</Status><StatusDate>2010-07-15 00:00:00</StatusDate><StatusSortCode>1</StatusSortCode><TherapyArea id="185">Immune disorder</TherapyArea></Row><Row><Action id="14323">Angiopoietin ligand-2 inhibitor</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="US">US</Country><Drug id="71794">adalimumab + anti-Ang2 Zybody (inflammatory disease), Zyngenia</Drug><DrugRelationship>Product</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Priority</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PRI</HighestPatStatusIdForCnty><Indication id="3003">Juvenile rheumatoid arthritis</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA6726805">WO-2012009705</Patent><Status id="PRI">First Priority</Status><StatusDate>2010-07-15 00:00:00</StatusDate><StatusSortCode>1</StatusSortCode><TherapyArea id="185">Immune disorder</TherapyArea></Row><Row><Action id="14323">Angiopoietin ligand-2 inhibitor</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="US">US</Country><Drug id="71794">adalimumab + anti-Ang2 Zybody (inflammatory disease), Zyngenia</Drug><DrugRelationship>Product</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Priority</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PRI</HighestPatStatusIdForCnty><Indication id="36">Autoimmune disease</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA6726805">WO-2012009705</Patent><Status id="PRI">First Priority</Status><StatusDate>2010-07-15 00:00:00</StatusDate><StatusSortCode>1</StatusSortCode><TherapyArea id="185">Immune disorder</TherapyArea></Row><Row><Action id="14323">Angiopoietin ligand-2 inhibitor</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="US">US</Country><Drug id="71794">adalimumab + anti-Ang2 Zybody (inflammatory disease), Zyngenia</Drug><DrugRelationship>Product</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Priority</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PRI</HighestPatStatusIdForCnty><Indication id="651">Cancer</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA6726805">WO-2012009705</Patent><Status id="PRI">First Priority</Status><StatusDate>2010-07-15 00:00:00</StatusDate><StatusSortCode>1</StatusSortCode><TherapyArea id="230">Neoplasm</TherapyArea></Row><Row><Action id="14323">Angiopoietin ligand-2 inhibitor</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="US">US</Country><Drug id="71794">adalimumab + anti-Ang2 Zybody (inflammatory disease), Zyngenia</Drug><DrugRelationship>Product</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Priority</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PRI</HighestPatStatusIdForCnty><Indication id="84">Crohns disease</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA6726805">WO-2012009705</Patent><Status id="PRI">First Priority</Status><StatusDate>2010-07-15 00:00:00</StatusDate><StatusSortCode>1</StatusSortCode><TherapyArea id="185">Immune disorder</TherapyArea></Row><Row><Action id="14323">Angiopoietin ligand-2 inhibitor</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="US">US</Country><Drug id="71794">adalimumab + anti-Ang2 Zybody (inflammatory disease), Zyngenia</Drug><DrugRelationship>Product</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Priority</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PRI</HighestPatStatusIdForCnty><Indication id="989">Colorectal tumor</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA6726805">WO-2012009705</Patent><Status id="PRI">First Priority</Status><StatusDate>2010-07-15 00:00:00</StatusDate><StatusSortCode>1</StatusSortCode><TherapyArea id="129">Gastrointestinal disease</TherapyArea></Row><Row><Action id="3756">Erbb2 tyrosine kinase receptor inhibitor</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="US">US</Country><Drug id="71794">adalimumab + anti-Ang2 Zybody (inflammatory disease), Zyngenia</Drug><DrugRelationship>Product</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Priority</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PRI</HighestPatStatusIdForCnty><Indication id="1781">Psoriatic arthritis</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA6726805">WO-2012009705</Patent><Status id="PRI">First Priority</Status><StatusDate>2010-07-15 00:00:00</StatusDate><StatusSortCode>1</StatusSortCode><TherapyArea id="185">Immune disorder</TherapyArea></Row><Row><Action id="3756">Erbb2 tyrosine kinase receptor inhibitor</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="US">US</Country><Drug id="71794">adalimumab + anti-Ang2 Zybody (inflammatory disease), Zyngenia</Drug><DrugRelationship>Product</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Priority</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PRI</HighestPatStatusIdForCnty><Indication id="188">Inflammatory disease</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA6726805">WO-2012009705</Patent><Status id="PRI">First Priority</Status><StatusDate>2010-07-15 00:00:00</StatusDate><StatusSortCode>1</StatusSortCode><TherapyArea id="188">Inflammatory disease</TherapyArea></Row><Row><Action id="3756">Erbb2 tyrosine kinase receptor inhibitor</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="US">US</Country><Drug id="71794">adalimumab + anti-Ang2 Zybody (inflammatory disease), Zyngenia</Drug><DrugRelationship>Product</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Priority</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PRI</HighestPatStatusIdForCnty><Indication id="189">Inflammatory bowel disease</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA6726805">WO-2012009705</Patent><Status id="PRI">First Priority</Status><StatusDate>2010-07-15 00:00:00</StatusDate><StatusSortCode>1</StatusSortCode><TherapyArea id="188">Inflammatory disease</TherapyArea></Row><Row><Action id="3756">Erbb2 tyrosine kinase receptor inhibitor</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="US">US</Country><Drug id="71794">adalimumab + anti-Ang2 Zybody (inflammatory disease), Zyngenia</Drug><DrugRelationship>Product</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Priority</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PRI</HighestPatStatusIdForCnty><Indication id="291">Rheumatoid arthritis</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA6726805">WO-2012009705</Patent><Status id="PRI">First Priority</Status><StatusDate>2010-07-15 00:00:00</StatusDate><StatusSortCode>1</StatusSortCode><TherapyArea id="185">Immune disorder</TherapyArea></Row><Row><Action id="3756">Erbb2 tyrosine kinase receptor inhibitor</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="US">US</Country><Drug id="71794">adalimumab + anti-Ang2 Zybody (inflammatory disease), Zyngenia</Drug><DrugRelationship>Product</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Priority</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PRI</HighestPatStatusIdForCnty><Indication id="3003">Juvenile rheumatoid arthritis</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA6726805">WO-2012009705</Patent><Status id="PRI">First Priority</Status><StatusDate>2010-07-15 00:00:00</StatusDate><StatusSortCode>1</StatusSortCode><TherapyArea id="185">Immune disorder</TherapyArea></Row><Row><Action id="3756">Erbb2 tyrosine kinase receptor inhibitor</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="US">US</Country><Drug id="71794">adalimumab + anti-Ang2 Zybody (inflammatory disease), Zyngenia</Drug><DrugRelationship>Product</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Priority</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PRI</HighestPatStatusIdForCnty><Indication id="36">Autoimmune disease</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA6726805">WO-2012009705</Patent><Status id="PRI">First Priority</Status><StatusDate>2010-07-15 00:00:00</StatusDate><StatusSortCode>1</StatusSortCode><TherapyArea id="185">Immune disorder</TherapyArea></Row><Row><Action id="3756">Erbb2 tyrosine kinase receptor inhibitor</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="US">US</Country><Drug id="71794">adalimumab + anti-Ang2 Zybody (inflammatory disease), Zyngenia</Drug><DrugRelationship>Product</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Priority</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PRI</HighestPatStatusIdForCnty><Indication id="651">Cancer</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA6726805">WO-2012009705</Patent><Status id="PRI">First Priority</Status><StatusDate>2010-07-15 00:00:00</StatusDate><StatusSortCode>1</StatusSortCode><TherapyArea id="230">Neoplasm</TherapyArea></Row><Row><Action id="3756">Erbb2 tyrosine kinase receptor inhibitor</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="US">US</Country><Drug id="71794">adalimumab + anti-Ang2 Zybody (inflammatory disease), Zyngenia</Drug><DrugRelationship>Product</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Priority</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PRI</HighestPatStatusIdForCnty><Indication id="84">Crohns disease</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA6726805">WO-2012009705</Patent><Status id="PRI">First Priority</Status><StatusDate>2010-07-15 00:00:00</StatusDate><StatusSortCode>1</StatusSortCode><TherapyArea id="185">Immune disorder</TherapyArea></Row><Row><Action id="3756">Erbb2 tyrosine kinase receptor inhibitor</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="US">US</Country><Drug id="71794">adalimumab + anti-Ang2 Zybody (inflammatory disease), Zyngenia</Drug><DrugRelationship>Product</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Priority</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PRI</HighestPatStatusIdForCnty><Indication id="989">Colorectal tumor</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA6726805">WO-2012009705</Patent><Status id="PRI">First Priority</Status><StatusDate>2010-07-15 00:00:00</StatusDate><StatusSortCode>1</StatusSortCode><TherapyArea id="129">Gastrointestinal disease</TherapyArea></Row><Row><Action id="381">TNF alpha ligand inhibitor</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="US">US</Country><Drug id="71794">adalimumab + anti-Ang2 Zybody (inflammatory disease), Zyngenia</Drug><DrugRelationship>Product</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Priority</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PRI</HighestPatStatusIdForCnty><Indication id="1781">Psoriatic arthritis</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA6726805">WO-2012009705</Patent><Status id="PRI">First Priority</Status><StatusDate>2010-07-15 00:00:00</StatusDate><StatusSortCode>1</StatusSortCode><TherapyArea id="185">Immune disorder</TherapyArea></Row><Row><Action id="381">TNF alpha ligand inhibitor</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="US">US</Country><Drug id="71794">adalimumab + anti-Ang2 Zybody (inflammatory disease), Zyngenia</Drug><DrugRelationship>Product</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Priority</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PRI</HighestPatStatusIdForCnty><Indication id="188">Inflammatory disease</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA6726805">WO-2012009705</Patent><Status id="PRI">First Priority</Status><StatusDate>2010-07-15 00:00:00</StatusDate><StatusSortCode>1</StatusSortCode><TherapyArea id="188">Inflammatory disease</TherapyArea></Row><Row><Action id="381">TNF alpha ligand inhibitor</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="US">US</Country><Drug id="71794">adalimumab + anti-Ang2 Zybody (inflammatory disease), Zyngenia</Drug><DrugRelationship>Product</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Priority</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PRI</HighestPatStatusIdForCnty><Indication id="189">Inflammatory bowel disease</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA6726805">WO-2012009705</Patent><Status id="PRI">First Priority</Status><StatusDate>2010-07-15 00:00:00</StatusDate><StatusSortCode>1</StatusSortCode><TherapyArea id="188">Inflammatory disease</TherapyArea></Row><Row><Action id="381">TNF alpha ligand inhibitor</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="US">US</Country><Drug id="71794">adalimumab + anti-Ang2 Zybody (inflammatory disease), Zyngenia</Drug><DrugRelationship>Product</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Priority</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PRI</HighestPatStatusIdForCnty><Indication id="291">Rheumatoid arthritis</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA6726805">WO-2012009705</Patent><Status id="PRI">First Priority</Status><StatusDate>2010-07-15 00:00:00</StatusDate><StatusSortCode>1</StatusSortCode><TherapyArea id="185">Immune disorder</TherapyArea></Row><Row><Action id="381">TNF alpha ligand inhibitor</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="US">US</Country><Drug id="71794">adalimumab + anti-Ang2 Zybody (inflammatory disease), Zyngenia</Drug><DrugRelationship>Product</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Priority</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PRI</HighestPatStatusIdForCnty><Indication id="3003">Juvenile rheumatoid arthritis</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA6726805">WO-2012009705</Patent><Status id="PRI">First Priority</Status><StatusDate>2010-07-15 00:00:00</StatusDate><StatusSortCode>1</StatusSortCode><TherapyArea id="185">Immune disorder</TherapyArea></Row><Row><Action id="381">TNF alpha ligand inhibitor</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="US">US</Country><Drug id="71794">adalimumab + anti-Ang2 Zybody (inflammatory disease), Zyngenia</Drug><DrugRelationship>Product</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Priority</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PRI</HighestPatStatusIdForCnty><Indication id="36">Autoimmune disease</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA6726805">WO-2012009705</Patent><Status id="PRI">First Priority</Status><StatusDate>2010-07-15 00:00:00</StatusDate><StatusSortCode>1</StatusSortCode><TherapyArea id="185">Immune disorder</TherapyArea></Row><Row><Action id="381">TNF alpha ligand inhibitor</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="US">US</Country><Drug id="71794">adalimumab + anti-Ang2 Zybody (inflammatory disease), Zyngenia</Drug><DrugRelationship>Product</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Priority</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PRI</HighestPatStatusIdForCnty><Indication id="651">Cancer</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA6726805">WO-2012009705</Patent><Status id="PRI">First Priority</Status><StatusDate>2010-07-15 00:00:00</StatusDate><StatusSortCode>1</StatusSortCode><TherapyArea id="230">Neoplasm</TherapyArea></Row><Row><Action id="381">TNF alpha ligand inhibitor</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="US">US</Country><Drug id="71794">adalimumab + anti-Ang2 Zybody (inflammatory disease), Zyngenia</Drug><DrugRelationship>Product</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Priority</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PRI</HighestPatStatusIdForCnty><Indication id="84">Crohns disease</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA6726805">WO-2012009705</Patent><Status id="PRI">First Priority</Status><StatusDate>2010-07-15 00:00:00</StatusDate><StatusSortCode>1</StatusSortCode><TherapyArea id="185">Immune disorder</TherapyArea></Row><Row><Action id="381">TNF alpha ligand inhibitor</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="US">US</Country><Drug id="71794">adalimumab + anti-Ang2 Zybody (inflammatory disease), Zyngenia</Drug><DrugRelationship>Product</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Priority</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PRI</HighestPatStatusIdForCnty><Indication id="989">Colorectal tumor</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA6726805">WO-2012009705</Patent><Status id="PRI">First Priority</Status><StatusDate>2010-07-15 00:00:00</StatusDate><StatusSortCode>1</StatusSortCode><TherapyArea id="129">Gastrointestinal disease</TherapyArea></Row><Row><Action id="14323">Angiopoietin ligand-2 inhibitor</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="US">US</Country><Drug id="71795">anti-Her-2/anti-Ang2 mAb (cancer), Zyngenia</Drug><DrugRelationship>Product</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Priority</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PRI</HighestPatStatusIdForCnty><Indication id="1781">Psoriatic arthritis</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA6726805">WO-2012009705</Patent><Status id="PRI">First Priority</Status><StatusDate>2010-07-15 00:00:00</StatusDate><StatusSortCode>1</StatusSortCode><TherapyArea id="185">Immune disorder</TherapyArea></Row><Row><Action id="14323">Angiopoietin ligand-2 inhibitor</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="US">US</Country><Drug id="71795">anti-Her-2/anti-Ang2 mAb (cancer), Zyngenia</Drug><DrugRelationship>Product</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Priority</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PRI</HighestPatStatusIdForCnty><Indication id="188">Inflammatory disease</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA6726805">WO-2012009705</Patent><Status id="PRI">First Priority</Status><StatusDate>2010-07-15 00:00:00</StatusDate><StatusSortCode>1</StatusSortCode><TherapyArea id="188">Inflammatory disease</TherapyArea></Row><Row><Action id="14323">Angiopoietin ligand-2 inhibitor</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="US">US</Country><Drug id="71795">anti-Her-2/anti-Ang2 mAb (cancer), Zyngenia</Drug><DrugRelationship>Product</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Priority</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PRI</HighestPatStatusIdForCnty><Indication id="189">Inflammatory bowel disease</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA6726805">WO-2012009705</Patent><Status id="PRI">First Priority</Status><StatusDate>2010-07-15 00:00:00</StatusDate><StatusSortCode>1</StatusSortCode><TherapyArea id="188">Inflammatory disease</TherapyArea></Row><Row><Action id="14323">Angiopoietin ligand-2 inhibitor</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="US">US</Country><Drug id="71795">anti-Her-2/anti-Ang2 mAb (cancer), Zyngenia</Drug><DrugRelationship>Product</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Priority</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PRI</HighestPatStatusIdForCnty><Indication id="291">Rheumatoid arthritis</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA6726805">WO-2012009705</Patent><Status id="PRI">First Priority</Status><StatusDate>2010-07-15 00:00:00</StatusDate><StatusSortCode>1</StatusSortCode><TherapyArea id="185">Immune disorder</TherapyArea></Row><Row><Action id="14323">Angiopoietin ligand-2 inhibitor</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="US">US</Country><Drug id="71795">anti-Her-2/anti-Ang2 mAb (cancer), Zyngenia</Drug><DrugRelationship>Product</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Priority</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PRI</HighestPatStatusIdForCnty><Indication id="3003">Juvenile rheumatoid arthritis</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA6726805">WO-2012009705</Patent><Status id="PRI">First Priority</Status><StatusDate>2010-07-15 00:00:00</StatusDate><StatusSortCode>1</StatusSortCode><TherapyArea id="185">Immune disorder</TherapyArea></Row><Row><Action id="14323">Angiopoietin ligand-2 inhibitor</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="US">US</Country><Drug id="71795">anti-Her-2/anti-Ang2 mAb (cancer), Zyngenia</Drug><DrugRelationship>Product</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Priority</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PRI</HighestPatStatusIdForCnty><Indication id="36">Autoimmune disease</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA6726805">WO-2012009705</Patent><Status id="PRI">First Priority</Status><StatusDate>2010-07-15 00:00:00</StatusDate><StatusSortCode>1</StatusSortCode><TherapyArea id="185">Immune disorder</TherapyArea></Row><Row><Action id="14323">Angiopoietin ligand-2 inhibitor</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="US">US</Country><Drug id="71795">anti-Her-2/anti-Ang2 mAb (cancer), Zyngenia</Drug><DrugRelationship>Product</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Priority</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PRI</HighestPatStatusIdForCnty><Indication id="651">Cancer</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA6726805">WO-2012009705</Patent><Status id="PRI">First Priority</Status><StatusDate>2010-07-15 00:00:00</StatusDate><StatusSortCode>1</StatusSortCode><TherapyArea id="230">Neoplasm</TherapyArea></Row><Row><Action id="14323">Angiopoietin ligand-2 inhibitor</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="US">US</Country><Drug id="71795">anti-Her-2/anti-Ang2 mAb (cancer), Zyngenia</Drug><DrugRelationship>Product</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Priority</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PRI</HighestPatStatusIdForCnty><Indication id="84">Crohns disease</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA6726805">WO-2012009705</Patent><Status id="PRI">First Priority</Status><StatusDate>2010-07-15 00:00:00</StatusDate><StatusSortCode>1</StatusSortCode><TherapyArea id="185">Immune disorder</TherapyArea></Row><Row><Action id="14323">Angiopoietin ligand-2 inhibitor</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="US">US</Country><Drug id="71795">anti-Her-2/anti-Ang2 mAb (cancer), Zyngenia</Drug><DrugRelationship>Product</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Priority</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PRI</HighestPatStatusIdForCnty><Indication id="989">Colorectal tumor</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA6726805">WO-2012009705</Patent><Status id="PRI">First Priority</Status><StatusDate>2010-07-15 00:00:00</StatusDate><StatusSortCode>1</StatusSortCode><TherapyArea id="129">Gastrointestinal disease</TherapyArea></Row><Row><Action id="3756">Erbb2 tyrosine kinase receptor inhibitor</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="US">US</Country><Drug id="71795">anti-Her-2/anti-Ang2 mAb (cancer), Zyngenia</Drug><DrugRelationship>Product</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Priority</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PRI</HighestPatStatusIdForCnty><Indication id="1781">Psoriatic arthritis</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA6726805">WO-2012009705</Patent><Status id="PRI">First Priority</Status><StatusDate>2010-07-15 00:00:00</StatusDate><StatusSortCode>1</StatusSortCode><TherapyArea id="185">Immune disorder</TherapyArea></Row><Row><Action id="3756">Erbb2 tyrosine kinase receptor inhibitor</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="US">US</Country><Drug id="71795">anti-Her-2/anti-Ang2 mAb (cancer), Zyngenia</Drug><DrugRelationship>Product</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Priority</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PRI</HighestPatStatusIdForCnty><Indication id="188">Inflammatory disease</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA6726805">WO-2012009705</Patent><Status id="PRI">First Priority</Status><StatusDate>2010-07-15 00:00:00</StatusDate><StatusSortCode>1</StatusSortCode><TherapyArea id="188">Inflammatory disease</TherapyArea></Row><Row><Action id="3756">Erbb2 tyrosine kinase receptor inhibitor</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="US">US</Country><Drug id="71795">anti-Her-2/anti-Ang2 mAb (cancer), Zyngenia</Drug><DrugRelationship>Product</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Priority</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PRI</HighestPatStatusIdForCnty><Indication id="189">Inflammatory bowel disease</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA6726805">WO-2012009705</Patent><Status id="PRI">First Priority</Status><StatusDate>2010-07-15 00:00:00</StatusDate><StatusSortCode>1</StatusSortCode><TherapyArea id="188">Inflammatory disease</TherapyArea></Row><Row><Action id="3756">Erbb2 tyrosine kinase receptor inhibitor</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="US">US</Country><Drug id="71795">anti-Her-2/anti-Ang2 mAb (cancer), Zyngenia</Drug><DrugRelationship>Product</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Priority</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PRI</HighestPatStatusIdForCnty><Indication id="291">Rheumatoid arthritis</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA6726805">WO-2012009705</Patent><Status id="PRI">First Priority</Status><StatusDate>2010-07-15 00:00:00</StatusDate><StatusSortCode>1</StatusSortCode><TherapyArea id="185">Immune disorder</TherapyArea></Row><Row><Action id="3756">Erbb2 tyrosine kinase receptor inhibitor</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="US">US</Country><Drug id="71795">anti-Her-2/anti-Ang2 mAb (cancer), Zyngenia</Drug><DrugRelationship>Product</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Priority</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PRI</HighestPatStatusIdForCnty><Indication id="3003">Juvenile rheumatoid arthritis</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA6726805">WO-2012009705</Patent><Status id="PRI">First Priority</Status><StatusDate>2010-07-15 00:00:00</StatusDate><StatusSortCode>1</StatusSortCode><TherapyArea id="185">Immune disorder</TherapyArea></Row><Row><Action id="3756">Erbb2 tyrosine kinase receptor inhibitor</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="US">US</Country><Drug id="71795">anti-Her-2/anti-Ang2 mAb (cancer), Zyngenia</Drug><DrugRelationship>Product</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Priority</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PRI</HighestPatStatusIdForCnty><Indication id="36">Autoimmune disease</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA6726805">WO-2012009705</Patent><Status id="PRI">First Priority</Status><StatusDate>2010-07-15 00:00:00</StatusDate><StatusSortCode>1</StatusSortCode><TherapyArea id="185">Immune disorder</TherapyArea></Row><Row><Action id="3756">Erbb2 tyrosine kinase receptor inhibitor</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="US">US</Country><Drug id="71795">anti-Her-2/anti-Ang2 mAb (cancer), Zyngenia</Drug><DrugRelationship>Product</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Priority</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PRI</HighestPatStatusIdForCnty><Indication id="651">Cancer</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA6726805">WO-2012009705</Patent><Status id="PRI">First Priority</Status><StatusDate>2010-07-15 00:00:00</StatusDate><StatusSortCode>1</StatusSortCode><TherapyArea id="230">Neoplasm</TherapyArea></Row><Row><Action id="3756">Erbb2 tyrosine kinase receptor inhibitor</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="US">US</Country><Drug id="71795">anti-Her-2/anti-Ang2 mAb (cancer), Zyngenia</Drug><DrugRelationship>Product</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Priority</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PRI</HighestPatStatusIdForCnty><Indication id="84">Crohns disease</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA6726805">WO-2012009705</Patent><Status id="PRI">First Priority</Status><StatusDate>2010-07-15 00:00:00</StatusDate><StatusSortCode>1</StatusSortCode><TherapyArea id="185">Immune disorder</TherapyArea></Row><Row><Action id="3756">Erbb2 tyrosine kinase receptor inhibitor</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="US">US</Country><Drug id="71795">anti-Her-2/anti-Ang2 mAb (cancer), Zyngenia</Drug><DrugRelationship>Product</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Priority</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PRI</HighestPatStatusIdForCnty><Indication id="989">Colorectal tumor</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA6726805">WO-2012009705</Patent><Status id="PRI">First Priority</Status><StatusDate>2010-07-15 00:00:00</StatusDate><StatusSortCode>1</StatusSortCode><TherapyArea id="129">Gastrointestinal disease</TherapyArea></Row><Row><Action id="381">TNF alpha ligand inhibitor</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="US">US</Country><Drug id="71795">anti-Her-2/anti-Ang2 mAb (cancer), Zyngenia</Drug><DrugRelationship>Product</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Priority</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PRI</HighestPatStatusIdForCnty><Indication id="1781">Psoriatic arthritis</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA6726805">WO-2012009705</Patent><Status id="PRI">First Priority</Status><StatusDate>2010-07-15 00:00:00</StatusDate><StatusSortCode>1</StatusSortCode><TherapyArea id="185">Immune disorder</TherapyArea></Row><Row><Action id="381">TNF alpha ligand inhibitor</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="US">US</Country><Drug id="71795">anti-Her-2/anti-Ang2 mAb (cancer), Zyngenia</Drug><DrugRelationship>Product</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Priority</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PRI</HighestPatStatusIdForCnty><Indication id="188">Inflammatory disease</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA6726805">WO-2012009705</Patent><Status id="PRI">First Priority</Status><StatusDate>2010-07-15 00:00:00</StatusDate><StatusSortCode>1</StatusSortCode><TherapyArea id="188">Inflammatory disease</TherapyArea></Row><Row><Action id="381">TNF alpha ligand inhibitor</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="US">US</Country><Drug id="71795">anti-Her-2/anti-Ang2 mAb (cancer), Zyngenia</Drug><DrugRelationship>Product</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Priority</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PRI</HighestPatStatusIdForCnty><Indication id="189">Inflammatory bowel disease</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA6726805">WO-2012009705</Patent><Status id="PRI">First Priority</Status><StatusDate>2010-07-15 00:00:00</StatusDate><StatusSortCode>1</StatusSortCode><TherapyArea id="188">Inflammatory disease</TherapyArea></Row><Row><Action id="381">TNF alpha ligand inhibitor</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="US">US</Country><Drug id="71795">anti-Her-2/anti-Ang2 mAb (cancer), Zyngenia</Drug><DrugRelationship>Product</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Priority</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PRI</HighestPatStatusIdForCnty><Indication id="291">Rheumatoid arthritis</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA6726805">WO-2012009705</Patent><Status id="PRI">First Priority</Status><StatusDate>2010-07-15 00:00:00</StatusDate><StatusSortCode>1</StatusSortCode><TherapyArea id="185">Immune disorder</TherapyArea></Row><Row><Action id="381">TNF alpha ligand inhibitor</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="US">US</Country><Drug id="71795">anti-Her-2/anti-Ang2 mAb (cancer), Zyngenia</Drug><DrugRelationship>Product</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Priority</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PRI</HighestPatStatusIdForCnty><Indication id="3003">Juvenile rheumatoid arthritis</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA6726805">WO-2012009705</Patent><Status id="PRI">First Priority</Status><StatusDate>2010-07-15 00:00:00</StatusDate><StatusSortCode>1</StatusSortCode><TherapyArea id="185">Immune disorder</TherapyArea></Row><Row><Action id="381">TNF alpha ligand inhibitor</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="US">US</Country><Drug id="71795">anti-Her-2/anti-Ang2 mAb (cancer), Zyngenia</Drug><DrugRelationship>Product</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Priority</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PRI</HighestPatStatusIdForCnty><Indication id="36">Autoimmune disease</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA6726805">WO-2012009705</Patent><Status id="PRI">First Priority</Status><StatusDate>2010-07-15 00:00:00</StatusDate><StatusSortCode>1</StatusSortCode><TherapyArea id="185">Immune disorder</TherapyArea></Row><Row><Action id="381">TNF alpha ligand inhibitor</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="US">US</Country><Drug id="71795">anti-Her-2/anti-Ang2 mAb (cancer), Zyngenia</Drug><DrugRelationship>Product</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Priority</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PRI</HighestPatStatusIdForCnty><Indication id="651">Cancer</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA6726805">WO-2012009705</Patent><Status id="PRI">First Priority</Status><StatusDate>2010-07-15 00:00:00</StatusDate><StatusSortCode>1</StatusSortCode><TherapyArea id="230">Neoplasm</TherapyArea></Row><Row><Action id="381">TNF alpha ligand inhibitor</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="US">US</Country><Drug id="71795">anti-Her-2/anti-Ang2 mAb (cancer), Zyngenia</Drug><DrugRelationship>Product</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Priority</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PRI</HighestPatStatusIdForCnty><Indication id="84">Crohns disease</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA6726805">WO-2012009705</Patent><Status id="PRI">First Priority</Status><StatusDate>2010-07-15 00:00:00</StatusDate><StatusSortCode>1</StatusSortCode><TherapyArea id="185">Immune disorder</TherapyArea></Row><Row><Action id="381">TNF alpha ligand inhibitor</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="US">US</Country><Drug id="71795">anti-Her-2/anti-Ang2 mAb (cancer), Zyngenia</Drug><DrugRelationship>Product</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Priority</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PRI</HighestPatStatusIdForCnty><Indication id="989">Colorectal tumor</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA6726805">WO-2012009705</Patent><Status id="PRI">First Priority</Status><StatusDate>2010-07-15 00:00:00</StatusDate><StatusSortCode>1</StatusSortCode><TherapyArea id="129">Gastrointestinal disease</TherapyArea></Row><Row><Action id="14323">Angiopoietin ligand-2 inhibitor</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="US">US</Country><Drug id="71794">adalimumab + anti-Ang2 Zybody (inflammatory disease), Zyngenia</Drug><DrugRelationship>Product</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Priority</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PRI</HighestPatStatusIdForCnty><Indication id="1781">Psoriatic arthritis</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA6726805">WO-2012009705</Patent><Status id="PRI">First Priority</Status><StatusDate>2010-07-15 00:00:00</StatusDate><StatusSortCode>1</StatusSortCode><TherapyArea id="185">Immune disorder</TherapyArea></Row><Row><Action id="14323">Angiopoietin ligand-2 inhibitor</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="US">US</Country><Drug id="71794">adalimumab + anti-Ang2 Zybody (inflammatory disease), Zyngenia</Drug><DrugRelationship>Product</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Priority</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PRI</HighestPatStatusIdForCnty><Indication id="188">Inflammatory disease</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA6726805">WO-2012009705</Patent><Status id="PRI">First Priority</Status><StatusDate>2010-07-15 00:00:00</StatusDate><StatusSortCode>1</StatusSortCode><TherapyArea id="188">Inflammatory disease</TherapyArea></Row><Row><Action id="14323">Angiopoietin ligand-2 inhibitor</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="US">US</Country><Drug id="71794">adalimumab + anti-Ang2 Zybody (inflammatory disease), Zyngenia</Drug><DrugRelationship>Product</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Priority</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PRI</HighestPatStatusIdForCnty><Indication id="189">Inflammatory bowel disease</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA6726805">WO-2012009705</Patent><Status id="PRI">First Priority</Status><StatusDate>2010-07-15 00:00:00</StatusDate><StatusSortCode>1</StatusSortCode><TherapyArea id="188">Inflammatory disease</TherapyArea></Row><Row><Action id="14323">Angiopoietin ligand-2 inhibitor</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="US">US</Country><Drug id="71794">adalimumab + anti-Ang2 Zybody (inflammatory disease), Zyngenia</Drug><DrugRelationship>Product</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Priority</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PRI</HighestPatStatusIdForCnty><Indication id="291">Rheumatoid arthritis</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA6726805">WO-2012009705</Patent><Status id="PRI">First Priority</Status><StatusDate>2010-07-15 00:00:00</StatusDate><StatusSortCode>1</StatusSortCode><TherapyArea id="185">Immune disorder</TherapyArea></Row><Row><Action id="14323">Angiopoietin ligand-2 inhibitor</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="US">US</Country><Drug id="71794">adalimumab + anti-Ang2 Zybody (inflammatory disease), Zyngenia</Drug><DrugRelationship>Product</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Priority</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PRI</HighestPatStatusIdForCnty><Indication id="3003">Juvenile rheumatoid arthritis</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA6726805">WO-2012009705</Patent><Status id="PRI">First Priority</Status><StatusDate>2010-07-15 00:00:00</StatusDate><StatusSortCode>1</StatusSortCode><TherapyArea id="185">Immune disorder</TherapyArea></Row><Row><Action id="14323">Angiopoietin ligand-2 inhibitor</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="US">US</Country><Drug id="71794">adalimumab + anti-Ang2 Zybody (inflammatory disease), Zyngenia</Drug><DrugRelationship>Product</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Priority</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PRI</HighestPatStatusIdForCnty><Indication id="36">Autoimmune disease</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA6726805">WO-2012009705</Patent><Status id="PRI">First Priority</Status><StatusDate>2010-07-15 00:00:00</StatusDate><StatusSortCode>1</StatusSortCode><TherapyArea id="185">Immune disorder</TherapyArea></Row><Row><Action id="14323">Angiopoietin ligand-2 inhibitor</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="US">US</Country><Drug id="71794">adalimumab + anti-Ang2 Zybody (inflammatory disease), Zyngenia</Drug><DrugRelationship>Product</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Priority</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PRI</HighestPatStatusIdForCnty><Indication id="651">Cancer</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA6726805">WO-2012009705</Patent><Status id="PRI">First Priority</Status><StatusDate>2010-07-15 00:00:00</StatusDate><StatusSortCode>1</StatusSortCode><TherapyArea id="230">Neoplasm</TherapyArea></Row><Row><Action id="14323">Angiopoietin ligand-2 inhibitor</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="US">US</Country><Drug id="71794">adalimumab + anti-Ang2 Zybody (inflammatory disease), Zyngenia</Drug><DrugRelationship>Product</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Priority</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PRI</HighestPatStatusIdForCnty><Indication id="84">Crohns disease</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA6726805">WO-2012009705</Patent><Status id="PRI">First Priority</Status><StatusDate>2010-07-15 00:00:00</StatusDate><StatusSortCode>1</StatusSortCode><TherapyArea id="185">Immune disorder</TherapyArea></Row><Row><Action id="14323">Angiopoietin ligand-2 inhibitor</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="US">US</Country><Drug id="71794">adalimumab + anti-Ang2 Zybody (inflammatory disease), Zyngenia</Drug><DrugRelationship>Product</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Priority</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PRI</HighestPatStatusIdForCnty><Indication id="989">Colorectal tumor</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA6726805">WO-2012009705</Patent><Status id="PRI">First Priority</Status><StatusDate>2010-07-15 00:00:00</StatusDate><StatusSortCode>1</StatusSortCode><TherapyArea id="129">Gastrointestinal disease</TherapyArea></Row><Row><Action id="3756">Erbb2 tyrosine kinase receptor inhibitor</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="US">US</Country><Drug id="71794">adalimumab + anti-Ang2 Zybody (inflammatory disease), Zyngenia</Drug><DrugRelationship>Product</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Priority</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PRI</HighestPatStatusIdForCnty><Indication id="1781">Psoriatic arthritis</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA6726805">WO-2012009705</Patent><Status id="PRI">First Priority</Status><StatusDate>2010-07-15 00:00:00</StatusDate><StatusSortCode>1</StatusSortCode><TherapyArea id="185">Immune disorder</TherapyArea></Row><Row><Action id="3756">Erbb2 tyrosine kinase receptor inhibitor</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="US">US</Country><Drug id="71794">adalimumab + anti-Ang2 Zybody (inflammatory disease), Zyngenia</Drug><DrugRelationship>Product</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Priority</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PRI</HighestPatStatusIdForCnty><Indication id="188">Inflammatory disease</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA6726805">WO-2012009705</Patent><Status id="PRI">First Priority</Status><StatusDate>2010-07-15 00:00:00</StatusDate><StatusSortCode>1</StatusSortCode><TherapyArea id="188">Inflammatory disease</TherapyArea></Row><Row><Action id="3756">Erbb2 tyrosine kinase receptor inhibitor</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="US">US</Country><Drug id="71794">adalimumab + anti-Ang2 Zybody (inflammatory disease), Zyngenia</Drug><DrugRelationship>Product</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Priority</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PRI</HighestPatStatusIdForCnty><Indication id="189">Inflammatory bowel disease</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA6726805">WO-2012009705</Patent><Status id="PRI">First Priority</Status><StatusDate>2010-07-15 00:00:00</StatusDate><StatusSortCode>1</StatusSortCode><TherapyArea id="188">Inflammatory disease</TherapyArea></Row><Row><Action id="3756">Erbb2 tyrosine kinase receptor inhibitor</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="US">US</Country><Drug id="71794">adalimumab + anti-Ang2 Zybody (inflammatory disease), Zyngenia</Drug><DrugRelationship>Product</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Priority</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PRI</HighestPatStatusIdForCnty><Indication id="291">Rheumatoid arthritis</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA6726805">WO-2012009705</Patent><Status id="PRI">First Priority</Status><StatusDate>2010-07-15 00:00:00</StatusDate><StatusSortCode>1</StatusSortCode><TherapyArea id="185">Immune disorder</TherapyArea></Row><Row><Action id="3756">Erbb2 tyrosine kinase receptor inhibitor</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="US">US</Country><Drug id="71794">adalimumab + anti-Ang2 Zybody (inflammatory disease), Zyngenia</Drug><DrugRelationship>Product</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Priority</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PRI</HighestPatStatusIdForCnty><Indication id="3003">Juvenile rheumatoid arthritis</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA6726805">WO-2012009705</Patent><Status id="PRI">First Priority</Status><StatusDate>2010-07-15 00:00:00</StatusDate><StatusSortCode>1</StatusSortCode><TherapyArea id="185">Immune disorder</TherapyArea></Row><Row><Action id="3756">Erbb2 tyrosine kinase receptor inhibitor</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="US">US</Country><Drug id="71794">adalimumab + anti-Ang2 Zybody (inflammatory disease), Zyngenia</Drug><DrugRelationship>Product</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Priority</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PRI</HighestPatStatusIdForCnty><Indication id="36">Autoimmune disease</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA6726805">WO-2012009705</Patent><Status id="PRI">First Priority</Status><StatusDate>2010-07-15 00:00:00</StatusDate><StatusSortCode>1</StatusSortCode><TherapyArea id="185">Immune disorder</TherapyArea></Row><Row><Action id="3756">Erbb2 tyrosine kinase receptor inhibitor</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="US">US</Country><Drug id="71794">adalimumab + anti-Ang2 Zybody (inflammatory disease), Zyngenia</Drug><DrugRelationship>Product</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Priority</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PRI</HighestPatStatusIdForCnty><Indication id="651">Cancer</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA6726805">WO-2012009705</Patent><Status id="PRI">First Priority</Status><StatusDate>2010-07-15 00:00:00</StatusDate><StatusSortCode>1</StatusSortCode><TherapyArea id="230">Neoplasm</TherapyArea></Row><Row><Action id="3756">Erbb2 tyrosine kinase receptor inhibitor</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="US">US</Country><Drug id="71794">adalimumab + anti-Ang2 Zybody (inflammatory disease), Zyngenia</Drug><DrugRelationship>Product</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Priority</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PRI</HighestPatStatusIdForCnty><Indication id="84">Crohns disease</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA6726805">WO-2012009705</Patent><Status id="PRI">First Priority</Status><StatusDate>2010-07-15 00:00:00</StatusDate><StatusSortCode>1</StatusSortCode><TherapyArea id="185">Immune disorder</TherapyArea></Row><Row><Action id="3756">Erbb2 tyrosine kinase receptor inhibitor</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="US">US</Country><Drug id="71794">adalimumab + anti-Ang2 Zybody (inflammatory disease), Zyngenia</Drug><DrugRelationship>Product</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Priority</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PRI</HighestPatStatusIdForCnty><Indication id="989">Colorectal tumor</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA6726805">WO-2012009705</Patent><Status id="PRI">First Priority</Status><StatusDate>2010-07-15 00:00:00</StatusDate><StatusSortCode>1</StatusSortCode><TherapyArea id="129">Gastrointestinal disease</TherapyArea></Row><Row><Action id="381">TNF alpha ligand inhibitor</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="US">US</Country><Drug id="71794">adalimumab + anti-Ang2 Zybody (inflammatory disease), Zyngenia</Drug><DrugRelationship>Product</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Priority</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PRI</HighestPatStatusIdForCnty><Indication id="1781">Psoriatic arthritis</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA6726805">WO-2012009705</Patent><Status id="PRI">First Priority</Status><StatusDate>2010-07-15 00:00:00</StatusDate><StatusSortCode>1</StatusSortCode><TherapyArea id="185">Immune disorder</TherapyArea></Row><Row><Action id="381">TNF alpha ligand inhibitor</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="US">US</Country><Drug id="71794">adalimumab + anti-Ang2 Zybody (inflammatory disease), Zyngenia</Drug><DrugRelationship>Product</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Priority</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PRI</HighestPatStatusIdForCnty><Indication id="188">Inflammatory disease</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA6726805">WO-2012009705</Patent><Status id="PRI">First Priority</Status><StatusDate>2010-07-15 00:00:00</StatusDate><StatusSortCode>1</StatusSortCode><TherapyArea id="188">Inflammatory disease</TherapyArea></Row><Row><Action id="381">TNF alpha ligand inhibitor</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="US">US</Country><Drug id="71794">adalimumab + anti-Ang2 Zybody (inflammatory disease), Zyngenia</Drug><DrugRelationship>Product</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Priority</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PRI</HighestPatStatusIdForCnty><Indication id="189">Inflammatory bowel disease</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA6726805">WO-2012009705</Patent><Status id="PRI">First Priority</Status><StatusDate>2010-07-15 00:00:00</StatusDate><StatusSortCode>1</StatusSortCode><TherapyArea id="188">Inflammatory disease</TherapyArea></Row><Row><Action id="381">TNF alpha ligand inhibitor</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="US">US</Country><Drug id="71794">adalimumab + anti-Ang2 Zybody (inflammatory disease), Zyngenia</Drug><DrugRelationship>Product</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Priority</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PRI</HighestPatStatusIdForCnty><Indication id="291">Rheumatoid arthritis</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA6726805">WO-2012009705</Patent><Status id="PRI">First Priority</Status><StatusDate>2010-07-15 00:00:00</StatusDate><StatusSortCode>1</StatusSortCode><TherapyArea id="185">Immune disorder</TherapyArea></Row><Row><Action id="381">TNF alpha ligand inhibitor</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="US">US</Country><Drug id="71794">adalimumab + anti-Ang2 Zybody (inflammatory disease), Zyngenia</Drug><DrugRelationship>Product</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Priority</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PRI</HighestPatStatusIdForCnty><Indication id="3003">Juvenile rheumatoid arthritis</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA6726805">WO-2012009705</Patent><Status id="PRI">First Priority</Status><StatusDate>2010-07-15 00:00:00</StatusDate><StatusSortCode>1</StatusSortCode><TherapyArea id="185">Immune disorder</TherapyArea></Row><Row><Action id="381">TNF alpha ligand inhibitor</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="US">US</Country><Drug id="71794">adalimumab + anti-Ang2 Zybody (inflammatory disease), Zyngenia</Drug><DrugRelationship>Product</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Priority</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PRI</HighestPatStatusIdForCnty><Indication id="36">Autoimmune disease</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA6726805">WO-2012009705</Patent><Status id="PRI">First Priority</Status><StatusDate>2010-07-15 00:00:00</StatusDate><StatusSortCode>1</StatusSortCode><TherapyArea id="185">Immune disorder</TherapyArea></Row><Row><Action id="381">TNF alpha ligand inhibitor</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="US">US</Country><Drug id="71794">adalimumab + anti-Ang2 Zybody (inflammatory disease), Zyngenia</Drug><DrugRelationship>Product</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Priority</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PRI</HighestPatStatusIdForCnty><Indication id="651">Cancer</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA6726805">WO-2012009705</Patent><Status id="PRI">First Priority</Status><StatusDate>2010-07-15 00:00:00</StatusDate><StatusSortCode>1</StatusSortCode><TherapyArea id="230">Neoplasm</TherapyArea></Row><Row><Action id="381">TNF alpha ligand inhibitor</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="US">US</Country><Drug id="71794">adalimumab + anti-Ang2 Zybody (inflammatory disease), Zyngenia</Drug><DrugRelationship>Product</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Priority</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PRI</HighestPatStatusIdForCnty><Indication id="84">Crohns disease</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA6726805">WO-2012009705</Patent><Status id="PRI">First Priority</Status><StatusDate>2010-07-15 00:00:00</StatusDate><StatusSortCode>1</StatusSortCode><TherapyArea id="185">Immune disorder</TherapyArea></Row><Row><Action id="381">TNF alpha ligand inhibitor</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="US">US</Country><Drug id="71794">adalimumab + anti-Ang2 Zybody (inflammatory disease), Zyngenia</Drug><DrugRelationship>Product</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Priority</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PRI</HighestPatStatusIdForCnty><Indication id="989">Colorectal tumor</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA6726805">WO-2012009705</Patent><Status id="PRI">First Priority</Status><StatusDate>2010-07-15 00:00:00</StatusDate><StatusSortCode>1</StatusSortCode><TherapyArea id="129">Gastrointestinal disease</TherapyArea></Row><Row><Action id="14323">Angiopoietin ligand-2 inhibitor</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="US">US</Country><Drug id="71795">anti-Her-2/anti-Ang2 mAb (cancer), Zyngenia</Drug><DrugRelationship>Product</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Priority</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PRI</HighestPatStatusIdForCnty><Indication id="1781">Psoriatic arthritis</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA6726805">WO-2012009705</Patent><Status id="PRI">First Priority</Status><StatusDate>2010-07-15 00:00:00</StatusDate><StatusSortCode>1</StatusSortCode><TherapyArea id="185">Immune disorder</TherapyArea></Row><Row><Action id="14323">Angiopoietin ligand-2 inhibitor</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="US">US</Country><Drug id="71795">anti-Her-2/anti-Ang2 mAb (cancer), Zyngenia</Drug><DrugRelationship>Product</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Priority</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PRI</HighestPatStatusIdForCnty><Indication id="188">Inflammatory disease</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA6726805">WO-2012009705</Patent><Status id="PRI">First Priority</Status><StatusDate>2010-07-15 00:00:00</StatusDate><StatusSortCode>1</StatusSortCode><TherapyArea id="188">Inflammatory disease</TherapyArea></Row><Row><Action id="14323">Angiopoietin ligand-2 inhibitor</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="US">US</Country><Drug id="71795">anti-Her-2/anti-Ang2 mAb (cancer), Zyngenia</Drug><DrugRelationship>Product</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Priority</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PRI</HighestPatStatusIdForCnty><Indication id="189">Inflammatory bowel disease</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA6726805">WO-2012009705</Patent><Status id="PRI">First Priority</Status><StatusDate>2010-07-15 00:00:00</StatusDate><StatusSortCode>1</StatusSortCode><TherapyArea id="188">Inflammatory disease</TherapyArea></Row><Row><Action id="14323">Angiopoietin ligand-2 inhibitor</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="US">US</Country><Drug id="71795">anti-Her-2/anti-Ang2 mAb (cancer), Zyngenia</Drug><DrugRelationship>Product</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Priority</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PRI</HighestPatStatusIdForCnty><Indication id="291">Rheumatoid arthritis</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA6726805">WO-2012009705</Patent><Status id="PRI">First Priority</Status><StatusDate>2010-07-15 00:00:00</StatusDate><StatusSortCode>1</StatusSortCode><TherapyArea id="185">Immune disorder</TherapyArea></Row><Row><Action id="14323">Angiopoietin ligand-2 inhibitor</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="US">US</Country><Drug id="71795">anti-Her-2/anti-Ang2 mAb (cancer), Zyngenia</Drug><DrugRelationship>Product</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Priority</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PRI</HighestPatStatusIdForCnty><Indication id="3003">Juvenile rheumatoid arthritis</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA6726805">WO-2012009705</Patent><Status id="PRI">First Priority</Status><StatusDate>2010-07-15 00:00:00</StatusDate><StatusSortCode>1</StatusSortCode><TherapyArea id="185">Immune disorder</TherapyArea></Row><Row><Action id="14323">Angiopoietin ligand-2 inhibitor</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="US">US</Country><Drug id="71795">anti-Her-2/anti-Ang2 mAb (cancer), Zyngenia</Drug><DrugRelationship>Product</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Priority</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PRI</HighestPatStatusIdForCnty><Indication id="36">Autoimmune disease</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA6726805">WO-2012009705</Patent><Status id="PRI">First Priority</Status><StatusDate>2010-07-15 00:00:00</StatusDate><StatusSortCode>1</StatusSortCode><TherapyArea id="185">Immune disorder</TherapyArea></Row><Row><Action id="14323">Angiopoietin ligand-2 inhibitor</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="US">US</Country><Drug id="71795">anti-Her-2/anti-Ang2 mAb (cancer), Zyngenia</Drug><DrugRelationship>Product</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Priority</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PRI</HighestPatStatusIdForCnty><Indication id="651">Cancer</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA6726805">WO-2012009705</Patent><Status id="PRI">First Priority</Status><StatusDate>2010-07-15 00:00:00</StatusDate><StatusSortCode>1</StatusSortCode><TherapyArea id="230">Neoplasm</TherapyArea></Row><Row><Action id="14323">Angiopoietin ligand-2 inhibitor</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="US">US</Country><Drug id="71795">anti-Her-2/anti-Ang2 mAb (cancer), Zyngenia</Drug><DrugRelationship>Product</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Priority</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PRI</HighestPatStatusIdForCnty><Indication id="84">Crohns disease</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA6726805">WO-2012009705</Patent><Status id="PRI">First Priority</Status><StatusDate>2010-07-15 00:00:00</StatusDate><StatusSortCode>1</StatusSortCode><TherapyArea id="185">Immune disorder</TherapyArea></Row><Row><Action id="14323">Angiopoietin ligand-2 inhibitor</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="US">US</Country><Drug id="71795">anti-Her-2/anti-Ang2 mAb (cancer), Zyngenia</Drug><DrugRelationship>Product</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Priority</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PRI</HighestPatStatusIdForCnty><Indication id="989">Colorectal tumor</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA6726805">WO-2012009705</Patent><Status id="PRI">First Priority</Status><StatusDate>2010-07-15 00:00:00</StatusDate><StatusSortCode>1</StatusSortCode><TherapyArea id="129">Gastrointestinal disease</TherapyArea></Row><Row><Action id="3756">Erbb2 tyrosine kinase receptor inhibitor</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="US">US</Country><Drug id="71795">anti-Her-2/anti-Ang2 mAb (cancer), Zyngenia</Drug><DrugRelationship>Product</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Priority</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PRI</HighestPatStatusIdForCnty><Indication id="1781">Psoriatic arthritis</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA6726805">WO-2012009705</Patent><Status id="PRI">First Priority</Status><StatusDate>2010-07-15 00:00:00</StatusDate><StatusSortCode>1</StatusSortCode><TherapyArea id="185">Immune disorder</TherapyArea></Row><Row><Action id="3756">Erbb2 tyrosine kinase receptor inhibitor</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="US">US</Country><Drug id="71795">anti-Her-2/anti-Ang2 mAb (cancer), Zyngenia</Drug><DrugRelationship>Product</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Priority</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PRI</HighestPatStatusIdForCnty><Indication id="188">Inflammatory disease</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA6726805">WO-2012009705</Patent><Status id="PRI">First Priority</Status><StatusDate>2010-07-15 00:00:00</StatusDate><StatusSortCode>1</StatusSortCode><TherapyArea id="188">Inflammatory disease</TherapyArea></Row><Row><Action id="3756">Erbb2 tyrosine kinase receptor inhibitor</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="US">US</Country><Drug id="71795">anti-Her-2/anti-Ang2 mAb (cancer), Zyngenia</Drug><DrugRelationship>Product</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Priority</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PRI</HighestPatStatusIdForCnty><Indication id="189">Inflammatory bowel disease</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA6726805">WO-2012009705</Patent><Status id="PRI">First Priority</Status><StatusDate>2010-07-15 00:00:00</StatusDate><StatusSortCode>1</StatusSortCode><TherapyArea id="188">Inflammatory disease</TherapyArea></Row><Row><Action id="3756">Erbb2 tyrosine kinase receptor inhibitor</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="US">US</Country><Drug id="71795">anti-Her-2/anti-Ang2 mAb (cancer), Zyngenia</Drug><DrugRelationship>Product</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Priority</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PRI</HighestPatStatusIdForCnty><Indication id="291">Rheumatoid arthritis</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA6726805">WO-2012009705</Patent><Status id="PRI">First Priority</Status><StatusDate>2010-07-15 00:00:00</StatusDate><StatusSortCode>1</StatusSortCode><TherapyArea id="185">Immune disorder</TherapyArea></Row><Row><Action id="3756">Erbb2 tyrosine kinase receptor inhibitor</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="US">US</Country><Drug id="71795">anti-Her-2/anti-Ang2 mAb (cancer), Zyngenia</Drug><DrugRelationship>Product</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Priority</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PRI</HighestPatStatusIdForCnty><Indication id="3003">Juvenile rheumatoid arthritis</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA6726805">WO-2012009705</Patent><Status id="PRI">First Priority</Status><StatusDate>2010-07-15 00:00:00</StatusDate><StatusSortCode>1</StatusSortCode><TherapyArea id="185">Immune disorder</TherapyArea></Row><Row><Action id="3756">Erbb2 tyrosine kinase receptor inhibitor</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="US">US</Country><Drug id="71795">anti-Her-2/anti-Ang2 mAb (cancer), Zyngenia</Drug><DrugRelationship>Product</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Priority</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PRI</HighestPatStatusIdForCnty><Indication id="36">Autoimmune disease</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA6726805">WO-2012009705</Patent><Status id="PRI">First Priority</Status><StatusDate>2010-07-15 00:00:00</StatusDate><StatusSortCode>1</StatusSortCode><TherapyArea id="185">Immune disorder</TherapyArea></Row><Row><Action id="3756">Erbb2 tyrosine kinase receptor inhibitor</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="US">US</Country><Drug id="71795">anti-Her-2/anti-Ang2 mAb (cancer), Zyngenia</Drug><DrugRelationship>Product</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Priority</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PRI</HighestPatStatusIdForCnty><Indication id="651">Cancer</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA6726805">WO-2012009705</Patent><Status id="PRI">First Priority</Status><StatusDate>2010-07-15 00:00:00</StatusDate><StatusSortCode>1</StatusSortCode><TherapyArea id="230">Neoplasm</TherapyArea></Row><Row><Action id="3756">Erbb2 tyrosine kinase receptor inhibitor</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="US">US</Country><Drug id="71795">anti-Her-2/anti-Ang2 mAb (cancer), Zyngenia</Drug><DrugRelationship>Product</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Priority</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PRI</HighestPatStatusIdForCnty><Indication id="84">Crohns disease</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA6726805">WO-2012009705</Patent><Status id="PRI">First Priority</Status><StatusDate>2010-07-15 00:00:00</StatusDate><StatusSortCode>1</StatusSortCode><TherapyArea id="185">Immune disorder</TherapyArea></Row><Row><Action id="3756">Erbb2 tyrosine kinase receptor inhibitor</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="US">US</Country><Drug id="71795">anti-Her-2/anti-Ang2 mAb (cancer), Zyngenia</Drug><DrugRelationship>Product</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Priority</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PRI</HighestPatStatusIdForCnty><Indication id="989">Colorectal tumor</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA6726805">WO-2012009705</Patent><Status id="PRI">First Priority</Status><StatusDate>2010-07-15 00:00:00</StatusDate><StatusSortCode>1</StatusSortCode><TherapyArea id="129">Gastrointestinal disease</TherapyArea></Row><Row><Action id="381">TNF alpha ligand inhibitor</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="US">US</Country><Drug id="71795">anti-Her-2/anti-Ang2 mAb (cancer), Zyngenia</Drug><DrugRelationship>Product</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Priority</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PRI</HighestPatStatusIdForCnty><Indication id="1781">Psoriatic arthritis</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA6726805">WO-2012009705</Patent><Status id="PRI">First Priority</Status><StatusDate>2010-07-15 00:00:00</StatusDate><StatusSortCode>1</StatusSortCode><TherapyArea id="185">Immune disorder</TherapyArea></Row><Row><Action id="381">TNF alpha ligand inhibitor</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="US">US</Country><Drug id="71795">anti-Her-2/anti-Ang2 mAb (cancer), Zyngenia</Drug><DrugRelationship>Product</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Priority</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PRI</HighestPatStatusIdForCnty><Indication id="188">Inflammatory disease</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA6726805">WO-2012009705</Patent><Status id="PRI">First Priority</Status><StatusDate>2010-07-15 00:00:00</StatusDate><StatusSortCode>1</StatusSortCode><TherapyArea id="188">Inflammatory disease</TherapyArea></Row><Row><Action id="381">TNF alpha ligand inhibitor</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="US">US</Country><Drug id="71795">anti-Her-2/anti-Ang2 mAb (cancer), Zyngenia</Drug><DrugRelationship>Product</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Priority</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PRI</HighestPatStatusIdForCnty><Indication id="189">Inflammatory bowel disease</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA6726805">WO-2012009705</Patent><Status id="PRI">First Priority</Status><StatusDate>2010-07-15 00:00:00</StatusDate><StatusSortCode>1</StatusSortCode><TherapyArea id="188">Inflammatory disease</TherapyArea></Row><Row><Action id="381">TNF alpha ligand inhibitor</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="US">US</Country><Drug id="71795">anti-Her-2/anti-Ang2 mAb (cancer), Zyngenia</Drug><DrugRelationship>Product</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Priority</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PRI</HighestPatStatusIdForCnty><Indication id="291">Rheumatoid arthritis</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA6726805">WO-2012009705</Patent><Status id="PRI">First Priority</Status><StatusDate>2010-07-15 00:00:00</StatusDate><StatusSortCode>1</StatusSortCode><TherapyArea id="185">Immune disorder</TherapyArea></Row><Row><Action id="381">TNF alpha ligand inhibitor</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="US">US</Country><Drug id="71795">anti-Her-2/anti-Ang2 mAb (cancer), Zyngenia</Drug><DrugRelationship>Product</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Priority</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PRI</HighestPatStatusIdForCnty><Indication id="3003">Juvenile rheumatoid arthritis</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA6726805">WO-2012009705</Patent><Status id="PRI">First Priority</Status><StatusDate>2010-07-15 00:00:00</StatusDate><StatusSortCode>1</StatusSortCode><TherapyArea id="185">Immune disorder</TherapyArea></Row><Row><Action id="381">TNF alpha ligand inhibitor</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="US">US</Country><Drug id="71795">anti-Her-2/anti-Ang2 mAb (cancer), Zyngenia</Drug><DrugRelationship>Product</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Priority</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PRI</HighestPatStatusIdForCnty><Indication id="36">Autoimmune disease</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA6726805">WO-2012009705</Patent><Status id="PRI">First Priority</Status><StatusDate>2010-07-15 00:00:00</StatusDate><StatusSortCode>1</StatusSortCode><TherapyArea id="185">Immune disorder</TherapyArea></Row><Row><Action id="381">TNF alpha ligand inhibitor</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="US">US</Country><Drug id="71795">anti-Her-2/anti-Ang2 mAb (cancer), Zyngenia</Drug><DrugRelationship>Product</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Priority</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PRI</HighestPatStatusIdForCnty><Indication id="651">Cancer</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA6726805">WO-2012009705</Patent><Status id="PRI">First Priority</Status><StatusDate>2010-07-15 00:00:00</StatusDate><StatusSortCode>1</StatusSortCode><TherapyArea id="230">Neoplasm</TherapyArea></Row><Row><Action id="381">TNF alpha ligand inhibitor</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="US">US</Country><Drug id="71795">anti-Her-2/anti-Ang2 mAb (cancer), Zyngenia</Drug><DrugRelationship>Product</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Priority</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PRI</HighestPatStatusIdForCnty><Indication id="84">Crohns disease</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA6726805">WO-2012009705</Patent><Status id="PRI">First Priority</Status><StatusDate>2010-07-15 00:00:00</StatusDate><StatusSortCode>1</StatusSortCode><TherapyArea id="185">Immune disorder</TherapyArea></Row><Row><Action id="381">TNF alpha ligand inhibitor</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="US">US</Country><Drug id="71795">anti-Her-2/anti-Ang2 mAb (cancer), Zyngenia</Drug><DrugRelationship>Product</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Priority</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PRI</HighestPatStatusIdForCnty><Indication id="989">Colorectal tumor</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA6726805">WO-2012009705</Patent><Status id="PRI">First Priority</Status><StatusDate>2010-07-15 00:00:00</StatusDate><StatusSortCode>1</StatusSortCode><TherapyArea id="129">Gastrointestinal disease</TherapyArea></Row><Row><Action id="14323">Angiopoietin ligand-2 inhibitor</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="US">US</Country><Drug id="71794">adalimumab + anti-Ang2 Zybody (inflammatory disease), Zyngenia</Drug><DrugRelationship>Product</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Priority</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PRI</HighestPatStatusIdForCnty><Indication id="1781">Psoriatic arthritis</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA6726805">WO-2012009705</Patent><Status id="PRI">First Priority</Status><StatusDate>2010-07-15 00:00:00</StatusDate><StatusSortCode>1</StatusSortCode><TherapyArea id="185">Immune disorder</TherapyArea></Row><Row><Action id="14323">Angiopoietin ligand-2 inhibitor</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="US">US</Country><Drug id="71794">adalimumab + anti-Ang2 Zybody (inflammatory disease), Zyngenia</Drug><DrugRelationship>Product</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Priority</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PRI</HighestPatStatusIdForCnty><Indication id="188">Inflammatory disease</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA6726805">WO-2012009705</Patent><Status id="PRI">First Priority</Status><StatusDate>2010-07-15 00:00:00</StatusDate><StatusSortCode>1</StatusSortCode><TherapyArea id="188">Inflammatory disease</TherapyArea></Row><Row><Action id="14323">Angiopoietin ligand-2 inhibitor</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="US">US</Country><Drug id="71794">adalimumab + anti-Ang2 Zybody (inflammatory disease), Zyngenia</Drug><DrugRelationship>Product</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Priority</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PRI</HighestPatStatusIdForCnty><Indication id="189">Inflammatory bowel disease</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA6726805">WO-2012009705</Patent><Status id="PRI">First Priority</Status><StatusDate>2010-07-15 00:00:00</StatusDate><StatusSortCode>1</StatusSortCode><TherapyArea id="188">Inflammatory disease</TherapyArea></Row><Row><Action id="14323">Angiopoietin ligand-2 inhibitor</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="US">US</Country><Drug id="71794">adalimumab + anti-Ang2 Zybody (inflammatory disease), Zyngenia</Drug><DrugRelationship>Product</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Priority</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PRI</HighestPatStatusIdForCnty><Indication id="291">Rheumatoid arthritis</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA6726805">WO-2012009705</Patent><Status id="PRI">First Priority</Status><StatusDate>2010-07-15 00:00:00</StatusDate><StatusSortCode>1</StatusSortCode><TherapyArea id="185">Immune disorder</TherapyArea></Row><Row><Action id="14323">Angiopoietin ligand-2 inhibitor</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="US">US</Country><Drug id="71794">adalimumab + anti-Ang2 Zybody (inflammatory disease), Zyngenia</Drug><DrugRelationship>Product</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Priority</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PRI</HighestPatStatusIdForCnty><Indication id="3003">Juvenile rheumatoid arthritis</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA6726805">WO-2012009705</Patent><Status id="PRI">First Priority</Status><StatusDate>2010-07-15 00:00:00</StatusDate><StatusSortCode>1</StatusSortCode><TherapyArea id="185">Immune disorder</TherapyArea></Row><Row><Action id="14323">Angiopoietin ligand-2 inhibitor</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="US">US</Country><Drug id="71794">adalimumab + anti-Ang2 Zybody (inflammatory disease), Zyngenia</Drug><DrugRelationship>Product</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Priority</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PRI</HighestPatStatusIdForCnty><Indication id="36">Autoimmune disease</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA6726805">WO-2012009705</Patent><Status id="PRI">First Priority</Status><StatusDate>2010-07-15 00:00:00</StatusDate><StatusSortCode>1</StatusSortCode><TherapyArea id="185">Immune disorder</TherapyArea></Row><Row><Action id="14323">Angiopoietin ligand-2 inhibitor</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="US">US</Country><Drug id="71794">adalimumab + anti-Ang2 Zybody (inflammatory disease), Zyngenia</Drug><DrugRelationship>Product</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Priority</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PRI</HighestPatStatusIdForCnty><Indication id="651">Cancer</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA6726805">WO-2012009705</Patent><Status id="PRI">First Priority</Status><StatusDate>2010-07-15 00:00:00</StatusDate><StatusSortCode>1</StatusSortCode><TherapyArea id="230">Neoplasm</TherapyArea></Row><Row><Action id="14323">Angiopoietin ligand-2 inhibitor</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="US">US</Country><Drug id="71794">adalimumab + anti-Ang2 Zybody (inflammatory disease), Zyngenia</Drug><DrugRelationship>Product</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Priority</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PRI</HighestPatStatusIdForCnty><Indication id="84">Crohns disease</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA6726805">WO-2012009705</Patent><Status id="PRI">First Priority</Status><StatusDate>2010-07-15 00:00:00</StatusDate><StatusSortCode>1</StatusSortCode><TherapyArea id="185">Immune disorder</TherapyArea></Row><Row><Action id="14323">Angiopoietin ligand-2 inhibitor</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="US">US</Country><Drug id="71794">adalimumab + anti-Ang2 Zybody (inflammatory disease), Zyngenia</Drug><DrugRelationship>Product</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Priority</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PRI</HighestPatStatusIdForCnty><Indication id="989">Colorectal tumor</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA6726805">WO-2012009705</Patent><Status id="PRI">First Priority</Status><StatusDate>2010-07-15 00:00:00</StatusDate><StatusSortCode>1</StatusSortCode><TherapyArea id="129">Gastrointestinal disease</TherapyArea></Row><Row><Action id="3756">Erbb2 tyrosine kinase receptor inhibitor</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="US">US</Country><Drug id="71794">adalimumab + anti-Ang2 Zybody (inflammatory disease), Zyngenia</Drug><DrugRelationship>Product</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Priority</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PRI</HighestPatStatusIdForCnty><Indication id="1781">Psoriatic arthritis</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA6726805">WO-2012009705</Patent><Status id="PRI">First Priority</Status><StatusDate>2010-07-15 00:00:00</StatusDate><StatusSortCode>1</StatusSortCode><TherapyArea id="185">Immune disorder</TherapyArea></Row><Row><Action id="3756">Erbb2 tyrosine kinase receptor inhibitor</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="US">US</Country><Drug id="71794">adalimumab + anti-Ang2 Zybody (inflammatory disease), Zyngenia</Drug><DrugRelationship>Product</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Priority</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PRI</HighestPatStatusIdForCnty><Indication id="188">Inflammatory disease</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA6726805">WO-2012009705</Patent><Status id="PRI">First Priority</Status><StatusDate>2010-07-15 00:00:00</StatusDate><StatusSortCode>1</StatusSortCode><TherapyArea id="188">Inflammatory disease</TherapyArea></Row><Row><Action id="3756">Erbb2 tyrosine kinase receptor inhibitor</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="US">US</Country><Drug id="71794">adalimumab + anti-Ang2 Zybody (inflammatory disease), Zyngenia</Drug><DrugRelationship>Product</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Priority</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PRI</HighestPatStatusIdForCnty><Indication id="189">Inflammatory bowel disease</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA6726805">WO-2012009705</Patent><Status id="PRI">First Priority</Status><StatusDate>2010-07-15 00:00:00</StatusDate><StatusSortCode>1</StatusSortCode><TherapyArea id="188">Inflammatory disease</TherapyArea></Row><Row><Action id="3756">Erbb2 tyrosine kinase receptor inhibitor</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="US">US</Country><Drug id="71794">adalimumab + anti-Ang2 Zybody (inflammatory disease), Zyngenia</Drug><DrugRelationship>Product</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Priority</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PRI</HighestPatStatusIdForCnty><Indication id="291">Rheumatoid arthritis</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA6726805">WO-2012009705</Patent><Status id="PRI">First Priority</Status><StatusDate>2010-07-15 00:00:00</StatusDate><StatusSortCode>1</StatusSortCode><TherapyArea id="185">Immune disorder</TherapyArea></Row><Row><Action id="3756">Erbb2 tyrosine kinase receptor inhibitor</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="US">US</Country><Drug id="71794">adalimumab + anti-Ang2 Zybody (inflammatory disease), Zyngenia</Drug><DrugRelationship>Product</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Priority</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PRI</HighestPatStatusIdForCnty><Indication id="3003">Juvenile rheumatoid arthritis</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA6726805">WO-2012009705</Patent><Status id="PRI">First Priority</Status><StatusDate>2010-07-15 00:00:00</StatusDate><StatusSortCode>1</StatusSortCode><TherapyArea id="185">Immune disorder</TherapyArea></Row><Row><Action id="3756">Erbb2 tyrosine kinase receptor inhibitor</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="US">US</Country><Drug id="71794">adalimumab + anti-Ang2 Zybody (inflammatory disease), Zyngenia</Drug><DrugRelationship>Product</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Priority</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PRI</HighestPatStatusIdForCnty><Indication id="36">Autoimmune disease</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA6726805">WO-2012009705</Patent><Status id="PRI">First Priority</Status><StatusDate>2010-07-15 00:00:00</StatusDate><StatusSortCode>1</StatusSortCode><TherapyArea id="185">Immune disorder</TherapyArea></Row><Row><Action id="3756">Erbb2 tyrosine kinase receptor inhibitor</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="US">US</Country><Drug id="71794">adalimumab + anti-Ang2 Zybody (inflammatory disease), Zyngenia</Drug><DrugRelationship>Product</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Priority</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PRI</HighestPatStatusIdForCnty><Indication id="651">Cancer</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA6726805">WO-2012009705</Patent><Status id="PRI">First Priority</Status><StatusDate>2010-07-15 00:00:00</StatusDate><StatusSortCode>1</StatusSortCode><TherapyArea id="230">Neoplasm</TherapyArea></Row><Row><Action id="3756">Erbb2 tyrosine kinase receptor inhibitor</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="US">US</Country><Drug id="71794">adalimumab + anti-Ang2 Zybody (inflammatory disease), Zyngenia</Drug><DrugRelationship>Product</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Priority</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PRI</HighestPatStatusIdForCnty><Indication id="84">Crohns disease</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA6726805">WO-2012009705</Patent><Status id="PRI">First Priority</Status><StatusDate>2010-07-15 00:00:00</StatusDate><StatusSortCode>1</StatusSortCode><TherapyArea id="185">Immune disorder</TherapyArea></Row><Row><Action id="3756">Erbb2 tyrosine kinase receptor inhibitor</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="US">US</Country><Drug id="71794">adalimumab + anti-Ang2 Zybody (inflammatory disease), Zyngenia</Drug><DrugRelationship>Product</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Priority</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PRI</HighestPatStatusIdForCnty><Indication id="989">Colorectal tumor</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA6726805">WO-2012009705</Patent><Status id="PRI">First Priority</Status><StatusDate>2010-07-15 00:00:00</StatusDate><StatusSortCode>1</StatusSortCode><TherapyArea id="129">Gastrointestinal disease</TherapyArea></Row><Row><Action id="381">TNF alpha ligand inhibitor</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="US">US</Country><Drug id="71794">adalimumab + anti-Ang2 Zybody (inflammatory disease), Zyngenia</Drug><DrugRelationship>Product</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Priority</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PRI</HighestPatStatusIdForCnty><Indication id="1781">Psoriatic arthritis</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA6726805">WO-2012009705</Patent><Status id="PRI">First Priority</Status><StatusDate>2010-07-15 00:00:00</StatusDate><StatusSortCode>1</StatusSortCode><TherapyArea id="185">Immune disorder</TherapyArea></Row><Row><Action id="381">TNF alpha ligand inhibitor</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="US">US</Country><Drug id="71794">adalimumab + anti-Ang2 Zybody (inflammatory disease), Zyngenia</Drug><DrugRelationship>Product</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Priority</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PRI</HighestPatStatusIdForCnty><Indication id="188">Inflammatory disease</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA6726805">WO-2012009705</Patent><Status id="PRI">First Priority</Status><StatusDate>2010-07-15 00:00:00</StatusDate><StatusSortCode>1</StatusSortCode><TherapyArea id="188">Inflammatory disease</TherapyArea></Row><Row><Action id="381">TNF alpha ligand inhibitor</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="US">US</Country><Drug id="71794">adalimumab + anti-Ang2 Zybody (inflammatory disease), Zyngenia</Drug><DrugRelationship>Product</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Priority</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PRI</HighestPatStatusIdForCnty><Indication id="189">Inflammatory bowel disease</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA6726805">WO-2012009705</Patent><Status id="PRI">First Priority</Status><StatusDate>2010-07-15 00:00:00</StatusDate><StatusSortCode>1</StatusSortCode><TherapyArea id="188">Inflammatory disease</TherapyArea></Row><Row><Action id="381">TNF alpha ligand inhibitor</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="US">US</Country><Drug id="71794">adalimumab + anti-Ang2 Zybody (inflammatory disease), Zyngenia</Drug><DrugRelationship>Product</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Priority</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PRI</HighestPatStatusIdForCnty><Indication id="291">Rheumatoid arthritis</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA6726805">WO-2012009705</Patent><Status id="PRI">First Priority</Status><StatusDate>2010-07-15 00:00:00</StatusDate><StatusSortCode>1</StatusSortCode><TherapyArea id="185">Immune disorder</TherapyArea></Row><Row><Action id="381">TNF alpha ligand inhibitor</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="US">US</Country><Drug id="71794">adalimumab + anti-Ang2 Zybody (inflammatory disease), Zyngenia</Drug><DrugRelationship>Product</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Priority</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PRI</HighestPatStatusIdForCnty><Indication id="3003">Juvenile rheumatoid arthritis</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA6726805">WO-2012009705</Patent><Status id="PRI">First Priority</Status><StatusDate>2010-07-15 00:00:00</StatusDate><StatusSortCode>1</StatusSortCode><TherapyArea id="185">Immune disorder</TherapyArea></Row><Row><Action id="381">TNF alpha ligand inhibitor</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="US">US</Country><Drug id="71794">adalimumab + anti-Ang2 Zybody (inflammatory disease), Zyngenia</Drug><DrugRelationship>Product</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Priority</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PRI</HighestPatStatusIdForCnty><Indication id="36">Autoimmune disease</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA6726805">WO-2012009705</Patent><Status id="PRI">First Priority</Status><StatusDate>2010-07-15 00:00:00</StatusDate><StatusSortCode>1</StatusSortCode><TherapyArea id="185">Immune disorder</TherapyArea></Row><Row><Action id="381">TNF alpha ligand inhibitor</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="US">US</Country><Drug id="71794">adalimumab + anti-Ang2 Zybody (inflammatory disease), Zyngenia</Drug><DrugRelationship>Product</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Priority</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PRI</HighestPatStatusIdForCnty><Indication id="651">Cancer</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA6726805">WO-2012009705</Patent><Status id="PRI">First Priority</Status><StatusDate>2010-07-15 00:00:00</StatusDate><StatusSortCode>1</StatusSortCode><TherapyArea id="230">Neoplasm</TherapyArea></Row><Row><Action id="381">TNF alpha ligand inhibitor</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="US">US</Country><Drug id="71794">adalimumab + anti-Ang2 Zybody (inflammatory disease), Zyngenia</Drug><DrugRelationship>Product</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Priority</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PRI</HighestPatStatusIdForCnty><Indication id="84">Crohns disease</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA6726805">WO-2012009705</Patent><Status id="PRI">First Priority</Status><StatusDate>2010-07-15 00:00:00</StatusDate><StatusSortCode>1</StatusSortCode><TherapyArea id="185">Immune disorder</TherapyArea></Row><Row><Action id="381">TNF alpha ligand inhibitor</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="US">US</Country><Drug id="71794">adalimumab + anti-Ang2 Zybody (inflammatory disease), Zyngenia</Drug><DrugRelationship>Product</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Priority</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PRI</HighestPatStatusIdForCnty><Indication id="989">Colorectal tumor</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA6726805">WO-2012009705</Patent><Status id="PRI">First Priority</Status><StatusDate>2010-07-15 00:00:00</StatusDate><StatusSortCode>1</StatusSortCode><TherapyArea id="129">Gastrointestinal disease</TherapyArea></Row><Row><Action id="14323">Angiopoietin ligand-2 inhibitor</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="US">US</Country><Drug id="71795">anti-Her-2/anti-Ang2 mAb (cancer), Zyngenia</Drug><DrugRelationship>Product</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Priority</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PRI</HighestPatStatusIdForCnty><Indication id="1781">Psoriatic arthritis</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA6726805">WO-2012009705</Patent><Status id="PRI">First Priority</Status><StatusDate>2010-07-15 00:00:00</StatusDate><StatusSortCode>1</StatusSortCode><TherapyArea id="185">Immune disorder</TherapyArea></Row><Row><Action id="14323">Angiopoietin ligand-2 inhibitor</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="US">US</Country><Drug id="71795">anti-Her-2/anti-Ang2 mAb (cancer), Zyngenia</Drug><DrugRelationship>Product</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Priority</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PRI</HighestPatStatusIdForCnty><Indication id="188">Inflammatory disease</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA6726805">WO-2012009705</Patent><Status id="PRI">First Priority</Status><StatusDate>2010-07-15 00:00:00</StatusDate><StatusSortCode>1</StatusSortCode><TherapyArea id="188">Inflammatory disease</TherapyArea></Row><Row><Action id="14323">Angiopoietin ligand-2 inhibitor</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="US">US</Country><Drug id="71795">anti-Her-2/anti-Ang2 mAb (cancer), Zyngenia</Drug><DrugRelationship>Product</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Priority</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PRI</HighestPatStatusIdForCnty><Indication id="189">Inflammatory bowel disease</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA6726805">WO-2012009705</Patent><Status id="PRI">First Priority</Status><StatusDate>2010-07-15 00:00:00</StatusDate><StatusSortCode>1</StatusSortCode><TherapyArea id="188">Inflammatory disease</TherapyArea></Row><Row><Action id="14323">Angiopoietin ligand-2 inhibitor</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="US">US</Country><Drug id="71795">anti-Her-2/anti-Ang2 mAb (cancer), Zyngenia</Drug><DrugRelationship>Product</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Priority</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PRI</HighestPatStatusIdForCnty><Indication id="291">Rheumatoid arthritis</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA6726805">WO-2012009705</Patent><Status id="PRI">First Priority</Status><StatusDate>2010-07-15 00:00:00</StatusDate><StatusSortCode>1</StatusSortCode><TherapyArea id="185">Immune disorder</TherapyArea></Row><Row><Action id="14323">Angiopoietin ligand-2 inhibitor</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="US">US</Country><Drug id="71795">anti-Her-2/anti-Ang2 mAb (cancer), Zyngenia</Drug><DrugRelationship>Product</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Priority</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PRI</HighestPatStatusIdForCnty><Indication id="3003">Juvenile rheumatoid arthritis</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA6726805">WO-2012009705</Patent><Status id="PRI">First Priority</Status><StatusDate>2010-07-15 00:00:00</StatusDate><StatusSortCode>1</StatusSortCode><TherapyArea id="185">Immune disorder</TherapyArea></Row><Row><Action id="14323">Angiopoietin ligand-2 inhibitor</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="US">US</Country><Drug id="71795">anti-Her-2/anti-Ang2 mAb (cancer), Zyngenia</Drug><DrugRelationship>Product</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Priority</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PRI</HighestPatStatusIdForCnty><Indication id="36">Autoimmune disease</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA6726805">WO-2012009705</Patent><Status id="PRI">First Priority</Status><StatusDate>2010-07-15 00:00:00</StatusDate><StatusSortCode>1</StatusSortCode><TherapyArea id="185">Immune disorder</TherapyArea></Row><Row><Action id="14323">Angiopoietin ligand-2 inhibitor</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="US">US</Country><Drug id="71795">anti-Her-2/anti-Ang2 mAb (cancer), Zyngenia</Drug><DrugRelationship>Product</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Priority</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PRI</HighestPatStatusIdForCnty><Indication id="651">Cancer</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA6726805">WO-2012009705</Patent><Status id="PRI">First Priority</Status><StatusDate>2010-07-15 00:00:00</StatusDate><StatusSortCode>1</StatusSortCode><TherapyArea id="230">Neoplasm</TherapyArea></Row><Row><Action id="14323">Angiopoietin ligand-2 inhibitor</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="US">US</Country><Drug id="71795">anti-Her-2/anti-Ang2 mAb (cancer), Zyngenia</Drug><DrugRelationship>Product</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Priority</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PRI</HighestPatStatusIdForCnty><Indication id="84">Crohns disease</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA6726805">WO-2012009705</Patent><Status id="PRI">First Priority</Status><StatusDate>2010-07-15 00:00:00</StatusDate><StatusSortCode>1</StatusSortCode><TherapyArea id="185">Immune disorder</TherapyArea></Row><Row><Action id="14323">Angiopoietin ligand-2 inhibitor</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="US">US</Country><Drug id="71795">anti-Her-2/anti-Ang2 mAb (cancer), Zyngenia</Drug><DrugRelationship>Product</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Priority</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PRI</HighestPatStatusIdForCnty><Indication id="989">Colorectal tumor</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA6726805">WO-2012009705</Patent><Status id="PRI">First Priority</Status><StatusDate>2010-07-15 00:00:00</StatusDate><StatusSortCode>1</StatusSortCode><TherapyArea id="129">Gastrointestinal disease</TherapyArea></Row><Row><Action id="3756">Erbb2 tyrosine kinase receptor inhibitor</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="US">US</Country><Drug id="71795">anti-Her-2/anti-Ang2 mAb (cancer), Zyngenia</Drug><DrugRelationship>Product</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Priority</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PRI</HighestPatStatusIdForCnty><Indication id="1781">Psoriatic arthritis</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA6726805">WO-2012009705</Patent><Status id="PRI">First Priority</Status><StatusDate>2010-07-15 00:00:00</StatusDate><StatusSortCode>1</StatusSortCode><TherapyArea id="185">Immune disorder</TherapyArea></Row><Row><Action id="3756">Erbb2 tyrosine kinase receptor inhibitor</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="US">US</Country><Drug id="71795">anti-Her-2/anti-Ang2 mAb (cancer), Zyngenia</Drug><DrugRelationship>Product</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Priority</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PRI</HighestPatStatusIdForCnty><Indication id="188">Inflammatory disease</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA6726805">WO-2012009705</Patent><Status id="PRI">First Priority</Status><StatusDate>2010-07-15 00:00:00</StatusDate><StatusSortCode>1</StatusSortCode><TherapyArea id="188">Inflammatory disease</TherapyArea></Row><Row><Action id="3756">Erbb2 tyrosine kinase receptor inhibitor</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="US">US</Country><Drug id="71795">anti-Her-2/anti-Ang2 mAb (cancer), Zyngenia</Drug><DrugRelationship>Product</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Priority</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PRI</HighestPatStatusIdForCnty><Indication id="189">Inflammatory bowel disease</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA6726805">WO-2012009705</Patent><Status id="PRI">First Priority</Status><StatusDate>2010-07-15 00:00:00</StatusDate><StatusSortCode>1</StatusSortCode><TherapyArea id="188">Inflammatory disease</TherapyArea></Row><Row><Action id="3756">Erbb2 tyrosine kinase receptor inhibitor</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="US">US</Country><Drug id="71795">anti-Her-2/anti-Ang2 mAb (cancer), Zyngenia</Drug><DrugRelationship>Product</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Priority</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PRI</HighestPatStatusIdForCnty><Indication id="291">Rheumatoid arthritis</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA6726805">WO-2012009705</Patent><Status id="PRI">First Priority</Status><StatusDate>2010-07-15 00:00:00</StatusDate><StatusSortCode>1</StatusSortCode><TherapyArea id="185">Immune disorder</TherapyArea></Row><Row><Action id="3756">Erbb2 tyrosine kinase receptor inhibitor</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="US">US</Country><Drug id="71795">anti-Her-2/anti-Ang2 mAb (cancer), Zyngenia</Drug><DrugRelationship>Product</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Priority</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PRI</HighestPatStatusIdForCnty><Indication id="3003">Juvenile rheumatoid arthritis</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA6726805">WO-2012009705</Patent><Status id="PRI">First Priority</Status><StatusDate>2010-07-15 00:00:00</StatusDate><StatusSortCode>1</StatusSortCode><TherapyArea id="185">Immune disorder</TherapyArea></Row><Row><Action id="3756">Erbb2 tyrosine kinase receptor inhibitor</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="US">US</Country><Drug id="71795">anti-Her-2/anti-Ang2 mAb (cancer), Zyngenia</Drug><DrugRelationship>Product</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Priority</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PRI</HighestPatStatusIdForCnty><Indication id="36">Autoimmune disease</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA6726805">WO-2012009705</Patent><Status id="PRI">First Priority</Status><StatusDate>2010-07-15 00:00:00</StatusDate><StatusSortCode>1</StatusSortCode><TherapyArea id="185">Immune disorder</TherapyArea></Row><Row><Action id="3756">Erbb2 tyrosine kinase receptor inhibitor</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="US">US</Country><Drug id="71795">anti-Her-2/anti-Ang2 mAb (cancer), Zyngenia</Drug><DrugRelationship>Product</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Priority</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PRI</HighestPatStatusIdForCnty><Indication id="651">Cancer</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA6726805">WO-2012009705</Patent><Status id="PRI">First Priority</Status><StatusDate>2010-07-15 00:00:00</StatusDate><StatusSortCode>1</StatusSortCode><TherapyArea id="230">Neoplasm</TherapyArea></Row><Row><Action id="3756">Erbb2 tyrosine kinase receptor inhibitor</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="US">US</Country><Drug id="71795">anti-Her-2/anti-Ang2 mAb (cancer), Zyngenia</Drug><DrugRelationship>Product</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Priority</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PRI</HighestPatStatusIdForCnty><Indication id="84">Crohns disease</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA6726805">WO-2012009705</Patent><Status id="PRI">First Priority</Status><StatusDate>2010-07-15 00:00:00</StatusDate><StatusSortCode>1</StatusSortCode><TherapyArea id="185">Immune disorder</TherapyArea></Row><Row><Action id="3756">Erbb2 tyrosine kinase receptor inhibitor</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="US">US</Country><Drug id="71795">anti-Her-2/anti-Ang2 mAb (cancer), Zyngenia</Drug><DrugRelationship>Product</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Priority</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PRI</HighestPatStatusIdForCnty><Indication id="989">Colorectal tumor</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA6726805">WO-2012009705</Patent><Status id="PRI">First Priority</Status><StatusDate>2010-07-15 00:00:00</StatusDate><StatusSortCode>1</StatusSortCode><TherapyArea id="129">Gastrointestinal disease</TherapyArea></Row><Row><Action id="381">TNF alpha ligand inhibitor</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="US">US</Country><Drug id="71795">anti-Her-2/anti-Ang2 mAb (cancer), Zyngenia</Drug><DrugRelationship>Product</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Priority</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PRI</HighestPatStatusIdForCnty><Indication id="1781">Psoriatic arthritis</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA6726805">WO-2012009705</Patent><Status id="PRI">First Priority</Status><StatusDate>2010-07-15 00:00:00</StatusDate><StatusSortCode>1</StatusSortCode><TherapyArea id="185">Immune disorder</TherapyArea></Row><Row><Action id="381">TNF alpha ligand inhibitor</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="US">US</Country><Drug id="71795">anti-Her-2/anti-Ang2 mAb (cancer), Zyngenia</Drug><DrugRelationship>Product</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Priority</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PRI</HighestPatStatusIdForCnty><Indication id="188">Inflammatory disease</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA6726805">WO-2012009705</Patent><Status id="PRI">First Priority</Status><StatusDate>2010-07-15 00:00:00</StatusDate><StatusSortCode>1</StatusSortCode><TherapyArea id="188">Inflammatory disease</TherapyArea></Row><Row><Action id="381">TNF alpha ligand inhibitor</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="US">US</Country><Drug id="71795">anti-Her-2/anti-Ang2 mAb (cancer), Zyngenia</Drug><DrugRelationship>Product</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Priority</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PRI</HighestPatStatusIdForCnty><Indication id="189">Inflammatory bowel disease</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA6726805">WO-2012009705</Patent><Status id="PRI">First Priority</Status><StatusDate>2010-07-15 00:00:00</StatusDate><StatusSortCode>1</StatusSortCode><TherapyArea id="188">Inflammatory disease</TherapyArea></Row><Row><Action id="381">TNF alpha ligand inhibitor</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="US">US</Country><Drug id="71795">anti-Her-2/anti-Ang2 mAb (cancer), Zyngenia</Drug><DrugRelationship>Product</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Priority</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PRI</HighestPatStatusIdForCnty><Indication id="291">Rheumatoid arthritis</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA6726805">WO-2012009705</Patent><Status id="PRI">First Priority</Status><StatusDate>2010-07-15 00:00:00</StatusDate><StatusSortCode>1</StatusSortCode><TherapyArea id="185">Immune disorder</TherapyArea></Row><Row><Action id="381">TNF alpha ligand inhibitor</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="US">US</Country><Drug id="71795">anti-Her-2/anti-Ang2 mAb (cancer), Zyngenia</Drug><DrugRelationship>Product</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Priority</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PRI</HighestPatStatusIdForCnty><Indication id="3003">Juvenile rheumatoid arthritis</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA6726805">WO-2012009705</Patent><Status id="PRI">First Priority</Status><StatusDate>2010-07-15 00:00:00</StatusDate><StatusSortCode>1</StatusSortCode><TherapyArea id="185">Immune disorder</TherapyArea></Row><Row><Action id="381">TNF alpha ligand inhibitor</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="US">US</Country><Drug id="71795">anti-Her-2/anti-Ang2 mAb (cancer), Zyngenia</Drug><DrugRelationship>Product</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Priority</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PRI</HighestPatStatusIdForCnty><Indication id="36">Autoimmune disease</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA6726805">WO-2012009705</Patent><Status id="PRI">First Priority</Status><StatusDate>2010-07-15 00:00:00</StatusDate><StatusSortCode>1</StatusSortCode><TherapyArea id="185">Immune disorder</TherapyArea></Row><Row><Action id="381">TNF alpha ligand inhibitor</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="US">US</Country><Drug id="71795">anti-Her-2/anti-Ang2 mAb (cancer), Zyngenia</Drug><DrugRelationship>Product</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Priority</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PRI</HighestPatStatusIdForCnty><Indication id="651">Cancer</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA6726805">WO-2012009705</Patent><Status id="PRI">First Priority</Status><StatusDate>2010-07-15 00:00:00</StatusDate><StatusSortCode>1</StatusSortCode><TherapyArea id="230">Neoplasm</TherapyArea></Row><Row><Action id="381">TNF alpha ligand inhibitor</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="US">US</Country><Drug id="71795">anti-Her-2/anti-Ang2 mAb (cancer), Zyngenia</Drug><DrugRelationship>Product</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Priority</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PRI</HighestPatStatusIdForCnty><Indication id="84">Crohns disease</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA6726805">WO-2012009705</Patent><Status id="PRI">First Priority</Status><StatusDate>2010-07-15 00:00:00</StatusDate><StatusSortCode>1</StatusSortCode><TherapyArea id="185">Immune disorder</TherapyArea></Row><Row><Action id="381">TNF alpha ligand inhibitor</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="US">US</Country><Drug id="71795">anti-Her-2/anti-Ang2 mAb (cancer), Zyngenia</Drug><DrugRelationship>Product</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Priority</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PRI</HighestPatStatusIdForCnty><Indication id="989">Colorectal tumor</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA6726805">WO-2012009705</Patent><Status id="PRI">First Priority</Status><StatusDate>2010-07-15 00:00:00</StatusDate><StatusSortCode>1</StatusSortCode><TherapyArea id="129">Gastrointestinal disease</TherapyArea></Row><Row><Action id="14323">Angiopoietin ligand-2 inhibitor</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="WO">World</Country><Drug id="71794">adalimumab + anti-Ang2 Zybody (inflammatory disease), Zyngenia</Drug><DrugRelationship>Product</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Publication</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PUB</HighestPatStatusIdForCnty><Indication id="1781">Psoriatic arthritis</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA6726805">WO-2012009705</Patent><Status id="PUB">First Publication</Status><StatusDate>2012-01-19 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="185">Immune disorder</TherapyArea></Row><Row><Action id="14323">Angiopoietin ligand-2 inhibitor</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="WO">World</Country><Drug id="71794">adalimumab + anti-Ang2 Zybody (inflammatory disease), Zyngenia</Drug><DrugRelationship>Product</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Publication</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PUB</HighestPatStatusIdForCnty><Indication id="188">Inflammatory disease</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA6726805">WO-2012009705</Patent><Status id="PUB">First Publication</Status><StatusDate>2012-01-19 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="188">Inflammatory disease</TherapyArea></Row><Row><Action id="14323">Angiopoietin ligand-2 inhibitor</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="WO">World</Country><Drug id="71794">adalimumab + anti-Ang2 Zybody (inflammatory disease), Zyngenia</Drug><DrugRelationship>Product</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Publication</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PUB</HighestPatStatusIdForCnty><Indication id="189">Inflammatory bowel disease</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA6726805">WO-2012009705</Patent><Status id="PUB">First Publication</Status><StatusDate>2012-01-19 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="188">Inflammatory disease</TherapyArea></Row><Row><Action id="14323">Angiopoietin ligand-2 inhibitor</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="WO">World</Country><Drug id="71794">adalimumab + anti-Ang2 Zybody (inflammatory disease), Zyngenia</Drug><DrugRelationship>Product</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Publication</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PUB</HighestPatStatusIdForCnty><Indication id="291">Rheumatoid arthritis</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA6726805">WO-2012009705</Patent><Status id="PUB">First Publication</Status><StatusDate>2012-01-19 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="185">Immune disorder</TherapyArea></Row><Row><Action id="14323">Angiopoietin ligand-2 inhibitor</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="WO">World</Country><Drug id="71794">adalimumab + anti-Ang2 Zybody (inflammatory disease), Zyngenia</Drug><DrugRelationship>Product</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Publication</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PUB</HighestPatStatusIdForCnty><Indication id="3003">Juvenile rheumatoid arthritis</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA6726805">WO-2012009705</Patent><Status id="PUB">First Publication</Status><StatusDate>2012-01-19 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="185">Immune disorder</TherapyArea></Row><Row><Action id="14323">Angiopoietin ligand-2 inhibitor</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="WO">World</Country><Drug id="71794">adalimumab + anti-Ang2 Zybody (inflammatory disease), Zyngenia</Drug><DrugRelationship>Product</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Publication</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PUB</HighestPatStatusIdForCnty><Indication id="36">Autoimmune disease</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA6726805">WO-2012009705</Patent><Status id="PUB">First Publication</Status><StatusDate>2012-01-19 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="185">Immune disorder</TherapyArea></Row><Row><Action id="14323">Angiopoietin ligand-2 inhibitor</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="WO">World</Country><Drug id="71794">adalimumab + anti-Ang2 Zybody (inflammatory disease), Zyngenia</Drug><DrugRelationship>Product</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Publication</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PUB</HighestPatStatusIdForCnty><Indication id="651">Cancer</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA6726805">WO-2012009705</Patent><Status id="PUB">First Publication</Status><StatusDate>2012-01-19 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="230">Neoplasm</TherapyArea></Row><Row><Action id="14323">Angiopoietin ligand-2 inhibitor</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="WO">World</Country><Drug id="71794">adalimumab + anti-Ang2 Zybody (inflammatory disease), Zyngenia</Drug><DrugRelationship>Product</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Publication</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PUB</HighestPatStatusIdForCnty><Indication id="84">Crohns disease</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA6726805">WO-2012009705</Patent><Status id="PUB">First Publication</Status><StatusDate>2012-01-19 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="185">Immune disorder</TherapyArea></Row><Row><Action id="14323">Angiopoietin ligand-2 inhibitor</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="WO">World</Country><Drug id="71794">adalimumab + anti-Ang2 Zybody (inflammatory disease), Zyngenia</Drug><DrugRelationship>Product</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Publication</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PUB</HighestPatStatusIdForCnty><Indication id="989">Colorectal tumor</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA6726805">WO-2012009705</Patent><Status id="PUB">First Publication</Status><StatusDate>2012-01-19 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="129">Gastrointestinal disease</TherapyArea></Row><Row><Action id="3756">Erbb2 tyrosine kinase receptor inhibitor</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="WO">World</Country><Drug id="71794">adalimumab + anti-Ang2 Zybody (inflammatory disease), Zyngenia</Drug><DrugRelationship>Product</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Publication</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PUB</HighestPatStatusIdForCnty><Indication id="1781">Psoriatic arthritis</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA6726805">WO-2012009705</Patent><Status id="PUB">First Publication</Status><StatusDate>2012-01-19 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="185">Immune disorder</TherapyArea></Row><Row><Action id="3756">Erbb2 tyrosine kinase receptor inhibitor</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="WO">World</Country><Drug id="71794">adalimumab + anti-Ang2 Zybody (inflammatory disease), Zyngenia</Drug><DrugRelationship>Product</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Publication</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PUB</HighestPatStatusIdForCnty><Indication id="188">Inflammatory disease</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA6726805">WO-2012009705</Patent><Status id="PUB">First Publication</Status><StatusDate>2012-01-19 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="188">Inflammatory disease</TherapyArea></Row><Row><Action id="3756">Erbb2 tyrosine kinase receptor inhibitor</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="WO">World</Country><Drug id="71794">adalimumab + anti-Ang2 Zybody (inflammatory disease), Zyngenia</Drug><DrugRelationship>Product</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Publication</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PUB</HighestPatStatusIdForCnty><Indication id="189">Inflammatory bowel disease</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA6726805">WO-2012009705</Patent><Status id="PUB">First Publication</Status><StatusDate>2012-01-19 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="188">Inflammatory disease</TherapyArea></Row><Row><Action id="3756">Erbb2 tyrosine kinase receptor inhibitor</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="WO">World</Country><Drug id="71794">adalimumab + anti-Ang2 Zybody (inflammatory disease), Zyngenia</Drug><DrugRelationship>Product</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Publication</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PUB</HighestPatStatusIdForCnty><Indication id="291">Rheumatoid arthritis</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA6726805">WO-2012009705</Patent><Status id="PUB">First Publication</Status><StatusDate>2012-01-19 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="185">Immune disorder</TherapyArea></Row><Row><Action id="3756">Erbb2 tyrosine kinase receptor inhibitor</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="WO">World</Country><Drug id="71794">adalimumab + anti-Ang2 Zybody (inflammatory disease), Zyngenia</Drug><DrugRelationship>Product</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Publication</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PUB</HighestPatStatusIdForCnty><Indication id="3003">Juvenile rheumatoid arthritis</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA6726805">WO-2012009705</Patent><Status id="PUB">First Publication</Status><StatusDate>2012-01-19 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="185">Immune disorder</TherapyArea></Row><Row><Action id="3756">Erbb2 tyrosine kinase receptor inhibitor</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="WO">World</Country><Drug id="71794">adalimumab + anti-Ang2 Zybody (inflammatory disease), Zyngenia</Drug><DrugRelationship>Product</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Publication</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PUB</HighestPatStatusIdForCnty><Indication id="36">Autoimmune disease</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA6726805">WO-2012009705</Patent><Status id="PUB">First Publication</Status><StatusDate>2012-01-19 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="185">Immune disorder</TherapyArea></Row><Row><Action id="3756">Erbb2 tyrosine kinase receptor inhibitor</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="WO">World</Country><Drug id="71794">adalimumab + anti-Ang2 Zybody (inflammatory disease), Zyngenia</Drug><DrugRelationship>Product</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Publication</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PUB</HighestPatStatusIdForCnty><Indication id="651">Cancer</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA6726805">WO-2012009705</Patent><Status id="PUB">First Publication</Status><StatusDate>2012-01-19 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="230">Neoplasm</TherapyArea></Row><Row><Action id="3756">Erbb2 tyrosine kinase receptor inhibitor</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="WO">World</Country><Drug id="71794">adalimumab + anti-Ang2 Zybody (inflammatory disease), Zyngenia</Drug><DrugRelationship>Product</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Publication</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PUB</HighestPatStatusIdForCnty><Indication id="84">Crohns disease</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA6726805">WO-2012009705</Patent><Status id="PUB">First Publication</Status><StatusDate>2012-01-19 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="185">Immune disorder</TherapyArea></Row><Row><Action id="3756">Erbb2 tyrosine kinase receptor inhibitor</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="WO">World</Country><Drug id="71794">adalimumab + anti-Ang2 Zybody (inflammatory disease), Zyngenia</Drug><DrugRelationship>Product</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Publication</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PUB</HighestPatStatusIdForCnty><Indication id="989">Colorectal tumor</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA6726805">WO-2012009705</Patent><Status id="PUB">First Publication</Status><StatusDate>2012-01-19 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="129">Gastrointestinal disease</TherapyArea></Row><Row><Action id="381">TNF alpha ligand inhibitor</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="WO">World</Country><Drug id="71794">adalimumab + anti-Ang2 Zybody (inflammatory disease), Zyngenia</Drug><DrugRelationship>Product</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Publication</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PUB</HighestPatStatusIdForCnty><Indication id="1781">Psoriatic arthritis</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA6726805">WO-2012009705</Patent><Status id="PUB">First Publication</Status><StatusDate>2012-01-19 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="185">Immune disorder</TherapyArea></Row><Row><Action id="381">TNF alpha ligand inhibitor</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="WO">World</Country><Drug id="71794">adalimumab + anti-Ang2 Zybody (inflammatory disease), Zyngenia</Drug><DrugRelationship>Product</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Publication</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PUB</HighestPatStatusIdForCnty><Indication id="188">Inflammatory disease</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA6726805">WO-2012009705</Patent><Status id="PUB">First Publication</Status><StatusDate>2012-01-19 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="188">Inflammatory disease</TherapyArea></Row><Row><Action id="381">TNF alpha ligand inhibitor</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="WO">World</Country><Drug id="71794">adalimumab + anti-Ang2 Zybody (inflammatory disease), Zyngenia</Drug><DrugRelationship>Product</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Publication</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PUB</HighestPatStatusIdForCnty><Indication id="189">Inflammatory bowel disease</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA6726805">WO-2012009705</Patent><Status id="PUB">First Publication</Status><StatusDate>2012-01-19 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="188">Inflammatory disease</TherapyArea></Row><Row><Action id="381">TNF alpha ligand inhibitor</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="WO">World</Country><Drug id="71794">adalimumab + anti-Ang2 Zybody (inflammatory disease), Zyngenia</Drug><DrugRelationship>Product</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Publication</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PUB</HighestPatStatusIdForCnty><Indication id="291">Rheumatoid arthritis</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA6726805">WO-2012009705</Patent><Status id="PUB">First Publication</Status><StatusDate>2012-01-19 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="185">Immune disorder</TherapyArea></Row><Row><Action id="381">TNF alpha ligand inhibitor</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="WO">World</Country><Drug id="71794">adalimumab + anti-Ang2 Zybody (inflammatory disease), Zyngenia</Drug><DrugRelationship>Product</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Publication</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PUB</HighestPatStatusIdForCnty><Indication id="3003">Juvenile rheumatoid arthritis</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA6726805">WO-2012009705</Patent><Status id="PUB">First Publication</Status><StatusDate>2012-01-19 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="185">Immune disorder</TherapyArea></Row><Row><Action id="381">TNF alpha ligand inhibitor</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="WO">World</Country><Drug id="71794">adalimumab + anti-Ang2 Zybody (inflammatory disease), Zyngenia</Drug><DrugRelationship>Product</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Publication</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PUB</HighestPatStatusIdForCnty><Indication id="36">Autoimmune disease</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA6726805">WO-2012009705</Patent><Status id="PUB">First Publication</Status><StatusDate>2012-01-19 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="185">Immune disorder</TherapyArea></Row><Row><Action id="381">TNF alpha ligand inhibitor</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="WO">World</Country><Drug id="71794">adalimumab + anti-Ang2 Zybody (inflammatory disease), Zyngenia</Drug><DrugRelationship>Product</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Publication</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PUB</HighestPatStatusIdForCnty><Indication id="651">Cancer</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA6726805">WO-2012009705</Patent><Status id="PUB">First Publication</Status><StatusDate>2012-01-19 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="230">Neoplasm</TherapyArea></Row><Row><Action id="381">TNF alpha ligand inhibitor</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="WO">World</Country><Drug id="71794">adalimumab + anti-Ang2 Zybody (inflammatory disease), Zyngenia</Drug><DrugRelationship>Product</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Publication</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PUB</HighestPatStatusIdForCnty><Indication id="84">Crohns disease</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA6726805">WO-2012009705</Patent><Status id="PUB">First Publication</Status><StatusDate>2012-01-19 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="185">Immune disorder</TherapyArea></Row><Row><Action id="381">TNF alpha ligand inhibitor</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="WO">World</Country><Drug id="71794">adalimumab + anti-Ang2 Zybody (inflammatory disease), Zyngenia</Drug><DrugRelationship>Product</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Publication</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PUB</HighestPatStatusIdForCnty><Indication id="989">Colorectal tumor</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA6726805">WO-2012009705</Patent><Status id="PUB">First Publication</Status><StatusDate>2012-01-19 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="129">Gastrointestinal disease</TherapyArea></Row><Row><Action id="14323">Angiopoietin ligand-2 inhibitor</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="WO">World</Country><Drug id="71795">anti-Her-2/anti-Ang2 mAb (cancer), Zyngenia</Drug><DrugRelationship>Product</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Publication</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PUB</HighestPatStatusIdForCnty><Indication id="1781">Psoriatic arthritis</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA6726805">WO-2012009705</Patent><Status id="PUB">First Publication</Status><StatusDate>2012-01-19 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="185">Immune disorder</TherapyArea></Row><Row><Action id="14323">Angiopoietin ligand-2 inhibitor</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="WO">World</Country><Drug id="71795">anti-Her-2/anti-Ang2 mAb (cancer), Zyngenia</Drug><DrugRelationship>Product</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Publication</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PUB</HighestPatStatusIdForCnty><Indication id="188">Inflammatory disease</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA6726805">WO-2012009705</Patent><Status id="PUB">First Publication</Status><StatusDate>2012-01-19 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="188">Inflammatory disease</TherapyArea></Row><Row><Action id="14323">Angiopoietin ligand-2 inhibitor</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="WO">World</Country><Drug id="71795">anti-Her-2/anti-Ang2 mAb (cancer), Zyngenia</Drug><DrugRelationship>Product</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Publication</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PUB</HighestPatStatusIdForCnty><Indication id="189">Inflammatory bowel disease</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA6726805">WO-2012009705</Patent><Status id="PUB">First Publication</Status><StatusDate>2012-01-19 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="188">Inflammatory disease</TherapyArea></Row><Row><Action id="14323">Angiopoietin ligand-2 inhibitor</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="WO">World</Country><Drug id="71795">anti-Her-2/anti-Ang2 mAb (cancer), Zyngenia</Drug><DrugRelationship>Product</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Publication</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PUB</HighestPatStatusIdForCnty><Indication id="291">Rheumatoid arthritis</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA6726805">WO-2012009705</Patent><Status id="PUB">First Publication</Status><StatusDate>2012-01-19 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="185">Immune disorder</TherapyArea></Row><Row><Action id="14323">Angiopoietin ligand-2 inhibitor</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="WO">World</Country><Drug id="71795">anti-Her-2/anti-Ang2 mAb (cancer), Zyngenia</Drug><DrugRelationship>Product</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Publication</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PUB</HighestPatStatusIdForCnty><Indication id="3003">Juvenile rheumatoid arthritis</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA6726805">WO-2012009705</Patent><Status id="PUB">First Publication</Status><StatusDate>2012-01-19 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="185">Immune disorder</TherapyArea></Row><Row><Action id="14323">Angiopoietin ligand-2 inhibitor</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="WO">World</Country><Drug id="71795">anti-Her-2/anti-Ang2 mAb (cancer), Zyngenia</Drug><DrugRelationship>Product</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Publication</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PUB</HighestPatStatusIdForCnty><Indication id="36">Autoimmune disease</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA6726805">WO-2012009705</Patent><Status id="PUB">First Publication</Status><StatusDate>2012-01-19 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="185">Immune disorder</TherapyArea></Row><Row><Action id="14323">Angiopoietin ligand-2 inhibitor</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="WO">World</Country><Drug id="71795">anti-Her-2/anti-Ang2 mAb (cancer), Zyngenia</Drug><DrugRelationship>Product</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Publication</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PUB</HighestPatStatusIdForCnty><Indication id="651">Cancer</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA6726805">WO-2012009705</Patent><Status id="PUB">First Publication</Status><StatusDate>2012-01-19 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="230">Neoplasm</TherapyArea></Row><Row><Action id="14323">Angiopoietin ligand-2 inhibitor</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="WO">World</Country><Drug id="71795">anti-Her-2/anti-Ang2 mAb (cancer), Zyngenia</Drug><DrugRelationship>Product</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Publication</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PUB</HighestPatStatusIdForCnty><Indication id="84">Crohns disease</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA6726805">WO-2012009705</Patent><Status id="PUB">First Publication</Status><StatusDate>2012-01-19 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="185">Immune disorder</TherapyArea></Row><Row><Action id="14323">Angiopoietin ligand-2 inhibitor</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="WO">World</Country><Drug id="71795">anti-Her-2/anti-Ang2 mAb (cancer), Zyngenia</Drug><DrugRelationship>Product</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Publication</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PUB</HighestPatStatusIdForCnty><Indication id="989">Colorectal tumor</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA6726805">WO-2012009705</Patent><Status id="PUB">First Publication</Status><StatusDate>2012-01-19 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="129">Gastrointestinal disease</TherapyArea></Row><Row><Action id="3756">Erbb2 tyrosine kinase receptor inhibitor</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="WO">World</Country><Drug id="71795">anti-Her-2/anti-Ang2 mAb (cancer), Zyngenia</Drug><DrugRelationship>Product</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Publication</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PUB</HighestPatStatusIdForCnty><Indication id="1781">Psoriatic arthritis</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA6726805">WO-2012009705</Patent><Status id="PUB">First Publication</Status><StatusDate>2012-01-19 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="185">Immune disorder</TherapyArea></Row><Row><Action id="3756">Erbb2 tyrosine kinase receptor inhibitor</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="WO">World</Country><Drug id="71795">anti-Her-2/anti-Ang2 mAb (cancer), Zyngenia</Drug><DrugRelationship>Product</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Publication</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PUB</HighestPatStatusIdForCnty><Indication id="188">Inflammatory disease</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA6726805">WO-2012009705</Patent><Status id="PUB">First Publication</Status><StatusDate>2012-01-19 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="188">Inflammatory disease</TherapyArea></Row><Row><Action id="3756">Erbb2 tyrosine kinase receptor inhibitor</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="WO">World</Country><Drug id="71795">anti-Her-2/anti-Ang2 mAb (cancer), Zyngenia</Drug><DrugRelationship>Product</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Publication</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PUB</HighestPatStatusIdForCnty><Indication id="189">Inflammatory bowel disease</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA6726805">WO-2012009705</Patent><Status id="PUB">First Publication</Status><StatusDate>2012-01-19 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="188">Inflammatory disease</TherapyArea></Row><Row><Action id="3756">Erbb2 tyrosine kinase receptor inhibitor</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="WO">World</Country><Drug id="71795">anti-Her-2/anti-Ang2 mAb (cancer), Zyngenia</Drug><DrugRelationship>Product</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Publication</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PUB</HighestPatStatusIdForCnty><Indication id="291">Rheumatoid arthritis</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA6726805">WO-2012009705</Patent><Status id="PUB">First Publication</Status><StatusDate>2012-01-19 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="185">Immune disorder</TherapyArea></Row><Row><Action id="3756">Erbb2 tyrosine kinase receptor inhibitor</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="WO">World</Country><Drug id="71795">anti-Her-2/anti-Ang2 mAb (cancer), Zyngenia</Drug><DrugRelationship>Product</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Publication</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PUB</HighestPatStatusIdForCnty><Indication id="3003">Juvenile rheumatoid arthritis</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA6726805">WO-2012009705</Patent><Status id="PUB">First Publication</Status><StatusDate>2012-01-19 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="185">Immune disorder</TherapyArea></Row><Row><Action id="3756">Erbb2 tyrosine kinase receptor inhibitor</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="WO">World</Country><Drug id="71795">anti-Her-2/anti-Ang2 mAb (cancer), Zyngenia</Drug><DrugRelationship>Product</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Publication</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PUB</HighestPatStatusIdForCnty><Indication id="36">Autoimmune disease</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA6726805">WO-2012009705</Patent><Status id="PUB">First Publication</Status><StatusDate>2012-01-19 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="185">Immune disorder</TherapyArea></Row><Row><Action id="3756">Erbb2 tyrosine kinase receptor inhibitor</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="WO">World</Country><Drug id="71795">anti-Her-2/anti-Ang2 mAb (cancer), Zyngenia</Drug><DrugRelationship>Product</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Publication</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PUB</HighestPatStatusIdForCnty><Indication id="651">Cancer</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA6726805">WO-2012009705</Patent><Status id="PUB">First Publication</Status><StatusDate>2012-01-19 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="230">Neoplasm</TherapyArea></Row><Row><Action id="3756">Erbb2 tyrosine kinase receptor inhibitor</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="WO">World</Country><Drug id="71795">anti-Her-2/anti-Ang2 mAb (cancer), Zyngenia</Drug><DrugRelationship>Product</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Publication</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PUB</HighestPatStatusIdForCnty><Indication id="84">Crohns disease</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA6726805">WO-2012009705</Patent><Status id="PUB">First Publication</Status><StatusDate>2012-01-19 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="185">Immune disorder</TherapyArea></Row><Row><Action id="3756">Erbb2 tyrosine kinase receptor inhibitor</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="WO">World</Country><Drug id="71795">anti-Her-2/anti-Ang2 mAb (cancer), Zyngenia</Drug><DrugRelationship>Product</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Publication</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PUB</HighestPatStatusIdForCnty><Indication id="989">Colorectal tumor</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA6726805">WO-2012009705</Patent><Status id="PUB">First Publication</Status><StatusDate>2012-01-19 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="129">Gastrointestinal disease</TherapyArea></Row><Row><Action id="381">TNF alpha ligand inhibitor</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="WO">World</Country><Drug id="71795">anti-Her-2/anti-Ang2 mAb (cancer), Zyngenia</Drug><DrugRelationship>Product</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Publication</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PUB</HighestPatStatusIdForCnty><Indication id="1781">Psoriatic arthritis</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA6726805">WO-2012009705</Patent><Status id="PUB">First Publication</Status><StatusDate>2012-01-19 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="185">Immune disorder</TherapyArea></Row><Row><Action id="381">TNF alpha ligand inhibitor</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="WO">World</Country><Drug id="71795">anti-Her-2/anti-Ang2 mAb (cancer), Zyngenia</Drug><DrugRelationship>Product</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Publication</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PUB</HighestPatStatusIdForCnty><Indication id="188">Inflammatory disease</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA6726805">WO-2012009705</Patent><Status id="PUB">First Publication</Status><StatusDate>2012-01-19 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="188">Inflammatory disease</TherapyArea></Row><Row><Action id="381">TNF alpha ligand inhibitor</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="WO">World</Country><Drug id="71795">anti-Her-2/anti-Ang2 mAb (cancer), Zyngenia</Drug><DrugRelationship>Product</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Publication</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PUB</HighestPatStatusIdForCnty><Indication id="189">Inflammatory bowel disease</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA6726805">WO-2012009705</Patent><Status id="PUB">First Publication</Status><StatusDate>2012-01-19 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="188">Inflammatory disease</TherapyArea></Row><Row><Action id="381">TNF alpha ligand inhibitor</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="WO">World</Country><Drug id="71795">anti-Her-2/anti-Ang2 mAb (cancer), Zyngenia</Drug><DrugRelationship>Product</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Publication</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PUB</HighestPatStatusIdForCnty><Indication id="291">Rheumatoid arthritis</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA6726805">WO-2012009705</Patent><Status id="PUB">First Publication</Status><StatusDate>2012-01-19 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="185">Immune disorder</TherapyArea></Row><Row><Action id="381">TNF alpha ligand inhibitor</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="WO">World</Country><Drug id="71795">anti-Her-2/anti-Ang2 mAb (cancer), Zyngenia</Drug><DrugRelationship>Product</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Publication</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PUB</HighestPatStatusIdForCnty><Indication id="3003">Juvenile rheumatoid arthritis</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA6726805">WO-2012009705</Patent><Status id="PUB">First Publication</Status><StatusDate>2012-01-19 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="185">Immune disorder</TherapyArea></Row><Row><Action id="381">TNF alpha ligand inhibitor</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="WO">World</Country><Drug id="71795">anti-Her-2/anti-Ang2 mAb (cancer), Zyngenia</Drug><DrugRelationship>Product</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Publication</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PUB</HighestPatStatusIdForCnty><Indication id="36">Autoimmune disease</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA6726805">WO-2012009705</Patent><Status id="PUB">First Publication</Status><StatusDate>2012-01-19 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="185">Immune disorder</TherapyArea></Row><Row><Action id="381">TNF alpha ligand inhibitor</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="WO">World</Country><Drug id="71795">anti-Her-2/anti-Ang2 mAb (cancer), Zyngenia</Drug><DrugRelationship>Product</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Publication</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PUB</HighestPatStatusIdForCnty><Indication id="651">Cancer</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA6726805">WO-2012009705</Patent><Status id="PUB">First Publication</Status><StatusDate>2012-01-19 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="230">Neoplasm</TherapyArea></Row><Row><Action id="381">TNF alpha ligand inhibitor</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="WO">World</Country><Drug id="71795">anti-Her-2/anti-Ang2 mAb (cancer), Zyngenia</Drug><DrugRelationship>Product</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Publication</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PUB</HighestPatStatusIdForCnty><Indication id="84">Crohns disease</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA6726805">WO-2012009705</Patent><Status id="PUB">First Publication</Status><StatusDate>2012-01-19 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="185">Immune disorder</TherapyArea></Row><Row><Action id="381">TNF alpha ligand inhibitor</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="WO">World</Country><Drug id="71795">anti-Her-2/anti-Ang2 mAb (cancer), Zyngenia</Drug><DrugRelationship>Product</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Publication</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PUB</HighestPatStatusIdForCnty><Indication id="989">Colorectal tumor</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA6726805">WO-2012009705</Patent><Status id="PUB">First Publication</Status><StatusDate>2012-01-19 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="129">Gastrointestinal disease</TherapyArea></Row><Row><Action id="12521">VEGF ligand inhibitor</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="US">US</Country><Drug id="71794">adalimumab + anti-Ang2 Zybody (inflammatory disease), Zyngenia</Drug><DrugRelationship>General interest</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Priority</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PRI</HighestPatStatusIdForCnty><Indication id="188">Inflammatory disease</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA7191557">WO-2012162561</Patent><Status id="PRI">First Priority</Status><StatusDate>2011-05-24 00:00:00</StatusDate><StatusSortCode>1</StatusSortCode><TherapyArea id="188">Inflammatory disease</TherapyArea></Row><Row><Action id="12521">VEGF ligand inhibitor</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="US">US</Country><Drug id="71794">adalimumab + anti-Ang2 Zybody (inflammatory disease), Zyngenia</Drug><DrugRelationship>General interest</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Priority</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PRI</HighestPatStatusIdForCnty><Indication id="189">Inflammatory bowel disease</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA7191557">WO-2012162561</Patent><Status id="PRI">First Priority</Status><StatusDate>2011-05-24 00:00:00</StatusDate><StatusSortCode>1</StatusSortCode><TherapyArea id="188">Inflammatory disease</TherapyArea></Row><Row><Action id="12521">VEGF ligand inhibitor</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="US">US</Country><Drug id="71794">adalimumab + anti-Ang2 Zybody (inflammatory disease), Zyngenia</Drug><DrugRelationship>General interest</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Priority</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PRI</HighestPatStatusIdForCnty><Indication id="213">Multiple sclerosis</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA7191557">WO-2012162561</Patent><Status id="PRI">First Priority</Status><StatusDate>2011-05-24 00:00:00</StatusDate><StatusSortCode>1</StatusSortCode><TherapyArea id="185">Immune disorder</TherapyArea></Row><Row><Action id="12521">VEGF ligand inhibitor</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="US">US</Country><Drug id="71794">adalimumab + anti-Ang2 Zybody (inflammatory disease), Zyngenia</Drug><DrugRelationship>General interest</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Priority</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PRI</HighestPatStatusIdForCnty><Indication id="281">Psoriasis</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA7191557">WO-2012162561</Patent><Status id="PRI">First Priority</Status><StatusDate>2011-05-24 00:00:00</StatusDate><StatusSortCode>1</StatusSortCode><TherapyArea id="95">Dermatological disease</TherapyArea></Row><Row><Action id="12521">VEGF ligand inhibitor</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="US">US</Country><Drug id="71794">adalimumab + anti-Ang2 Zybody (inflammatory disease), Zyngenia</Drug><DrugRelationship>General interest</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Priority</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PRI</HighestPatStatusIdForCnty><Indication id="291">Rheumatoid arthritis</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA7191557">WO-2012162561</Patent><Status id="PRI">First Priority</Status><StatusDate>2011-05-24 00:00:00</StatusDate><StatusSortCode>1</StatusSortCode><TherapyArea id="185">Immune disorder</TherapyArea></Row><Row><Action id="12521">VEGF ligand inhibitor</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="US">US</Country><Drug id="71794">adalimumab + anti-Ang2 Zybody (inflammatory disease), Zyngenia</Drug><DrugRelationship>General interest</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Priority</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PRI</HighestPatStatusIdForCnty><Indication id="318">Systemic lupus erythematosus</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA7191557">WO-2012162561</Patent><Status id="PRI">First Priority</Status><StatusDate>2011-05-24 00:00:00</StatusDate><StatusSortCode>1</StatusSortCode><TherapyArea id="95">Dermatological disease</TherapyArea></Row><Row><Action id="12521">VEGF ligand inhibitor</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="US">US</Country><Drug id="71794">adalimumab + anti-Ang2 Zybody (inflammatory disease), Zyngenia</Drug><DrugRelationship>General interest</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Priority</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PRI</HighestPatStatusIdForCnty><Indication id="337">Ulcerative colitis</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA7191557">WO-2012162561</Patent><Status id="PRI">First Priority</Status><StatusDate>2011-05-24 00:00:00</StatusDate><StatusSortCode>1</StatusSortCode><TherapyArea id="185">Immune disorder</TherapyArea></Row><Row><Action id="12521">VEGF ligand inhibitor</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="US">US</Country><Drug id="71794">adalimumab + anti-Ang2 Zybody (inflammatory disease), Zyngenia</Drug><DrugRelationship>General interest</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Priority</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PRI</HighestPatStatusIdForCnty><Indication id="651">Cancer</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA7191557">WO-2012162561</Patent><Status id="PRI">First Priority</Status><StatusDate>2011-05-24 00:00:00</StatusDate><StatusSortCode>1</StatusSortCode><TherapyArea id="230">Neoplasm</TherapyArea></Row><Row><Action id="12521">VEGF ligand inhibitor</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="US">US</Country><Drug id="71794">adalimumab + anti-Ang2 Zybody (inflammatory disease), Zyngenia</Drug><DrugRelationship>General interest</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Priority</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PRI</HighestPatStatusIdForCnty><Indication id="746">Infectious disease</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA7191557">WO-2012162561</Patent><Status id="PRI">First Priority</Status><StatusDate>2011-05-24 00:00:00</StatusDate><StatusSortCode>1</StatusSortCode><TherapyArea id="746">Infectious disease</TherapyArea></Row><Row><Action id="12521">VEGF ligand inhibitor</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="US">US</Country><Drug id="71794">adalimumab + anti-Ang2 Zybody (inflammatory disease), Zyngenia</Drug><DrugRelationship>General interest</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Priority</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PRI</HighestPatStatusIdForCnty><Indication id="84">Crohns disease</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA7191557">WO-2012162561</Patent><Status id="PRI">First Priority</Status><StatusDate>2011-05-24 00:00:00</StatusDate><StatusSortCode>1</StatusSortCode><TherapyArea id="185">Immune disorder</TherapyArea></Row><Row><Action id="12521">VEGF ligand inhibitor</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="US">US</Country><Drug id="71794">adalimumab + anti-Ang2 Zybody (inflammatory disease), Zyngenia</Drug><DrugRelationship>General interest</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Priority</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PRI</HighestPatStatusIdForCnty><Indication id="97">Diabetes mellitus</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA7191557">WO-2012162561</Patent><Status id="PRI">First Priority</Status><StatusDate>2011-05-24 00:00:00</StatusDate><StatusSortCode>1</StatusSortCode><TherapyArea id="112">Endocrine disease</TherapyArea></Row><Row><Action id="3252">Insulin-like growth factor 1 receptor antagonist</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="US">US</Country><Drug id="71794">adalimumab + anti-Ang2 Zybody (inflammatory disease), Zyngenia</Drug><DrugRelationship>General interest</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Priority</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PRI</HighestPatStatusIdForCnty><Indication id="188">Inflammatory disease</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA7191557">WO-2012162561</Patent><Status id="PRI">First Priority</Status><StatusDate>2011-05-24 00:00:00</StatusDate><StatusSortCode>1</StatusSortCode><TherapyArea id="188">Inflammatory disease</TherapyArea></Row><Row><Action id="3252">Insulin-like growth factor 1 receptor antagonist</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="US">US</Country><Drug id="71794">adalimumab + anti-Ang2 Zybody (inflammatory disease), Zyngenia</Drug><DrugRelationship>General interest</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Priority</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PRI</HighestPatStatusIdForCnty><Indication id="189">Inflammatory bowel disease</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA7191557">WO-2012162561</Patent><Status id="PRI">First Priority</Status><StatusDate>2011-05-24 00:00:00</StatusDate><StatusSortCode>1</StatusSortCode><TherapyArea id="188">Inflammatory disease</TherapyArea></Row><Row><Action id="3252">Insulin-like growth factor 1 receptor antagonist</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="US">US</Country><Drug id="71794">adalimumab + anti-Ang2 Zybody (inflammatory disease), Zyngenia</Drug><DrugRelationship>General interest</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Priority</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PRI</HighestPatStatusIdForCnty><Indication id="213">Multiple sclerosis</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA7191557">WO-2012162561</Patent><Status id="PRI">First Priority</Status><StatusDate>2011-05-24 00:00:00</StatusDate><StatusSortCode>1</StatusSortCode><TherapyArea id="185">Immune disorder</TherapyArea></Row><Row><Action id="3252">Insulin-like growth factor 1 receptor antagonist</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="US">US</Country><Drug id="71794">adalimumab + anti-Ang2 Zybody (inflammatory disease), Zyngenia</Drug><DrugRelationship>General interest</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Priority</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PRI</HighestPatStatusIdForCnty><Indication id="281">Psoriasis</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA7191557">WO-2012162561</Patent><Status id="PRI">First Priority</Status><StatusDate>2011-05-24 00:00:00</StatusDate><StatusSortCode>1</StatusSortCode><TherapyArea id="95">Dermatological disease</TherapyArea></Row><Row><Action id="3252">Insulin-like growth factor 1 receptor antagonist</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="US">US</Country><Drug id="71794">adalimumab + anti-Ang2 Zybody (inflammatory disease), Zyngenia</Drug><DrugRelationship>General interest</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Priority</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PRI</HighestPatStatusIdForCnty><Indication id="291">Rheumatoid arthritis</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA7191557">WO-2012162561</Patent><Status id="PRI">First Priority</Status><StatusDate>2011-05-24 00:00:00</StatusDate><StatusSortCode>1</StatusSortCode><TherapyArea id="185">Immune disorder</TherapyArea></Row><Row><Action id="3252">Insulin-like growth factor 1 receptor antagonist</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="US">US</Country><Drug id="71794">adalimumab + anti-Ang2 Zybody (inflammatory disease), Zyngenia</Drug><DrugRelationship>General interest</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Priority</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PRI</HighestPatStatusIdForCnty><Indication id="318">Systemic lupus erythematosus</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA7191557">WO-2012162561</Patent><Status id="PRI">First Priority</Status><StatusDate>2011-05-24 00:00:00</StatusDate><StatusSortCode>1</StatusSortCode><TherapyArea id="95">Dermatological disease</TherapyArea></Row><Row><Action id="3252">Insulin-like growth factor 1 receptor antagonist</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="US">US</Country><Drug id="71794">adalimumab + anti-Ang2 Zybody (inflammatory disease), Zyngenia</Drug><DrugRelationship>General interest</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Priority</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PRI</HighestPatStatusIdForCnty><Indication id="337">Ulcerative colitis</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA7191557">WO-2012162561</Patent><Status id="PRI">First Priority</Status><StatusDate>2011-05-24 00:00:00</StatusDate><StatusSortCode>1</StatusSortCode><TherapyArea id="185">Immune disorder</TherapyArea></Row><Row><Action id="3252">Insulin-like growth factor 1 receptor antagonist</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="US">US</Country><Drug id="71794">adalimumab + anti-Ang2 Zybody (inflammatory disease), Zyngenia</Drug><DrugRelationship>General interest</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Priority</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PRI</HighestPatStatusIdForCnty><Indication id="651">Cancer</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA7191557">WO-2012162561</Patent><Status id="PRI">First Priority</Status><StatusDate>2011-05-24 00:00:00</StatusDate><StatusSortCode>1</StatusSortCode><TherapyArea id="230">Neoplasm</TherapyArea></Row><Row><Action id="3252">Insulin-like growth factor 1 receptor antagonist</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="US">US</Country><Drug id="71794">adalimumab + anti-Ang2 Zybody (inflammatory disease), Zyngenia</Drug><DrugRelationship>General interest</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Priority</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PRI</HighestPatStatusIdForCnty><Indication id="746">Infectious disease</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA7191557">WO-2012162561</Patent><Status id="PRI">First Priority</Status><StatusDate>2011-05-24 00:00:00</StatusDate><StatusSortCode>1</StatusSortCode><TherapyArea id="746">Infectious disease</TherapyArea></Row><Row><Action id="3252">Insulin-like growth factor 1 receptor antagonist</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="US">US</Country><Drug id="71794">adalimumab + anti-Ang2 Zybody (inflammatory disease), Zyngenia</Drug><DrugRelationship>General interest</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Priority</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PRI</HighestPatStatusIdForCnty><Indication id="84">Crohns disease</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA7191557">WO-2012162561</Patent><Status id="PRI">First Priority</Status><StatusDate>2011-05-24 00:00:00</StatusDate><StatusSortCode>1</StatusSortCode><TherapyArea id="185">Immune disorder</TherapyArea></Row><Row><Action id="3252">Insulin-like growth factor 1 receptor antagonist</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="US">US</Country><Drug id="71794">adalimumab + anti-Ang2 Zybody (inflammatory disease), Zyngenia</Drug><DrugRelationship>General interest</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Priority</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PRI</HighestPatStatusIdForCnty><Indication id="97">Diabetes mellitus</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA7191557">WO-2012162561</Patent><Status id="PRI">First Priority</Status><StatusDate>2011-05-24 00:00:00</StatusDate><StatusSortCode>1</StatusSortCode><TherapyArea id="112">Endocrine disease</TherapyArea></Row><Row><Action id="3682">FGF1 receptor antagonist</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="US">US</Country><Drug id="71794">adalimumab + anti-Ang2 Zybody (inflammatory disease), Zyngenia</Drug><DrugRelationship>General interest</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Priority</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PRI</HighestPatStatusIdForCnty><Indication id="188">Inflammatory disease</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA7191557">WO-2012162561</Patent><Status id="PRI">First Priority</Status><StatusDate>2011-05-24 00:00:00</StatusDate><StatusSortCode>1</StatusSortCode><TherapyArea id="188">Inflammatory disease</TherapyArea></Row><Row><Action id="3682">FGF1 receptor antagonist</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="US">US</Country><Drug id="71794">adalimumab + anti-Ang2 Zybody (inflammatory disease), Zyngenia</Drug><DrugRelationship>General interest</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Priority</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PRI</HighestPatStatusIdForCnty><Indication id="189">Inflammatory bowel disease</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA7191557">WO-2012162561</Patent><Status id="PRI">First Priority</Status><StatusDate>2011-05-24 00:00:00</StatusDate><StatusSortCode>1</StatusSortCode><TherapyArea id="188">Inflammatory disease</TherapyArea></Row><Row><Action id="3682">FGF1 receptor antagonist</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="US">US</Country><Drug id="71794">adalimumab + anti-Ang2 Zybody (inflammatory disease), Zyngenia</Drug><DrugRelationship>General interest</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Priority</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PRI</HighestPatStatusIdForCnty><Indication id="213">Multiple sclerosis</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA7191557">WO-2012162561</Patent><Status id="PRI">First Priority</Status><StatusDate>2011-05-24 00:00:00</StatusDate><StatusSortCode>1</StatusSortCode><TherapyArea id="185">Immune disorder</TherapyArea></Row><Row><Action id="3682">FGF1 receptor antagonist</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="US">US</Country><Drug id="71794">adalimumab + anti-Ang2 Zybody (inflammatory disease), Zyngenia</Drug><DrugRelationship>General interest</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Priority</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PRI</HighestPatStatusIdForCnty><Indication id="281">Psoriasis</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA7191557">WO-2012162561</Patent><Status id="PRI">First Priority</Status><StatusDate>2011-05-24 00:00:00</StatusDate><StatusSortCode>1</StatusSortCode><TherapyArea id="95">Dermatological disease</TherapyArea></Row><Row><Action id="3682">FGF1 receptor antagonist</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="US">US</Country><Drug id="71794">adalimumab + anti-Ang2 Zybody (inflammatory disease), Zyngenia</Drug><DrugRelationship>General interest</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Priority</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PRI</HighestPatStatusIdForCnty><Indication id="291">Rheumatoid arthritis</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA7191557">WO-2012162561</Patent><Status id="PRI">First Priority</Status><StatusDate>2011-05-24 00:00:00</StatusDate><StatusSortCode>1</StatusSortCode><TherapyArea id="185">Immune disorder</TherapyArea></Row><Row><Action id="3682">FGF1 receptor antagonist</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="US">US</Country><Drug id="71794">adalimumab + anti-Ang2 Zybody (inflammatory disease), Zyngenia</Drug><DrugRelationship>General interest</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Priority</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PRI</HighestPatStatusIdForCnty><Indication id="318">Systemic lupus erythematosus</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA7191557">WO-2012162561</Patent><Status id="PRI">First Priority</Status><StatusDate>2011-05-24 00:00:00</StatusDate><StatusSortCode>1</StatusSortCode><TherapyArea id="95">Dermatological disease</TherapyArea></Row><Row><Action id="3682">FGF1 receptor antagonist</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="US">US</Country><Drug id="71794">adalimumab + anti-Ang2 Zybody (inflammatory disease), Zyngenia</Drug><DrugRelationship>General interest</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Priority</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PRI</HighestPatStatusIdForCnty><Indication id="337">Ulcerative colitis</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA7191557">WO-2012162561</Patent><Status id="PRI">First Priority</Status><StatusDate>2011-05-24 00:00:00</StatusDate><StatusSortCode>1</StatusSortCode><TherapyArea id="185">Immune disorder</TherapyArea></Row><Row><Action id="3682">FGF1 receptor antagonist</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="US">US</Country><Drug id="71794">adalimumab + anti-Ang2 Zybody (inflammatory disease), Zyngenia</Drug><DrugRelationship>General interest</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Priority</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PRI</HighestPatStatusIdForCnty><Indication id="651">Cancer</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA7191557">WO-2012162561</Patent><Status id="PRI">First Priority</Status><StatusDate>2011-05-24 00:00:00</StatusDate><StatusSortCode>1</StatusSortCode><TherapyArea id="230">Neoplasm</TherapyArea></Row><Row><Action id="3682">FGF1 receptor antagonist</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="US">US</Country><Drug id="71794">adalimumab + anti-Ang2 Zybody (inflammatory disease), Zyngenia</Drug><DrugRelationship>General interest</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Priority</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PRI</HighestPatStatusIdForCnty><Indication id="746">Infectious disease</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA7191557">WO-2012162561</Patent><Status id="PRI">First Priority</Status><StatusDate>2011-05-24 00:00:00</StatusDate><StatusSortCode>1</StatusSortCode><TherapyArea id="746">Infectious disease</TherapyArea></Row><Row><Action id="3682">FGF1 receptor antagonist</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="US">US</Country><Drug id="71794">adalimumab + anti-Ang2 Zybody (inflammatory disease), Zyngenia</Drug><DrugRelationship>General interest</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Priority</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PRI</HighestPatStatusIdForCnty><Indication id="84">Crohns disease</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA7191557">WO-2012162561</Patent><Status id="PRI">First Priority</Status><StatusDate>2011-05-24 00:00:00</StatusDate><StatusSortCode>1</StatusSortCode><TherapyArea id="185">Immune disorder</TherapyArea></Row><Row><Action id="3682">FGF1 receptor antagonist</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="US">US</Country><Drug id="71794">adalimumab + anti-Ang2 Zybody (inflammatory disease), Zyngenia</Drug><DrugRelationship>General interest</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Priority</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PRI</HighestPatStatusIdForCnty><Indication id="97">Diabetes mellitus</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA7191557">WO-2012162561</Patent><Status id="PRI">First Priority</Status><StatusDate>2011-05-24 00:00:00</StatusDate><StatusSortCode>1</StatusSortCode><TherapyArea id="112">Endocrine disease</TherapyArea></Row><Row><Action id="3685">FGF2 receptor antagonist</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="US">US</Country><Drug id="71794">adalimumab + anti-Ang2 Zybody (inflammatory disease), Zyngenia</Drug><DrugRelationship>General interest</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Priority</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PRI</HighestPatStatusIdForCnty><Indication id="188">Inflammatory disease</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA7191557">WO-2012162561</Patent><Status id="PRI">First Priority</Status><StatusDate>2011-05-24 00:00:00</StatusDate><StatusSortCode>1</StatusSortCode><TherapyArea id="188">Inflammatory disease</TherapyArea></Row><Row><Action id="3685">FGF2 receptor antagonist</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="US">US</Country><Drug id="71794">adalimumab + anti-Ang2 Zybody (inflammatory disease), Zyngenia</Drug><DrugRelationship>General interest</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Priority</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PRI</HighestPatStatusIdForCnty><Indication id="189">Inflammatory bowel disease</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA7191557">WO-2012162561</Patent><Status id="PRI">First Priority</Status><StatusDate>2011-05-24 00:00:00</StatusDate><StatusSortCode>1</StatusSortCode><TherapyArea id="188">Inflammatory disease</TherapyArea></Row><Row><Action id="3685">FGF2 receptor antagonist</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="US">US</Country><Drug id="71794">adalimumab + anti-Ang2 Zybody (inflammatory disease), Zyngenia</Drug><DrugRelationship>General interest</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Priority</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PRI</HighestPatStatusIdForCnty><Indication id="213">Multiple sclerosis</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA7191557">WO-2012162561</Patent><Status id="PRI">First Priority</Status><StatusDate>2011-05-24 00:00:00</StatusDate><StatusSortCode>1</StatusSortCode><TherapyArea id="185">Immune disorder</TherapyArea></Row><Row><Action id="3685">FGF2 receptor antagonist</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="US">US</Country><Drug id="71794">adalimumab + anti-Ang2 Zybody (inflammatory disease), Zyngenia</Drug><DrugRelationship>General interest</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Priority</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PRI</HighestPatStatusIdForCnty><Indication id="281">Psoriasis</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA7191557">WO-2012162561</Patent><Status id="PRI">First Priority</Status><StatusDate>2011-05-24 00:00:00</StatusDate><StatusSortCode>1</StatusSortCode><TherapyArea id="95">Dermatological disease</TherapyArea></Row><Row><Action id="3685">FGF2 receptor antagonist</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="US">US</Country><Drug id="71794">adalimumab + anti-Ang2 Zybody (inflammatory disease), Zyngenia</Drug><DrugRelationship>General interest</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Priority</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PRI</HighestPatStatusIdForCnty><Indication id="291">Rheumatoid arthritis</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA7191557">WO-2012162561</Patent><Status id="PRI">First Priority</Status><StatusDate>2011-05-24 00:00:00</StatusDate><StatusSortCode>1</StatusSortCode><TherapyArea id="185">Immune disorder</TherapyArea></Row><Row><Action id="3685">FGF2 receptor antagonist</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="US">US</Country><Drug id="71794">adalimumab + anti-Ang2 Zybody (inflammatory disease), Zyngenia</Drug><DrugRelationship>General interest</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Priority</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PRI</HighestPatStatusIdForCnty><Indication id="318">Systemic lupus erythematosus</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA7191557">WO-2012162561</Patent><Status id="PRI">First Priority</Status><StatusDate>2011-05-24 00:00:00</StatusDate><StatusSortCode>1</StatusSortCode><TherapyArea id="95">Dermatological disease</TherapyArea></Row><Row><Action id="3685">FGF2 receptor antagonist</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="US">US</Country><Drug id="71794">adalimumab + anti-Ang2 Zybody (inflammatory disease), Zyngenia</Drug><DrugRelationship>General interest</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Priority</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PRI</HighestPatStatusIdForCnty><Indication id="337">Ulcerative colitis</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA7191557">WO-2012162561</Patent><Status id="PRI">First Priority</Status><StatusDate>2011-05-24 00:00:00</StatusDate><StatusSortCode>1</StatusSortCode><TherapyArea id="185">Immune disorder</TherapyArea></Row><Row><Action id="3685">FGF2 receptor antagonist</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="US">US</Country><Drug id="71794">adalimumab + anti-Ang2 Zybody (inflammatory disease), Zyngenia</Drug><DrugRelationship>General interest</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Priority</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PRI</HighestPatStatusIdForCnty><Indication id="651">Cancer</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA7191557">WO-2012162561</Patent><Status id="PRI">First Priority</Status><StatusDate>2011-05-24 00:00:00</StatusDate><StatusSortCode>1</StatusSortCode><TherapyArea id="230">Neoplasm</TherapyArea></Row><Row><Action id="3685">FGF2 receptor antagonist</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="US">US</Country><Drug id="71794">adalimumab + anti-Ang2 Zybody (inflammatory disease), Zyngenia</Drug><DrugRelationship>General interest</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Priority</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PRI</HighestPatStatusIdForCnty><Indication id="746">Infectious disease</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA7191557">WO-2012162561</Patent><Status id="PRI">First Priority</Status><StatusDate>2011-05-24 00:00:00</StatusDate><StatusSortCode>1</StatusSortCode><TherapyArea id="746">Infectious disease</TherapyArea></Row><Row><Action id="3685">FGF2 receptor antagonist</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="US">US</Country><Drug id="71794">adalimumab + anti-Ang2 Zybody (inflammatory disease), Zyngenia</Drug><DrugRelationship>General interest</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Priority</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PRI</HighestPatStatusIdForCnty><Indication id="84">Crohns disease</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA7191557">WO-2012162561</Patent><Status id="PRI">First Priority</Status><StatusDate>2011-05-24 00:00:00</StatusDate><StatusSortCode>1</StatusSortCode><TherapyArea id="185">Immune disorder</TherapyArea></Row><Row><Action id="3685">FGF2 receptor antagonist</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="US">US</Country><Drug id="71794">adalimumab + anti-Ang2 Zybody (inflammatory disease), Zyngenia</Drug><DrugRelationship>General interest</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Priority</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PRI</HighestPatStatusIdForCnty><Indication id="97">Diabetes mellitus</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA7191557">WO-2012162561</Patent><Status id="PRI">First Priority</Status><StatusDate>2011-05-24 00:00:00</StatusDate><StatusSortCode>1</StatusSortCode><TherapyArea id="112">Endocrine disease</TherapyArea></Row><Row><Action id="3756">Erbb2 tyrosine kinase receptor inhibitor</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="US">US</Country><Drug id="71794">adalimumab + anti-Ang2 Zybody (inflammatory disease), Zyngenia</Drug><DrugRelationship>General interest</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Priority</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PRI</HighestPatStatusIdForCnty><Indication id="188">Inflammatory disease</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA7191557">WO-2012162561</Patent><Status id="PRI">First Priority</Status><StatusDate>2011-05-24 00:00:00</StatusDate><StatusSortCode>1</StatusSortCode><TherapyArea id="188">Inflammatory disease</TherapyArea></Row><Row><Action id="3756">Erbb2 tyrosine kinase receptor inhibitor</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="US">US</Country><Drug id="71794">adalimumab + anti-Ang2 Zybody (inflammatory disease), Zyngenia</Drug><DrugRelationship>General interest</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Priority</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PRI</HighestPatStatusIdForCnty><Indication id="189">Inflammatory bowel disease</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA7191557">WO-2012162561</Patent><Status id="PRI">First Priority</Status><StatusDate>2011-05-24 00:00:00</StatusDate><StatusSortCode>1</StatusSortCode><TherapyArea id="188">Inflammatory disease</TherapyArea></Row><Row><Action id="3756">Erbb2 tyrosine kinase receptor inhibitor</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="US">US</Country><Drug id="71794">adalimumab + anti-Ang2 Zybody (inflammatory disease), Zyngenia</Drug><DrugRelationship>General interest</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Priority</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PRI</HighestPatStatusIdForCnty><Indication id="213">Multiple sclerosis</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA7191557">WO-2012162561</Patent><Status id="PRI">First Priority</Status><StatusDate>2011-05-24 00:00:00</StatusDate><StatusSortCode>1</StatusSortCode><TherapyArea id="185">Immune disorder</TherapyArea></Row><Row><Action id="3756">Erbb2 tyrosine kinase receptor inhibitor</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="US">US</Country><Drug id="71794">adalimumab + anti-Ang2 Zybody (inflammatory disease), Zyngenia</Drug><DrugRelationship>General interest</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Priority</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PRI</HighestPatStatusIdForCnty><Indication id="281">Psoriasis</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA7191557">WO-2012162561</Patent><Status id="PRI">First Priority</Status><StatusDate>2011-05-24 00:00:00</StatusDate><StatusSortCode>1</StatusSortCode><TherapyArea id="95">Dermatological disease</TherapyArea></Row><Row><Action id="3756">Erbb2 tyrosine kinase receptor inhibitor</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="US">US</Country><Drug id="71794">adalimumab + anti-Ang2 Zybody (inflammatory disease), Zyngenia</Drug><DrugRelationship>General interest</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Priority</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PRI</HighestPatStatusIdForCnty><Indication id="291">Rheumatoid arthritis</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA7191557">WO-2012162561</Patent><Status id="PRI">First Priority</Status><StatusDate>2011-05-24 00:00:00</StatusDate><StatusSortCode>1</StatusSortCode><TherapyArea id="185">Immune disorder</TherapyArea></Row><Row><Action id="3756">Erbb2 tyrosine kinase receptor inhibitor</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="US">US</Country><Drug id="71794">adalimumab + anti-Ang2 Zybody (inflammatory disease), Zyngenia</Drug><DrugRelationship>General interest</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Priority</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PRI</HighestPatStatusIdForCnty><Indication id="318">Systemic lupus erythematosus</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA7191557">WO-2012162561</Patent><Status id="PRI">First Priority</Status><StatusDate>2011-05-24 00:00:00</StatusDate><StatusSortCode>1</StatusSortCode><TherapyArea id="95">Dermatological disease</TherapyArea></Row><Row><Action id="3756">Erbb2 tyrosine kinase receptor inhibitor</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="US">US</Country><Drug id="71794">adalimumab + anti-Ang2 Zybody (inflammatory disease), Zyngenia</Drug><DrugRelationship>General interest</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Priority</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PRI</HighestPatStatusIdForCnty><Indication id="337">Ulcerative colitis</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA7191557">WO-2012162561</Patent><Status id="PRI">First Priority</Status><StatusDate>2011-05-24 00:00:00</StatusDate><StatusSortCode>1</StatusSortCode><TherapyArea id="185">Immune disorder</TherapyArea></Row><Row><Action id="3756">Erbb2 tyrosine kinase receptor inhibitor</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="US">US</Country><Drug id="71794">adalimumab + anti-Ang2 Zybody (inflammatory disease), Zyngenia</Drug><DrugRelationship>General interest</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Priority</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PRI</HighestPatStatusIdForCnty><Indication id="651">Cancer</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA7191557">WO-2012162561</Patent><Status id="PRI">First Priority</Status><StatusDate>2011-05-24 00:00:00</StatusDate><StatusSortCode>1</StatusSortCode><TherapyArea id="230">Neoplasm</TherapyArea></Row><Row><Action id="3756">Erbb2 tyrosine kinase receptor inhibitor</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="US">US</Country><Drug id="71794">adalimumab + anti-Ang2 Zybody (inflammatory disease), Zyngenia</Drug><DrugRelationship>General interest</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Priority</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PRI</HighestPatStatusIdForCnty><Indication id="746">Infectious disease</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA7191557">WO-2012162561</Patent><Status id="PRI">First Priority</Status><StatusDate>2011-05-24 00:00:00</StatusDate><StatusSortCode>1</StatusSortCode><TherapyArea id="746">Infectious disease</TherapyArea></Row><Row><Action id="3756">Erbb2 tyrosine kinase receptor inhibitor</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="US">US</Country><Drug id="71794">adalimumab + anti-Ang2 Zybody (inflammatory disease), Zyngenia</Drug><DrugRelationship>General interest</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Priority</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PRI</HighestPatStatusIdForCnty><Indication id="84">Crohns disease</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA7191557">WO-2012162561</Patent><Status id="PRI">First Priority</Status><StatusDate>2011-05-24 00:00:00</StatusDate><StatusSortCode>1</StatusSortCode><TherapyArea id="185">Immune disorder</TherapyArea></Row><Row><Action id="3756">Erbb2 tyrosine kinase receptor inhibitor</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="US">US</Country><Drug id="71794">adalimumab + anti-Ang2 Zybody (inflammatory disease), Zyngenia</Drug><DrugRelationship>General interest</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Priority</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PRI</HighestPatStatusIdForCnty><Indication id="97">Diabetes mellitus</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA7191557">WO-2012162561</Patent><Status id="PRI">First Priority</Status><StatusDate>2011-05-24 00:00:00</StatusDate><StatusSortCode>1</StatusSortCode><TherapyArea id="112">Endocrine disease</TherapyArea></Row><Row><Action id="3846">VEGF-1 receptor antagonist</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="US">US</Country><Drug id="71794">adalimumab + anti-Ang2 Zybody (inflammatory disease), Zyngenia</Drug><DrugRelationship>General interest</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Priority</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PRI</HighestPatStatusIdForCnty><Indication id="188">Inflammatory disease</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA7191557">WO-2012162561</Patent><Status id="PRI">First Priority</Status><StatusDate>2011-05-24 00:00:00</StatusDate><StatusSortCode>1</StatusSortCode><TherapyArea id="188">Inflammatory disease</TherapyArea></Row><Row><Action id="3846">VEGF-1 receptor antagonist</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="US">US</Country><Drug id="71794">adalimumab + anti-Ang2 Zybody (inflammatory disease), Zyngenia</Drug><DrugRelationship>General interest</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Priority</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PRI</HighestPatStatusIdForCnty><Indication id="189">Inflammatory bowel disease</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA7191557">WO-2012162561</Patent><Status id="PRI">First Priority</Status><StatusDate>2011-05-24 00:00:00</StatusDate><StatusSortCode>1</StatusSortCode><TherapyArea id="188">Inflammatory disease</TherapyArea></Row><Row><Action id="3846">VEGF-1 receptor antagonist</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="US">US</Country><Drug id="71794">adalimumab + anti-Ang2 Zybody (inflammatory disease), Zyngenia</Drug><DrugRelationship>General interest</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Priority</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PRI</HighestPatStatusIdForCnty><Indication id="213">Multiple sclerosis</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA7191557">WO-2012162561</Patent><Status id="PRI">First Priority</Status><StatusDate>2011-05-24 00:00:00</StatusDate><StatusSortCode>1</StatusSortCode><TherapyArea id="185">Immune disorder</TherapyArea></Row><Row><Action id="3846">VEGF-1 receptor antagonist</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="US">US</Country><Drug id="71794">adalimumab + anti-Ang2 Zybody (inflammatory disease), Zyngenia</Drug><DrugRelationship>General interest</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Priority</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PRI</HighestPatStatusIdForCnty><Indication id="281">Psoriasis</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA7191557">WO-2012162561</Patent><Status id="PRI">First Priority</Status><StatusDate>2011-05-24 00:00:00</StatusDate><StatusSortCode>1</StatusSortCode><TherapyArea id="95">Dermatological disease</TherapyArea></Row><Row><Action id="3846">VEGF-1 receptor antagonist</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="US">US</Country><Drug id="71794">adalimumab + anti-Ang2 Zybody (inflammatory disease), Zyngenia</Drug><DrugRelationship>General interest</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Priority</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PRI</HighestPatStatusIdForCnty><Indication id="291">Rheumatoid arthritis</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA7191557">WO-2012162561</Patent><Status id="PRI">First Priority</Status><StatusDate>2011-05-24 00:00:00</StatusDate><StatusSortCode>1</StatusSortCode><TherapyArea id="185">Immune disorder</TherapyArea></Row><Row><Action id="3846">VEGF-1 receptor antagonist</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="US">US</Country><Drug id="71794">adalimumab + anti-Ang2 Zybody (inflammatory disease), Zyngenia</Drug><DrugRelationship>General interest</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Priority</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PRI</HighestPatStatusIdForCnty><Indication id="318">Systemic lupus erythematosus</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA7191557">WO-2012162561</Patent><Status id="PRI">First Priority</Status><StatusDate>2011-05-24 00:00:00</StatusDate><StatusSortCode>1</StatusSortCode><TherapyArea id="95">Dermatological disease</TherapyArea></Row><Row><Action id="3846">VEGF-1 receptor antagonist</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="US">US</Country><Drug id="71794">adalimumab + anti-Ang2 Zybody (inflammatory disease), Zyngenia</Drug><DrugRelationship>General interest</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Priority</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PRI</HighestPatStatusIdForCnty><Indication id="337">Ulcerative colitis</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA7191557">WO-2012162561</Patent><Status id="PRI">First Priority</Status><StatusDate>2011-05-24 00:00:00</StatusDate><StatusSortCode>1</StatusSortCode><TherapyArea id="185">Immune disorder</TherapyArea></Row><Row><Action id="3846">VEGF-1 receptor antagonist</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="US">US</Country><Drug id="71794">adalimumab + anti-Ang2 Zybody (inflammatory disease), Zyngenia</Drug><DrugRelationship>General interest</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Priority</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PRI</HighestPatStatusIdForCnty><Indication id="651">Cancer</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA7191557">WO-2012162561</Patent><Status id="PRI">First Priority</Status><StatusDate>2011-05-24 00:00:00</StatusDate><StatusSortCode>1</StatusSortCode><TherapyArea id="230">Neoplasm</TherapyArea></Row><Row><Action id="3846">VEGF-1 receptor antagonist</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="US">US</Country><Drug id="71794">adalimumab + anti-Ang2 Zybody (inflammatory disease), Zyngenia</Drug><DrugRelationship>General interest</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Priority</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PRI</HighestPatStatusIdForCnty><Indication id="746">Infectious disease</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA7191557">WO-2012162561</Patent><Status id="PRI">First Priority</Status><StatusDate>2011-05-24 00:00:00</StatusDate><StatusSortCode>1</StatusSortCode><TherapyArea id="746">Infectious disease</TherapyArea></Row><Row><Action id="3846">VEGF-1 receptor antagonist</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="US">US</Country><Drug id="71794">adalimumab + anti-Ang2 Zybody (inflammatory disease), Zyngenia</Drug><DrugRelationship>General interest</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Priority</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PRI</HighestPatStatusIdForCnty><Indication id="84">Crohns disease</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA7191557">WO-2012162561</Patent><Status id="PRI">First Priority</Status><StatusDate>2011-05-24 00:00:00</StatusDate><StatusSortCode>1</StatusSortCode><TherapyArea id="185">Immune disorder</TherapyArea></Row><Row><Action id="3846">VEGF-1 receptor antagonist</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="US">US</Country><Drug id="71794">adalimumab + anti-Ang2 Zybody (inflammatory disease), Zyngenia</Drug><DrugRelationship>General interest</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Priority</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PRI</HighestPatStatusIdForCnty><Indication id="97">Diabetes mellitus</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA7191557">WO-2012162561</Patent><Status id="PRI">First Priority</Status><StatusDate>2011-05-24 00:00:00</StatusDate><StatusSortCode>1</StatusSortCode><TherapyArea id="112">Endocrine disease</TherapyArea></Row><Row><Action id="5025">CD3 antagonist</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="US">US</Country><Drug id="71794">adalimumab + anti-Ang2 Zybody (inflammatory disease), Zyngenia</Drug><DrugRelationship>General interest</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Priority</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PRI</HighestPatStatusIdForCnty><Indication id="188">Inflammatory disease</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA7191557">WO-2012162561</Patent><Status id="PRI">First Priority</Status><StatusDate>2011-05-24 00:00:00</StatusDate><StatusSortCode>1</StatusSortCode><TherapyArea id="188">Inflammatory disease</TherapyArea></Row><Row><Action id="5025">CD3 antagonist</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="US">US</Country><Drug id="71794">adalimumab + anti-Ang2 Zybody (inflammatory disease), Zyngenia</Drug><DrugRelationship>General interest</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Priority</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PRI</HighestPatStatusIdForCnty><Indication id="189">Inflammatory bowel disease</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA7191557">WO-2012162561</Patent><Status id="PRI">First Priority</Status><StatusDate>2011-05-24 00:00:00</StatusDate><StatusSortCode>1</StatusSortCode><TherapyArea id="188">Inflammatory disease</TherapyArea></Row><Row><Action id="5025">CD3 antagonist</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="US">US</Country><Drug id="71794">adalimumab + anti-Ang2 Zybody (inflammatory disease), Zyngenia</Drug><DrugRelationship>General interest</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Priority</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PRI</HighestPatStatusIdForCnty><Indication id="213">Multiple sclerosis</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA7191557">WO-2012162561</Patent><Status id="PRI">First Priority</Status><StatusDate>2011-05-24 00:00:00</StatusDate><StatusSortCode>1</StatusSortCode><TherapyArea id="185">Immune disorder</TherapyArea></Row><Row><Action id="5025">CD3 antagonist</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="US">US</Country><Drug id="71794">adalimumab + anti-Ang2 Zybody (inflammatory disease), Zyngenia</Drug><DrugRelationship>General interest</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Priority</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PRI</HighestPatStatusIdForCnty><Indication id="281">Psoriasis</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA7191557">WO-2012162561</Patent><Status id="PRI">First Priority</Status><StatusDate>2011-05-24 00:00:00</StatusDate><StatusSortCode>1</StatusSortCode><TherapyArea id="95">Dermatological disease</TherapyArea></Row><Row><Action id="5025">CD3 antagonist</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="US">US</Country><Drug id="71794">adalimumab + anti-Ang2 Zybody (inflammatory disease), Zyngenia</Drug><DrugRelationship>General interest</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Priority</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PRI</HighestPatStatusIdForCnty><Indication id="291">Rheumatoid arthritis</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA7191557">WO-2012162561</Patent><Status id="PRI">First Priority</Status><StatusDate>2011-05-24 00:00:00</StatusDate><StatusSortCode>1</StatusSortCode><TherapyArea id="185">Immune disorder</TherapyArea></Row><Row><Action id="5025">CD3 antagonist</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="US">US</Country><Drug id="71794">adalimumab + anti-Ang2 Zybody (inflammatory disease), Zyngenia</Drug><DrugRelationship>General interest</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Priority</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PRI</HighestPatStatusIdForCnty><Indication id="318">Systemic lupus erythematosus</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA7191557">WO-2012162561</Patent><Status id="PRI">First Priority</Status><StatusDate>2011-05-24 00:00:00</StatusDate><StatusSortCode>1</StatusSortCode><TherapyArea id="95">Dermatological disease</TherapyArea></Row><Row><Action id="5025">CD3 antagonist</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="US">US</Country><Drug id="71794">adalimumab + anti-Ang2 Zybody (inflammatory disease), Zyngenia</Drug><DrugRelationship>General interest</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Priority</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PRI</HighestPatStatusIdForCnty><Indication id="337">Ulcerative colitis</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA7191557">WO-2012162561</Patent><Status id="PRI">First Priority</Status><StatusDate>2011-05-24 00:00:00</StatusDate><StatusSortCode>1</StatusSortCode><TherapyArea id="185">Immune disorder</TherapyArea></Row><Row><Action id="5025">CD3 antagonist</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="US">US</Country><Drug id="71794">adalimumab + anti-Ang2 Zybody (inflammatory disease), Zyngenia</Drug><DrugRelationship>General interest</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Priority</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PRI</HighestPatStatusIdForCnty><Indication id="651">Cancer</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA7191557">WO-2012162561</Patent><Status id="PRI">First Priority</Status><StatusDate>2011-05-24 00:00:00</StatusDate><StatusSortCode>1</StatusSortCode><TherapyArea id="230">Neoplasm</TherapyArea></Row><Row><Action id="5025">CD3 antagonist</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="US">US</Country><Drug id="71794">adalimumab + anti-Ang2 Zybody (inflammatory disease), Zyngenia</Drug><DrugRelationship>General interest</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Priority</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PRI</HighestPatStatusIdForCnty><Indication id="746">Infectious disease</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA7191557">WO-2012162561</Patent><Status id="PRI">First Priority</Status><StatusDate>2011-05-24 00:00:00</StatusDate><StatusSortCode>1</StatusSortCode><TherapyArea id="746">Infectious disease</TherapyArea></Row><Row><Action id="5025">CD3 antagonist</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="US">US</Country><Drug id="71794">adalimumab + anti-Ang2 Zybody (inflammatory disease), Zyngenia</Drug><DrugRelationship>General interest</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Priority</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PRI</HighestPatStatusIdForCnty><Indication id="84">Crohns disease</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA7191557">WO-2012162561</Patent><Status id="PRI">First Priority</Status><StatusDate>2011-05-24 00:00:00</StatusDate><StatusSortCode>1</StatusSortCode><TherapyArea id="185">Immune disorder</TherapyArea></Row><Row><Action id="5025">CD3 antagonist</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="US">US</Country><Drug id="71794">adalimumab + anti-Ang2 Zybody (inflammatory disease), Zyngenia</Drug><DrugRelationship>General interest</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Priority</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PRI</HighestPatStatusIdForCnty><Indication id="97">Diabetes mellitus</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA7191557">WO-2012162561</Patent><Status id="PRI">First Priority</Status><StatusDate>2011-05-24 00:00:00</StatusDate><StatusSortCode>1</StatusSortCode><TherapyArea id="112">Endocrine disease</TherapyArea></Row><Row><Action id="5082">B-lymphocyte antigen CD19 inhibitor</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="US">US</Country><Drug id="71794">adalimumab + anti-Ang2 Zybody (inflammatory disease), Zyngenia</Drug><DrugRelationship>General interest</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Priority</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PRI</HighestPatStatusIdForCnty><Indication id="188">Inflammatory disease</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA7191557">WO-2012162561</Patent><Status id="PRI">First Priority</Status><StatusDate>2011-05-24 00:00:00</StatusDate><StatusSortCode>1</StatusSortCode><TherapyArea id="188">Inflammatory disease</TherapyArea></Row><Row><Action id="5082">B-lymphocyte antigen CD19 inhibitor</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="US">US</Country><Drug id="71794">adalimumab + anti-Ang2 Zybody (inflammatory disease), Zyngenia</Drug><DrugRelationship>General interest</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Priority</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PRI</HighestPatStatusIdForCnty><Indication id="189">Inflammatory bowel disease</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA7191557">WO-2012162561</Patent><Status id="PRI">First Priority</Status><StatusDate>2011-05-24 00:00:00</StatusDate><StatusSortCode>1</StatusSortCode><TherapyArea id="188">Inflammatory disease</TherapyArea></Row><Row><Action id="5082">B-lymphocyte antigen CD19 inhibitor</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="US">US</Country><Drug id="71794">adalimumab + anti-Ang2 Zybody (inflammatory disease), Zyngenia</Drug><DrugRelationship>General interest</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Priority</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PRI</HighestPatStatusIdForCnty><Indication id="213">Multiple sclerosis</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA7191557">WO-2012162561</Patent><Status id="PRI">First Priority</Status><StatusDate>2011-05-24 00:00:00</StatusDate><StatusSortCode>1</StatusSortCode><TherapyArea id="185">Immune disorder</TherapyArea></Row><Row><Action id="5082">B-lymphocyte antigen CD19 inhibitor</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="US">US</Country><Drug id="71794">adalimumab + anti-Ang2 Zybody (inflammatory disease), Zyngenia</Drug><DrugRelationship>General interest</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Priority</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PRI</HighestPatStatusIdForCnty><Indication id="281">Psoriasis</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA7191557">WO-2012162561</Patent><Status id="PRI">First Priority</Status><StatusDate>2011-05-24 00:00:00</StatusDate><StatusSortCode>1</StatusSortCode><TherapyArea id="95">Dermatological disease</TherapyArea></Row><Row><Action id="5082">B-lymphocyte antigen CD19 inhibitor</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="US">US</Country><Drug id="71794">adalimumab + anti-Ang2 Zybody (inflammatory disease), Zyngenia</Drug><DrugRelationship>General interest</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Priority</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PRI</HighestPatStatusIdForCnty><Indication id="291">Rheumatoid arthritis</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA7191557">WO-2012162561</Patent><Status id="PRI">First Priority</Status><StatusDate>2011-05-24 00:00:00</StatusDate><StatusSortCode>1</StatusSortCode><TherapyArea id="185">Immune disorder</TherapyArea></Row><Row><Action id="5082">B-lymphocyte antigen CD19 inhibitor</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="US">US</Country><Drug id="71794">adalimumab + anti-Ang2 Zybody (inflammatory disease), Zyngenia</Drug><DrugRelationship>General interest</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Priority</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PRI</HighestPatStatusIdForCnty><Indication id="318">Systemic lupus erythematosus</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA7191557">WO-2012162561</Patent><Status id="PRI">First Priority</Status><StatusDate>2011-05-24 00:00:00</StatusDate><StatusSortCode>1</StatusSortCode><TherapyArea id="95">Dermatological disease</TherapyArea></Row><Row><Action id="5082">B-lymphocyte antigen CD19 inhibitor</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="US">US</Country><Drug id="71794">adalimumab + anti-Ang2 Zybody (inflammatory disease), Zyngenia</Drug><DrugRelationship>General interest</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Priority</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PRI</HighestPatStatusIdForCnty><Indication id="337">Ulcerative colitis</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA7191557">WO-2012162561</Patent><Status id="PRI">First Priority</Status><StatusDate>2011-05-24 00:00:00</StatusDate><StatusSortCode>1</StatusSortCode><TherapyArea id="185">Immune disorder</TherapyArea></Row><Row><Action id="5082">B-lymphocyte antigen CD19 inhibitor</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="US">US</Country><Drug id="71794">adalimumab + anti-Ang2 Zybody (inflammatory disease), Zyngenia</Drug><DrugRelationship>General interest</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Priority</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PRI</HighestPatStatusIdForCnty><Indication id="651">Cancer</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA7191557">WO-2012162561</Patent><Status id="PRI">First Priority</Status><StatusDate>2011-05-24 00:00:00</StatusDate><StatusSortCode>1</StatusSortCode><TherapyArea id="230">Neoplasm</TherapyArea></Row><Row><Action id="5082">B-lymphocyte antigen CD19 inhibitor</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="US">US</Country><Drug id="71794">adalimumab + anti-Ang2 Zybody (inflammatory disease), Zyngenia</Drug><DrugRelationship>General interest</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Priority</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PRI</HighestPatStatusIdForCnty><Indication id="746">Infectious disease</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA7191557">WO-2012162561</Patent><Status id="PRI">First Priority</Status><StatusDate>2011-05-24 00:00:00</StatusDate><StatusSortCode>1</StatusSortCode><TherapyArea id="746">Infectious disease</TherapyArea></Row><Row><Action id="5082">B-lymphocyte antigen CD19 inhibitor</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="US">US</Country><Drug id="71794">adalimumab + anti-Ang2 Zybody (inflammatory disease), Zyngenia</Drug><DrugRelationship>General interest</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Priority</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PRI</HighestPatStatusIdForCnty><Indication id="84">Crohns disease</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA7191557">WO-2012162561</Patent><Status id="PRI">First Priority</Status><StatusDate>2011-05-24 00:00:00</StatusDate><StatusSortCode>1</StatusSortCode><TherapyArea id="185">Immune disorder</TherapyArea></Row><Row><Action id="5082">B-lymphocyte antigen CD19 inhibitor</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="US">US</Country><Drug id="71794">adalimumab + anti-Ang2 Zybody (inflammatory disease), Zyngenia</Drug><DrugRelationship>General interest</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Priority</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PRI</HighestPatStatusIdForCnty><Indication id="97">Diabetes mellitus</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA7191557">WO-2012162561</Patent><Status id="PRI">First Priority</Status><StatusDate>2011-05-24 00:00:00</StatusDate><StatusSortCode>1</StatusSortCode><TherapyArea id="112">Endocrine disease</TherapyArea></Row><Row><Action id="5085">B-lymphocyte antigen CD20 inhibitor</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="US">US</Country><Drug id="71794">adalimumab + anti-Ang2 Zybody (inflammatory disease), Zyngenia</Drug><DrugRelationship>General interest</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Priority</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PRI</HighestPatStatusIdForCnty><Indication id="188">Inflammatory disease</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA7191557">WO-2012162561</Patent><Status id="PRI">First Priority</Status><StatusDate>2011-05-24 00:00:00</StatusDate><StatusSortCode>1</StatusSortCode><TherapyArea id="188">Inflammatory disease</TherapyArea></Row><Row><Action id="5085">B-lymphocyte antigen CD20 inhibitor</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="US">US</Country><Drug id="71794">adalimumab + anti-Ang2 Zybody (inflammatory disease), Zyngenia</Drug><DrugRelationship>General interest</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Priority</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PRI</HighestPatStatusIdForCnty><Indication id="189">Inflammatory bowel disease</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA7191557">WO-2012162561</Patent><Status id="PRI">First Priority</Status><StatusDate>2011-05-24 00:00:00</StatusDate><StatusSortCode>1</StatusSortCode><TherapyArea id="188">Inflammatory disease</TherapyArea></Row><Row><Action id="5085">B-lymphocyte antigen CD20 inhibitor</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="US">US</Country><Drug id="71794">adalimumab + anti-Ang2 Zybody (inflammatory disease), Zyngenia</Drug><DrugRelationship>General interest</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Priority</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PRI</HighestPatStatusIdForCnty><Indication id="213">Multiple sclerosis</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA7191557">WO-2012162561</Patent><Status id="PRI">First Priority</Status><StatusDate>2011-05-24 00:00:00</StatusDate><StatusSortCode>1</StatusSortCode><TherapyArea id="185">Immune disorder</TherapyArea></Row><Row><Action id="5085">B-lymphocyte antigen CD20 inhibitor</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="US">US</Country><Drug id="71794">adalimumab + anti-Ang2 Zybody (inflammatory disease), Zyngenia</Drug><DrugRelationship>General interest</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Priority</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PRI</HighestPatStatusIdForCnty><Indication id="281">Psoriasis</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA7191557">WO-2012162561</Patent><Status id="PRI">First Priority</Status><StatusDate>2011-05-24 00:00:00</StatusDate><StatusSortCode>1</StatusSortCode><TherapyArea id="95">Dermatological disease</TherapyArea></Row><Row><Action id="5085">B-lymphocyte antigen CD20 inhibitor</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="US">US</Country><Drug id="71794">adalimumab + anti-Ang2 Zybody (inflammatory disease), Zyngenia</Drug><DrugRelationship>General interest</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Priority</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PRI</HighestPatStatusIdForCnty><Indication id="291">Rheumatoid arthritis</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA7191557">WO-2012162561</Patent><Status id="PRI">First Priority</Status><StatusDate>2011-05-24 00:00:00</StatusDate><StatusSortCode>1</StatusSortCode><TherapyArea id="185">Immune disorder</TherapyArea></Row><Row><Action id="5085">B-lymphocyte antigen CD20 inhibitor</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="US">US</Country><Drug id="71794">adalimumab + anti-Ang2 Zybody (inflammatory disease), Zyngenia</Drug><DrugRelationship>General interest</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Priority</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PRI</HighestPatStatusIdForCnty><Indication id="318">Systemic lupus erythematosus</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA7191557">WO-2012162561</Patent><Status id="PRI">First Priority</Status><StatusDate>2011-05-24 00:00:00</StatusDate><StatusSortCode>1</StatusSortCode><TherapyArea id="95">Dermatological disease</TherapyArea></Row><Row><Action id="5085">B-lymphocyte antigen CD20 inhibitor</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="US">US</Country><Drug id="71794">adalimumab + anti-Ang2 Zybody (inflammatory disease), Zyngenia</Drug><DrugRelationship>General interest</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Priority</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PRI</HighestPatStatusIdForCnty><Indication id="337">Ulcerative colitis</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA7191557">WO-2012162561</Patent><Status id="PRI">First Priority</Status><StatusDate>2011-05-24 00:00:00</StatusDate><StatusSortCode>1</StatusSortCode><TherapyArea id="185">Immune disorder</TherapyArea></Row><Row><Action id="5085">B-lymphocyte antigen CD20 inhibitor</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="US">US</Country><Drug id="71794">adalimumab + anti-Ang2 Zybody (inflammatory disease), Zyngenia</Drug><DrugRelationship>General interest</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Priority</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PRI</HighestPatStatusIdForCnty><Indication id="651">Cancer</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA7191557">WO-2012162561</Patent><Status id="PRI">First Priority</Status><StatusDate>2011-05-24 00:00:00</StatusDate><StatusSortCode>1</StatusSortCode><TherapyArea id="230">Neoplasm</TherapyArea></Row><Row><Action id="5085">B-lymphocyte antigen CD20 inhibitor</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="US">US</Country><Drug id="71794">adalimumab + anti-Ang2 Zybody (inflammatory disease), Zyngenia</Drug><DrugRelationship>General interest</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Priority</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PRI</HighestPatStatusIdForCnty><Indication id="746">Infectious disease</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA7191557">WO-2012162561</Patent><Status id="PRI">First Priority</Status><StatusDate>2011-05-24 00:00:00</StatusDate><StatusSortCode>1</StatusSortCode><TherapyArea id="746">Infectious disease</TherapyArea></Row><Row><Action id="5085">B-lymphocyte antigen CD20 inhibitor</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="US">US</Country><Drug id="71794">adalimumab + anti-Ang2 Zybody (inflammatory disease), Zyngenia</Drug><DrugRelationship>General interest</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Priority</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PRI</HighestPatStatusIdForCnty><Indication id="84">Crohns disease</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA7191557">WO-2012162561</Patent><Status id="PRI">First Priority</Status><StatusDate>2011-05-24 00:00:00</StatusDate><StatusSortCode>1</StatusSortCode><TherapyArea id="185">Immune disorder</TherapyArea></Row><Row><Action id="5085">B-lymphocyte antigen CD20 inhibitor</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="US">US</Country><Drug id="71794">adalimumab + anti-Ang2 Zybody (inflammatory disease), Zyngenia</Drug><DrugRelationship>General interest</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Priority</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PRI</HighestPatStatusIdForCnty><Indication id="97">Diabetes mellitus</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA7191557">WO-2012162561</Patent><Status id="PRI">First Priority</Status><StatusDate>2011-05-24 00:00:00</StatusDate><StatusSortCode>1</StatusSortCode><TherapyArea id="112">Endocrine disease</TherapyArea></Row><Row><Action id="511">TNF antagonist</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="US">US</Country><Drug id="71794">adalimumab + anti-Ang2 Zybody (inflammatory disease), Zyngenia</Drug><DrugRelationship>General interest</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Priority</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PRI</HighestPatStatusIdForCnty><Indication id="188">Inflammatory disease</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA7191557">WO-2012162561</Patent><Status id="PRI">First Priority</Status><StatusDate>2011-05-24 00:00:00</StatusDate><StatusSortCode>1</StatusSortCode><TherapyArea id="188">Inflammatory disease</TherapyArea></Row><Row><Action id="511">TNF antagonist</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="US">US</Country><Drug id="71794">adalimumab + anti-Ang2 Zybody (inflammatory disease), Zyngenia</Drug><DrugRelationship>General interest</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Priority</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PRI</HighestPatStatusIdForCnty><Indication id="189">Inflammatory bowel disease</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA7191557">WO-2012162561</Patent><Status id="PRI">First Priority</Status><StatusDate>2011-05-24 00:00:00</StatusDate><StatusSortCode>1</StatusSortCode><TherapyArea id="188">Inflammatory disease</TherapyArea></Row><Row><Action id="511">TNF antagonist</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="US">US</Country><Drug id="71794">adalimumab + anti-Ang2 Zybody (inflammatory disease), Zyngenia</Drug><DrugRelationship>General interest</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Priority</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PRI</HighestPatStatusIdForCnty><Indication id="213">Multiple sclerosis</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA7191557">WO-2012162561</Patent><Status id="PRI">First Priority</Status><StatusDate>2011-05-24 00:00:00</StatusDate><StatusSortCode>1</StatusSortCode><TherapyArea id="185">Immune disorder</TherapyArea></Row><Row><Action id="511">TNF antagonist</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="US">US</Country><Drug id="71794">adalimumab + anti-Ang2 Zybody (inflammatory disease), Zyngenia</Drug><DrugRelationship>General interest</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Priority</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PRI</HighestPatStatusIdForCnty><Indication id="281">Psoriasis</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA7191557">WO-2012162561</Patent><Status id="PRI">First Priority</Status><StatusDate>2011-05-24 00:00:00</StatusDate><StatusSortCode>1</StatusSortCode><TherapyArea id="95">Dermatological disease</TherapyArea></Row><Row><Action id="511">TNF antagonist</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="US">US</Country><Drug id="71794">adalimumab + anti-Ang2 Zybody (inflammatory disease), Zyngenia</Drug><DrugRelationship>General interest</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Priority</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PRI</HighestPatStatusIdForCnty><Indication id="291">Rheumatoid arthritis</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA7191557">WO-2012162561</Patent><Status id="PRI">First Priority</Status><StatusDate>2011-05-24 00:00:00</StatusDate><StatusSortCode>1</StatusSortCode><TherapyArea id="185">Immune disorder</TherapyArea></Row><Row><Action id="511">TNF antagonist</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="US">US</Country><Drug id="71794">adalimumab + anti-Ang2 Zybody (inflammatory disease), Zyngenia</Drug><DrugRelationship>General interest</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Priority</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PRI</HighestPatStatusIdForCnty><Indication id="318">Systemic lupus erythematosus</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA7191557">WO-2012162561</Patent><Status id="PRI">First Priority</Status><StatusDate>2011-05-24 00:00:00</StatusDate><StatusSortCode>1</StatusSortCode><TherapyArea id="95">Dermatological disease</TherapyArea></Row><Row><Action id="511">TNF antagonist</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="US">US</Country><Drug id="71794">adalimumab + anti-Ang2 Zybody (inflammatory disease), Zyngenia</Drug><DrugRelationship>General interest</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Priority</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PRI</HighestPatStatusIdForCnty><Indication id="337">Ulcerative colitis</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA7191557">WO-2012162561</Patent><Status id="PRI">First Priority</Status><StatusDate>2011-05-24 00:00:00</StatusDate><StatusSortCode>1</StatusSortCode><TherapyArea id="185">Immune disorder</TherapyArea></Row><Row><Action id="511">TNF antagonist</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="US">US</Country><Drug id="71794">adalimumab + anti-Ang2 Zybody (inflammatory disease), Zyngenia</Drug><DrugRelationship>General interest</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Priority</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PRI</HighestPatStatusIdForCnty><Indication id="651">Cancer</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA7191557">WO-2012162561</Patent><Status id="PRI">First Priority</Status><StatusDate>2011-05-24 00:00:00</StatusDate><StatusSortCode>1</StatusSortCode><TherapyArea id="230">Neoplasm</TherapyArea></Row><Row><Action id="511">TNF antagonist</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="US">US</Country><Drug id="71794">adalimumab + anti-Ang2 Zybody (inflammatory disease), Zyngenia</Drug><DrugRelationship>General interest</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Priority</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PRI</HighestPatStatusIdForCnty><Indication id="746">Infectious disease</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA7191557">WO-2012162561</Patent><Status id="PRI">First Priority</Status><StatusDate>2011-05-24 00:00:00</StatusDate><StatusSortCode>1</StatusSortCode><TherapyArea id="746">Infectious disease</TherapyArea></Row><Row><Action id="511">TNF antagonist</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="US">US</Country><Drug id="71794">adalimumab + anti-Ang2 Zybody (inflammatory disease), Zyngenia</Drug><DrugRelationship>General interest</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Priority</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PRI</HighestPatStatusIdForCnty><Indication id="84">Crohns disease</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA7191557">WO-2012162561</Patent><Status id="PRI">First Priority</Status><StatusDate>2011-05-24 00:00:00</StatusDate><StatusSortCode>1</StatusSortCode><TherapyArea id="185">Immune disorder</TherapyArea></Row><Row><Action id="511">TNF antagonist</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="US">US</Country><Drug id="71794">adalimumab + anti-Ang2 Zybody (inflammatory disease), Zyngenia</Drug><DrugRelationship>General interest</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Priority</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PRI</HighestPatStatusIdForCnty><Indication id="97">Diabetes mellitus</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA7191557">WO-2012162561</Patent><Status id="PRI">First Priority</Status><StatusDate>2011-05-24 00:00:00</StatusDate><StatusSortCode>1</StatusSortCode><TherapyArea id="112">Endocrine disease</TherapyArea></Row><Row><Action id="675">Hepatocyte growth factor receptor antagonist</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="US">US</Country><Drug id="71794">adalimumab + anti-Ang2 Zybody (inflammatory disease), Zyngenia</Drug><DrugRelationship>General interest</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Priority</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PRI</HighestPatStatusIdForCnty><Indication id="188">Inflammatory disease</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA7191557">WO-2012162561</Patent><Status id="PRI">First Priority</Status><StatusDate>2011-05-24 00:00:00</StatusDate><StatusSortCode>1</StatusSortCode><TherapyArea id="188">Inflammatory disease</TherapyArea></Row><Row><Action id="675">Hepatocyte growth factor receptor antagonist</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="US">US</Country><Drug id="71794">adalimumab + anti-Ang2 Zybody (inflammatory disease), Zyngenia</Drug><DrugRelationship>General interest</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Priority</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PRI</HighestPatStatusIdForCnty><Indication id="189">Inflammatory bowel disease</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA7191557">WO-2012162561</Patent><Status id="PRI">First Priority</Status><StatusDate>2011-05-24 00:00:00</StatusDate><StatusSortCode>1</StatusSortCode><TherapyArea id="188">Inflammatory disease</TherapyArea></Row><Row><Action id="675">Hepatocyte growth factor receptor antagonist</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="US">US</Country><Drug id="71794">adalimumab + anti-Ang2 Zybody (inflammatory disease), Zyngenia</Drug><DrugRelationship>General interest</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Priority</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PRI</HighestPatStatusIdForCnty><Indication id="213">Multiple sclerosis</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA7191557">WO-2012162561</Patent><Status id="PRI">First Priority</Status><StatusDate>2011-05-24 00:00:00</StatusDate><StatusSortCode>1</StatusSortCode><TherapyArea id="185">Immune disorder</TherapyArea></Row><Row><Action id="675">Hepatocyte growth factor receptor antagonist</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="US">US</Country><Drug id="71794">adalimumab + anti-Ang2 Zybody (inflammatory disease), Zyngenia</Drug><DrugRelationship>General interest</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Priority</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PRI</HighestPatStatusIdForCnty><Indication id="281">Psoriasis</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA7191557">WO-2012162561</Patent><Status id="PRI">First Priority</Status><StatusDate>2011-05-24 00:00:00</StatusDate><StatusSortCode>1</StatusSortCode><TherapyArea id="95">Dermatological disease</TherapyArea></Row><Row><Action id="675">Hepatocyte growth factor receptor antagonist</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="US">US</Country><Drug id="71794">adalimumab + anti-Ang2 Zybody (inflammatory disease), Zyngenia</Drug><DrugRelationship>General interest</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Priority</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PRI</HighestPatStatusIdForCnty><Indication id="291">Rheumatoid arthritis</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA7191557">WO-2012162561</Patent><Status id="PRI">First Priority</Status><StatusDate>2011-05-24 00:00:00</StatusDate><StatusSortCode>1</StatusSortCode><TherapyArea id="185">Immune disorder</TherapyArea></Row><Row><Action id="675">Hepatocyte growth factor receptor antagonist</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="US">US</Country><Drug id="71794">adalimumab + anti-Ang2 Zybody (inflammatory disease), Zyngenia</Drug><DrugRelationship>General interest</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Priority</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PRI</HighestPatStatusIdForCnty><Indication id="318">Systemic lupus erythematosus</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA7191557">WO-2012162561</Patent><Status id="PRI">First Priority</Status><StatusDate>2011-05-24 00:00:00</StatusDate><StatusSortCode>1</StatusSortCode><TherapyArea id="95">Dermatological disease</TherapyArea></Row><Row><Action id="675">Hepatocyte growth factor receptor antagonist</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="US">US</Country><Drug id="71794">adalimumab + anti-Ang2 Zybody (inflammatory disease), Zyngenia</Drug><DrugRelationship>General interest</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Priority</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PRI</HighestPatStatusIdForCnty><Indication id="337">Ulcerative colitis</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA7191557">WO-2012162561</Patent><Status id="PRI">First Priority</Status><StatusDate>2011-05-24 00:00:00</StatusDate><StatusSortCode>1</StatusSortCode><TherapyArea id="185">Immune disorder</TherapyArea></Row><Row><Action id="675">Hepatocyte growth factor receptor antagonist</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="US">US</Country><Drug id="71794">adalimumab + anti-Ang2 Zybody (inflammatory disease), Zyngenia</Drug><DrugRelationship>General interest</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Priority</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PRI</HighestPatStatusIdForCnty><Indication id="651">Cancer</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA7191557">WO-2012162561</Patent><Status id="PRI">First Priority</Status><StatusDate>2011-05-24 00:00:00</StatusDate><StatusSortCode>1</StatusSortCode><TherapyArea id="230">Neoplasm</TherapyArea></Row><Row><Action id="675">Hepatocyte growth factor receptor antagonist</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="US">US</Country><Drug id="71794">adalimumab + anti-Ang2 Zybody (inflammatory disease), Zyngenia</Drug><DrugRelationship>General interest</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Priority</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PRI</HighestPatStatusIdForCnty><Indication id="746">Infectious disease</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA7191557">WO-2012162561</Patent><Status id="PRI">First Priority</Status><StatusDate>2011-05-24 00:00:00</StatusDate><StatusSortCode>1</StatusSortCode><TherapyArea id="746">Infectious disease</TherapyArea></Row><Row><Action id="675">Hepatocyte growth factor receptor antagonist</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="US">US</Country><Drug id="71794">adalimumab + anti-Ang2 Zybody (inflammatory disease), Zyngenia</Drug><DrugRelationship>General interest</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Priority</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PRI</HighestPatStatusIdForCnty><Indication id="84">Crohns disease</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA7191557">WO-2012162561</Patent><Status id="PRI">First Priority</Status><StatusDate>2011-05-24 00:00:00</StatusDate><StatusSortCode>1</StatusSortCode><TherapyArea id="185">Immune disorder</TherapyArea></Row><Row><Action id="675">Hepatocyte growth factor receptor antagonist</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="US">US</Country><Drug id="71794">adalimumab + anti-Ang2 Zybody (inflammatory disease), Zyngenia</Drug><DrugRelationship>General interest</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Priority</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PRI</HighestPatStatusIdForCnty><Indication id="97">Diabetes mellitus</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA7191557">WO-2012162561</Patent><Status id="PRI">First Priority</Status><StatusDate>2011-05-24 00:00:00</StatusDate><StatusSortCode>1</StatusSortCode><TherapyArea id="112">Endocrine disease</TherapyArea></Row><Row><Action id="740">Epidermal growth factor receptor antagonist</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="US">US</Country><Drug id="71794">adalimumab + anti-Ang2 Zybody (inflammatory disease), Zyngenia</Drug><DrugRelationship>General interest</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Priority</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PRI</HighestPatStatusIdForCnty><Indication id="188">Inflammatory disease</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA7191557">WO-2012162561</Patent><Status id="PRI">First Priority</Status><StatusDate>2011-05-24 00:00:00</StatusDate><StatusSortCode>1</StatusSortCode><TherapyArea id="188">Inflammatory disease</TherapyArea></Row><Row><Action id="740">Epidermal growth factor receptor antagonist</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="US">US</Country><Drug id="71794">adalimumab + anti-Ang2 Zybody (inflammatory disease), Zyngenia</Drug><DrugRelationship>General interest</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Priority</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PRI</HighestPatStatusIdForCnty><Indication id="189">Inflammatory bowel disease</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA7191557">WO-2012162561</Patent><Status id="PRI">First Priority</Status><StatusDate>2011-05-24 00:00:00</StatusDate><StatusSortCode>1</StatusSortCode><TherapyArea id="188">Inflammatory disease</TherapyArea></Row><Row><Action id="740">Epidermal growth factor receptor antagonist</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="US">US</Country><Drug id="71794">adalimumab + anti-Ang2 Zybody (inflammatory disease), Zyngenia</Drug><DrugRelationship>General interest</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Priority</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PRI</HighestPatStatusIdForCnty><Indication id="213">Multiple sclerosis</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA7191557">WO-2012162561</Patent><Status id="PRI">First Priority</Status><StatusDate>2011-05-24 00:00:00</StatusDate><StatusSortCode>1</StatusSortCode><TherapyArea id="185">Immune disorder</TherapyArea></Row><Row><Action id="740">Epidermal growth factor receptor antagonist</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="US">US</Country><Drug id="71794">adalimumab + anti-Ang2 Zybody (inflammatory disease), Zyngenia</Drug><DrugRelationship>General interest</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Priority</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PRI</HighestPatStatusIdForCnty><Indication id="281">Psoriasis</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA7191557">WO-2012162561</Patent><Status id="PRI">First Priority</Status><StatusDate>2011-05-24 00:00:00</StatusDate><StatusSortCode>1</StatusSortCode><TherapyArea id="95">Dermatological disease</TherapyArea></Row><Row><Action id="740">Epidermal growth factor receptor antagonist</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="US">US</Country><Drug id="71794">adalimumab + anti-Ang2 Zybody (inflammatory disease), Zyngenia</Drug><DrugRelationship>General interest</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Priority</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PRI</HighestPatStatusIdForCnty><Indication id="291">Rheumatoid arthritis</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA7191557">WO-2012162561</Patent><Status id="PRI">First Priority</Status><StatusDate>2011-05-24 00:00:00</StatusDate><StatusSortCode>1</StatusSortCode><TherapyArea id="185">Immune disorder</TherapyArea></Row><Row><Action id="740">Epidermal growth factor receptor antagonist</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="US">US</Country><Drug id="71794">adalimumab + anti-Ang2 Zybody (inflammatory disease), Zyngenia</Drug><DrugRelationship>General interest</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Priority</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PRI</HighestPatStatusIdForCnty><Indication id="318">Systemic lupus erythematosus</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA7191557">WO-2012162561</Patent><Status id="PRI">First Priority</Status><StatusDate>2011-05-24 00:00:00</StatusDate><StatusSortCode>1</StatusSortCode><TherapyArea id="95">Dermatological disease</TherapyArea></Row><Row><Action id="740">Epidermal growth factor receptor antagonist</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="US">US</Country><Drug id="71794">adalimumab + anti-Ang2 Zybody (inflammatory disease), Zyngenia</Drug><DrugRelationship>General interest</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Priority</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PRI</HighestPatStatusIdForCnty><Indication id="337">Ulcerative colitis</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA7191557">WO-2012162561</Patent><Status id="PRI">First Priority</Status><StatusDate>2011-05-24 00:00:00</StatusDate><StatusSortCode>1</StatusSortCode><TherapyArea id="185">Immune disorder</TherapyArea></Row><Row><Action id="740">Epidermal growth factor receptor antagonist</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="US">US</Country><Drug id="71794">adalimumab + anti-Ang2 Zybody (inflammatory disease), Zyngenia</Drug><DrugRelationship>General interest</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Priority</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PRI</HighestPatStatusIdForCnty><Indication id="651">Cancer</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA7191557">WO-2012162561</Patent><Status id="PRI">First Priority</Status><StatusDate>2011-05-24 00:00:00</StatusDate><StatusSortCode>1</StatusSortCode><TherapyArea id="230">Neoplasm</TherapyArea></Row><Row><Action id="740">Epidermal growth factor receptor antagonist</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="US">US</Country><Drug id="71794">adalimumab + anti-Ang2 Zybody (inflammatory disease), Zyngenia</Drug><DrugRelationship>General interest</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Priority</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PRI</HighestPatStatusIdForCnty><Indication id="746">Infectious disease</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA7191557">WO-2012162561</Patent><Status id="PRI">First Priority</Status><StatusDate>2011-05-24 00:00:00</StatusDate><StatusSortCode>1</StatusSortCode><TherapyArea id="746">Infectious disease</TherapyArea></Row><Row><Action id="740">Epidermal growth factor receptor antagonist</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="US">US</Country><Drug id="71794">adalimumab + anti-Ang2 Zybody (inflammatory disease), Zyngenia</Drug><DrugRelationship>General interest</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Priority</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PRI</HighestPatStatusIdForCnty><Indication id="84">Crohns disease</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA7191557">WO-2012162561</Patent><Status id="PRI">First Priority</Status><StatusDate>2011-05-24 00:00:00</StatusDate><StatusSortCode>1</StatusSortCode><TherapyArea id="185">Immune disorder</TherapyArea></Row><Row><Action id="740">Epidermal growth factor receptor antagonist</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="US">US</Country><Drug id="71794">adalimumab + anti-Ang2 Zybody (inflammatory disease), Zyngenia</Drug><DrugRelationship>General interest</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Priority</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PRI</HighestPatStatusIdForCnty><Indication id="97">Diabetes mellitus</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA7191557">WO-2012162561</Patent><Status id="PRI">First Priority</Status><StatusDate>2011-05-24 00:00:00</StatusDate><StatusSortCode>1</StatusSortCode><TherapyArea id="112">Endocrine disease</TherapyArea></Row><Row><Action id="12521">VEGF ligand inhibitor</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="US">US</Country><Drug id="71795">anti-Her-2/anti-Ang2 mAb (cancer), Zyngenia</Drug><DrugRelationship>General interest</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Priority</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PRI</HighestPatStatusIdForCnty><Indication id="188">Inflammatory disease</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA7191557">WO-2012162561</Patent><Status id="PRI">First Priority</Status><StatusDate>2011-05-24 00:00:00</StatusDate><StatusSortCode>1</StatusSortCode><TherapyArea id="188">Inflammatory disease</TherapyArea></Row><Row><Action id="12521">VEGF ligand inhibitor</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="US">US</Country><Drug id="71795">anti-Her-2/anti-Ang2 mAb (cancer), Zyngenia</Drug><DrugRelationship>General interest</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Priority</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PRI</HighestPatStatusIdForCnty><Indication id="189">Inflammatory bowel disease</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA7191557">WO-2012162561</Patent><Status id="PRI">First Priority</Status><StatusDate>2011-05-24 00:00:00</StatusDate><StatusSortCode>1</StatusSortCode><TherapyArea id="188">Inflammatory disease</TherapyArea></Row><Row><Action id="12521">VEGF ligand inhibitor</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="US">US</Country><Drug id="71795">anti-Her-2/anti-Ang2 mAb (cancer), Zyngenia</Drug><DrugRelationship>General interest</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Priority</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PRI</HighestPatStatusIdForCnty><Indication id="213">Multiple sclerosis</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA7191557">WO-2012162561</Patent><Status id="PRI">First Priority</Status><StatusDate>2011-05-24 00:00:00</StatusDate><StatusSortCode>1</StatusSortCode><TherapyArea id="185">Immune disorder</TherapyArea></Row><Row><Action id="12521">VEGF ligand inhibitor</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="US">US</Country><Drug id="71795">anti-Her-2/anti-Ang2 mAb (cancer), Zyngenia</Drug><DrugRelationship>General interest</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Priority</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PRI</HighestPatStatusIdForCnty><Indication id="281">Psoriasis</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA7191557">WO-2012162561</Patent><Status id="PRI">First Priority</Status><StatusDate>2011-05-24 00:00:00</StatusDate><StatusSortCode>1</StatusSortCode><TherapyArea id="95">Dermatological disease</TherapyArea></Row><Row><Action id="12521">VEGF ligand inhibitor</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="US">US</Country><Drug id="71795">anti-Her-2/anti-Ang2 mAb (cancer), Zyngenia</Drug><DrugRelationship>General interest</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Priority</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PRI</HighestPatStatusIdForCnty><Indication id="291">Rheumatoid arthritis</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA7191557">WO-2012162561</Patent><Status id="PRI">First Priority</Status><StatusDate>2011-05-24 00:00:00</StatusDate><StatusSortCode>1</StatusSortCode><TherapyArea id="185">Immune disorder</TherapyArea></Row><Row><Action id="12521">VEGF ligand inhibitor</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="US">US</Country><Drug id="71795">anti-Her-2/anti-Ang2 mAb (cancer), Zyngenia</Drug><DrugRelationship>General interest</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Priority</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PRI</HighestPatStatusIdForCnty><Indication id="318">Systemic lupus erythematosus</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA7191557">WO-2012162561</Patent><Status id="PRI">First Priority</Status><StatusDate>2011-05-24 00:00:00</StatusDate><StatusSortCode>1</StatusSortCode><TherapyArea id="95">Dermatological disease</TherapyArea></Row><Row><Action id="12521">VEGF ligand inhibitor</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="US">US</Country><Drug id="71795">anti-Her-2/anti-Ang2 mAb (cancer), Zyngenia</Drug><DrugRelationship>General interest</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Priority</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PRI</HighestPatStatusIdForCnty><Indication id="337">Ulcerative colitis</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA7191557">WO-2012162561</Patent><Status id="PRI">First Priority</Status><StatusDate>2011-05-24 00:00:00</StatusDate><StatusSortCode>1</StatusSortCode><TherapyArea id="185">Immune disorder</TherapyArea></Row><Row><Action id="12521">VEGF ligand inhibitor</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="US">US</Country><Drug id="71795">anti-Her-2/anti-Ang2 mAb (cancer), Zyngenia</Drug><DrugRelationship>General interest</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Priority</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PRI</HighestPatStatusIdForCnty><Indication id="651">Cancer</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA7191557">WO-2012162561</Patent><Status id="PRI">First Priority</Status><StatusDate>2011-05-24 00:00:00</StatusDate><StatusSortCode>1</StatusSortCode><TherapyArea id="230">Neoplasm</TherapyArea></Row><Row><Action id="12521">VEGF ligand inhibitor</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="US">US</Country><Drug id="71795">anti-Her-2/anti-Ang2 mAb (cancer), Zyngenia</Drug><DrugRelationship>General interest</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Priority</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PRI</HighestPatStatusIdForCnty><Indication id="746">Infectious disease</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA7191557">WO-2012162561</Patent><Status id="PRI">First Priority</Status><StatusDate>2011-05-24 00:00:00</StatusDate><StatusSortCode>1</StatusSortCode><TherapyArea id="746">Infectious disease</TherapyArea></Row><Row><Action id="12521">VEGF ligand inhibitor</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="US">US</Country><Drug id="71795">anti-Her-2/anti-Ang2 mAb (cancer), Zyngenia</Drug><DrugRelationship>General interest</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Priority</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PRI</HighestPatStatusIdForCnty><Indication id="84">Crohns disease</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA7191557">WO-2012162561</Patent><Status id="PRI">First Priority</Status><StatusDate>2011-05-24 00:00:00</StatusDate><StatusSortCode>1</StatusSortCode><TherapyArea id="185">Immune disorder</TherapyArea></Row><Row><Action id="12521">VEGF ligand inhibitor</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="US">US</Country><Drug id="71795">anti-Her-2/anti-Ang2 mAb (cancer), Zyngenia</Drug><DrugRelationship>General interest</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Priority</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PRI</HighestPatStatusIdForCnty><Indication id="97">Diabetes mellitus</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA7191557">WO-2012162561</Patent><Status id="PRI">First Priority</Status><StatusDate>2011-05-24 00:00:00</StatusDate><StatusSortCode>1</StatusSortCode><TherapyArea id="112">Endocrine disease</TherapyArea></Row><Row><Action id="3252">Insulin-like growth factor 1 receptor antagonist</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="US">US</Country><Drug id="71795">anti-Her-2/anti-Ang2 mAb (cancer), Zyngenia</Drug><DrugRelationship>General interest</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Priority</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PRI</HighestPatStatusIdForCnty><Indication id="188">Inflammatory disease</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA7191557">WO-2012162561</Patent><Status id="PRI">First Priority</Status><StatusDate>2011-05-24 00:00:00</StatusDate><StatusSortCode>1</StatusSortCode><TherapyArea id="188">Inflammatory disease</TherapyArea></Row><Row><Action id="3252">Insulin-like growth factor 1 receptor antagonist</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="US">US</Country><Drug id="71795">anti-Her-2/anti-Ang2 mAb (cancer), Zyngenia</Drug><DrugRelationship>General interest</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Priority</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PRI</HighestPatStatusIdForCnty><Indication id="189">Inflammatory bowel disease</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA7191557">WO-2012162561</Patent><Status id="PRI">First Priority</Status><StatusDate>2011-05-24 00:00:00</StatusDate><StatusSortCode>1</StatusSortCode><TherapyArea id="188">Inflammatory disease</TherapyArea></Row><Row><Action id="3252">Insulin-like growth factor 1 receptor antagonist</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="US">US</Country><Drug id="71795">anti-Her-2/anti-Ang2 mAb (cancer), Zyngenia</Drug><DrugRelationship>General interest</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Priority</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PRI</HighestPatStatusIdForCnty><Indication id="213">Multiple sclerosis</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA7191557">WO-2012162561</Patent><Status id="PRI">First Priority</Status><StatusDate>2011-05-24 00:00:00</StatusDate><StatusSortCode>1</StatusSortCode><TherapyArea id="185">Immune disorder</TherapyArea></Row><Row><Action id="3252">Insulin-like growth factor 1 receptor antagonist</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="US">US</Country><Drug id="71795">anti-Her-2/anti-Ang2 mAb (cancer), Zyngenia</Drug><DrugRelationship>General interest</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Priority</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PRI</HighestPatStatusIdForCnty><Indication id="281">Psoriasis</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA7191557">WO-2012162561</Patent><Status id="PRI">First Priority</Status><StatusDate>2011-05-24 00:00:00</StatusDate><StatusSortCode>1</StatusSortCode><TherapyArea id="95">Dermatological disease</TherapyArea></Row><Row><Action id="3252">Insulin-like growth factor 1 receptor antagonist</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="US">US</Country><Drug id="71795">anti-Her-2/anti-Ang2 mAb (cancer), Zyngenia</Drug><DrugRelationship>General interest</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Priority</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PRI</HighestPatStatusIdForCnty><Indication id="291">Rheumatoid arthritis</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA7191557">WO-2012162561</Patent><Status id="PRI">First Priority</Status><StatusDate>2011-05-24 00:00:00</StatusDate><StatusSortCode>1</StatusSortCode><TherapyArea id="185">Immune disorder</TherapyArea></Row><Row><Action id="3252">Insulin-like growth factor 1 receptor antagonist</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="US">US</Country><Drug id="71795">anti-Her-2/anti-Ang2 mAb (cancer), Zyngenia</Drug><DrugRelationship>General interest</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Priority</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PRI</HighestPatStatusIdForCnty><Indication id="318">Systemic lupus erythematosus</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA7191557">WO-2012162561</Patent><Status id="PRI">First Priority</Status><StatusDate>2011-05-24 00:00:00</StatusDate><StatusSortCode>1</StatusSortCode><TherapyArea id="95">Dermatological disease</TherapyArea></Row><Row><Action id="3252">Insulin-like growth factor 1 receptor antagonist</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="US">US</Country><Drug id="71795">anti-Her-2/anti-Ang2 mAb (cancer), Zyngenia</Drug><DrugRelationship>General interest</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Priority</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PRI</HighestPatStatusIdForCnty><Indication id="337">Ulcerative colitis</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA7191557">WO-2012162561</Patent><Status id="PRI">First Priority</Status><StatusDate>2011-05-24 00:00:00</StatusDate><StatusSortCode>1</StatusSortCode><TherapyArea id="185">Immune disorder</TherapyArea></Row><Row><Action id="3252">Insulin-like growth factor 1 receptor antagonist</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="US">US</Country><Drug id="71795">anti-Her-2/anti-Ang2 mAb (cancer), Zyngenia</Drug><DrugRelationship>General interest</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Priority</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PRI</HighestPatStatusIdForCnty><Indication id="651">Cancer</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA7191557">WO-2012162561</Patent><Status id="PRI">First Priority</Status><StatusDate>2011-05-24 00:00:00</StatusDate><StatusSortCode>1</StatusSortCode><TherapyArea id="230">Neoplasm</TherapyArea></Row><Row><Action id="3252">Insulin-like growth factor 1 receptor antagonist</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="US">US</Country><Drug id="71795">anti-Her-2/anti-Ang2 mAb (cancer), Zyngenia</Drug><DrugRelationship>General interest</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Priority</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PRI</HighestPatStatusIdForCnty><Indication id="746">Infectious disease</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA7191557">WO-2012162561</Patent><Status id="PRI">First Priority</Status><StatusDate>2011-05-24 00:00:00</StatusDate><StatusSortCode>1</StatusSortCode><TherapyArea id="746">Infectious disease</TherapyArea></Row><Row><Action id="3252">Insulin-like growth factor 1 receptor antagonist</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="US">US</Country><Drug id="71795">anti-Her-2/anti-Ang2 mAb (cancer), Zyngenia</Drug><DrugRelationship>General interest</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Priority</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PRI</HighestPatStatusIdForCnty><Indication id="84">Crohns disease</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA7191557">WO-2012162561</Patent><Status id="PRI">First Priority</Status><StatusDate>2011-05-24 00:00:00</StatusDate><StatusSortCode>1</StatusSortCode><TherapyArea id="185">Immune disorder</TherapyArea></Row><Row><Action id="3252">Insulin-like growth factor 1 receptor antagonist</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="US">US</Country><Drug id="71795">anti-Her-2/anti-Ang2 mAb (cancer), Zyngenia</Drug><DrugRelationship>General interest</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Priority</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PRI</HighestPatStatusIdForCnty><Indication id="97">Diabetes mellitus</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA7191557">WO-2012162561</Patent><Status id="PRI">First Priority</Status><StatusDate>2011-05-24 00:00:00</StatusDate><StatusSortCode>1</StatusSortCode><TherapyArea id="112">Endocrine disease</TherapyArea></Row><Row><Action id="3682">FGF1 receptor antagonist</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="US">US</Country><Drug id="71795">anti-Her-2/anti-Ang2 mAb (cancer), Zyngenia</Drug><DrugRelationship>General interest</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Priority</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PRI</HighestPatStatusIdForCnty><Indication id="188">Inflammatory disease</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA7191557">WO-2012162561</Patent><Status id="PRI">First Priority</Status><StatusDate>2011-05-24 00:00:00</StatusDate><StatusSortCode>1</StatusSortCode><TherapyArea id="188">Inflammatory disease</TherapyArea></Row><Row><Action id="3682">FGF1 receptor antagonist</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="US">US</Country><Drug id="71795">anti-Her-2/anti-Ang2 mAb (cancer), Zyngenia</Drug><DrugRelationship>General interest</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Priority</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PRI</HighestPatStatusIdForCnty><Indication id="189">Inflammatory bowel disease</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA7191557">WO-2012162561</Patent><Status id="PRI">First Priority</Status><StatusDate>2011-05-24 00:00:00</StatusDate><StatusSortCode>1</StatusSortCode><TherapyArea id="188">Inflammatory disease</TherapyArea></Row><Row><Action id="3682">FGF1 receptor antagonist</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="US">US</Country><Drug id="71795">anti-Her-2/anti-Ang2 mAb (cancer), Zyngenia</Drug><DrugRelationship>General interest</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Priority</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PRI</HighestPatStatusIdForCnty><Indication id="213">Multiple sclerosis</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA7191557">WO-2012162561</Patent><Status id="PRI">First Priority</Status><StatusDate>2011-05-24 00:00:00</StatusDate><StatusSortCode>1</StatusSortCode><TherapyArea id="185">Immune disorder</TherapyArea></Row><Row><Action id="3682">FGF1 receptor antagonist</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="US">US</Country><Drug id="71795">anti-Her-2/anti-Ang2 mAb (cancer), Zyngenia</Drug><DrugRelationship>General interest</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Priority</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PRI</HighestPatStatusIdForCnty><Indication id="281">Psoriasis</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA7191557">WO-2012162561</Patent><Status id="PRI">First Priority</Status><StatusDate>2011-05-24 00:00:00</StatusDate><StatusSortCode>1</StatusSortCode><TherapyArea id="95">Dermatological disease</TherapyArea></Row><Row><Action id="3682">FGF1 receptor antagonist</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="US">US</Country><Drug id="71795">anti-Her-2/anti-Ang2 mAb (cancer), Zyngenia</Drug><DrugRelationship>General interest</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Priority</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PRI</HighestPatStatusIdForCnty><Indication id="291">Rheumatoid arthritis</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA7191557">WO-2012162561</Patent><Status id="PRI">First Priority</Status><StatusDate>2011-05-24 00:00:00</StatusDate><StatusSortCode>1</StatusSortCode><TherapyArea id="185">Immune disorder</TherapyArea></Row><Row><Action id="3682">FGF1 receptor antagonist</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="US">US</Country><Drug id="71795">anti-Her-2/anti-Ang2 mAb (cancer), Zyngenia</Drug><DrugRelationship>General interest</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Priority</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PRI</HighestPatStatusIdForCnty><Indication id="318">Systemic lupus erythematosus</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA7191557">WO-2012162561</Patent><Status id="PRI">First Priority</Status><StatusDate>2011-05-24 00:00:00</StatusDate><StatusSortCode>1</StatusSortCode><TherapyArea id="95">Dermatological disease</TherapyArea></Row><Row><Action id="3682">FGF1 receptor antagonist</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="US">US</Country><Drug id="71795">anti-Her-2/anti-Ang2 mAb (cancer), Zyngenia</Drug><DrugRelationship>General interest</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Priority</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PRI</HighestPatStatusIdForCnty><Indication id="337">Ulcerative colitis</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA7191557">WO-2012162561</Patent><Status id="PRI">First Priority</Status><StatusDate>2011-05-24 00:00:00</StatusDate><StatusSortCode>1</StatusSortCode><TherapyArea id="185">Immune disorder</TherapyArea></Row><Row><Action id="3682">FGF1 receptor antagonist</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="US">US</Country><Drug id="71795">anti-Her-2/anti-Ang2 mAb (cancer), Zyngenia</Drug><DrugRelationship>General interest</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Priority</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PRI</HighestPatStatusIdForCnty><Indication id="651">Cancer</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA7191557">WO-2012162561</Patent><Status id="PRI">First Priority</Status><StatusDate>2011-05-24 00:00:00</StatusDate><StatusSortCode>1</StatusSortCode><TherapyArea id="230">Neoplasm</TherapyArea></Row><Row><Action id="3682">FGF1 receptor antagonist</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="US">US</Country><Drug id="71795">anti-Her-2/anti-Ang2 mAb (cancer), Zyngenia</Drug><DrugRelationship>General interest</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Priority</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PRI</HighestPatStatusIdForCnty><Indication id="746">Infectious disease</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA7191557">WO-2012162561</Patent><Status id="PRI">First Priority</Status><StatusDate>2011-05-24 00:00:00</StatusDate><StatusSortCode>1</StatusSortCode><TherapyArea id="746">Infectious disease</TherapyArea></Row><Row><Action id="3682">FGF1 receptor antagonist</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="US">US</Country><Drug id="71795">anti-Her-2/anti-Ang2 mAb (cancer), Zyngenia</Drug><DrugRelationship>General interest</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Priority</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PRI</HighestPatStatusIdForCnty><Indication id="84">Crohns disease</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA7191557">WO-2012162561</Patent><Status id="PRI">First Priority</Status><StatusDate>2011-05-24 00:00:00</StatusDate><StatusSortCode>1</StatusSortCode><TherapyArea id="185">Immune disorder</TherapyArea></Row><Row><Action id="3682">FGF1 receptor antagonist</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="US">US</Country><Drug id="71795">anti-Her-2/anti-Ang2 mAb (cancer), Zyngenia</Drug><DrugRelationship>General interest</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Priority</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PRI</HighestPatStatusIdForCnty><Indication id="97">Diabetes mellitus</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA7191557">WO-2012162561</Patent><Status id="PRI">First Priority</Status><StatusDate>2011-05-24 00:00:00</StatusDate><StatusSortCode>1</StatusSortCode><TherapyArea id="112">Endocrine disease</TherapyArea></Row><Row><Action id="3685">FGF2 receptor antagonist</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="US">US</Country><Drug id="71795">anti-Her-2/anti-Ang2 mAb (cancer), Zyngenia</Drug><DrugRelationship>General interest</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Priority</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PRI</HighestPatStatusIdForCnty><Indication id="188">Inflammatory disease</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA7191557">WO-2012162561</Patent><Status id="PRI">First Priority</Status><StatusDate>2011-05-24 00:00:00</StatusDate><StatusSortCode>1</StatusSortCode><TherapyArea id="188">Inflammatory disease</TherapyArea></Row><Row><Action id="3685">FGF2 receptor antagonist</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="US">US</Country><Drug id="71795">anti-Her-2/anti-Ang2 mAb (cancer), Zyngenia</Drug><DrugRelationship>General interest</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Priority</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PRI</HighestPatStatusIdForCnty><Indication id="189">Inflammatory bowel disease</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA7191557">WO-2012162561</Patent><Status id="PRI">First Priority</Status><StatusDate>2011-05-24 00:00:00</StatusDate><StatusSortCode>1</StatusSortCode><TherapyArea id="188">Inflammatory disease</TherapyArea></Row><Row><Action id="3685">FGF2 receptor antagonist</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="US">US</Country><Drug id="71795">anti-Her-2/anti-Ang2 mAb (cancer), Zyngenia</Drug><DrugRelationship>General interest</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Priority</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PRI</HighestPatStatusIdForCnty><Indication id="213">Multiple sclerosis</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA7191557">WO-2012162561</Patent><Status id="PRI">First Priority</Status><StatusDate>2011-05-24 00:00:00</StatusDate><StatusSortCode>1</StatusSortCode><TherapyArea id="185">Immune disorder</TherapyArea></Row><Row><Action id="3685">FGF2 receptor antagonist</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="US">US</Country><Drug id="71795">anti-Her-2/anti-Ang2 mAb (cancer), Zyngenia</Drug><DrugRelationship>General interest</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Priority</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PRI</HighestPatStatusIdForCnty><Indication id="281">Psoriasis</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA7191557">WO-2012162561</Patent><Status id="PRI">First Priority</Status><StatusDate>2011-05-24 00:00:00</StatusDate><StatusSortCode>1</StatusSortCode><TherapyArea id="95">Dermatological disease</TherapyArea></Row><Row><Action id="3685">FGF2 receptor antagonist</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="US">US</Country><Drug id="71795">anti-Her-2/anti-Ang2 mAb (cancer), Zyngenia</Drug><DrugRelationship>General interest</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Priority</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PRI</HighestPatStatusIdForCnty><Indication id="291">Rheumatoid arthritis</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA7191557">WO-2012162561</Patent><Status id="PRI">First Priority</Status><StatusDate>2011-05-24 00:00:00</StatusDate><StatusSortCode>1</StatusSortCode><TherapyArea id="185">Immune disorder</TherapyArea></Row><Row><Action id="3685">FGF2 receptor antagonist</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="US">US</Country><Drug id="71795">anti-Her-2/anti-Ang2 mAb (cancer), Zyngenia</Drug><DrugRelationship>General interest</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Priority</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PRI</HighestPatStatusIdForCnty><Indication id="318">Systemic lupus erythematosus</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA7191557">WO-2012162561</Patent><Status id="PRI">First Priority</Status><StatusDate>2011-05-24 00:00:00</StatusDate><StatusSortCode>1</StatusSortCode><TherapyArea id="95">Dermatological disease</TherapyArea></Row><Row><Action id="3685">FGF2 receptor antagonist</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="US">US</Country><Drug id="71795">anti-Her-2/anti-Ang2 mAb (cancer), Zyngenia</Drug><DrugRelationship>General interest</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Priority</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PRI</HighestPatStatusIdForCnty><Indication id="337">Ulcerative colitis</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA7191557">WO-2012162561</Patent><Status id="PRI">First Priority</Status><StatusDate>2011-05-24 00:00:00</StatusDate><StatusSortCode>1</StatusSortCode><TherapyArea id="185">Immune disorder</TherapyArea></Row><Row><Action id="3685">FGF2 receptor antagonist</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="US">US</Country><Drug id="71795">anti-Her-2/anti-Ang2 mAb (cancer), Zyngenia</Drug><DrugRelationship>General interest</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Priority</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PRI</HighestPatStatusIdForCnty><Indication id="651">Cancer</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA7191557">WO-2012162561</Patent><Status id="PRI">First Priority</Status><StatusDate>2011-05-24 00:00:00</StatusDate><StatusSortCode>1</StatusSortCode><TherapyArea id="230">Neoplasm</TherapyArea></Row><Row><Action id="3685">FGF2 receptor antagonist</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="US">US</Country><Drug id="71795">anti-Her-2/anti-Ang2 mAb (cancer), Zyngenia</Drug><DrugRelationship>General interest</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Priority</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PRI</HighestPatStatusIdForCnty><Indication id="746">Infectious disease</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA7191557">WO-2012162561</Patent><Status id="PRI">First Priority</Status><StatusDate>2011-05-24 00:00:00</StatusDate><StatusSortCode>1</StatusSortCode><TherapyArea id="746">Infectious disease</TherapyArea></Row><Row><Action id="3685">FGF2 receptor antagonist</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="US">US</Country><Drug id="71795">anti-Her-2/anti-Ang2 mAb (cancer), Zyngenia</Drug><DrugRelationship>General interest</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Priority</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PRI</HighestPatStatusIdForCnty><Indication id="84">Crohns disease</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA7191557">WO-2012162561</Patent><Status id="PRI">First Priority</Status><StatusDate>2011-05-24 00:00:00</StatusDate><StatusSortCode>1</StatusSortCode><TherapyArea id="185">Immune disorder</TherapyArea></Row><Row><Action id="3685">FGF2 receptor antagonist</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="US">US</Country><Drug id="71795">anti-Her-2/anti-Ang2 mAb (cancer), Zyngenia</Drug><DrugRelationship>General interest</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Priority</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PRI</HighestPatStatusIdForCnty><Indication id="97">Diabetes mellitus</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA7191557">WO-2012162561</Patent><Status id="PRI">First Priority</Status><StatusDate>2011-05-24 00:00:00</StatusDate><StatusSortCode>1</StatusSortCode><TherapyArea id="112">Endocrine disease</TherapyArea></Row><Row><Action id="3756">Erbb2 tyrosine kinase receptor inhibitor</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="US">US</Country><Drug id="71795">anti-Her-2/anti-Ang2 mAb (cancer), Zyngenia</Drug><DrugRelationship>General interest</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Priority</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PRI</HighestPatStatusIdForCnty><Indication id="188">Inflammatory disease</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA7191557">WO-2012162561</Patent><Status id="PRI">First Priority</Status><StatusDate>2011-05-24 00:00:00</StatusDate><StatusSortCode>1</StatusSortCode><TherapyArea id="188">Inflammatory disease</TherapyArea></Row><Row><Action id="3756">Erbb2 tyrosine kinase receptor inhibitor</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="US">US</Country><Drug id="71795">anti-Her-2/anti-Ang2 mAb (cancer), Zyngenia</Drug><DrugRelationship>General interest</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Priority</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PRI</HighestPatStatusIdForCnty><Indication id="189">Inflammatory bowel disease</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA7191557">WO-2012162561</Patent><Status id="PRI">First Priority</Status><StatusDate>2011-05-24 00:00:00</StatusDate><StatusSortCode>1</StatusSortCode><TherapyArea id="188">Inflammatory disease</TherapyArea></Row><Row><Action id="3756">Erbb2 tyrosine kinase receptor inhibitor</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="US">US</Country><Drug id="71795">anti-Her-2/anti-Ang2 mAb (cancer), Zyngenia</Drug><DrugRelationship>General interest</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Priority</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PRI</HighestPatStatusIdForCnty><Indication id="213">Multiple sclerosis</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA7191557">WO-2012162561</Patent><Status id="PRI">First Priority</Status><StatusDate>2011-05-24 00:00:00</StatusDate><StatusSortCode>1</StatusSortCode><TherapyArea id="185">Immune disorder</TherapyArea></Row><Row><Action id="3756">Erbb2 tyrosine kinase receptor inhibitor</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="US">US</Country><Drug id="71795">anti-Her-2/anti-Ang2 mAb (cancer), Zyngenia</Drug><DrugRelationship>General interest</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Priority</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PRI</HighestPatStatusIdForCnty><Indication id="281">Psoriasis</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA7191557">WO-2012162561</Patent><Status id="PRI">First Priority</Status><StatusDate>2011-05-24 00:00:00</StatusDate><StatusSortCode>1</StatusSortCode><TherapyArea id="95">Dermatological disease</TherapyArea></Row><Row><Action id="3756">Erbb2 tyrosine kinase receptor inhibitor</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="US">US</Country><Drug id="71795">anti-Her-2/anti-Ang2 mAb (cancer), Zyngenia</Drug><DrugRelationship>General interest</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Priority</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PRI</HighestPatStatusIdForCnty><Indication id="291">Rheumatoid arthritis</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA7191557">WO-2012162561</Patent><Status id="PRI">First Priority</Status><StatusDate>2011-05-24 00:00:00</StatusDate><StatusSortCode>1</StatusSortCode><TherapyArea id="185">Immune disorder</TherapyArea></Row><Row><Action id="3756">Erbb2 tyrosine kinase receptor inhibitor</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="US">US</Country><Drug id="71795">anti-Her-2/anti-Ang2 mAb (cancer), Zyngenia</Drug><DrugRelationship>General interest</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Priority</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PRI</HighestPatStatusIdForCnty><Indication id="318">Systemic lupus erythematosus</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA7191557">WO-2012162561</Patent><Status id="PRI">First Priority</Status><StatusDate>2011-05-24 00:00:00</StatusDate><StatusSortCode>1</StatusSortCode><TherapyArea id="95">Dermatological disease</TherapyArea></Row><Row><Action id="3756">Erbb2 tyrosine kinase receptor inhibitor</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="US">US</Country><Drug id="71795">anti-Her-2/anti-Ang2 mAb (cancer), Zyngenia</Drug><DrugRelationship>General interest</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Priority</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PRI</HighestPatStatusIdForCnty><Indication id="337">Ulcerative colitis</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA7191557">WO-2012162561</Patent><Status id="PRI">First Priority</Status><StatusDate>2011-05-24 00:00:00</StatusDate><StatusSortCode>1</StatusSortCode><TherapyArea id="185">Immune disorder</TherapyArea></Row><Row><Action id="3756">Erbb2 tyrosine kinase receptor inhibitor</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="US">US</Country><Drug id="71795">anti-Her-2/anti-Ang2 mAb (cancer), Zyngenia</Drug><DrugRelationship>General interest</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Priority</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PRI</HighestPatStatusIdForCnty><Indication id="651">Cancer</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA7191557">WO-2012162561</Patent><Status id="PRI">First Priority</Status><StatusDate>2011-05-24 00:00:00</StatusDate><StatusSortCode>1</StatusSortCode><TherapyArea id="230">Neoplasm</TherapyArea></Row><Row><Action id="3756">Erbb2 tyrosine kinase receptor inhibitor</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="US">US</Country><Drug id="71795">anti-Her-2/anti-Ang2 mAb (cancer), Zyngenia</Drug><DrugRelationship>General interest</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Priority</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PRI</HighestPatStatusIdForCnty><Indication id="746">Infectious disease</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA7191557">WO-2012162561</Patent><Status id="PRI">First Priority</Status><StatusDate>2011-05-24 00:00:00</StatusDate><StatusSortCode>1</StatusSortCode><TherapyArea id="746">Infectious disease</TherapyArea></Row><Row><Action id="3756">Erbb2 tyrosine kinase receptor inhibitor</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="US">US</Country><Drug id="71795">anti-Her-2/anti-Ang2 mAb (cancer), Zyngenia</Drug><DrugRelationship>General interest</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Priority</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PRI</HighestPatStatusIdForCnty><Indication id="84">Crohns disease</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA7191557">WO-2012162561</Patent><Status id="PRI">First Priority</Status><StatusDate>2011-05-24 00:00:00</StatusDate><StatusSortCode>1</StatusSortCode><TherapyArea id="185">Immune disorder</TherapyArea></Row><Row><Action id="3756">Erbb2 tyrosine kinase receptor inhibitor</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="US">US</Country><Drug id="71795">anti-Her-2/anti-Ang2 mAb (cancer), Zyngenia</Drug><DrugRelationship>General interest</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Priority</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PRI</HighestPatStatusIdForCnty><Indication id="97">Diabetes mellitus</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA7191557">WO-2012162561</Patent><Status id="PRI">First Priority</Status><StatusDate>2011-05-24 00:00:00</StatusDate><StatusSortCode>1</StatusSortCode><TherapyArea id="112">Endocrine disease</TherapyArea></Row><Row><Action id="3846">VEGF-1 receptor antagonist</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="US">US</Country><Drug id="71795">anti-Her-2/anti-Ang2 mAb (cancer), Zyngenia</Drug><DrugRelationship>General interest</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Priority</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PRI</HighestPatStatusIdForCnty><Indication id="188">Inflammatory disease</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA7191557">WO-2012162561</Patent><Status id="PRI">First Priority</Status><StatusDate>2011-05-24 00:00:00</StatusDate><StatusSortCode>1</StatusSortCode><TherapyArea id="188">Inflammatory disease</TherapyArea></Row><Row><Action id="3846">VEGF-1 receptor antagonist</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="US">US</Country><Drug id="71795">anti-Her-2/anti-Ang2 mAb (cancer), Zyngenia</Drug><DrugRelationship>General interest</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Priority</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PRI</HighestPatStatusIdForCnty><Indication id="189">Inflammatory bowel disease</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA7191557">WO-2012162561</Patent><Status id="PRI">First Priority</Status><StatusDate>2011-05-24 00:00:00</StatusDate><StatusSortCode>1</StatusSortCode><TherapyArea id="188">Inflammatory disease</TherapyArea></Row><Row><Action id="3846">VEGF-1 receptor antagonist</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="US">US</Country><Drug id="71795">anti-Her-2/anti-Ang2 mAb (cancer), Zyngenia</Drug><DrugRelationship>General interest</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Priority</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PRI</HighestPatStatusIdForCnty><Indication id="213">Multiple sclerosis</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA7191557">WO-2012162561</Patent><Status id="PRI">First Priority</Status><StatusDate>2011-05-24 00:00:00</StatusDate><StatusSortCode>1</StatusSortCode><TherapyArea id="185">Immune disorder</TherapyArea></Row><Row><Action id="3846">VEGF-1 receptor antagonist</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="US">US</Country><Drug id="71795">anti-Her-2/anti-Ang2 mAb (cancer), Zyngenia</Drug><DrugRelationship>General interest</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Priority</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PRI</HighestPatStatusIdForCnty><Indication id="281">Psoriasis</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA7191557">WO-2012162561</Patent><Status id="PRI">First Priority</Status><StatusDate>2011-05-24 00:00:00</StatusDate><StatusSortCode>1</StatusSortCode><TherapyArea id="95">Dermatological disease</TherapyArea></Row><Row><Action id="3846">VEGF-1 receptor antagonist</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="US">US</Country><Drug id="71795">anti-Her-2/anti-Ang2 mAb (cancer), Zyngenia</Drug><DrugRelationship>General interest</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Priority</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PRI</HighestPatStatusIdForCnty><Indication id="291">Rheumatoid arthritis</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA7191557">WO-2012162561</Patent><Status id="PRI">First Priority</Status><StatusDate>2011-05-24 00:00:00</StatusDate><StatusSortCode>1</StatusSortCode><TherapyArea id="185">Immune disorder</TherapyArea></Row><Row><Action id="3846">VEGF-1 receptor antagonist</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="US">US</Country><Drug id="71795">anti-Her-2/anti-Ang2 mAb (cancer), Zyngenia</Drug><DrugRelationship>General interest</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Priority</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PRI</HighestPatStatusIdForCnty><Indication id="318">Systemic lupus erythematosus</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA7191557">WO-2012162561</Patent><Status id="PRI">First Priority</Status><StatusDate>2011-05-24 00:00:00</StatusDate><StatusSortCode>1</StatusSortCode><TherapyArea id="95">Dermatological disease</TherapyArea></Row><Row><Action id="3846">VEGF-1 receptor antagonist</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="US">US</Country><Drug id="71795">anti-Her-2/anti-Ang2 mAb (cancer), Zyngenia</Drug><DrugRelationship>General interest</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Priority</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PRI</HighestPatStatusIdForCnty><Indication id="337">Ulcerative colitis</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA7191557">WO-2012162561</Patent><Status id="PRI">First Priority</Status><StatusDate>2011-05-24 00:00:00</StatusDate><StatusSortCode>1</StatusSortCode><TherapyArea id="185">Immune disorder</TherapyArea></Row><Row><Action id="3846">VEGF-1 receptor antagonist</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="US">US</Country><Drug id="71795">anti-Her-2/anti-Ang2 mAb (cancer), Zyngenia</Drug><DrugRelationship>General interest</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Priority</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PRI</HighestPatStatusIdForCnty><Indication id="651">Cancer</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA7191557">WO-2012162561</Patent><Status id="PRI">First Priority</Status><StatusDate>2011-05-24 00:00:00</StatusDate><StatusSortCode>1</StatusSortCode><TherapyArea id="230">Neoplasm</TherapyArea></Row><Row><Action id="3846">VEGF-1 receptor antagonist</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="US">US</Country><Drug id="71795">anti-Her-2/anti-Ang2 mAb (cancer), Zyngenia</Drug><DrugRelationship>General interest</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Priority</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PRI</HighestPatStatusIdForCnty><Indication id="746">Infectious disease</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA7191557">WO-2012162561</Patent><Status id="PRI">First Priority</Status><StatusDate>2011-05-24 00:00:00</StatusDate><StatusSortCode>1</StatusSortCode><TherapyArea id="746">Infectious disease</TherapyArea></Row><Row><Action id="3846">VEGF-1 receptor antagonist</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="US">US</Country><Drug id="71795">anti-Her-2/anti-Ang2 mAb (cancer), Zyngenia</Drug><DrugRelationship>General interest</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Priority</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PRI</HighestPatStatusIdForCnty><Indication id="84">Crohns disease</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA7191557">WO-2012162561</Patent><Status id="PRI">First Priority</Status><StatusDate>2011-05-24 00:00:00</StatusDate><StatusSortCode>1</StatusSortCode><TherapyArea id="185">Immune disorder</TherapyArea></Row><Row><Action id="3846">VEGF-1 receptor antagonist</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="US">US</Country><Drug id="71795">anti-Her-2/anti-Ang2 mAb (cancer), Zyngenia</Drug><DrugRelationship>General interest</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Priority</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PRI</HighestPatStatusIdForCnty><Indication id="97">Diabetes mellitus</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA7191557">WO-2012162561</Patent><Status id="PRI">First Priority</Status><StatusDate>2011-05-24 00:00:00</StatusDate><StatusSortCode>1</StatusSortCode><TherapyArea id="112">Endocrine disease</TherapyArea></Row><Row><Action id="5025">CD3 antagonist</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="US">US</Country><Drug id="71795">anti-Her-2/anti-Ang2 mAb (cancer), Zyngenia</Drug><DrugRelationship>General interest</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Priority</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PRI</HighestPatStatusIdForCnty><Indication id="188">Inflammatory disease</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA7191557">WO-2012162561</Patent><Status id="PRI">First Priority</Status><StatusDate>2011-05-24 00:00:00</StatusDate><StatusSortCode>1</StatusSortCode><TherapyArea id="188">Inflammatory disease</TherapyArea></Row><Row><Action id="5025">CD3 antagonist</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="US">US</Country><Drug id="71795">anti-Her-2/anti-Ang2 mAb (cancer), Zyngenia</Drug><DrugRelationship>General interest</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Priority</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PRI</HighestPatStatusIdForCnty><Indication id="189">Inflammatory bowel disease</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA7191557">WO-2012162561</Patent><Status id="PRI">First Priority</Status><StatusDate>2011-05-24 00:00:00</StatusDate><StatusSortCode>1</StatusSortCode><TherapyArea id="188">Inflammatory disease</TherapyArea></Row><Row><Action id="5025">CD3 antagonist</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="US">US</Country><Drug id="71795">anti-Her-2/anti-Ang2 mAb (cancer), Zyngenia</Drug><DrugRelationship>General interest</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Priority</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PRI</HighestPatStatusIdForCnty><Indication id="213">Multiple sclerosis</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA7191557">WO-2012162561</Patent><Status id="PRI">First Priority</Status><StatusDate>2011-05-24 00:00:00</StatusDate><StatusSortCode>1</StatusSortCode><TherapyArea id="185">Immune disorder</TherapyArea></Row><Row><Action id="5025">CD3 antagonist</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="US">US</Country><Drug id="71795">anti-Her-2/anti-Ang2 mAb (cancer), Zyngenia</Drug><DrugRelationship>General interest</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Priority</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PRI</HighestPatStatusIdForCnty><Indication id="281">Psoriasis</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA7191557">WO-2012162561</Patent><Status id="PRI">First Priority</Status><StatusDate>2011-05-24 00:00:00</StatusDate><StatusSortCode>1</StatusSortCode><TherapyArea id="95">Dermatological disease</TherapyArea></Row><Row><Action id="5025">CD3 antagonist</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="US">US</Country><Drug id="71795">anti-Her-2/anti-Ang2 mAb (cancer), Zyngenia</Drug><DrugRelationship>General interest</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Priority</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PRI</HighestPatStatusIdForCnty><Indication id="291">Rheumatoid arthritis</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA7191557">WO-2012162561</Patent><Status id="PRI">First Priority</Status><StatusDate>2011-05-24 00:00:00</StatusDate><StatusSortCode>1</StatusSortCode><TherapyArea id="185">Immune disorder</TherapyArea></Row><Row><Action id="5025">CD3 antagonist</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="US">US</Country><Drug id="71795">anti-Her-2/anti-Ang2 mAb (cancer), Zyngenia</Drug><DrugRelationship>General interest</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Priority</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PRI</HighestPatStatusIdForCnty><Indication id="318">Systemic lupus erythematosus</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA7191557">WO-2012162561</Patent><Status id="PRI">First Priority</Status><StatusDate>2011-05-24 00:00:00</StatusDate><StatusSortCode>1</StatusSortCode><TherapyArea id="95">Dermatological disease</TherapyArea></Row><Row><Action id="5025">CD3 antagonist</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="US">US</Country><Drug id="71795">anti-Her-2/anti-Ang2 mAb (cancer), Zyngenia</Drug><DrugRelationship>General interest</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Priority</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PRI</HighestPatStatusIdForCnty><Indication id="337">Ulcerative colitis</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA7191557">WO-2012162561</Patent><Status id="PRI">First Priority</Status><StatusDate>2011-05-24 00:00:00</StatusDate><StatusSortCode>1</StatusSortCode><TherapyArea id="185">Immune disorder</TherapyArea></Row><Row><Action id="5025">CD3 antagonist</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="US">US</Country><Drug id="71795">anti-Her-2/anti-Ang2 mAb (cancer), Zyngenia</Drug><DrugRelationship>General interest</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Priority</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PRI</HighestPatStatusIdForCnty><Indication id="651">Cancer</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA7191557">WO-2012162561</Patent><Status id="PRI">First Priority</Status><StatusDate>2011-05-24 00:00:00</StatusDate><StatusSortCode>1</StatusSortCode><TherapyArea id="230">Neoplasm</TherapyArea></Row><Row><Action id="5025">CD3 antagonist</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="US">US</Country><Drug id="71795">anti-Her-2/anti-Ang2 mAb (cancer), Zyngenia</Drug><DrugRelationship>General interest</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Priority</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PRI</HighestPatStatusIdForCnty><Indication id="746">Infectious disease</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA7191557">WO-2012162561</Patent><Status id="PRI">First Priority</Status><StatusDate>2011-05-24 00:00:00</StatusDate><StatusSortCode>1</StatusSortCode><TherapyArea id="746">Infectious disease</TherapyArea></Row><Row><Action id="5025">CD3 antagonist</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="US">US</Country><Drug id="71795">anti-Her-2/anti-Ang2 mAb (cancer), Zyngenia</Drug><DrugRelationship>General interest</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Priority</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PRI</HighestPatStatusIdForCnty><Indication id="84">Crohns disease</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA7191557">WO-2012162561</Patent><Status id="PRI">First Priority</Status><StatusDate>2011-05-24 00:00:00</StatusDate><StatusSortCode>1</StatusSortCode><TherapyArea id="185">Immune disorder</TherapyArea></Row><Row><Action id="5025">CD3 antagonist</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="US">US</Country><Drug id="71795">anti-Her-2/anti-Ang2 mAb (cancer), Zyngenia</Drug><DrugRelationship>General interest</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Priority</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PRI</HighestPatStatusIdForCnty><Indication id="97">Diabetes mellitus</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA7191557">WO-2012162561</Patent><Status id="PRI">First Priority</Status><StatusDate>2011-05-24 00:00:00</StatusDate><StatusSortCode>1</StatusSortCode><TherapyArea id="112">Endocrine disease</TherapyArea></Row><Row><Action id="5082">B-lymphocyte antigen CD19 inhibitor</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="US">US</Country><Drug id="71795">anti-Her-2/anti-Ang2 mAb (cancer), Zyngenia</Drug><DrugRelationship>General interest</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Priority</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PRI</HighestPatStatusIdForCnty><Indication id="188">Inflammatory disease</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA7191557">WO-2012162561</Patent><Status id="PRI">First Priority</Status><StatusDate>2011-05-24 00:00:00</StatusDate><StatusSortCode>1</StatusSortCode><TherapyArea id="188">Inflammatory disease</TherapyArea></Row><Row><Action id="5082">B-lymphocyte antigen CD19 inhibitor</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="US">US</Country><Drug id="71795">anti-Her-2/anti-Ang2 mAb (cancer), Zyngenia</Drug><DrugRelationship>General interest</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Priority</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PRI</HighestPatStatusIdForCnty><Indication id="189">Inflammatory bowel disease</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA7191557">WO-2012162561</Patent><Status id="PRI">First Priority</Status><StatusDate>2011-05-24 00:00:00</StatusDate><StatusSortCode>1</StatusSortCode><TherapyArea id="188">Inflammatory disease</TherapyArea></Row><Row><Action id="5082">B-lymphocyte antigen CD19 inhibitor</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="US">US</Country><Drug id="71795">anti-Her-2/anti-Ang2 mAb (cancer), Zyngenia</Drug><DrugRelationship>General interest</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Priority</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PRI</HighestPatStatusIdForCnty><Indication id="213">Multiple sclerosis</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA7191557">WO-2012162561</Patent><Status id="PRI">First Priority</Status><StatusDate>2011-05-24 00:00:00</StatusDate><StatusSortCode>1</StatusSortCode><TherapyArea id="185">Immune disorder</TherapyArea></Row><Row><Action id="5082">B-lymphocyte antigen CD19 inhibitor</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="US">US</Country><Drug id="71795">anti-Her-2/anti-Ang2 mAb (cancer), Zyngenia</Drug><DrugRelationship>General interest</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Priority</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PRI</HighestPatStatusIdForCnty><Indication id="281">Psoriasis</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA7191557">WO-2012162561</Patent><Status id="PRI">First Priority</Status><StatusDate>2011-05-24 00:00:00</StatusDate><StatusSortCode>1</StatusSortCode><TherapyArea id="95">Dermatological disease</TherapyArea></Row><Row><Action id="5082">B-lymphocyte antigen CD19 inhibitor</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="US">US</Country><Drug id="71795">anti-Her-2/anti-Ang2 mAb (cancer), Zyngenia</Drug><DrugRelationship>General interest</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Priority</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PRI</HighestPatStatusIdForCnty><Indication id="291">Rheumatoid arthritis</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA7191557">WO-2012162561</Patent><Status id="PRI">First Priority</Status><StatusDate>2011-05-24 00:00:00</StatusDate><StatusSortCode>1</StatusSortCode><TherapyArea id="185">Immune disorder</TherapyArea></Row><Row><Action id="5082">B-lymphocyte antigen CD19 inhibitor</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="US">US</Country><Drug id="71795">anti-Her-2/anti-Ang2 mAb (cancer), Zyngenia</Drug><DrugRelationship>General interest</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Priority</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PRI</HighestPatStatusIdForCnty><Indication id="318">Systemic lupus erythematosus</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA7191557">WO-2012162561</Patent><Status id="PRI">First Priority</Status><StatusDate>2011-05-24 00:00:00</StatusDate><StatusSortCode>1</StatusSortCode><TherapyArea id="95">Dermatological disease</TherapyArea></Row><Row><Action id="5082">B-lymphocyte antigen CD19 inhibitor</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="US">US</Country><Drug id="71795">anti-Her-2/anti-Ang2 mAb (cancer), Zyngenia</Drug><DrugRelationship>General interest</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Priority</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PRI</HighestPatStatusIdForCnty><Indication id="337">Ulcerative colitis</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA7191557">WO-2012162561</Patent><Status id="PRI">First Priority</Status><StatusDate>2011-05-24 00:00:00</StatusDate><StatusSortCode>1</StatusSortCode><TherapyArea id="185">Immune disorder</TherapyArea></Row><Row><Action id="5082">B-lymphocyte antigen CD19 inhibitor</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="US">US</Country><Drug id="71795">anti-Her-2/anti-Ang2 mAb (cancer), Zyngenia</Drug><DrugRelationship>General interest</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Priority</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PRI</HighestPatStatusIdForCnty><Indication id="651">Cancer</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA7191557">WO-2012162561</Patent><Status id="PRI">First Priority</Status><StatusDate>2011-05-24 00:00:00</StatusDate><StatusSortCode>1</StatusSortCode><TherapyArea id="230">Neoplasm</TherapyArea></Row><Row><Action id="5082">B-lymphocyte antigen CD19 inhibitor</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="US">US</Country><Drug id="71795">anti-Her-2/anti-Ang2 mAb (cancer), Zyngenia</Drug><DrugRelationship>General interest</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Priority</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PRI</HighestPatStatusIdForCnty><Indication id="746">Infectious disease</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA7191557">WO-2012162561</Patent><Status id="PRI">First Priority</Status><StatusDate>2011-05-24 00:00:00</StatusDate><StatusSortCode>1</StatusSortCode><TherapyArea id="746">Infectious disease</TherapyArea></Row><Row><Action id="5082">B-lymphocyte antigen CD19 inhibitor</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="US">US</Country><Drug id="71795">anti-Her-2/anti-Ang2 mAb (cancer), Zyngenia</Drug><DrugRelationship>General interest</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Priority</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PRI</HighestPatStatusIdForCnty><Indication id="84">Crohns disease</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA7191557">WO-2012162561</Patent><Status id="PRI">First Priority</Status><StatusDate>2011-05-24 00:00:00</StatusDate><StatusSortCode>1</StatusSortCode><TherapyArea id="185">Immune disorder</TherapyArea></Row><Row><Action id="5082">B-lymphocyte antigen CD19 inhibitor</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="US">US</Country><Drug id="71795">anti-Her-2/anti-Ang2 mAb (cancer), Zyngenia</Drug><DrugRelationship>General interest</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Priority</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PRI</HighestPatStatusIdForCnty><Indication id="97">Diabetes mellitus</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA7191557">WO-2012162561</Patent><Status id="PRI">First Priority</Status><StatusDate>2011-05-24 00:00:00</StatusDate><StatusSortCode>1</StatusSortCode><TherapyArea id="112">Endocrine disease</TherapyArea></Row><Row><Action id="5085">B-lymphocyte antigen CD20 inhibitor</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="US">US</Country><Drug id="71795">anti-Her-2/anti-Ang2 mAb (cancer), Zyngenia</Drug><DrugRelationship>General interest</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Priority</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PRI</HighestPatStatusIdForCnty><Indication id="188">Inflammatory disease</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA7191557">WO-2012162561</Patent><Status id="PRI">First Priority</Status><StatusDate>2011-05-24 00:00:00</StatusDate><StatusSortCode>1</StatusSortCode><TherapyArea id="188">Inflammatory disease</TherapyArea></Row><Row><Action id="5085">B-lymphocyte antigen CD20 inhibitor</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="US">US</Country><Drug id="71795">anti-Her-2/anti-Ang2 mAb (cancer), Zyngenia</Drug><DrugRelationship>General interest</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Priority</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PRI</HighestPatStatusIdForCnty><Indication id="189">Inflammatory bowel disease</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA7191557">WO-2012162561</Patent><Status id="PRI">First Priority</Status><StatusDate>2011-05-24 00:00:00</StatusDate><StatusSortCode>1</StatusSortCode><TherapyArea id="188">Inflammatory disease</TherapyArea></Row><Row><Action id="5085">B-lymphocyte antigen CD20 inhibitor</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="US">US</Country><Drug id="71795">anti-Her-2/anti-Ang2 mAb (cancer), Zyngenia</Drug><DrugRelationship>General interest</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Priority</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PRI</HighestPatStatusIdForCnty><Indication id="213">Multiple sclerosis</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA7191557">WO-2012162561</Patent><Status id="PRI">First Priority</Status><StatusDate>2011-05-24 00:00:00</StatusDate><StatusSortCode>1</StatusSortCode><TherapyArea id="185">Immune disorder</TherapyArea></Row><Row><Action id="5085">B-lymphocyte antigen CD20 inhibitor</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="US">US</Country><Drug id="71795">anti-Her-2/anti-Ang2 mAb (cancer), Zyngenia</Drug><DrugRelationship>General interest</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Priority</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PRI</HighestPatStatusIdForCnty><Indication id="281">Psoriasis</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA7191557">WO-2012162561</Patent><Status id="PRI">First Priority</Status><StatusDate>2011-05-24 00:00:00</StatusDate><StatusSortCode>1</StatusSortCode><TherapyArea id="95">Dermatological disease</TherapyArea></Row><Row><Action id="5085">B-lymphocyte antigen CD20 inhibitor</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="US">US</Country><Drug id="71795">anti-Her-2/anti-Ang2 mAb (cancer), Zyngenia</Drug><DrugRelationship>General interest</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Priority</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PRI</HighestPatStatusIdForCnty><Indication id="291">Rheumatoid arthritis</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA7191557">WO-2012162561</Patent><Status id="PRI">First Priority</Status><StatusDate>2011-05-24 00:00:00</StatusDate><StatusSortCode>1</StatusSortCode><TherapyArea id="185">Immune disorder</TherapyArea></Row><Row><Action id="5085">B-lymphocyte antigen CD20 inhibitor</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="US">US</Country><Drug id="71795">anti-Her-2/anti-Ang2 mAb (cancer), Zyngenia</Drug><DrugRelationship>General interest</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Priority</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PRI</HighestPatStatusIdForCnty><Indication id="318">Systemic lupus erythematosus</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA7191557">WO-2012162561</Patent><Status id="PRI">First Priority</Status><StatusDate>2011-05-24 00:00:00</StatusDate><StatusSortCode>1</StatusSortCode><TherapyArea id="95">Dermatological disease</TherapyArea></Row><Row><Action id="5085">B-lymphocyte antigen CD20 inhibitor</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="US">US</Country><Drug id="71795">anti-Her-2/anti-Ang2 mAb (cancer), Zyngenia</Drug><DrugRelationship>General interest</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Priority</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PRI</HighestPatStatusIdForCnty><Indication id="337">Ulcerative colitis</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA7191557">WO-2012162561</Patent><Status id="PRI">First Priority</Status><StatusDate>2011-05-24 00:00:00</StatusDate><StatusSortCode>1</StatusSortCode><TherapyArea id="185">Immune disorder</TherapyArea></Row><Row><Action id="5085">B-lymphocyte antigen CD20 inhibitor</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="US">US</Country><Drug id="71795">anti-Her-2/anti-Ang2 mAb (cancer), Zyngenia</Drug><DrugRelationship>General interest</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Priority</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PRI</HighestPatStatusIdForCnty><Indication id="651">Cancer</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA7191557">WO-2012162561</Patent><Status id="PRI">First Priority</Status><StatusDate>2011-05-24 00:00:00</StatusDate><StatusSortCode>1</StatusSortCode><TherapyArea id="230">Neoplasm</TherapyArea></Row><Row><Action id="5085">B-lymphocyte antigen CD20 inhibitor</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="US">US</Country><Drug id="71795">anti-Her-2/anti-Ang2 mAb (cancer), Zyngenia</Drug><DrugRelationship>General interest</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Priority</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PRI</HighestPatStatusIdForCnty><Indication id="746">Infectious disease</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA7191557">WO-2012162561</Patent><Status id="PRI">First Priority</Status><StatusDate>2011-05-24 00:00:00</StatusDate><StatusSortCode>1</StatusSortCode><TherapyArea id="746">Infectious disease</TherapyArea></Row><Row><Action id="5085">B-lymphocyte antigen CD20 inhibitor</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="US">US</Country><Drug id="71795">anti-Her-2/anti-Ang2 mAb (cancer), Zyngenia</Drug><DrugRelationship>General interest</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Priority</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PRI</HighestPatStatusIdForCnty><Indication id="84">Crohns disease</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA7191557">WO-2012162561</Patent><Status id="PRI">First Priority</Status><StatusDate>2011-05-24 00:00:00</StatusDate><StatusSortCode>1</StatusSortCode><TherapyArea id="185">Immune disorder</TherapyArea></Row><Row><Action id="5085">B-lymphocyte antigen CD20 inhibitor</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="US">US</Country><Drug id="71795">anti-Her-2/anti-Ang2 mAb (cancer), Zyngenia</Drug><DrugRelationship>General interest</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Priority</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PRI</HighestPatStatusIdForCnty><Indication id="97">Diabetes mellitus</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA7191557">WO-2012162561</Patent><Status id="PRI">First Priority</Status><StatusDate>2011-05-24 00:00:00</StatusDate><StatusSortCode>1</StatusSortCode><TherapyArea id="112">Endocrine disease</TherapyArea></Row><Row><Action id="511">TNF antagonist</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="US">US</Country><Drug id="71795">anti-Her-2/anti-Ang2 mAb (cancer), Zyngenia</Drug><DrugRelationship>General interest</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Priority</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PRI</HighestPatStatusIdForCnty><Indication id="188">Inflammatory disease</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA7191557">WO-2012162561</Patent><Status id="PRI">First Priority</Status><StatusDate>2011-05-24 00:00:00</StatusDate><StatusSortCode>1</StatusSortCode><TherapyArea id="188">Inflammatory disease</TherapyArea></Row><Row><Action id="511">TNF antagonist</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="US">US</Country><Drug id="71795">anti-Her-2/anti-Ang2 mAb (cancer), Zyngenia</Drug><DrugRelationship>General interest</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Priority</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PRI</HighestPatStatusIdForCnty><Indication id="189">Inflammatory bowel disease</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA7191557">WO-2012162561</Patent><Status id="PRI">First Priority</Status><StatusDate>2011-05-24 00:00:00</StatusDate><StatusSortCode>1</StatusSortCode><TherapyArea id="188">Inflammatory disease</TherapyArea></Row><Row><Action id="511">TNF antagonist</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="US">US</Country><Drug id="71795">anti-Her-2/anti-Ang2 mAb (cancer), Zyngenia</Drug><DrugRelationship>General interest</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Priority</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PRI</HighestPatStatusIdForCnty><Indication id="213">Multiple sclerosis</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA7191557">WO-2012162561</Patent><Status id="PRI">First Priority</Status><StatusDate>2011-05-24 00:00:00</StatusDate><StatusSortCode>1</StatusSortCode><TherapyArea id="185">Immune disorder</TherapyArea></Row><Row><Action id="511">TNF antagonist</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="US">US</Country><Drug id="71795">anti-Her-2/anti-Ang2 mAb (cancer), Zyngenia</Drug><DrugRelationship>General interest</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Priority</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PRI</HighestPatStatusIdForCnty><Indication id="281">Psoriasis</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA7191557">WO-2012162561</Patent><Status id="PRI">First Priority</Status><StatusDate>2011-05-24 00:00:00</StatusDate><StatusSortCode>1</StatusSortCode><TherapyArea id="95">Dermatological disease</TherapyArea></Row><Row><Action id="511">TNF antagonist</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="US">US</Country><Drug id="71795">anti-Her-2/anti-Ang2 mAb (cancer), Zyngenia</Drug><DrugRelationship>General interest</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Priority</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PRI</HighestPatStatusIdForCnty><Indication id="291">Rheumatoid arthritis</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA7191557">WO-2012162561</Patent><Status id="PRI">First Priority</Status><StatusDate>2011-05-24 00:00:00</StatusDate><StatusSortCode>1</StatusSortCode><TherapyArea id="185">Immune disorder</TherapyArea></Row><Row><Action id="511">TNF antagonist</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="US">US</Country><Drug id="71795">anti-Her-2/anti-Ang2 mAb (cancer), Zyngenia</Drug><DrugRelationship>General interest</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Priority</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PRI</HighestPatStatusIdForCnty><Indication id="318">Systemic lupus erythematosus</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA7191557">WO-2012162561</Patent><Status id="PRI">First Priority</Status><StatusDate>2011-05-24 00:00:00</StatusDate><StatusSortCode>1</StatusSortCode><TherapyArea id="95">Dermatological disease</TherapyArea></Row><Row><Action id="511">TNF antagonist</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="US">US</Country><Drug id="71795">anti-Her-2/anti-Ang2 mAb (cancer), Zyngenia</Drug><DrugRelationship>General interest</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Priority</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PRI</HighestPatStatusIdForCnty><Indication id="337">Ulcerative colitis</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA7191557">WO-2012162561</Patent><Status id="PRI">First Priority</Status><StatusDate>2011-05-24 00:00:00</StatusDate><StatusSortCode>1</StatusSortCode><TherapyArea id="185">Immune disorder</TherapyArea></Row><Row><Action id="511">TNF antagonist</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="US">US</Country><Drug id="71795">anti-Her-2/anti-Ang2 mAb (cancer), Zyngenia</Drug><DrugRelationship>General interest</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Priority</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PRI</HighestPatStatusIdForCnty><Indication id="651">Cancer</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA7191557">WO-2012162561</Patent><Status id="PRI">First Priority</Status><StatusDate>2011-05-24 00:00:00</StatusDate><StatusSortCode>1</StatusSortCode><TherapyArea id="230">Neoplasm</TherapyArea></Row><Row><Action id="511">TNF antagonist</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="US">US</Country><Drug id="71795">anti-Her-2/anti-Ang2 mAb (cancer), Zyngenia</Drug><DrugRelationship>General interest</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Priority</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PRI</HighestPatStatusIdForCnty><Indication id="746">Infectious disease</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA7191557">WO-2012162561</Patent><Status id="PRI">First Priority</Status><StatusDate>2011-05-24 00:00:00</StatusDate><StatusSortCode>1</StatusSortCode><TherapyArea id="746">Infectious disease</TherapyArea></Row><Row><Action id="511">TNF antagonist</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="US">US</Country><Drug id="71795">anti-Her-2/anti-Ang2 mAb (cancer), Zyngenia</Drug><DrugRelationship>General interest</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Priority</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PRI</HighestPatStatusIdForCnty><Indication id="84">Crohns disease</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA7191557">WO-2012162561</Patent><Status id="PRI">First Priority</Status><StatusDate>2011-05-24 00:00:00</StatusDate><StatusSortCode>1</StatusSortCode><TherapyArea id="185">Immune disorder</TherapyArea></Row><Row><Action id="511">TNF antagonist</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="US">US</Country><Drug id="71795">anti-Her-2/anti-Ang2 mAb (cancer), Zyngenia</Drug><DrugRelationship>General interest</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Priority</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PRI</HighestPatStatusIdForCnty><Indication id="97">Diabetes mellitus</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA7191557">WO-2012162561</Patent><Status id="PRI">First Priority</Status><StatusDate>2011-05-24 00:00:00</StatusDate><StatusSortCode>1</StatusSortCode><TherapyArea id="112">Endocrine disease</TherapyArea></Row><Row><Action id="675">Hepatocyte growth factor receptor antagonist</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="US">US</Country><Drug id="71795">anti-Her-2/anti-Ang2 mAb (cancer), Zyngenia</Drug><DrugRelationship>General interest</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Priority</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PRI</HighestPatStatusIdForCnty><Indication id="188">Inflammatory disease</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA7191557">WO-2012162561</Patent><Status id="PRI">First Priority</Status><StatusDate>2011-05-24 00:00:00</StatusDate><StatusSortCode>1</StatusSortCode><TherapyArea id="188">Inflammatory disease</TherapyArea></Row><Row><Action id="675">Hepatocyte growth factor receptor antagonist</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="US">US</Country><Drug id="71795">anti-Her-2/anti-Ang2 mAb (cancer), Zyngenia</Drug><DrugRelationship>General interest</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Priority</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PRI</HighestPatStatusIdForCnty><Indication id="189">Inflammatory bowel disease</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA7191557">WO-2012162561</Patent><Status id="PRI">First Priority</Status><StatusDate>2011-05-24 00:00:00</StatusDate><StatusSortCode>1</StatusSortCode><TherapyArea id="188">Inflammatory disease</TherapyArea></Row><Row><Action id="675">Hepatocyte growth factor receptor antagonist</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="US">US</Country><Drug id="71795">anti-Her-2/anti-Ang2 mAb (cancer), Zyngenia</Drug><DrugRelationship>General interest</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Priority</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PRI</HighestPatStatusIdForCnty><Indication id="213">Multiple sclerosis</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA7191557">WO-2012162561</Patent><Status id="PRI">First Priority</Status><StatusDate>2011-05-24 00:00:00</StatusDate><StatusSortCode>1</StatusSortCode><TherapyArea id="185">Immune disorder</TherapyArea></Row><Row><Action id="675">Hepatocyte growth factor receptor antagonist</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="US">US</Country><Drug id="71795">anti-Her-2/anti-Ang2 mAb (cancer), Zyngenia</Drug><DrugRelationship>General interest</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Priority</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PRI</HighestPatStatusIdForCnty><Indication id="281">Psoriasis</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA7191557">WO-2012162561</Patent><Status id="PRI">First Priority</Status><StatusDate>2011-05-24 00:00:00</StatusDate><StatusSortCode>1</StatusSortCode><TherapyArea id="95">Dermatological disease</TherapyArea></Row><Row><Action id="675">Hepatocyte growth factor receptor antagonist</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="US">US</Country><Drug id="71795">anti-Her-2/anti-Ang2 mAb (cancer), Zyngenia</Drug><DrugRelationship>General interest</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Priority</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PRI</HighestPatStatusIdForCnty><Indication id="291">Rheumatoid arthritis</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA7191557">WO-2012162561</Patent><Status id="PRI">First Priority</Status><StatusDate>2011-05-24 00:00:00</StatusDate><StatusSortCode>1</StatusSortCode><TherapyArea id="185">Immune disorder</TherapyArea></Row><Row><Action id="675">Hepatocyte growth factor receptor antagonist</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="US">US</Country><Drug id="71795">anti-Her-2/anti-Ang2 mAb (cancer), Zyngenia</Drug><DrugRelationship>General interest</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Priority</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PRI</HighestPatStatusIdForCnty><Indication id="318">Systemic lupus erythematosus</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA7191557">WO-2012162561</Patent><Status id="PRI">First Priority</Status><StatusDate>2011-05-24 00:00:00</StatusDate><StatusSortCode>1</StatusSortCode><TherapyArea id="95">Dermatological disease</TherapyArea></Row><Row><Action id="675">Hepatocyte growth factor receptor antagonist</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="US">US</Country><Drug id="71795">anti-Her-2/anti-Ang2 mAb (cancer), Zyngenia</Drug><DrugRelationship>General interest</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Priority</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PRI</HighestPatStatusIdForCnty><Indication id="337">Ulcerative colitis</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA7191557">WO-2012162561</Patent><Status id="PRI">First Priority</Status><StatusDate>2011-05-24 00:00:00</StatusDate><StatusSortCode>1</StatusSortCode><TherapyArea id="185">Immune disorder</TherapyArea></Row><Row><Action id="675">Hepatocyte growth factor receptor antagonist</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="US">US</Country><Drug id="71795">anti-Her-2/anti-Ang2 mAb (cancer), Zyngenia</Drug><DrugRelationship>General interest</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Priority</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PRI</HighestPatStatusIdForCnty><Indication id="651">Cancer</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA7191557">WO-2012162561</Patent><Status id="PRI">First Priority</Status><StatusDate>2011-05-24 00:00:00</StatusDate><StatusSortCode>1</StatusSortCode><TherapyArea id="230">Neoplasm</TherapyArea></Row><Row><Action id="675">Hepatocyte growth factor receptor antagonist</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="US">US</Country><Drug id="71795">anti-Her-2/anti-Ang2 mAb (cancer), Zyngenia</Drug><DrugRelationship>General interest</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Priority</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PRI</HighestPatStatusIdForCnty><Indication id="746">Infectious disease</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA7191557">WO-2012162561</Patent><Status id="PRI">First Priority</Status><StatusDate>2011-05-24 00:00:00</StatusDate><StatusSortCode>1</StatusSortCode><TherapyArea id="746">Infectious disease</TherapyArea></Row><Row><Action id="675">Hepatocyte growth factor receptor antagonist</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="US">US</Country><Drug id="71795">anti-Her-2/anti-Ang2 mAb (cancer), Zyngenia</Drug><DrugRelationship>General interest</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Priority</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PRI</HighestPatStatusIdForCnty><Indication id="84">Crohns disease</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA7191557">WO-2012162561</Patent><Status id="PRI">First Priority</Status><StatusDate>2011-05-24 00:00:00</StatusDate><StatusSortCode>1</StatusSortCode><TherapyArea id="185">Immune disorder</TherapyArea></Row><Row><Action id="675">Hepatocyte growth factor receptor antagonist</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="US">US</Country><Drug id="71795">anti-Her-2/anti-Ang2 mAb (cancer), Zyngenia</Drug><DrugRelationship>General interest</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Priority</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PRI</HighestPatStatusIdForCnty><Indication id="97">Diabetes mellitus</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA7191557">WO-2012162561</Patent><Status id="PRI">First Priority</Status><StatusDate>2011-05-24 00:00:00</StatusDate><StatusSortCode>1</StatusSortCode><TherapyArea id="112">Endocrine disease</TherapyArea></Row><Row><Action id="740">Epidermal growth factor receptor antagonist</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="US">US</Country><Drug id="71795">anti-Her-2/anti-Ang2 mAb (cancer), Zyngenia</Drug><DrugRelationship>General interest</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Priority</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PRI</HighestPatStatusIdForCnty><Indication id="188">Inflammatory disease</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA7191557">WO-2012162561</Patent><Status id="PRI">First Priority</Status><StatusDate>2011-05-24 00:00:00</StatusDate><StatusSortCode>1</StatusSortCode><TherapyArea id="188">Inflammatory disease</TherapyArea></Row><Row><Action id="740">Epidermal growth factor receptor antagonist</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="US">US</Country><Drug id="71795">anti-Her-2/anti-Ang2 mAb (cancer), Zyngenia</Drug><DrugRelationship>General interest</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Priority</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PRI</HighestPatStatusIdForCnty><Indication id="189">Inflammatory bowel disease</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA7191557">WO-2012162561</Patent><Status id="PRI">First Priority</Status><StatusDate>2011-05-24 00:00:00</StatusDate><StatusSortCode>1</StatusSortCode><TherapyArea id="188">Inflammatory disease</TherapyArea></Row><Row><Action id="740">Epidermal growth factor receptor antagonist</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="US">US</Country><Drug id="71795">anti-Her-2/anti-Ang2 mAb (cancer), Zyngenia</Drug><DrugRelationship>General interest</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Priority</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PRI</HighestPatStatusIdForCnty><Indication id="213">Multiple sclerosis</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA7191557">WO-2012162561</Patent><Status id="PRI">First Priority</Status><StatusDate>2011-05-24 00:00:00</StatusDate><StatusSortCode>1</StatusSortCode><TherapyArea id="185">Immune disorder</TherapyArea></Row><Row><Action id="740">Epidermal growth factor receptor antagonist</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="US">US</Country><Drug id="71795">anti-Her-2/anti-Ang2 mAb (cancer), Zyngenia</Drug><DrugRelationship>General interest</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Priority</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PRI</HighestPatStatusIdForCnty><Indication id="281">Psoriasis</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA7191557">WO-2012162561</Patent><Status id="PRI">First Priority</Status><StatusDate>2011-05-24 00:00:00</StatusDate><StatusSortCode>1</StatusSortCode><TherapyArea id="95">Dermatological disease</TherapyArea></Row><Row><Action id="740">Epidermal growth factor receptor antagonist</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="US">US</Country><Drug id="71795">anti-Her-2/anti-Ang2 mAb (cancer), Zyngenia</Drug><DrugRelationship>General interest</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Priority</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PRI</HighestPatStatusIdForCnty><Indication id="291">Rheumatoid arthritis</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA7191557">WO-2012162561</Patent><Status id="PRI">First Priority</Status><StatusDate>2011-05-24 00:00:00</StatusDate><StatusSortCode>1</StatusSortCode><TherapyArea id="185">Immune disorder</TherapyArea></Row><Row><Action id="740">Epidermal growth factor receptor antagonist</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="US">US</Country><Drug id="71795">anti-Her-2/anti-Ang2 mAb (cancer), Zyngenia</Drug><DrugRelationship>General interest</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Priority</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PRI</HighestPatStatusIdForCnty><Indication id="318">Systemic lupus erythematosus</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA7191557">WO-2012162561</Patent><Status id="PRI">First Priority</Status><StatusDate>2011-05-24 00:00:00</StatusDate><StatusSortCode>1</StatusSortCode><TherapyArea id="95">Dermatological disease</TherapyArea></Row><Row><Action id="740">Epidermal growth factor receptor antagonist</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="US">US</Country><Drug id="71795">anti-Her-2/anti-Ang2 mAb (cancer), Zyngenia</Drug><DrugRelationship>General interest</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Priority</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PRI</HighestPatStatusIdForCnty><Indication id="337">Ulcerative colitis</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA7191557">WO-2012162561</Patent><Status id="PRI">First Priority</Status><StatusDate>2011-05-24 00:00:00</StatusDate><StatusSortCode>1</StatusSortCode><TherapyArea id="185">Immune disorder</TherapyArea></Row><Row><Action id="740">Epidermal growth factor receptor antagonist</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="US">US</Country><Drug id="71795">anti-Her-2/anti-Ang2 mAb (cancer), Zyngenia</Drug><DrugRelationship>General interest</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Priority</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PRI</HighestPatStatusIdForCnty><Indication id="651">Cancer</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA7191557">WO-2012162561</Patent><Status id="PRI">First Priority</Status><StatusDate>2011-05-24 00:00:00</StatusDate><StatusSortCode>1</StatusSortCode><TherapyArea id="230">Neoplasm</TherapyArea></Row><Row><Action id="740">Epidermal growth factor receptor antagonist</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="US">US</Country><Drug id="71795">anti-Her-2/anti-Ang2 mAb (cancer), Zyngenia</Drug><DrugRelationship>General interest</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Priority</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PRI</HighestPatStatusIdForCnty><Indication id="746">Infectious disease</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA7191557">WO-2012162561</Patent><Status id="PRI">First Priority</Status><StatusDate>2011-05-24 00:00:00</StatusDate><StatusSortCode>1</StatusSortCode><TherapyArea id="746">Infectious disease</TherapyArea></Row><Row><Action id="740">Epidermal growth factor receptor antagonist</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="US">US</Country><Drug id="71795">anti-Her-2/anti-Ang2 mAb (cancer), Zyngenia</Drug><DrugRelationship>General interest</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Priority</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PRI</HighestPatStatusIdForCnty><Indication id="84">Crohns disease</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA7191557">WO-2012162561</Patent><Status id="PRI">First Priority</Status><StatusDate>2011-05-24 00:00:00</StatusDate><StatusSortCode>1</StatusSortCode><TherapyArea id="185">Immune disorder</TherapyArea></Row><Row><Action id="740">Epidermal growth factor receptor antagonist</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="US">US</Country><Drug id="71795">anti-Her-2/anti-Ang2 mAb (cancer), Zyngenia</Drug><DrugRelationship>General interest</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Priority</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PRI</HighestPatStatusIdForCnty><Indication id="97">Diabetes mellitus</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA7191557">WO-2012162561</Patent><Status id="PRI">First Priority</Status><StatusDate>2011-05-24 00:00:00</StatusDate><StatusSortCode>1</StatusSortCode><TherapyArea id="112">Endocrine disease</TherapyArea></Row><Row><Action id="12521">VEGF ligand inhibitor</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="US">US</Country><Drug id="77135">tri-specific anti-Her1/Her3 Zybody (cancer), Zyngenia</Drug><DrugRelationship>General interest</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Priority</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PRI</HighestPatStatusIdForCnty><Indication id="188">Inflammatory disease</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA7191557">WO-2012162561</Patent><Status id="PRI">First Priority</Status><StatusDate>2011-05-24 00:00:00</StatusDate><StatusSortCode>1</StatusSortCode><TherapyArea id="188">Inflammatory disease</TherapyArea></Row><Row><Action id="12521">VEGF ligand inhibitor</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="US">US</Country><Drug id="77135">tri-specific anti-Her1/Her3 Zybody (cancer), Zyngenia</Drug><DrugRelationship>General interest</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Priority</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PRI</HighestPatStatusIdForCnty><Indication id="189">Inflammatory bowel disease</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA7191557">WO-2012162561</Patent><Status id="PRI">First Priority</Status><StatusDate>2011-05-24 00:00:00</StatusDate><StatusSortCode>1</StatusSortCode><TherapyArea id="188">Inflammatory disease</TherapyArea></Row><Row><Action id="12521">VEGF ligand inhibitor</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="US">US</Country><Drug id="77135">tri-specific anti-Her1/Her3 Zybody (cancer), Zyngenia</Drug><DrugRelationship>General interest</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Priority</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PRI</HighestPatStatusIdForCnty><Indication id="213">Multiple sclerosis</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA7191557">WO-2012162561</Patent><Status id="PRI">First Priority</Status><StatusDate>2011-05-24 00:00:00</StatusDate><StatusSortCode>1</StatusSortCode><TherapyArea id="185">Immune disorder</TherapyArea></Row><Row><Action id="12521">VEGF ligand inhibitor</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="US">US</Country><Drug id="77135">tri-specific anti-Her1/Her3 Zybody (cancer), Zyngenia</Drug><DrugRelationship>General interest</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Priority</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PRI</HighestPatStatusIdForCnty><Indication id="281">Psoriasis</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA7191557">WO-2012162561</Patent><Status id="PRI">First Priority</Status><StatusDate>2011-05-24 00:00:00</StatusDate><StatusSortCode>1</StatusSortCode><TherapyArea id="95">Dermatological disease</TherapyArea></Row><Row><Action id="12521">VEGF ligand inhibitor</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="US">US</Country><Drug id="77135">tri-specific anti-Her1/Her3 Zybody (cancer), Zyngenia</Drug><DrugRelationship>General interest</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Priority</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PRI</HighestPatStatusIdForCnty><Indication id="291">Rheumatoid arthritis</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA7191557">WO-2012162561</Patent><Status id="PRI">First Priority</Status><StatusDate>2011-05-24 00:00:00</StatusDate><StatusSortCode>1</StatusSortCode><TherapyArea id="185">Immune disorder</TherapyArea></Row><Row><Action id="12521">VEGF ligand inhibitor</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="US">US</Country><Drug id="77135">tri-specific anti-Her1/Her3 Zybody (cancer), Zyngenia</Drug><DrugRelationship>General interest</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Priority</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PRI</HighestPatStatusIdForCnty><Indication id="318">Systemic lupus erythematosus</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA7191557">WO-2012162561</Patent><Status id="PRI">First Priority</Status><StatusDate>2011-05-24 00:00:00</StatusDate><StatusSortCode>1</StatusSortCode><TherapyArea id="95">Dermatological disease</TherapyArea></Row><Row><Action id="12521">VEGF ligand inhibitor</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="US">US</Country><Drug id="77135">tri-specific anti-Her1/Her3 Zybody (cancer), Zyngenia</Drug><DrugRelationship>General interest</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Priority</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PRI</HighestPatStatusIdForCnty><Indication id="337">Ulcerative colitis</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA7191557">WO-2012162561</Patent><Status id="PRI">First Priority</Status><StatusDate>2011-05-24 00:00:00</StatusDate><StatusSortCode>1</StatusSortCode><TherapyArea id="185">Immune disorder</TherapyArea></Row><Row><Action id="12521">VEGF ligand inhibitor</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="US">US</Country><Drug id="77135">tri-specific anti-Her1/Her3 Zybody (cancer), Zyngenia</Drug><DrugRelationship>General interest</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Priority</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PRI</HighestPatStatusIdForCnty><Indication id="651">Cancer</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA7191557">WO-2012162561</Patent><Status id="PRI">First Priority</Status><StatusDate>2011-05-24 00:00:00</StatusDate><StatusSortCode>1</StatusSortCode><TherapyArea id="230">Neoplasm</TherapyArea></Row><Row><Action id="12521">VEGF ligand inhibitor</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="US">US</Country><Drug id="77135">tri-specific anti-Her1/Her3 Zybody (cancer), Zyngenia</Drug><DrugRelationship>General interest</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Priority</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PRI</HighestPatStatusIdForCnty><Indication id="746">Infectious disease</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA7191557">WO-2012162561</Patent><Status id="PRI">First Priority</Status><StatusDate>2011-05-24 00:00:00</StatusDate><StatusSortCode>1</StatusSortCode><TherapyArea id="746">Infectious disease</TherapyArea></Row><Row><Action id="12521">VEGF ligand inhibitor</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="US">US</Country><Drug id="77135">tri-specific anti-Her1/Her3 Zybody (cancer), Zyngenia</Drug><DrugRelationship>General interest</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Priority</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PRI</HighestPatStatusIdForCnty><Indication id="84">Crohns disease</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA7191557">WO-2012162561</Patent><Status id="PRI">First Priority</Status><StatusDate>2011-05-24 00:00:00</StatusDate><StatusSortCode>1</StatusSortCode><TherapyArea id="185">Immune disorder</TherapyArea></Row><Row><Action id="12521">VEGF ligand inhibitor</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="US">US</Country><Drug id="77135">tri-specific anti-Her1/Her3 Zybody (cancer), Zyngenia</Drug><DrugRelationship>General interest</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Priority</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PRI</HighestPatStatusIdForCnty><Indication id="97">Diabetes mellitus</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA7191557">WO-2012162561</Patent><Status id="PRI">First Priority</Status><StatusDate>2011-05-24 00:00:00</StatusDate><StatusSortCode>1</StatusSortCode><TherapyArea id="112">Endocrine disease</TherapyArea></Row><Row><Action id="3252">Insulin-like growth factor 1 receptor antagonist</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="US">US</Country><Drug id="77135">tri-specific anti-Her1/Her3 Zybody (cancer), Zyngenia</Drug><DrugRelationship>General interest</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Priority</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PRI</HighestPatStatusIdForCnty><Indication id="188">Inflammatory disease</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA7191557">WO-2012162561</Patent><Status id="PRI">First Priority</Status><StatusDate>2011-05-24 00:00:00</StatusDate><StatusSortCode>1</StatusSortCode><TherapyArea id="188">Inflammatory disease</TherapyArea></Row><Row><Action id="3252">Insulin-like growth factor 1 receptor antagonist</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="US">US</Country><Drug id="77135">tri-specific anti-Her1/Her3 Zybody (cancer), Zyngenia</Drug><DrugRelationship>General interest</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Priority</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PRI</HighestPatStatusIdForCnty><Indication id="189">Inflammatory bowel disease</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA7191557">WO-2012162561</Patent><Status id="PRI">First Priority</Status><StatusDate>2011-05-24 00:00:00</StatusDate><StatusSortCode>1</StatusSortCode><TherapyArea id="188">Inflammatory disease</TherapyArea></Row><Row><Action id="3252">Insulin-like growth factor 1 receptor antagonist</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="US">US</Country><Drug id="77135">tri-specific anti-Her1/Her3 Zybody (cancer), Zyngenia</Drug><DrugRelationship>General interest</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Priority</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PRI</HighestPatStatusIdForCnty><Indication id="213">Multiple sclerosis</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA7191557">WO-2012162561</Patent><Status id="PRI">First Priority</Status><StatusDate>2011-05-24 00:00:00</StatusDate><StatusSortCode>1</StatusSortCode><TherapyArea id="185">Immune disorder</TherapyArea></Row><Row><Action id="3252">Insulin-like growth factor 1 receptor antagonist</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="US">US</Country><Drug id="77135">tri-specific anti-Her1/Her3 Zybody (cancer), Zyngenia</Drug><DrugRelationship>General interest</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Priority</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PRI</HighestPatStatusIdForCnty><Indication id="281">Psoriasis</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA7191557">WO-2012162561</Patent><Status id="PRI">First Priority</Status><StatusDate>2011-05-24 00:00:00</StatusDate><StatusSortCode>1</StatusSortCode><TherapyArea id="95">Dermatological disease</TherapyArea></Row><Row><Action id="3252">Insulin-like growth factor 1 receptor antagonist</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="US">US</Country><Drug id="77135">tri-specific anti-Her1/Her3 Zybody (cancer), Zyngenia</Drug><DrugRelationship>General interest</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Priority</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PRI</HighestPatStatusIdForCnty><Indication id="291">Rheumatoid arthritis</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA7191557">WO-2012162561</Patent><Status id="PRI">First Priority</Status><StatusDate>2011-05-24 00:00:00</StatusDate><StatusSortCode>1</StatusSortCode><TherapyArea id="185">Immune disorder</TherapyArea></Row><Row><Action id="3252">Insulin-like growth factor 1 receptor antagonist</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="US">US</Country><Drug id="77135">tri-specific anti-Her1/Her3 Zybody (cancer), Zyngenia</Drug><DrugRelationship>General interest</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Priority</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PRI</HighestPatStatusIdForCnty><Indication id="318">Systemic lupus erythematosus</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA7191557">WO-2012162561</Patent><Status id="PRI">First Priority</Status><StatusDate>2011-05-24 00:00:00</StatusDate><StatusSortCode>1</StatusSortCode><TherapyArea id="95">Dermatological disease</TherapyArea></Row><Row><Action id="3252">Insulin-like growth factor 1 receptor antagonist</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="US">US</Country><Drug id="77135">tri-specific anti-Her1/Her3 Zybody (cancer), Zyngenia</Drug><DrugRelationship>General interest</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Priority</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PRI</HighestPatStatusIdForCnty><Indication id="337">Ulcerative colitis</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA7191557">WO-2012162561</Patent><Status id="PRI">First Priority</Status><StatusDate>2011-05-24 00:00:00</StatusDate><StatusSortCode>1</StatusSortCode><TherapyArea id="185">Immune disorder</TherapyArea></Row><Row><Action id="3252">Insulin-like growth factor 1 receptor antagonist</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="US">US</Country><Drug id="77135">tri-specific anti-Her1/Her3 Zybody (cancer), Zyngenia</Drug><DrugRelationship>General interest</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Priority</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PRI</HighestPatStatusIdForCnty><Indication id="651">Cancer</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA7191557">WO-2012162561</Patent><Status id="PRI">First Priority</Status><StatusDate>2011-05-24 00:00:00</StatusDate><StatusSortCode>1</StatusSortCode><TherapyArea id="230">Neoplasm</TherapyArea></Row><Row><Action id="3252">Insulin-like growth factor 1 receptor antagonist</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="US">US</Country><Drug id="77135">tri-specific anti-Her1/Her3 Zybody (cancer), Zyngenia</Drug><DrugRelationship>General interest</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Priority</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PRI</HighestPatStatusIdForCnty><Indication id="746">Infectious disease</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA7191557">WO-2012162561</Patent><Status id="PRI">First Priority</Status><StatusDate>2011-05-24 00:00:00</StatusDate><StatusSortCode>1</StatusSortCode><TherapyArea id="746">Infectious disease</TherapyArea></Row><Row><Action id="3252">Insulin-like growth factor 1 receptor antagonist</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="US">US</Country><Drug id="77135">tri-specific anti-Her1/Her3 Zybody (cancer), Zyngenia</Drug><DrugRelationship>General interest</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Priority</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PRI</HighestPatStatusIdForCnty><Indication id="84">Crohns disease</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA7191557">WO-2012162561</Patent><Status id="PRI">First Priority</Status><StatusDate>2011-05-24 00:00:00</StatusDate><StatusSortCode>1</StatusSortCode><TherapyArea id="185">Immune disorder</TherapyArea></Row><Row><Action id="3252">Insulin-like growth factor 1 receptor antagonist</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="US">US</Country><Drug id="77135">tri-specific anti-Her1/Her3 Zybody (cancer), Zyngenia</Drug><DrugRelationship>General interest</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Priority</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PRI</HighestPatStatusIdForCnty><Indication id="97">Diabetes mellitus</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA7191557">WO-2012162561</Patent><Status id="PRI">First Priority</Status><StatusDate>2011-05-24 00:00:00</StatusDate><StatusSortCode>1</StatusSortCode><TherapyArea id="112">Endocrine disease</TherapyArea></Row><Row><Action id="3682">FGF1 receptor antagonist</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="US">US</Country><Drug id="77135">tri-specific anti-Her1/Her3 Zybody (cancer), Zyngenia</Drug><DrugRelationship>General interest</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Priority</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PRI</HighestPatStatusIdForCnty><Indication id="188">Inflammatory disease</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA7191557">WO-2012162561</Patent><Status id="PRI">First Priority</Status><StatusDate>2011-05-24 00:00:00</StatusDate><StatusSortCode>1</StatusSortCode><TherapyArea id="188">Inflammatory disease</TherapyArea></Row><Row><Action id="3682">FGF1 receptor antagonist</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="US">US</Country><Drug id="77135">tri-specific anti-Her1/Her3 Zybody (cancer), Zyngenia</Drug><DrugRelationship>General interest</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Priority</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PRI</HighestPatStatusIdForCnty><Indication id="189">Inflammatory bowel disease</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA7191557">WO-2012162561</Patent><Status id="PRI">First Priority</Status><StatusDate>2011-05-24 00:00:00</StatusDate><StatusSortCode>1</StatusSortCode><TherapyArea id="188">Inflammatory disease</TherapyArea></Row><Row><Action id="3682">FGF1 receptor antagonist</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="US">US</Country><Drug id="77135">tri-specific anti-Her1/Her3 Zybody (cancer), Zyngenia</Drug><DrugRelationship>General interest</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Priority</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PRI</HighestPatStatusIdForCnty><Indication id="213">Multiple sclerosis</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA7191557">WO-2012162561</Patent><Status id="PRI">First Priority</Status><StatusDate>2011-05-24 00:00:00</StatusDate><StatusSortCode>1</StatusSortCode><TherapyArea id="185">Immune disorder</TherapyArea></Row><Row><Action id="3682">FGF1 receptor antagonist</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="US">US</Country><Drug id="77135">tri-specific anti-Her1/Her3 Zybody (cancer), Zyngenia</Drug><DrugRelationship>General interest</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Priority</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PRI</HighestPatStatusIdForCnty><Indication id="281">Psoriasis</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA7191557">WO-2012162561</Patent><Status id="PRI">First Priority</Status><StatusDate>2011-05-24 00:00:00</StatusDate><StatusSortCode>1</StatusSortCode><TherapyArea id="95">Dermatological disease</TherapyArea></Row><Row><Action id="3682">FGF1 receptor antagonist</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="US">US</Country><Drug id="77135">tri-specific anti-Her1/Her3 Zybody (cancer), Zyngenia</Drug><DrugRelationship>General interest</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Priority</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PRI</HighestPatStatusIdForCnty><Indication id="291">Rheumatoid arthritis</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA7191557">WO-2012162561</Patent><Status id="PRI">First Priority</Status><StatusDate>2011-05-24 00:00:00</StatusDate><StatusSortCode>1</StatusSortCode><TherapyArea id="185">Immune disorder</TherapyArea></Row><Row><Action id="3682">FGF1 receptor antagonist</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="US">US</Country><Drug id="77135">tri-specific anti-Her1/Her3 Zybody (cancer), Zyngenia</Drug><DrugRelationship>General interest</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Priority</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PRI</HighestPatStatusIdForCnty><Indication id="318">Systemic lupus erythematosus</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA7191557">WO-2012162561</Patent><Status id="PRI">First Priority</Status><StatusDate>2011-05-24 00:00:00</StatusDate><StatusSortCode>1</StatusSortCode><TherapyArea id="95">Dermatological disease</TherapyArea></Row><Row><Action id="3682">FGF1 receptor antagonist</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="US">US</Country><Drug id="77135">tri-specific anti-Her1/Her3 Zybody (cancer), Zyngenia</Drug><DrugRelationship>General interest</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Priority</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PRI</HighestPatStatusIdForCnty><Indication id="337">Ulcerative colitis</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA7191557">WO-2012162561</Patent><Status id="PRI">First Priority</Status><StatusDate>2011-05-24 00:00:00</StatusDate><StatusSortCode>1</StatusSortCode><TherapyArea id="185">Immune disorder</TherapyArea></Row><Row><Action id="3682">FGF1 receptor antagonist</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="US">US</Country><Drug id="77135">tri-specific anti-Her1/Her3 Zybody (cancer), Zyngenia</Drug><DrugRelationship>General interest</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Priority</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PRI</HighestPatStatusIdForCnty><Indication id="651">Cancer</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA7191557">WO-2012162561</Patent><Status id="PRI">First Priority</Status><StatusDate>2011-05-24 00:00:00</StatusDate><StatusSortCode>1</StatusSortCode><TherapyArea id="230">Neoplasm</TherapyArea></Row><Row><Action id="3682">FGF1 receptor antagonist</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="US">US</Country><Drug id="77135">tri-specific anti-Her1/Her3 Zybody (cancer), Zyngenia</Drug><DrugRelationship>General interest</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Priority</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PRI</HighestPatStatusIdForCnty><Indication id="746">Infectious disease</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA7191557">WO-2012162561</Patent><Status id="PRI">First Priority</Status><StatusDate>2011-05-24 00:00:00</StatusDate><StatusSortCode>1</StatusSortCode><TherapyArea id="746">Infectious disease</TherapyArea></Row><Row><Action id="3682">FGF1 receptor antagonist</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="US">US</Country><Drug id="77135">tri-specific anti-Her1/Her3 Zybody (cancer), Zyngenia</Drug><DrugRelationship>General interest</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Priority</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PRI</HighestPatStatusIdForCnty><Indication id="84">Crohns disease</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA7191557">WO-2012162561</Patent><Status id="PRI">First Priority</Status><StatusDate>2011-05-24 00:00:00</StatusDate><StatusSortCode>1</StatusSortCode><TherapyArea id="185">Immune disorder</TherapyArea></Row><Row><Action id="3682">FGF1 receptor antagonist</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="US">US</Country><Drug id="77135">tri-specific anti-Her1/Her3 Zybody (cancer), Zyngenia</Drug><DrugRelationship>General interest</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Priority</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PRI</HighestPatStatusIdForCnty><Indication id="97">Diabetes mellitus</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA7191557">WO-2012162561</Patent><Status id="PRI">First Priority</Status><StatusDate>2011-05-24 00:00:00</StatusDate><StatusSortCode>1</StatusSortCode><TherapyArea id="112">Endocrine disease</TherapyArea></Row><Row><Action id="3685">FGF2 receptor antagonist</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="US">US</Country><Drug id="77135">tri-specific anti-Her1/Her3 Zybody (cancer), Zyngenia</Drug><DrugRelationship>General interest</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Priority</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PRI</HighestPatStatusIdForCnty><Indication id="188">Inflammatory disease</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA7191557">WO-2012162561</Patent><Status id="PRI">First Priority</Status><StatusDate>2011-05-24 00:00:00</StatusDate><StatusSortCode>1</StatusSortCode><TherapyArea id="188">Inflammatory disease</TherapyArea></Row><Row><Action id="3685">FGF2 receptor antagonist</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="US">US</Country><Drug id="77135">tri-specific anti-Her1/Her3 Zybody (cancer), Zyngenia</Drug><DrugRelationship>General interest</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Priority</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PRI</HighestPatStatusIdForCnty><Indication id="189">Inflammatory bowel disease</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA7191557">WO-2012162561</Patent><Status id="PRI">First Priority</Status><StatusDate>2011-05-24 00:00:00</StatusDate><StatusSortCode>1</StatusSortCode><TherapyArea id="188">Inflammatory disease</TherapyArea></Row><Row><Action id="3685">FGF2 receptor antagonist</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="US">US</Country><Drug id="77135">tri-specific anti-Her1/Her3 Zybody (cancer), Zyngenia</Drug><DrugRelationship>General interest</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Priority</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PRI</HighestPatStatusIdForCnty><Indication id="213">Multiple sclerosis</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA7191557">WO-2012162561</Patent><Status id="PRI">First Priority</Status><StatusDate>2011-05-24 00:00:00</StatusDate><StatusSortCode>1</StatusSortCode><TherapyArea id="185">Immune disorder</TherapyArea></Row><Row><Action id="3685">FGF2 receptor antagonist</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="US">US</Country><Drug id="77135">tri-specific anti-Her1/Her3 Zybody (cancer), Zyngenia</Drug><DrugRelationship>General interest</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Priority</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PRI</HighestPatStatusIdForCnty><Indication id="281">Psoriasis</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA7191557">WO-2012162561</Patent><Status id="PRI">First Priority</Status><StatusDate>2011-05-24 00:00:00</StatusDate><StatusSortCode>1</StatusSortCode><TherapyArea id="95">Dermatological disease</TherapyArea></Row><Row><Action id="3685">FGF2 receptor antagonist</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="US">US</Country><Drug id="77135">tri-specific anti-Her1/Her3 Zybody (cancer), Zyngenia</Drug><DrugRelationship>General interest</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Priority</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PRI</HighestPatStatusIdForCnty><Indication id="291">Rheumatoid arthritis</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA7191557">WO-2012162561</Patent><Status id="PRI">First Priority</Status><StatusDate>2011-05-24 00:00:00</StatusDate><StatusSortCode>1</StatusSortCode><TherapyArea id="185">Immune disorder</TherapyArea></Row><Row><Action id="3685">FGF2 receptor antagonist</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="US">US</Country><Drug id="77135">tri-specific anti-Her1/Her3 Zybody (cancer), Zyngenia</Drug><DrugRelationship>General interest</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Priority</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PRI</HighestPatStatusIdForCnty><Indication id="318">Systemic lupus erythematosus</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA7191557">WO-2012162561</Patent><Status id="PRI">First Priority</Status><StatusDate>2011-05-24 00:00:00</StatusDate><StatusSortCode>1</StatusSortCode><TherapyArea id="95">Dermatological disease</TherapyArea></Row><Row><Action id="3685">FGF2 receptor antagonist</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="US">US</Country><Drug id="77135">tri-specific anti-Her1/Her3 Zybody (cancer), Zyngenia</Drug><DrugRelationship>General interest</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Priority</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PRI</HighestPatStatusIdForCnty><Indication id="337">Ulcerative colitis</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA7191557">WO-2012162561</Patent><Status id="PRI">First Priority</Status><StatusDate>2011-05-24 00:00:00</StatusDate><StatusSortCode>1</StatusSortCode><TherapyArea id="185">Immune disorder</TherapyArea></Row><Row><Action id="3685">FGF2 receptor antagonist</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="US">US</Country><Drug id="77135">tri-specific anti-Her1/Her3 Zybody (cancer), Zyngenia</Drug><DrugRelationship>General interest</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Priority</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PRI</HighestPatStatusIdForCnty><Indication id="651">Cancer</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA7191557">WO-2012162561</Patent><Status id="PRI">First Priority</Status><StatusDate>2011-05-24 00:00:00</StatusDate><StatusSortCode>1</StatusSortCode><TherapyArea id="230">Neoplasm</TherapyArea></Row><Row><Action id="3685">FGF2 receptor antagonist</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="US">US</Country><Drug id="77135">tri-specific anti-Her1/Her3 Zybody (cancer), Zyngenia</Drug><DrugRelationship>General interest</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Priority</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PRI</HighestPatStatusIdForCnty><Indication id="746">Infectious disease</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA7191557">WO-2012162561</Patent><Status id="PRI">First Priority</Status><StatusDate>2011-05-24 00:00:00</StatusDate><StatusSortCode>1</StatusSortCode><TherapyArea id="746">Infectious disease</TherapyArea></Row><Row><Action id="3685">FGF2 receptor antagonist</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="US">US</Country><Drug id="77135">tri-specific anti-Her1/Her3 Zybody (cancer), Zyngenia</Drug><DrugRelationship>General interest</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Priority</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PRI</HighestPatStatusIdForCnty><Indication id="84">Crohns disease</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA7191557">WO-2012162561</Patent><Status id="PRI">First Priority</Status><StatusDate>2011-05-24 00:00:00</StatusDate><StatusSortCode>1</StatusSortCode><TherapyArea id="185">Immune disorder</TherapyArea></Row><Row><Action id="3685">FGF2 receptor antagonist</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="US">US</Country><Drug id="77135">tri-specific anti-Her1/Her3 Zybody (cancer), Zyngenia</Drug><DrugRelationship>General interest</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Priority</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PRI</HighestPatStatusIdForCnty><Indication id="97">Diabetes mellitus</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA7191557">WO-2012162561</Patent><Status id="PRI">First Priority</Status><StatusDate>2011-05-24 00:00:00</StatusDate><StatusSortCode>1</StatusSortCode><TherapyArea id="112">Endocrine disease</TherapyArea></Row><Row><Action id="3756">Erbb2 tyrosine kinase receptor inhibitor</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="US">US</Country><Drug id="77135">tri-specific anti-Her1/Her3 Zybody (cancer), Zyngenia</Drug><DrugRelationship>General interest</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Priority</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PRI</HighestPatStatusIdForCnty><Indication id="188">Inflammatory disease</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA7191557">WO-2012162561</Patent><Status id="PRI">First Priority</Status><StatusDate>2011-05-24 00:00:00</StatusDate><StatusSortCode>1</StatusSortCode><TherapyArea id="188">Inflammatory disease</TherapyArea></Row><Row><Action id="3756">Erbb2 tyrosine kinase receptor inhibitor</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="US">US</Country><Drug id="77135">tri-specific anti-Her1/Her3 Zybody (cancer), Zyngenia</Drug><DrugRelationship>General interest</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Priority</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PRI</HighestPatStatusIdForCnty><Indication id="189">Inflammatory bowel disease</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA7191557">WO-2012162561</Patent><Status id="PRI">First Priority</Status><StatusDate>2011-05-24 00:00:00</StatusDate><StatusSortCode>1</StatusSortCode><TherapyArea id="188">Inflammatory disease</TherapyArea></Row><Row><Action id="3756">Erbb2 tyrosine kinase receptor inhibitor</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="US">US</Country><Drug id="77135">tri-specific anti-Her1/Her3 Zybody (cancer), Zyngenia</Drug><DrugRelationship>General interest</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Priority</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PRI</HighestPatStatusIdForCnty><Indication id="213">Multiple sclerosis</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA7191557">WO-2012162561</Patent><Status id="PRI">First Priority</Status><StatusDate>2011-05-24 00:00:00</StatusDate><StatusSortCode>1</StatusSortCode><TherapyArea id="185">Immune disorder</TherapyArea></Row><Row><Action id="3756">Erbb2 tyrosine kinase receptor inhibitor</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="US">US</Country><Drug id="77135">tri-specific anti-Her1/Her3 Zybody (cancer), Zyngenia</Drug><DrugRelationship>General interest</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Priority</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PRI</HighestPatStatusIdForCnty><Indication id="281">Psoriasis</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA7191557">WO-2012162561</Patent><Status id="PRI">First Priority</Status><StatusDate>2011-05-24 00:00:00</StatusDate><StatusSortCode>1</StatusSortCode><TherapyArea id="95">Dermatological disease</TherapyArea></Row><Row><Action id="3756">Erbb2 tyrosine kinase receptor inhibitor</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="US">US</Country><Drug id="77135">tri-specific anti-Her1/Her3 Zybody (cancer), Zyngenia</Drug><DrugRelationship>General interest</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Priority</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PRI</HighestPatStatusIdForCnty><Indication id="291">Rheumatoid arthritis</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA7191557">WO-2012162561</Patent><Status id="PRI">First Priority</Status><StatusDate>2011-05-24 00:00:00</StatusDate><StatusSortCode>1</StatusSortCode><TherapyArea id="185">Immune disorder</TherapyArea></Row><Row><Action id="3756">Erbb2 tyrosine kinase receptor inhibitor</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="US">US</Country><Drug id="77135">tri-specific anti-Her1/Her3 Zybody (cancer), Zyngenia</Drug><DrugRelationship>General interest</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Priority</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PRI</HighestPatStatusIdForCnty><Indication id="318">Systemic lupus erythematosus</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA7191557">WO-2012162561</Patent><Status id="PRI">First Priority</Status><StatusDate>2011-05-24 00:00:00</StatusDate><StatusSortCode>1</StatusSortCode><TherapyArea id="95">Dermatological disease</TherapyArea></Row><Row><Action id="3756">Erbb2 tyrosine kinase receptor inhibitor</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="US">US</Country><Drug id="77135">tri-specific anti-Her1/Her3 Zybody (cancer), Zyngenia</Drug><DrugRelationship>General interest</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Priority</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PRI</HighestPatStatusIdForCnty><Indication id="337">Ulcerative colitis</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA7191557">WO-2012162561</Patent><Status id="PRI">First Priority</Status><StatusDate>2011-05-24 00:00:00</StatusDate><StatusSortCode>1</StatusSortCode><TherapyArea id="185">Immune disorder</TherapyArea></Row><Row><Action id="3756">Erbb2 tyrosine kinase receptor inhibitor</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="US">US</Country><Drug id="77135">tri-specific anti-Her1/Her3 Zybody (cancer), Zyngenia</Drug><DrugRelationship>General interest</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Priority</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PRI</HighestPatStatusIdForCnty><Indication id="651">Cancer</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA7191557">WO-2012162561</Patent><Status id="PRI">First Priority</Status><StatusDate>2011-05-24 00:00:00</StatusDate><StatusSortCode>1</StatusSortCode><TherapyArea id="230">Neoplasm</TherapyArea></Row><Row><Action id="3756">Erbb2 tyrosine kinase receptor inhibitor</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="US">US</Country><Drug id="77135">tri-specific anti-Her1/Her3 Zybody (cancer), Zyngenia</Drug><DrugRelationship>General interest</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Priority</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PRI</HighestPatStatusIdForCnty><Indication id="746">Infectious disease</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA7191557">WO-2012162561</Patent><Status id="PRI">First Priority</Status><StatusDate>2011-05-24 00:00:00</StatusDate><StatusSortCode>1</StatusSortCode><TherapyArea id="746">Infectious disease</TherapyArea></Row><Row><Action id="3756">Erbb2 tyrosine kinase receptor inhibitor</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="US">US</Country><Drug id="77135">tri-specific anti-Her1/Her3 Zybody (cancer), Zyngenia</Drug><DrugRelationship>General interest</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Priority</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PRI</HighestPatStatusIdForCnty><Indication id="84">Crohns disease</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA7191557">WO-2012162561</Patent><Status id="PRI">First Priority</Status><StatusDate>2011-05-24 00:00:00</StatusDate><StatusSortCode>1</StatusSortCode><TherapyArea id="185">Immune disorder</TherapyArea></Row><Row><Action id="3756">Erbb2 tyrosine kinase receptor inhibitor</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="US">US</Country><Drug id="77135">tri-specific anti-Her1/Her3 Zybody (cancer), Zyngenia</Drug><DrugRelationship>General interest</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Priority</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PRI</HighestPatStatusIdForCnty><Indication id="97">Diabetes mellitus</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA7191557">WO-2012162561</Patent><Status id="PRI">First Priority</Status><StatusDate>2011-05-24 00:00:00</StatusDate><StatusSortCode>1</StatusSortCode><TherapyArea id="112">Endocrine disease</TherapyArea></Row><Row><Action id="3846">VEGF-1 receptor antagonist</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="US">US</Country><Drug id="77135">tri-specific anti-Her1/Her3 Zybody (cancer), Zyngenia</Drug><DrugRelationship>General interest</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Priority</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PRI</HighestPatStatusIdForCnty><Indication id="188">Inflammatory disease</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA7191557">WO-2012162561</Patent><Status id="PRI">First Priority</Status><StatusDate>2011-05-24 00:00:00</StatusDate><StatusSortCode>1</StatusSortCode><TherapyArea id="188">Inflammatory disease</TherapyArea></Row><Row><Action id="3846">VEGF-1 receptor antagonist</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="US">US</Country><Drug id="77135">tri-specific anti-Her1/Her3 Zybody (cancer), Zyngenia</Drug><DrugRelationship>General interest</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Priority</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PRI</HighestPatStatusIdForCnty><Indication id="189">Inflammatory bowel disease</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA7191557">WO-2012162561</Patent><Status id="PRI">First Priority</Status><StatusDate>2011-05-24 00:00:00</StatusDate><StatusSortCode>1</StatusSortCode><TherapyArea id="188">Inflammatory disease</TherapyArea></Row><Row><Action id="3846">VEGF-1 receptor antagonist</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="US">US</Country><Drug id="77135">tri-specific anti-Her1/Her3 Zybody (cancer), Zyngenia</Drug><DrugRelationship>General interest</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Priority</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PRI</HighestPatStatusIdForCnty><Indication id="213">Multiple sclerosis</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA7191557">WO-2012162561</Patent><Status id="PRI">First Priority</Status><StatusDate>2011-05-24 00:00:00</StatusDate><StatusSortCode>1</StatusSortCode><TherapyArea id="185">Immune disorder</TherapyArea></Row><Row><Action id="3846">VEGF-1 receptor antagonist</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="US">US</Country><Drug id="77135">tri-specific anti-Her1/Her3 Zybody (cancer), Zyngenia</Drug><DrugRelationship>General interest</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Priority</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PRI</HighestPatStatusIdForCnty><Indication id="281">Psoriasis</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA7191557">WO-2012162561</Patent><Status id="PRI">First Priority</Status><StatusDate>2011-05-24 00:00:00</StatusDate><StatusSortCode>1</StatusSortCode><TherapyArea id="95">Dermatological disease</TherapyArea></Row><Row><Action id="3846">VEGF-1 receptor antagonist</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="US">US</Country><Drug id="77135">tri-specific anti-Her1/Her3 Zybody (cancer), Zyngenia</Drug><DrugRelationship>General interest</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Priority</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PRI</HighestPatStatusIdForCnty><Indication id="291">Rheumatoid arthritis</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA7191557">WO-2012162561</Patent><Status id="PRI">First Priority</Status><StatusDate>2011-05-24 00:00:00</StatusDate><StatusSortCode>1</StatusSortCode><TherapyArea id="185">Immune disorder</TherapyArea></Row><Row><Action id="3846">VEGF-1 receptor antagonist</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="US">US</Country><Drug id="77135">tri-specific anti-Her1/Her3 Zybody (cancer), Zyngenia</Drug><DrugRelationship>General interest</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Priority</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PRI</HighestPatStatusIdForCnty><Indication id="318">Systemic lupus erythematosus</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA7191557">WO-2012162561</Patent><Status id="PRI">First Priority</Status><StatusDate>2011-05-24 00:00:00</StatusDate><StatusSortCode>1</StatusSortCode><TherapyArea id="95">Dermatological disease</TherapyArea></Row><Row><Action id="3846">VEGF-1 receptor antagonist</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="US">US</Country><Drug id="77135">tri-specific anti-Her1/Her3 Zybody (cancer), Zyngenia</Drug><DrugRelationship>General interest</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Priority</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PRI</HighestPatStatusIdForCnty><Indication id="337">Ulcerative colitis</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA7191557">WO-2012162561</Patent><Status id="PRI">First Priority</Status><StatusDate>2011-05-24 00:00:00</StatusDate><StatusSortCode>1</StatusSortCode><TherapyArea id="185">Immune disorder</TherapyArea></Row><Row><Action id="3846">VEGF-1 receptor antagonist</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="US">US</Country><Drug id="77135">tri-specific anti-Her1/Her3 Zybody (cancer), Zyngenia</Drug><DrugRelationship>General interest</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Priority</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PRI</HighestPatStatusIdForCnty><Indication id="651">Cancer</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA7191557">WO-2012162561</Patent><Status id="PRI">First Priority</Status><StatusDate>2011-05-24 00:00:00</StatusDate><StatusSortCode>1</StatusSortCode><TherapyArea id="230">Neoplasm</TherapyArea></Row><Row><Action id="3846">VEGF-1 receptor antagonist</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="US">US</Country><Drug id="77135">tri-specific anti-Her1/Her3 Zybody (cancer), Zyngenia</Drug><DrugRelationship>General interest</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Priority</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PRI</HighestPatStatusIdForCnty><Indication id="746">Infectious disease</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA7191557">WO-2012162561</Patent><Status id="PRI">First Priority</Status><StatusDate>2011-05-24 00:00:00</StatusDate><StatusSortCode>1</StatusSortCode><TherapyArea id="746">Infectious disease</TherapyArea></Row><Row><Action id="3846">VEGF-1 receptor antagonist</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="US">US</Country><Drug id="77135">tri-specific anti-Her1/Her3 Zybody (cancer), Zyngenia</Drug><DrugRelationship>General interest</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Priority</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PRI</HighestPatStatusIdForCnty><Indication id="84">Crohns disease</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA7191557">WO-2012162561</Patent><Status id="PRI">First Priority</Status><StatusDate>2011-05-24 00:00:00</StatusDate><StatusSortCode>1</StatusSortCode><TherapyArea id="185">Immune disorder</TherapyArea></Row><Row><Action id="3846">VEGF-1 receptor antagonist</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="US">US</Country><Drug id="77135">tri-specific anti-Her1/Her3 Zybody (cancer), Zyngenia</Drug><DrugRelationship>General interest</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Priority</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PRI</HighestPatStatusIdForCnty><Indication id="97">Diabetes mellitus</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA7191557">WO-2012162561</Patent><Status id="PRI">First Priority</Status><StatusDate>2011-05-24 00:00:00</StatusDate><StatusSortCode>1</StatusSortCode><TherapyArea id="112">Endocrine disease</TherapyArea></Row><Row><Action id="5025">CD3 antagonist</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="US">US</Country><Drug id="77135">tri-specific anti-Her1/Her3 Zybody (cancer), Zyngenia</Drug><DrugRelationship>General interest</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Priority</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PRI</HighestPatStatusIdForCnty><Indication id="188">Inflammatory disease</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA7191557">WO-2012162561</Patent><Status id="PRI">First Priority</Status><StatusDate>2011-05-24 00:00:00</StatusDate><StatusSortCode>1</StatusSortCode><TherapyArea id="188">Inflammatory disease</TherapyArea></Row><Row><Action id="5025">CD3 antagonist</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="US">US</Country><Drug id="77135">tri-specific anti-Her1/Her3 Zybody (cancer), Zyngenia</Drug><DrugRelationship>General interest</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Priority</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PRI</HighestPatStatusIdForCnty><Indication id="189">Inflammatory bowel disease</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA7191557">WO-2012162561</Patent><Status id="PRI">First Priority</Status><StatusDate>2011-05-24 00:00:00</StatusDate><StatusSortCode>1</StatusSortCode><TherapyArea id="188">Inflammatory disease</TherapyArea></Row><Row><Action id="5025">CD3 antagonist</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="US">US</Country><Drug id="77135">tri-specific anti-Her1/Her3 Zybody (cancer), Zyngenia</Drug><DrugRelationship>General interest</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Priority</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PRI</HighestPatStatusIdForCnty><Indication id="213">Multiple sclerosis</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA7191557">WO-2012162561</Patent><Status id="PRI">First Priority</Status><StatusDate>2011-05-24 00:00:00</StatusDate><StatusSortCode>1</StatusSortCode><TherapyArea id="185">Immune disorder</TherapyArea></Row><Row><Action id="5025">CD3 antagonist</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="US">US</Country><Drug id="77135">tri-specific anti-Her1/Her3 Zybody (cancer), Zyngenia</Drug><DrugRelationship>General interest</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Priority</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PRI</HighestPatStatusIdForCnty><Indication id="281">Psoriasis</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA7191557">WO-2012162561</Patent><Status id="PRI">First Priority</Status><StatusDate>2011-05-24 00:00:00</StatusDate><StatusSortCode>1</StatusSortCode><TherapyArea id="95">Dermatological disease</TherapyArea></Row><Row><Action id="5025">CD3 antagonist</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="US">US</Country><Drug id="77135">tri-specific anti-Her1/Her3 Zybody (cancer), Zyngenia</Drug><DrugRelationship>General interest</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Priority</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PRI</HighestPatStatusIdForCnty><Indication id="291">Rheumatoid arthritis</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA7191557">WO-2012162561</Patent><Status id="PRI">First Priority</Status><StatusDate>2011-05-24 00:00:00</StatusDate><StatusSortCode>1</StatusSortCode><TherapyArea id="185">Immune disorder</TherapyArea></Row><Row><Action id="5025">CD3 antagonist</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="US">US</Country><Drug id="77135">tri-specific anti-Her1/Her3 Zybody (cancer), Zyngenia</Drug><DrugRelationship>General interest</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Priority</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PRI</HighestPatStatusIdForCnty><Indication id="318">Systemic lupus erythematosus</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA7191557">WO-2012162561</Patent><Status id="PRI">First Priority</Status><StatusDate>2011-05-24 00:00:00</StatusDate><StatusSortCode>1</StatusSortCode><TherapyArea id="95">Dermatological disease</TherapyArea></Row><Row><Action id="5025">CD3 antagonist</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="US">US</Country><Drug id="77135">tri-specific anti-Her1/Her3 Zybody (cancer), Zyngenia</Drug><DrugRelationship>General interest</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Priority</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PRI</HighestPatStatusIdForCnty><Indication id="337">Ulcerative colitis</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA7191557">WO-2012162561</Patent><Status id="PRI">First Priority</Status><StatusDate>2011-05-24 00:00:00</StatusDate><StatusSortCode>1</StatusSortCode><TherapyArea id="185">Immune disorder</TherapyArea></Row><Row><Action id="5025">CD3 antagonist</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="US">US</Country><Drug id="77135">tri-specific anti-Her1/Her3 Zybody (cancer), Zyngenia</Drug><DrugRelationship>General interest</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Priority</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PRI</HighestPatStatusIdForCnty><Indication id="651">Cancer</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA7191557">WO-2012162561</Patent><Status id="PRI">First Priority</Status><StatusDate>2011-05-24 00:00:00</StatusDate><StatusSortCode>1</StatusSortCode><TherapyArea id="230">Neoplasm</TherapyArea></Row><Row><Action id="5025">CD3 antagonist</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="US">US</Country><Drug id="77135">tri-specific anti-Her1/Her3 Zybody (cancer), Zyngenia</Drug><DrugRelationship>General interest</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Priority</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PRI</HighestPatStatusIdForCnty><Indication id="746">Infectious disease</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA7191557">WO-2012162561</Patent><Status id="PRI">First Priority</Status><StatusDate>2011-05-24 00:00:00</StatusDate><StatusSortCode>1</StatusSortCode><TherapyArea id="746">Infectious disease</TherapyArea></Row><Row><Action id="5025">CD3 antagonist</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="US">US</Country><Drug id="77135">tri-specific anti-Her1/Her3 Zybody (cancer), Zyngenia</Drug><DrugRelationship>General interest</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Priority</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PRI</HighestPatStatusIdForCnty><Indication id="84">Crohns disease</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA7191557">WO-2012162561</Patent><Status id="PRI">First Priority</Status><StatusDate>2011-05-24 00:00:00</StatusDate><StatusSortCode>1</StatusSortCode><TherapyArea id="185">Immune disorder</TherapyArea></Row><Row><Action id="5025">CD3 antagonist</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="US">US</Country><Drug id="77135">tri-specific anti-Her1/Her3 Zybody (cancer), Zyngenia</Drug><DrugRelationship>General interest</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Priority</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PRI</HighestPatStatusIdForCnty><Indication id="97">Diabetes mellitus</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA7191557">WO-2012162561</Patent><Status id="PRI">First Priority</Status><StatusDate>2011-05-24 00:00:00</StatusDate><StatusSortCode>1</StatusSortCode><TherapyArea id="112">Endocrine disease</TherapyArea></Row><Row><Action id="5082">B-lymphocyte antigen CD19 inhibitor</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="US">US</Country><Drug id="77135">tri-specific anti-Her1/Her3 Zybody (cancer), Zyngenia</Drug><DrugRelationship>General interest</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Priority</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PRI</HighestPatStatusIdForCnty><Indication id="188">Inflammatory disease</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA7191557">WO-2012162561</Patent><Status id="PRI">First Priority</Status><StatusDate>2011-05-24 00:00:00</StatusDate><StatusSortCode>1</StatusSortCode><TherapyArea id="188">Inflammatory disease</TherapyArea></Row><Row><Action id="5082">B-lymphocyte antigen CD19 inhibitor</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="US">US</Country><Drug id="77135">tri-specific anti-Her1/Her3 Zybody (cancer), Zyngenia</Drug><DrugRelationship>General interest</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Priority</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PRI</HighestPatStatusIdForCnty><Indication id="189">Inflammatory bowel disease</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA7191557">WO-2012162561</Patent><Status id="PRI">First Priority</Status><StatusDate>2011-05-24 00:00:00</StatusDate><StatusSortCode>1</StatusSortCode><TherapyArea id="188">Inflammatory disease</TherapyArea></Row><Row><Action id="5082">B-lymphocyte antigen CD19 inhibitor</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="US">US</Country><Drug id="77135">tri-specific anti-Her1/Her3 Zybody (cancer), Zyngenia</Drug><DrugRelationship>General interest</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Priority</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PRI</HighestPatStatusIdForCnty><Indication id="213">Multiple sclerosis</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA7191557">WO-2012162561</Patent><Status id="PRI">First Priority</Status><StatusDate>2011-05-24 00:00:00</StatusDate><StatusSortCode>1</StatusSortCode><TherapyArea id="185">Immune disorder</TherapyArea></Row><Row><Action id="5082">B-lymphocyte antigen CD19 inhibitor</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="US">US</Country><Drug id="77135">tri-specific anti-Her1/Her3 Zybody (cancer), Zyngenia</Drug><DrugRelationship>General interest</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Priority</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PRI</HighestPatStatusIdForCnty><Indication id="281">Psoriasis</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA7191557">WO-2012162561</Patent><Status id="PRI">First Priority</Status><StatusDate>2011-05-24 00:00:00</StatusDate><StatusSortCode>1</StatusSortCode><TherapyArea id="95">Dermatological disease</TherapyArea></Row><Row><Action id="5082">B-lymphocyte antigen CD19 inhibitor</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="US">US</Country><Drug id="77135">tri-specific anti-Her1/Her3 Zybody (cancer), Zyngenia</Drug><DrugRelationship>General interest</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Priority</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PRI</HighestPatStatusIdForCnty><Indication id="291">Rheumatoid arthritis</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA7191557">WO-2012162561</Patent><Status id="PRI">First Priority</Status><StatusDate>2011-05-24 00:00:00</StatusDate><StatusSortCode>1</StatusSortCode><TherapyArea id="185">Immune disorder</TherapyArea></Row><Row><Action id="5082">B-lymphocyte antigen CD19 inhibitor</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="US">US</Country><Drug id="77135">tri-specific anti-Her1/Her3 Zybody (cancer), Zyngenia</Drug><DrugRelationship>General interest</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Priority</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PRI</HighestPatStatusIdForCnty><Indication id="318">Systemic lupus erythematosus</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA7191557">WO-2012162561</Patent><Status id="PRI">First Priority</Status><StatusDate>2011-05-24 00:00:00</StatusDate><StatusSortCode>1</StatusSortCode><TherapyArea id="95">Dermatological disease</TherapyArea></Row><Row><Action id="5082">B-lymphocyte antigen CD19 inhibitor</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="US">US</Country><Drug id="77135">tri-specific anti-Her1/Her3 Zybody (cancer), Zyngenia</Drug><DrugRelationship>General interest</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Priority</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PRI</HighestPatStatusIdForCnty><Indication id="337">Ulcerative colitis</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA7191557">WO-2012162561</Patent><Status id="PRI">First Priority</Status><StatusDate>2011-05-24 00:00:00</StatusDate><StatusSortCode>1</StatusSortCode><TherapyArea id="185">Immune disorder</TherapyArea></Row><Row><Action id="5082">B-lymphocyte antigen CD19 inhibitor</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="US">US</Country><Drug id="77135">tri-specific anti-Her1/Her3 Zybody (cancer), Zyngenia</Drug><DrugRelationship>General interest</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Priority</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PRI</HighestPatStatusIdForCnty><Indication id="651">Cancer</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA7191557">WO-2012162561</Patent><Status id="PRI">First Priority</Status><StatusDate>2011-05-24 00:00:00</StatusDate><StatusSortCode>1</StatusSortCode><TherapyArea id="230">Neoplasm</TherapyArea></Row><Row><Action id="5082">B-lymphocyte antigen CD19 inhibitor</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="US">US</Country><Drug id="77135">tri-specific anti-Her1/Her3 Zybody (cancer), Zyngenia</Drug><DrugRelationship>General interest</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Priority</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PRI</HighestPatStatusIdForCnty><Indication id="746">Infectious disease</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA7191557">WO-2012162561</Patent><Status id="PRI">First Priority</Status><StatusDate>2011-05-24 00:00:00</StatusDate><StatusSortCode>1</StatusSortCode><TherapyArea id="746">Infectious disease</TherapyArea></Row><Row><Action id="5082">B-lymphocyte antigen CD19 inhibitor</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="US">US</Country><Drug id="77135">tri-specific anti-Her1/Her3 Zybody (cancer), Zyngenia</Drug><DrugRelationship>General interest</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Priority</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PRI</HighestPatStatusIdForCnty><Indication id="84">Crohns disease</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA7191557">WO-2012162561</Patent><Status id="PRI">First Priority</Status><StatusDate>2011-05-24 00:00:00</StatusDate><StatusSortCode>1</StatusSortCode><TherapyArea id="185">Immune disorder</TherapyArea></Row><Row><Action id="5082">B-lymphocyte antigen CD19 inhibitor</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="US">US</Country><Drug id="77135">tri-specific anti-Her1/Her3 Zybody (cancer), Zyngenia</Drug><DrugRelationship>General interest</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Priority</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PRI</HighestPatStatusIdForCnty><Indication id="97">Diabetes mellitus</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA7191557">WO-2012162561</Patent><Status id="PRI">First Priority</Status><StatusDate>2011-05-24 00:00:00</StatusDate><StatusSortCode>1</StatusSortCode><TherapyArea id="112">Endocrine disease</TherapyArea></Row><Row><Action id="5085">B-lymphocyte antigen CD20 inhibitor</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="US">US</Country><Drug id="77135">tri-specific anti-Her1/Her3 Zybody (cancer), Zyngenia</Drug><DrugRelationship>General interest</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Priority</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PRI</HighestPatStatusIdForCnty><Indication id="188">Inflammatory disease</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA7191557">WO-2012162561</Patent><Status id="PRI">First Priority</Status><StatusDate>2011-05-24 00:00:00</StatusDate><StatusSortCode>1</StatusSortCode><TherapyArea id="188">Inflammatory disease</TherapyArea></Row><Row><Action id="5085">B-lymphocyte antigen CD20 inhibitor</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="US">US</Country><Drug id="77135">tri-specific anti-Her1/Her3 Zybody (cancer), Zyngenia</Drug><DrugRelationship>General interest</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Priority</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PRI</HighestPatStatusIdForCnty><Indication id="189">Inflammatory bowel disease</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA7191557">WO-2012162561</Patent><Status id="PRI">First Priority</Status><StatusDate>2011-05-24 00:00:00</StatusDate><StatusSortCode>1</StatusSortCode><TherapyArea id="188">Inflammatory disease</TherapyArea></Row><Row><Action id="5085">B-lymphocyte antigen CD20 inhibitor</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="US">US</Country><Drug id="77135">tri-specific anti-Her1/Her3 Zybody (cancer), Zyngenia</Drug><DrugRelationship>General interest</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Priority</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PRI</HighestPatStatusIdForCnty><Indication id="213">Multiple sclerosis</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA7191557">WO-2012162561</Patent><Status id="PRI">First Priority</Status><StatusDate>2011-05-24 00:00:00</StatusDate><StatusSortCode>1</StatusSortCode><TherapyArea id="185">Immune disorder</TherapyArea></Row><Row><Action id="5085">B-lymphocyte antigen CD20 inhibitor</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="US">US</Country><Drug id="77135">tri-specific anti-Her1/Her3 Zybody (cancer), Zyngenia</Drug><DrugRelationship>General interest</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Priority</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PRI</HighestPatStatusIdForCnty><Indication id="281">Psoriasis</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA7191557">WO-2012162561</Patent><Status id="PRI">First Priority</Status><StatusDate>2011-05-24 00:00:00</StatusDate><StatusSortCode>1</StatusSortCode><TherapyArea id="95">Dermatological disease</TherapyArea></Row><Row><Action id="5085">B-lymphocyte antigen CD20 inhibitor</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="US">US</Country><Drug id="77135">tri-specific anti-Her1/Her3 Zybody (cancer), Zyngenia</Drug><DrugRelationship>General interest</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Priority</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PRI</HighestPatStatusIdForCnty><Indication id="291">Rheumatoid arthritis</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA7191557">WO-2012162561</Patent><Status id="PRI">First Priority</Status><StatusDate>2011-05-24 00:00:00</StatusDate><StatusSortCode>1</StatusSortCode><TherapyArea id="185">Immune disorder</TherapyArea></Row><Row><Action id="5085">B-lymphocyte antigen CD20 inhibitor</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="US">US</Country><Drug id="77135">tri-specific anti-Her1/Her3 Zybody (cancer), Zyngenia</Drug><DrugRelationship>General interest</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Priority</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PRI</HighestPatStatusIdForCnty><Indication id="318">Systemic lupus erythematosus</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA7191557">WO-2012162561</Patent><Status id="PRI">First Priority</Status><StatusDate>2011-05-24 00:00:00</StatusDate><StatusSortCode>1</StatusSortCode><TherapyArea id="95">Dermatological disease</TherapyArea></Row><Row><Action id="5085">B-lymphocyte antigen CD20 inhibitor</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="US">US</Country><Drug id="77135">tri-specific anti-Her1/Her3 Zybody (cancer), Zyngenia</Drug><DrugRelationship>General interest</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Priority</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PRI</HighestPatStatusIdForCnty><Indication id="337">Ulcerative colitis</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA7191557">WO-2012162561</Patent><Status id="PRI">First Priority</Status><StatusDate>2011-05-24 00:00:00</StatusDate><StatusSortCode>1</StatusSortCode><TherapyArea id="185">Immune disorder</TherapyArea></Row><Row><Action id="5085">B-lymphocyte antigen CD20 inhibitor</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="US">US</Country><Drug id="77135">tri-specific anti-Her1/Her3 Zybody (cancer), Zyngenia</Drug><DrugRelationship>General interest</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Priority</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PRI</HighestPatStatusIdForCnty><Indication id="651">Cancer</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA7191557">WO-2012162561</Patent><Status id="PRI">First Priority</Status><StatusDate>2011-05-24 00:00:00</StatusDate><StatusSortCode>1</StatusSortCode><TherapyArea id="230">Neoplasm</TherapyArea></Row><Row><Action id="5085">B-lymphocyte antigen CD20 inhibitor</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="US">US</Country><Drug id="77135">tri-specific anti-Her1/Her3 Zybody (cancer), Zyngenia</Drug><DrugRelationship>General interest</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Priority</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PRI</HighestPatStatusIdForCnty><Indication id="746">Infectious disease</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA7191557">WO-2012162561</Patent><Status id="PRI">First Priority</Status><StatusDate>2011-05-24 00:00:00</StatusDate><StatusSortCode>1</StatusSortCode><TherapyArea id="746">Infectious disease</TherapyArea></Row><Row><Action id="5085">B-lymphocyte antigen CD20 inhibitor</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="US">US</Country><Drug id="77135">tri-specific anti-Her1/Her3 Zybody (cancer), Zyngenia</Drug><DrugRelationship>General interest</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Priority</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PRI</HighestPatStatusIdForCnty><Indication id="84">Crohns disease</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA7191557">WO-2012162561</Patent><Status id="PRI">First Priority</Status><StatusDate>2011-05-24 00:00:00</StatusDate><StatusSortCode>1</StatusSortCode><TherapyArea id="185">Immune disorder</TherapyArea></Row><Row><Action id="5085">B-lymphocyte antigen CD20 inhibitor</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="US">US</Country><Drug id="77135">tri-specific anti-Her1/Her3 Zybody (cancer), Zyngenia</Drug><DrugRelationship>General interest</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Priority</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PRI</HighestPatStatusIdForCnty><Indication id="97">Diabetes mellitus</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA7191557">WO-2012162561</Patent><Status id="PRI">First Priority</Status><StatusDate>2011-05-24 00:00:00</StatusDate><StatusSortCode>1</StatusSortCode><TherapyArea id="112">Endocrine disease</TherapyArea></Row><Row><Action id="511">TNF antagonist</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="US">US</Country><Drug id="77135">tri-specific anti-Her1/Her3 Zybody (cancer), Zyngenia</Drug><DrugRelationship>General interest</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Priority</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PRI</HighestPatStatusIdForCnty><Indication id="188">Inflammatory disease</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA7191557">WO-2012162561</Patent><Status id="PRI">First Priority</Status><StatusDate>2011-05-24 00:00:00</StatusDate><StatusSortCode>1</StatusSortCode><TherapyArea id="188">Inflammatory disease</TherapyArea></Row><Row><Action id="511">TNF antagonist</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="US">US</Country><Drug id="77135">tri-specific anti-Her1/Her3 Zybody (cancer), Zyngenia</Drug><DrugRelationship>General interest</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Priority</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PRI</HighestPatStatusIdForCnty><Indication id="189">Inflammatory bowel disease</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA7191557">WO-2012162561</Patent><Status id="PRI">First Priority</Status><StatusDate>2011-05-24 00:00:00</StatusDate><StatusSortCode>1</StatusSortCode><TherapyArea id="188">Inflammatory disease</TherapyArea></Row><Row><Action id="511">TNF antagonist</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="US">US</Country><Drug id="77135">tri-specific anti-Her1/Her3 Zybody (cancer), Zyngenia</Drug><DrugRelationship>General interest</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Priority</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PRI</HighestPatStatusIdForCnty><Indication id="213">Multiple sclerosis</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA7191557">WO-2012162561</Patent><Status id="PRI">First Priority</Status><StatusDate>2011-05-24 00:00:00</StatusDate><StatusSortCode>1</StatusSortCode><TherapyArea id="185">Immune disorder</TherapyArea></Row><Row><Action id="511">TNF antagonist</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="US">US</Country><Drug id="77135">tri-specific anti-Her1/Her3 Zybody (cancer), Zyngenia</Drug><DrugRelationship>General interest</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Priority</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PRI</HighestPatStatusIdForCnty><Indication id="281">Psoriasis</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA7191557">WO-2012162561</Patent><Status id="PRI">First Priority</Status><StatusDate>2011-05-24 00:00:00</StatusDate><StatusSortCode>1</StatusSortCode><TherapyArea id="95">Dermatological disease</TherapyArea></Row><Row><Action id="511">TNF antagonist</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="US">US</Country><Drug id="77135">tri-specific anti-Her1/Her3 Zybody (cancer), Zyngenia</Drug><DrugRelationship>General interest</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Priority</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PRI</HighestPatStatusIdForCnty><Indication id="291">Rheumatoid arthritis</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA7191557">WO-2012162561</Patent><Status id="PRI">First Priority</Status><StatusDate>2011-05-24 00:00:00</StatusDate><StatusSortCode>1</StatusSortCode><TherapyArea id="185">Immune disorder</TherapyArea></Row><Row><Action id="511">TNF antagonist</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="US">US</Country><Drug id="77135">tri-specific anti-Her1/Her3 Zybody (cancer), Zyngenia</Drug><DrugRelationship>General interest</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Priority</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PRI</HighestPatStatusIdForCnty><Indication id="318">Systemic lupus erythematosus</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA7191557">WO-2012162561</Patent><Status id="PRI">First Priority</Status><StatusDate>2011-05-24 00:00:00</StatusDate><StatusSortCode>1</StatusSortCode><TherapyArea id="95">Dermatological disease</TherapyArea></Row><Row><Action id="511">TNF antagonist</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="US">US</Country><Drug id="77135">tri-specific anti-Her1/Her3 Zybody (cancer), Zyngenia</Drug><DrugRelationship>General interest</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Priority</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PRI</HighestPatStatusIdForCnty><Indication id="337">Ulcerative colitis</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA7191557">WO-2012162561</Patent><Status id="PRI">First Priority</Status><StatusDate>2011-05-24 00:00:00</StatusDate><StatusSortCode>1</StatusSortCode><TherapyArea id="185">Immune disorder</TherapyArea></Row><Row><Action id="511">TNF antagonist</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="US">US</Country><Drug id="77135">tri-specific anti-Her1/Her3 Zybody (cancer), Zyngenia</Drug><DrugRelationship>General interest</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Priority</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PRI</HighestPatStatusIdForCnty><Indication id="651">Cancer</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA7191557">WO-2012162561</Patent><Status id="PRI">First Priority</Status><StatusDate>2011-05-24 00:00:00</StatusDate><StatusSortCode>1</StatusSortCode><TherapyArea id="230">Neoplasm</TherapyArea></Row><Row><Action id="511">TNF antagonist</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="US">US</Country><Drug id="77135">tri-specific anti-Her1/Her3 Zybody (cancer), Zyngenia</Drug><DrugRelationship>General interest</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Priority</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PRI</HighestPatStatusIdForCnty><Indication id="746">Infectious disease</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA7191557">WO-2012162561</Patent><Status id="PRI">First Priority</Status><StatusDate>2011-05-24 00:00:00</StatusDate><StatusSortCode>1</StatusSortCode><TherapyArea id="746">Infectious disease</TherapyArea></Row><Row><Action id="511">TNF antagonist</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="US">US</Country><Drug id="77135">tri-specific anti-Her1/Her3 Zybody (cancer), Zyngenia</Drug><DrugRelationship>General interest</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Priority</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PRI</HighestPatStatusIdForCnty><Indication id="84">Crohns disease</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA7191557">WO-2012162561</Patent><Status id="PRI">First Priority</Status><StatusDate>2011-05-24 00:00:00</StatusDate><StatusSortCode>1</StatusSortCode><TherapyArea id="185">Immune disorder</TherapyArea></Row><Row><Action id="511">TNF antagonist</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="US">US</Country><Drug id="77135">tri-specific anti-Her1/Her3 Zybody (cancer), Zyngenia</Drug><DrugRelationship>General interest</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Priority</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PRI</HighestPatStatusIdForCnty><Indication id="97">Diabetes mellitus</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA7191557">WO-2012162561</Patent><Status id="PRI">First Priority</Status><StatusDate>2011-05-24 00:00:00</StatusDate><StatusSortCode>1</StatusSortCode><TherapyArea id="112">Endocrine disease</TherapyArea></Row><Row><Action id="675">Hepatocyte growth factor receptor antagonist</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="US">US</Country><Drug id="77135">tri-specific anti-Her1/Her3 Zybody (cancer), Zyngenia</Drug><DrugRelationship>General interest</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Priority</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PRI</HighestPatStatusIdForCnty><Indication id="188">Inflammatory disease</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA7191557">WO-2012162561</Patent><Status id="PRI">First Priority</Status><StatusDate>2011-05-24 00:00:00</StatusDate><StatusSortCode>1</StatusSortCode><TherapyArea id="188">Inflammatory disease</TherapyArea></Row><Row><Action id="675">Hepatocyte growth factor receptor antagonist</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="US">US</Country><Drug id="77135">tri-specific anti-Her1/Her3 Zybody (cancer), Zyngenia</Drug><DrugRelationship>General interest</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Priority</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PRI</HighestPatStatusIdForCnty><Indication id="189">Inflammatory bowel disease</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA7191557">WO-2012162561</Patent><Status id="PRI">First Priority</Status><StatusDate>2011-05-24 00:00:00</StatusDate><StatusSortCode>1</StatusSortCode><TherapyArea id="188">Inflammatory disease</TherapyArea></Row><Row><Action id="675">Hepatocyte growth factor receptor antagonist</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="US">US</Country><Drug id="77135">tri-specific anti-Her1/Her3 Zybody (cancer), Zyngenia</Drug><DrugRelationship>General interest</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Priority</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PRI</HighestPatStatusIdForCnty><Indication id="213">Multiple sclerosis</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA7191557">WO-2012162561</Patent><Status id="PRI">First Priority</Status><StatusDate>2011-05-24 00:00:00</StatusDate><StatusSortCode>1</StatusSortCode><TherapyArea id="185">Immune disorder</TherapyArea></Row><Row><Action id="675">Hepatocyte growth factor receptor antagonist</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="US">US</Country><Drug id="77135">tri-specific anti-Her1/Her3 Zybody (cancer), Zyngenia</Drug><DrugRelationship>General interest</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Priority</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PRI</HighestPatStatusIdForCnty><Indication id="281">Psoriasis</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA7191557">WO-2012162561</Patent><Status id="PRI">First Priority</Status><StatusDate>2011-05-24 00:00:00</StatusDate><StatusSortCode>1</StatusSortCode><TherapyArea id="95">Dermatological disease</TherapyArea></Row><Row><Action id="675">Hepatocyte growth factor receptor antagonist</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="US">US</Country><Drug id="77135">tri-specific anti-Her1/Her3 Zybody (cancer), Zyngenia</Drug><DrugRelationship>General interest</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Priority</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PRI</HighestPatStatusIdForCnty><Indication id="291">Rheumatoid arthritis</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA7191557">WO-2012162561</Patent><Status id="PRI">First Priority</Status><StatusDate>2011-05-24 00:00:00</StatusDate><StatusSortCode>1</StatusSortCode><TherapyArea id="185">Immune disorder</TherapyArea></Row><Row><Action id="675">Hepatocyte growth factor receptor antagonist</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="US">US</Country><Drug id="77135">tri-specific anti-Her1/Her3 Zybody (cancer), Zyngenia</Drug><DrugRelationship>General interest</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Priority</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PRI</HighestPatStatusIdForCnty><Indication id="318">Systemic lupus erythematosus</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA7191557">WO-2012162561</Patent><Status id="PRI">First Priority</Status><StatusDate>2011-05-24 00:00:00</StatusDate><StatusSortCode>1</StatusSortCode><TherapyArea id="95">Dermatological disease</TherapyArea></Row><Row><Action id="675">Hepatocyte growth factor receptor antagonist</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="US">US</Country><Drug id="77135">tri-specific anti-Her1/Her3 Zybody (cancer), Zyngenia</Drug><DrugRelationship>General interest</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Priority</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PRI</HighestPatStatusIdForCnty><Indication id="337">Ulcerative colitis</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA7191557">WO-2012162561</Patent><Status id="PRI">First Priority</Status><StatusDate>2011-05-24 00:00:00</StatusDate><StatusSortCode>1</StatusSortCode><TherapyArea id="185">Immune disorder</TherapyArea></Row><Row><Action id="675">Hepatocyte growth factor receptor antagonist</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="US">US</Country><Drug id="77135">tri-specific anti-Her1/Her3 Zybody (cancer), Zyngenia</Drug><DrugRelationship>General interest</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Priority</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PRI</HighestPatStatusIdForCnty><Indication id="651">Cancer</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA7191557">WO-2012162561</Patent><Status id="PRI">First Priority</Status><StatusDate>2011-05-24 00:00:00</StatusDate><StatusSortCode>1</StatusSortCode><TherapyArea id="230">Neoplasm</TherapyArea></Row><Row><Action id="675">Hepatocyte growth factor receptor antagonist</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="US">US</Country><Drug id="77135">tri-specific anti-Her1/Her3 Zybody (cancer), Zyngenia</Drug><DrugRelationship>General interest</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Priority</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PRI</HighestPatStatusIdForCnty><Indication id="746">Infectious disease</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA7191557">WO-2012162561</Patent><Status id="PRI">First Priority</Status><StatusDate>2011-05-24 00:00:00</StatusDate><StatusSortCode>1</StatusSortCode><TherapyArea id="746">Infectious disease</TherapyArea></Row><Row><Action id="675">Hepatocyte growth factor receptor antagonist</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="US">US</Country><Drug id="77135">tri-specific anti-Her1/Her3 Zybody (cancer), Zyngenia</Drug><DrugRelationship>General interest</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Priority</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PRI</HighestPatStatusIdForCnty><Indication id="84">Crohns disease</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA7191557">WO-2012162561</Patent><Status id="PRI">First Priority</Status><StatusDate>2011-05-24 00:00:00</StatusDate><StatusSortCode>1</StatusSortCode><TherapyArea id="185">Immune disorder</TherapyArea></Row><Row><Action id="675">Hepatocyte growth factor receptor antagonist</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="US">US</Country><Drug id="77135">tri-specific anti-Her1/Her3 Zybody (cancer), Zyngenia</Drug><DrugRelationship>General interest</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Priority</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PRI</HighestPatStatusIdForCnty><Indication id="97">Diabetes mellitus</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA7191557">WO-2012162561</Patent><Status id="PRI">First Priority</Status><StatusDate>2011-05-24 00:00:00</StatusDate><StatusSortCode>1</StatusSortCode><TherapyArea id="112">Endocrine disease</TherapyArea></Row><Row><Action id="740">Epidermal growth factor receptor antagonist</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="US">US</Country><Drug id="77135">tri-specific anti-Her1/Her3 Zybody (cancer), Zyngenia</Drug><DrugRelationship>General interest</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Priority</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PRI</HighestPatStatusIdForCnty><Indication id="188">Inflammatory disease</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA7191557">WO-2012162561</Patent><Status id="PRI">First Priority</Status><StatusDate>2011-05-24 00:00:00</StatusDate><StatusSortCode>1</StatusSortCode><TherapyArea id="188">Inflammatory disease</TherapyArea></Row><Row><Action id="740">Epidermal growth factor receptor antagonist</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="US">US</Country><Drug id="77135">tri-specific anti-Her1/Her3 Zybody (cancer), Zyngenia</Drug><DrugRelationship>General interest</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Priority</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PRI</HighestPatStatusIdForCnty><Indication id="189">Inflammatory bowel disease</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA7191557">WO-2012162561</Patent><Status id="PRI">First Priority</Status><StatusDate>2011-05-24 00:00:00</StatusDate><StatusSortCode>1</StatusSortCode><TherapyArea id="188">Inflammatory disease</TherapyArea></Row><Row><Action id="740">Epidermal growth factor receptor antagonist</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="US">US</Country><Drug id="77135">tri-specific anti-Her1/Her3 Zybody (cancer), Zyngenia</Drug><DrugRelationship>General interest</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Priority</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PRI</HighestPatStatusIdForCnty><Indication id="213">Multiple sclerosis</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA7191557">WO-2012162561</Patent><Status id="PRI">First Priority</Status><StatusDate>2011-05-24 00:00:00</StatusDate><StatusSortCode>1</StatusSortCode><TherapyArea id="185">Immune disorder</TherapyArea></Row><Row><Action id="740">Epidermal growth factor receptor antagonist</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="US">US</Country><Drug id="77135">tri-specific anti-Her1/Her3 Zybody (cancer), Zyngenia</Drug><DrugRelationship>General interest</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Priority</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PRI</HighestPatStatusIdForCnty><Indication id="281">Psoriasis</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA7191557">WO-2012162561</Patent><Status id="PRI">First Priority</Status><StatusDate>2011-05-24 00:00:00</StatusDate><StatusSortCode>1</StatusSortCode><TherapyArea id="95">Dermatological disease</TherapyArea></Row><Row><Action id="740">Epidermal growth factor receptor antagonist</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="US">US</Country><Drug id="77135">tri-specific anti-Her1/Her3 Zybody (cancer), Zyngenia</Drug><DrugRelationship>General interest</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Priority</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PRI</HighestPatStatusIdForCnty><Indication id="291">Rheumatoid arthritis</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA7191557">WO-2012162561</Patent><Status id="PRI">First Priority</Status><StatusDate>2011-05-24 00:00:00</StatusDate><StatusSortCode>1</StatusSortCode><TherapyArea id="185">Immune disorder</TherapyArea></Row><Row><Action id="740">Epidermal growth factor receptor antagonist</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="US">US</Country><Drug id="77135">tri-specific anti-Her1/Her3 Zybody (cancer), Zyngenia</Drug><DrugRelationship>General interest</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Priority</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PRI</HighestPatStatusIdForCnty><Indication id="318">Systemic lupus erythematosus</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA7191557">WO-2012162561</Patent><Status id="PRI">First Priority</Status><StatusDate>2011-05-24 00:00:00</StatusDate><StatusSortCode>1</StatusSortCode><TherapyArea id="95">Dermatological disease</TherapyArea></Row><Row><Action id="740">Epidermal growth factor receptor antagonist</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="US">US</Country><Drug id="77135">tri-specific anti-Her1/Her3 Zybody (cancer), Zyngenia</Drug><DrugRelationship>General interest</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Priority</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PRI</HighestPatStatusIdForCnty><Indication id="337">Ulcerative colitis</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA7191557">WO-2012162561</Patent><Status id="PRI">First Priority</Status><StatusDate>2011-05-24 00:00:00</StatusDate><StatusSortCode>1</StatusSortCode><TherapyArea id="185">Immune disorder</TherapyArea></Row><Row><Action id="740">Epidermal growth factor receptor antagonist</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="US">US</Country><Drug id="77135">tri-specific anti-Her1/Her3 Zybody (cancer), Zyngenia</Drug><DrugRelationship>General interest</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Priority</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PRI</HighestPatStatusIdForCnty><Indication id="651">Cancer</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA7191557">WO-2012162561</Patent><Status id="PRI">First Priority</Status><StatusDate>2011-05-24 00:00:00</StatusDate><StatusSortCode>1</StatusSortCode><TherapyArea id="230">Neoplasm</TherapyArea></Row><Row><Action id="740">Epidermal growth factor receptor antagonist</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="US">US</Country><Drug id="77135">tri-specific anti-Her1/Her3 Zybody (cancer), Zyngenia</Drug><DrugRelationship>General interest</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Priority</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PRI</HighestPatStatusIdForCnty><Indication id="746">Infectious disease</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA7191557">WO-2012162561</Patent><Status id="PRI">First Priority</Status><StatusDate>2011-05-24 00:00:00</StatusDate><StatusSortCode>1</StatusSortCode><TherapyArea id="746">Infectious disease</TherapyArea></Row><Row><Action id="740">Epidermal growth factor receptor antagonist</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="US">US</Country><Drug id="77135">tri-specific anti-Her1/Her3 Zybody (cancer), Zyngenia</Drug><DrugRelationship>General interest</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Priority</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PRI</HighestPatStatusIdForCnty><Indication id="84">Crohns disease</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA7191557">WO-2012162561</Patent><Status id="PRI">First Priority</Status><StatusDate>2011-05-24 00:00:00</StatusDate><StatusSortCode>1</StatusSortCode><TherapyArea id="185">Immune disorder</TherapyArea></Row><Row><Action id="740">Epidermal growth factor receptor antagonist</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="US">US</Country><Drug id="77135">tri-specific anti-Her1/Her3 Zybody (cancer), Zyngenia</Drug><DrugRelationship>General interest</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Priority</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PRI</HighestPatStatusIdForCnty><Indication id="97">Diabetes mellitus</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA7191557">WO-2012162561</Patent><Status id="PRI">First Priority</Status><StatusDate>2011-05-24 00:00:00</StatusDate><StatusSortCode>1</StatusSortCode><TherapyArea id="112">Endocrine disease</TherapyArea></Row><Row><Action id="14007">Programmed cell death ligand 1 inhibitor</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Third Party</CompanyOwnershipRelationship><Country id="US">US</Country><Drug id="23886">urelumab</Drug><DrugRelationship>General interest</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Priority</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PRI</HighestPatStatusIdForCnty><Indication id="1731">Acute myelogenous leukemia</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA8994513">WO-2016164305</Patent><Status id="PRI">First Priority</Status><StatusDate>2015-04-06 00:00:00</StatusDate><StatusSortCode>1</StatusSortCode><TherapyArea id="9099">Rare disease</TherapyArea></Row><Row><Action id="14007">Programmed cell death ligand 1 inhibitor</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Third Party</CompanyOwnershipRelationship><Country id="US">US</Country><Drug id="23886">urelumab</Drug><DrugRelationship>General interest</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Priority</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PRI</HighestPatStatusIdForCnty><Indication id="1735">Chronic myelocytic leukemia</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA8994513">WO-2016164305</Patent><Status id="PRI">First Priority</Status><StatusDate>2015-04-06 00:00:00</StatusDate><StatusSortCode>1</StatusSortCode><TherapyArea id="142">Hematological disease</TherapyArea></Row><Row><Action id="14007">Programmed cell death ligand 1 inhibitor</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Third Party</CompanyOwnershipRelationship><Country id="US">US</Country><Drug id="23886">urelumab</Drug><DrugRelationship>General interest</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Priority</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PRI</HighestPatStatusIdForCnty><Indication id="2054">Hematological neoplasm</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA8994513">WO-2016164305</Patent><Status id="PRI">First Priority</Status><StatusDate>2015-04-06 00:00:00</StatusDate><StatusSortCode>1</StatusSortCode><TherapyArea id="142">Hematological disease</TherapyArea></Row><Row><Action id="14007">Programmed cell death ligand 1 inhibitor</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Third Party</CompanyOwnershipRelationship><Country id="US">US</Country><Drug id="23886">urelumab</Drug><DrugRelationship>General interest</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Priority</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PRI</HighestPatStatusIdForCnty><Indication id="651">Cancer</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA8994513">WO-2016164305</Patent><Status id="PRI">First Priority</Status><StatusDate>2015-04-06 00:00:00</StatusDate><StatusSortCode>1</StatusSortCode><TherapyArea id="230">Neoplasm</TherapyArea></Row><Row><Action id="14007">Programmed cell death ligand 1 inhibitor</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Third Party</CompanyOwnershipRelationship><Country id="US">US</Country><Drug id="23886">urelumab</Drug><DrugRelationship>General interest</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Priority</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PRI</HighestPatStatusIdForCnty><Indication id="725">Solid tumor</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA8994513">WO-2016164305</Patent><Status id="PRI">First Priority</Status><StatusDate>2015-04-06 00:00:00</StatusDate><StatusSortCode>1</StatusSortCode><TherapyArea id="230">Neoplasm</TherapyArea></Row><Row><Action id="5429">CDw123 antagonist</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Third Party</CompanyOwnershipRelationship><Country id="US">US</Country><Drug id="23886">urelumab</Drug><DrugRelationship>General interest</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Priority</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PRI</HighestPatStatusIdForCnty><Indication id="1731">Acute myelogenous leukemia</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA8994513">WO-2016164305</Patent><Status id="PRI">First Priority</Status><StatusDate>2015-04-06 00:00:00</StatusDate><StatusSortCode>1</StatusSortCode><TherapyArea id="9099">Rare disease</TherapyArea></Row><Row><Action id="5429">CDw123 antagonist</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Third Party</CompanyOwnershipRelationship><Country id="US">US</Country><Drug id="23886">urelumab</Drug><DrugRelationship>General interest</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Priority</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PRI</HighestPatStatusIdForCnty><Indication id="1735">Chronic myelocytic leukemia</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA8994513">WO-2016164305</Patent><Status id="PRI">First Priority</Status><StatusDate>2015-04-06 00:00:00</StatusDate><StatusSortCode>1</StatusSortCode><TherapyArea id="142">Hematological disease</TherapyArea></Row><Row><Action id="5429">CDw123 antagonist</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Third Party</CompanyOwnershipRelationship><Country id="US">US</Country><Drug id="23886">urelumab</Drug><DrugRelationship>General interest</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Priority</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PRI</HighestPatStatusIdForCnty><Indication id="2054">Hematological neoplasm</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA8994513">WO-2016164305</Patent><Status id="PRI">First Priority</Status><StatusDate>2015-04-06 00:00:00</StatusDate><StatusSortCode>1</StatusSortCode><TherapyArea id="142">Hematological disease</TherapyArea></Row><Row><Action id="5429">CDw123 antagonist</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Third Party</CompanyOwnershipRelationship><Country id="US">US</Country><Drug id="23886">urelumab</Drug><DrugRelationship>General interest</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Priority</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PRI</HighestPatStatusIdForCnty><Indication id="651">Cancer</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA8994513">WO-2016164305</Patent><Status id="PRI">First Priority</Status><StatusDate>2015-04-06 00:00:00</StatusDate><StatusSortCode>1</StatusSortCode><TherapyArea id="230">Neoplasm</TherapyArea></Row><Row><Action id="5429">CDw123 antagonist</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Third Party</CompanyOwnershipRelationship><Country id="US">US</Country><Drug id="23886">urelumab</Drug><DrugRelationship>General interest</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Priority</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PRI</HighestPatStatusIdForCnty><Indication id="725">Solid tumor</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA8994513">WO-2016164305</Patent><Status id="PRI">First Priority</Status><StatusDate>2015-04-06 00:00:00</StatusDate><StatusSortCode>1</StatusSortCode><TherapyArea id="230">Neoplasm</TherapyArea></Row><Row><Action id="7761">T-lymphocyte stimulator</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Third Party</CompanyOwnershipRelationship><Country id="US">US</Country><Drug id="23886">urelumab</Drug><DrugRelationship>General interest</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Priority</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PRI</HighestPatStatusIdForCnty><Indication id="1731">Acute myelogenous leukemia</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA8994513">WO-2016164305</Patent><Status id="PRI">First Priority</Status><StatusDate>2015-04-06 00:00:00</StatusDate><StatusSortCode>1</StatusSortCode><TherapyArea id="9099">Rare disease</TherapyArea></Row><Row><Action id="7761">T-lymphocyte stimulator</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Third Party</CompanyOwnershipRelationship><Country id="US">US</Country><Drug id="23886">urelumab</Drug><DrugRelationship>General interest</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Priority</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PRI</HighestPatStatusIdForCnty><Indication id="1735">Chronic myelocytic leukemia</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA8994513">WO-2016164305</Patent><Status id="PRI">First Priority</Status><StatusDate>2015-04-06 00:00:00</StatusDate><StatusSortCode>1</StatusSortCode><TherapyArea id="142">Hematological disease</TherapyArea></Row><Row><Action id="7761">T-lymphocyte stimulator</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Third Party</CompanyOwnershipRelationship><Country id="US">US</Country><Drug id="23886">urelumab</Drug><DrugRelationship>General interest</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Priority</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PRI</HighestPatStatusIdForCnty><Indication id="2054">Hematological neoplasm</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA8994513">WO-2016164305</Patent><Status id="PRI">First Priority</Status><StatusDate>2015-04-06 00:00:00</StatusDate><StatusSortCode>1</StatusSortCode><TherapyArea id="142">Hematological disease</TherapyArea></Row><Row><Action id="7761">T-lymphocyte stimulator</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Third Party</CompanyOwnershipRelationship><Country id="US">US</Country><Drug id="23886">urelumab</Drug><DrugRelationship>General interest</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Priority</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PRI</HighestPatStatusIdForCnty><Indication id="651">Cancer</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA8994513">WO-2016164305</Patent><Status id="PRI">First Priority</Status><StatusDate>2015-04-06 00:00:00</StatusDate><StatusSortCode>1</StatusSortCode><TherapyArea id="230">Neoplasm</TherapyArea></Row><Row><Action id="7761">T-lymphocyte stimulator</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Third Party</CompanyOwnershipRelationship><Country id="US">US</Country><Drug id="23886">urelumab</Drug><DrugRelationship>General interest</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Priority</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PRI</HighestPatStatusIdForCnty><Indication id="725">Solid tumor</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA8994513">WO-2016164305</Patent><Status id="PRI">First Priority</Status><StatusDate>2015-04-06 00:00:00</StatusDate><StatusSortCode>1</StatusSortCode><TherapyArea id="230">Neoplasm</TherapyArea></Row><Row><Action id="14007">Programmed cell death ligand 1 inhibitor</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Third Party</CompanyOwnershipRelationship><Country id="US">US</Country><Drug id="8747">palivizumab</Drug><DrugRelationship>General interest</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Priority</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PRI</HighestPatStatusIdForCnty><Indication id="1731">Acute myelogenous leukemia</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA8994513">WO-2016164305</Patent><Status id="PRI">First Priority</Status><StatusDate>2015-04-06 00:00:00</StatusDate><StatusSortCode>1</StatusSortCode><TherapyArea id="9099">Rare disease</TherapyArea></Row><Row><Action id="14007">Programmed cell death ligand 1 inhibitor</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Third Party</CompanyOwnershipRelationship><Country id="US">US</Country><Drug id="8747">palivizumab</Drug><DrugRelationship>General interest</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Priority</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PRI</HighestPatStatusIdForCnty><Indication id="1735">Chronic myelocytic leukemia</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA8994513">WO-2016164305</Patent><Status id="PRI">First Priority</Status><StatusDate>2015-04-06 00:00:00</StatusDate><StatusSortCode>1</StatusSortCode><TherapyArea id="142">Hematological disease</TherapyArea></Row><Row><Action id="14007">Programmed cell death ligand 1 inhibitor</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Third Party</CompanyOwnershipRelationship><Country id="US">US</Country><Drug id="8747">palivizumab</Drug><DrugRelationship>General interest</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Priority</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PRI</HighestPatStatusIdForCnty><Indication id="2054">Hematological neoplasm</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA8994513">WO-2016164305</Patent><Status id="PRI">First Priority</Status><StatusDate>2015-04-06 00:00:00</StatusDate><StatusSortCode>1</StatusSortCode><TherapyArea id="142">Hematological disease</TherapyArea></Row><Row><Action id="14007">Programmed cell death ligand 1 inhibitor</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Third Party</CompanyOwnershipRelationship><Country id="US">US</Country><Drug id="8747">palivizumab</Drug><DrugRelationship>General interest</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Priority</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PRI</HighestPatStatusIdForCnty><Indication id="651">Cancer</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA8994513">WO-2016164305</Patent><Status id="PRI">First Priority</Status><StatusDate>2015-04-06 00:00:00</StatusDate><StatusSortCode>1</StatusSortCode><TherapyArea id="230">Neoplasm</TherapyArea></Row><Row><Action id="14007">Programmed cell death ligand 1 inhibitor</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Third Party</CompanyOwnershipRelationship><Country id="US">US</Country><Drug id="8747">palivizumab</Drug><DrugRelationship>General interest</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Priority</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PRI</HighestPatStatusIdForCnty><Indication id="725">Solid tumor</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA8994513">WO-2016164305</Patent><Status id="PRI">First Priority</Status><StatusDate>2015-04-06 00:00:00</StatusDate><StatusSortCode>1</StatusSortCode><TherapyArea id="230">Neoplasm</TherapyArea></Row><Row><Action id="5429">CDw123 antagonist</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Third Party</CompanyOwnershipRelationship><Country id="US">US</Country><Drug id="8747">palivizumab</Drug><DrugRelationship>General interest</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Priority</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PRI</HighestPatStatusIdForCnty><Indication id="1731">Acute myelogenous leukemia</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA8994513">WO-2016164305</Patent><Status id="PRI">First Priority</Status><StatusDate>2015-04-06 00:00:00</StatusDate><StatusSortCode>1</StatusSortCode><TherapyArea id="9099">Rare disease</TherapyArea></Row><Row><Action id="5429">CDw123 antagonist</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Third Party</CompanyOwnershipRelationship><Country id="US">US</Country><Drug id="8747">palivizumab</Drug><DrugRelationship>General interest</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Priority</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PRI</HighestPatStatusIdForCnty><Indication id="1735">Chronic myelocytic leukemia</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA8994513">WO-2016164305</Patent><Status id="PRI">First Priority</Status><StatusDate>2015-04-06 00:00:00</StatusDate><StatusSortCode>1</StatusSortCode><TherapyArea id="142">Hematological disease</TherapyArea></Row><Row><Action id="5429">CDw123 antagonist</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Third Party</CompanyOwnershipRelationship><Country id="US">US</Country><Drug id="8747">palivizumab</Drug><DrugRelationship>General interest</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Priority</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PRI</HighestPatStatusIdForCnty><Indication id="2054">Hematological neoplasm</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA8994513">WO-2016164305</Patent><Status id="PRI">First Priority</Status><StatusDate>2015-04-06 00:00:00</StatusDate><StatusSortCode>1</StatusSortCode><TherapyArea id="142">Hematological disease</TherapyArea></Row><Row><Action id="5429">CDw123 antagonist</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Third Party</CompanyOwnershipRelationship><Country id="US">US</Country><Drug id="8747">palivizumab</Drug><DrugRelationship>General interest</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Priority</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PRI</HighestPatStatusIdForCnty><Indication id="651">Cancer</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA8994513">WO-2016164305</Patent><Status id="PRI">First Priority</Status><StatusDate>2015-04-06 00:00:00</StatusDate><StatusSortCode>1</StatusSortCode><TherapyArea id="230">Neoplasm</TherapyArea></Row><Row><Action id="5429">CDw123 antagonist</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Third Party</CompanyOwnershipRelationship><Country id="US">US</Country><Drug id="8747">palivizumab</Drug><DrugRelationship>General interest</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Priority</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PRI</HighestPatStatusIdForCnty><Indication id="725">Solid tumor</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA8994513">WO-2016164305</Patent><Status id="PRI">First Priority</Status><StatusDate>2015-04-06 00:00:00</StatusDate><StatusSortCode>1</StatusSortCode><TherapyArea id="230">Neoplasm</TherapyArea></Row><Row><Action id="7761">T-lymphocyte stimulator</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Third Party</CompanyOwnershipRelationship><Country id="US">US</Country><Drug id="8747">palivizumab</Drug><DrugRelationship>General interest</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Priority</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PRI</HighestPatStatusIdForCnty><Indication id="1731">Acute myelogenous leukemia</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA8994513">WO-2016164305</Patent><Status id="PRI">First Priority</Status><StatusDate>2015-04-06 00:00:00</StatusDate><StatusSortCode>1</StatusSortCode><TherapyArea id="9099">Rare disease</TherapyArea></Row><Row><Action id="7761">T-lymphocyte stimulator</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Third Party</CompanyOwnershipRelationship><Country id="US">US</Country><Drug id="8747">palivizumab</Drug><DrugRelationship>General interest</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Priority</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PRI</HighestPatStatusIdForCnty><Indication id="1735">Chronic myelocytic leukemia</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA8994513">WO-2016164305</Patent><Status id="PRI">First Priority</Status><StatusDate>2015-04-06 00:00:00</StatusDate><StatusSortCode>1</StatusSortCode><TherapyArea id="142">Hematological disease</TherapyArea></Row><Row><Action id="7761">T-lymphocyte stimulator</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Third Party</CompanyOwnershipRelationship><Country id="US">US</Country><Drug id="8747">palivizumab</Drug><DrugRelationship>General interest</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Priority</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PRI</HighestPatStatusIdForCnty><Indication id="2054">Hematological neoplasm</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA8994513">WO-2016164305</Patent><Status id="PRI">First Priority</Status><StatusDate>2015-04-06 00:00:00</StatusDate><StatusSortCode>1</StatusSortCode><TherapyArea id="142">Hematological disease</TherapyArea></Row><Row><Action id="7761">T-lymphocyte stimulator</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Third Party</CompanyOwnershipRelationship><Country id="US">US</Country><Drug id="8747">palivizumab</Drug><DrugRelationship>General interest</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Priority</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PRI</HighestPatStatusIdForCnty><Indication id="651">Cancer</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA8994513">WO-2016164305</Patent><Status id="PRI">First Priority</Status><StatusDate>2015-04-06 00:00:00</StatusDate><StatusSortCode>1</StatusSortCode><TherapyArea id="230">Neoplasm</TherapyArea></Row><Row><Action id="7761">T-lymphocyte stimulator</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Third Party</CompanyOwnershipRelationship><Country id="US">US</Country><Drug id="8747">palivizumab</Drug><DrugRelationship>General interest</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Priority</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PRI</HighestPatStatusIdForCnty><Indication id="725">Solid tumor</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA8994513">WO-2016164305</Patent><Status id="PRI">First Priority</Status><StatusDate>2015-04-06 00:00:00</StatusDate><StatusSortCode>1</StatusSortCode><TherapyArea id="230">Neoplasm</TherapyArea></Row><Row><Action id="14007">Programmed cell death ligand 1 inhibitor</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Third Party</CompanyOwnershipRelationship><Country id="US">US</Country><Drug id="23886">urelumab</Drug><DrugRelationship>General interest</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Priority</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PRI</HighestPatStatusIdForCnty><Indication id="1731">Acute myelogenous leukemia</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA8994514">WO-2016164308</Patent><Status id="PRI">First Priority</Status><StatusDate>2015-04-06 00:00:00</StatusDate><StatusSortCode>1</StatusSortCode><TherapyArea id="9099">Rare disease</TherapyArea></Row><Row><Action id="14007">Programmed cell death ligand 1 inhibitor</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Third Party</CompanyOwnershipRelationship><Country id="US">US</Country><Drug id="23886">urelumab</Drug><DrugRelationship>General interest</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Priority</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PRI</HighestPatStatusIdForCnty><Indication id="1735">Chronic myelocytic leukemia</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA8994514">WO-2016164308</Patent><Status id="PRI">First Priority</Status><StatusDate>2015-04-06 00:00:00</StatusDate><StatusSortCode>1</StatusSortCode><TherapyArea id="142">Hematological disease</TherapyArea></Row><Row><Action id="14007">Programmed cell death ligand 1 inhibitor</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Third Party</CompanyOwnershipRelationship><Country id="US">US</Country><Drug id="23886">urelumab</Drug><DrugRelationship>General interest</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Priority</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PRI</HighestPatStatusIdForCnty><Indication id="2054">Hematological neoplasm</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA8994514">WO-2016164308</Patent><Status id="PRI">First Priority</Status><StatusDate>2015-04-06 00:00:00</StatusDate><StatusSortCode>1</StatusSortCode><TherapyArea id="142">Hematological disease</TherapyArea></Row><Row><Action id="14007">Programmed cell death ligand 1 inhibitor</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Third Party</CompanyOwnershipRelationship><Country id="US">US</Country><Drug id="23886">urelumab</Drug><DrugRelationship>General interest</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Priority</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PRI</HighestPatStatusIdForCnty><Indication id="725">Solid tumor</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA8994514">WO-2016164308</Patent><Status id="PRI">First Priority</Status><StatusDate>2015-04-06 00:00:00</StatusDate><StatusSortCode>1</StatusSortCode><TherapyArea id="230">Neoplasm</TherapyArea></Row><Row><Action id="5451">CDw137 antagonist</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Third Party</CompanyOwnershipRelationship><Country id="US">US</Country><Drug id="23886">urelumab</Drug><DrugRelationship>General interest</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Priority</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PRI</HighestPatStatusIdForCnty><Indication id="1731">Acute myelogenous leukemia</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA8994514">WO-2016164308</Patent><Status id="PRI">First Priority</Status><StatusDate>2015-04-06 00:00:00</StatusDate><StatusSortCode>1</StatusSortCode><TherapyArea id="9099">Rare disease</TherapyArea></Row><Row><Action id="5451">CDw137 antagonist</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Third Party</CompanyOwnershipRelationship><Country id="US">US</Country><Drug id="23886">urelumab</Drug><DrugRelationship>General interest</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Priority</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PRI</HighestPatStatusIdForCnty><Indication id="1735">Chronic myelocytic leukemia</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA8994514">WO-2016164308</Patent><Status id="PRI">First Priority</Status><StatusDate>2015-04-06 00:00:00</StatusDate><StatusSortCode>1</StatusSortCode><TherapyArea id="142">Hematological disease</TherapyArea></Row><Row><Action id="5451">CDw137 antagonist</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Third Party</CompanyOwnershipRelationship><Country id="US">US</Country><Drug id="23886">urelumab</Drug><DrugRelationship>General interest</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Priority</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PRI</HighestPatStatusIdForCnty><Indication id="2054">Hematological neoplasm</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA8994514">WO-2016164308</Patent><Status id="PRI">First Priority</Status><StatusDate>2015-04-06 00:00:00</StatusDate><StatusSortCode>1</StatusSortCode><TherapyArea id="142">Hematological disease</TherapyArea></Row><Row><Action id="5451">CDw137 antagonist</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Third Party</CompanyOwnershipRelationship><Country id="US">US</Country><Drug id="23886">urelumab</Drug><DrugRelationship>General interest</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Priority</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PRI</HighestPatStatusIdForCnty><Indication id="725">Solid tumor</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA8994514">WO-2016164308</Patent><Status id="PRI">First Priority</Status><StatusDate>2015-04-06 00:00:00</StatusDate><StatusSortCode>1</StatusSortCode><TherapyArea id="230">Neoplasm</TherapyArea></Row><Row><Action id="7220">Neoplasm diagnostic agent</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Third Party</CompanyOwnershipRelationship><Country id="US">US</Country><Drug id="23886">urelumab</Drug><DrugRelationship>General interest</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Priority</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PRI</HighestPatStatusIdForCnty><Indication id="1731">Acute myelogenous leukemia</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA8994514">WO-2016164308</Patent><Status id="PRI">First Priority</Status><StatusDate>2015-04-06 00:00:00</StatusDate><StatusSortCode>1</StatusSortCode><TherapyArea id="9099">Rare disease</TherapyArea></Row><Row><Action id="7220">Neoplasm diagnostic agent</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Third Party</CompanyOwnershipRelationship><Country id="US">US</Country><Drug id="23886">urelumab</Drug><DrugRelationship>General interest</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Priority</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PRI</HighestPatStatusIdForCnty><Indication id="1735">Chronic myelocytic leukemia</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA8994514">WO-2016164308</Patent><Status id="PRI">First Priority</Status><StatusDate>2015-04-06 00:00:00</StatusDate><StatusSortCode>1</StatusSortCode><TherapyArea id="142">Hematological disease</TherapyArea></Row><Row><Action id="7220">Neoplasm diagnostic agent</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Third Party</CompanyOwnershipRelationship><Country id="US">US</Country><Drug id="23886">urelumab</Drug><DrugRelationship>General interest</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Priority</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PRI</HighestPatStatusIdForCnty><Indication id="2054">Hematological neoplasm</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA8994514">WO-2016164308</Patent><Status id="PRI">First Priority</Status><StatusDate>2015-04-06 00:00:00</StatusDate><StatusSortCode>1</StatusSortCode><TherapyArea id="142">Hematological disease</TherapyArea></Row><Row><Action id="7220">Neoplasm diagnostic agent</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Third Party</CompanyOwnershipRelationship><Country id="US">US</Country><Drug id="23886">urelumab</Drug><DrugRelationship>General interest</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Priority</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PRI</HighestPatStatusIdForCnty><Indication id="725">Solid tumor</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA8994514">WO-2016164308</Patent><Status id="PRI">First Priority</Status><StatusDate>2015-04-06 00:00:00</StatusDate><StatusSortCode>1</StatusSortCode><TherapyArea id="230">Neoplasm</TherapyArea></Row><Row><Action id="7761">T-lymphocyte stimulator</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Third Party</CompanyOwnershipRelationship><Country id="US">US</Country><Drug id="23886">urelumab</Drug><DrugRelationship>General interest</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Priority</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PRI</HighestPatStatusIdForCnty><Indication id="1731">Acute myelogenous leukemia</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA8994514">WO-2016164308</Patent><Status id="PRI">First Priority</Status><StatusDate>2015-04-06 00:00:00</StatusDate><StatusSortCode>1</StatusSortCode><TherapyArea id="9099">Rare disease</TherapyArea></Row><Row><Action id="7761">T-lymphocyte stimulator</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Third Party</CompanyOwnershipRelationship><Country id="US">US</Country><Drug id="23886">urelumab</Drug><DrugRelationship>General interest</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Priority</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PRI</HighestPatStatusIdForCnty><Indication id="1735">Chronic myelocytic leukemia</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA8994514">WO-2016164308</Patent><Status id="PRI">First Priority</Status><StatusDate>2015-04-06 00:00:00</StatusDate><StatusSortCode>1</StatusSortCode><TherapyArea id="142">Hematological disease</TherapyArea></Row><Row><Action id="7761">T-lymphocyte stimulator</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Third Party</CompanyOwnershipRelationship><Country id="US">US</Country><Drug id="23886">urelumab</Drug><DrugRelationship>General interest</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Priority</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PRI</HighestPatStatusIdForCnty><Indication id="2054">Hematological neoplasm</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA8994514">WO-2016164308</Patent><Status id="PRI">First Priority</Status><StatusDate>2015-04-06 00:00:00</StatusDate><StatusSortCode>1</StatusSortCode><TherapyArea id="142">Hematological disease</TherapyArea></Row><Row><Action id="7761">T-lymphocyte stimulator</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Third Party</CompanyOwnershipRelationship><Country id="US">US</Country><Drug id="23886">urelumab</Drug><DrugRelationship>General interest</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Priority</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PRI</HighestPatStatusIdForCnty><Indication id="725">Solid tumor</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA8994514">WO-2016164308</Patent><Status id="PRI">First Priority</Status><StatusDate>2015-04-06 00:00:00</StatusDate><StatusSortCode>1</StatusSortCode><TherapyArea id="230">Neoplasm</TherapyArea></Row><Row><Action id="14007">Programmed cell death ligand 1 inhibitor</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Third Party</CompanyOwnershipRelationship><Country id="US">US</Country><Drug id="8747">palivizumab</Drug><DrugRelationship>General interest</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Priority</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PRI</HighestPatStatusIdForCnty><Indication id="1731">Acute myelogenous leukemia</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA8994514">WO-2016164308</Patent><Status id="PRI">First Priority</Status><StatusDate>2015-04-06 00:00:00</StatusDate><StatusSortCode>1</StatusSortCode><TherapyArea id="9099">Rare disease</TherapyArea></Row><Row><Action id="14007">Programmed cell death ligand 1 inhibitor</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Third Party</CompanyOwnershipRelationship><Country id="US">US</Country><Drug id="8747">palivizumab</Drug><DrugRelationship>General interest</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Priority</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PRI</HighestPatStatusIdForCnty><Indication id="1735">Chronic myelocytic leukemia</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA8994514">WO-2016164308</Patent><Status id="PRI">First Priority</Status><StatusDate>2015-04-06 00:00:00</StatusDate><StatusSortCode>1</StatusSortCode><TherapyArea id="142">Hematological disease</TherapyArea></Row><Row><Action id="14007">Programmed cell death ligand 1 inhibitor</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Third Party</CompanyOwnershipRelationship><Country id="US">US</Country><Drug id="8747">palivizumab</Drug><DrugRelationship>General interest</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Priority</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PRI</HighestPatStatusIdForCnty><Indication id="2054">Hematological neoplasm</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA8994514">WO-2016164308</Patent><Status id="PRI">First Priority</Status><StatusDate>2015-04-06 00:00:00</StatusDate><StatusSortCode>1</StatusSortCode><TherapyArea id="142">Hematological disease</TherapyArea></Row><Row><Action id="14007">Programmed cell death ligand 1 inhibitor</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Third Party</CompanyOwnershipRelationship><Country id="US">US</Country><Drug id="8747">palivizumab</Drug><DrugRelationship>General interest</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Priority</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PRI</HighestPatStatusIdForCnty><Indication id="725">Solid tumor</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA8994514">WO-2016164308</Patent><Status id="PRI">First Priority</Status><StatusDate>2015-04-06 00:00:00</StatusDate><StatusSortCode>1</StatusSortCode><TherapyArea id="230">Neoplasm</TherapyArea></Row><Row><Action id="5451">CDw137 antagonist</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Third Party</CompanyOwnershipRelationship><Country id="US">US</Country><Drug id="8747">palivizumab</Drug><DrugRelationship>General interest</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Priority</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PRI</HighestPatStatusIdForCnty><Indication id="1731">Acute myelogenous leukemia</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA8994514">WO-2016164308</Patent><Status id="PRI">First Priority</Status><StatusDate>2015-04-06 00:00:00</StatusDate><StatusSortCode>1</StatusSortCode><TherapyArea id="9099">Rare disease</TherapyArea></Row><Row><Action id="5451">CDw137 antagonist</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Third Party</CompanyOwnershipRelationship><Country id="US">US</Country><Drug id="8747">palivizumab</Drug><DrugRelationship>General interest</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Priority</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PRI</HighestPatStatusIdForCnty><Indication id="1735">Chronic myelocytic leukemia</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA8994514">WO-2016164308</Patent><Status id="PRI">First Priority</Status><StatusDate>2015-04-06 00:00:00</StatusDate><StatusSortCode>1</StatusSortCode><TherapyArea id="142">Hematological disease</TherapyArea></Row><Row><Action id="5451">CDw137 antagonist</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Third Party</CompanyOwnershipRelationship><Country id="US">US</Country><Drug id="8747">palivizumab</Drug><DrugRelationship>General interest</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Priority</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PRI</HighestPatStatusIdForCnty><Indication id="2054">Hematological neoplasm</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA8994514">WO-2016164308</Patent><Status id="PRI">First Priority</Status><StatusDate>2015-04-06 00:00:00</StatusDate><StatusSortCode>1</StatusSortCode><TherapyArea id="142">Hematological disease</TherapyArea></Row><Row><Action id="5451">CDw137 antagonist</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Third Party</CompanyOwnershipRelationship><Country id="US">US</Country><Drug id="8747">palivizumab</Drug><DrugRelationship>General interest</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Priority</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PRI</HighestPatStatusIdForCnty><Indication id="725">Solid tumor</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA8994514">WO-2016164308</Patent><Status id="PRI">First Priority</Status><StatusDate>2015-04-06 00:00:00</StatusDate><StatusSortCode>1</StatusSortCode><TherapyArea id="230">Neoplasm</TherapyArea></Row><Row><Action id="7220">Neoplasm diagnostic agent</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Third Party</CompanyOwnershipRelationship><Country id="US">US</Country><Drug id="8747">palivizumab</Drug><DrugRelationship>General interest</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Priority</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PRI</HighestPatStatusIdForCnty><Indication id="1731">Acute myelogenous leukemia</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA8994514">WO-2016164308</Patent><Status id="PRI">First Priority</Status><StatusDate>2015-04-06 00:00:00</StatusDate><StatusSortCode>1</StatusSortCode><TherapyArea id="9099">Rare disease</TherapyArea></Row><Row><Action id="7220">Neoplasm diagnostic agent</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Third Party</CompanyOwnershipRelationship><Country id="US">US</Country><Drug id="8747">palivizumab</Drug><DrugRelationship>General interest</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Priority</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PRI</HighestPatStatusIdForCnty><Indication id="1735">Chronic myelocytic leukemia</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA8994514">WO-2016164308</Patent><Status id="PRI">First Priority</Status><StatusDate>2015-04-06 00:00:00</StatusDate><StatusSortCode>1</StatusSortCode><TherapyArea id="142">Hematological disease</TherapyArea></Row><Row><Action id="7220">Neoplasm diagnostic agent</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Third Party</CompanyOwnershipRelationship><Country id="US">US</Country><Drug id="8747">palivizumab</Drug><DrugRelationship>General interest</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Priority</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PRI</HighestPatStatusIdForCnty><Indication id="2054">Hematological neoplasm</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA8994514">WO-2016164308</Patent><Status id="PRI">First Priority</Status><StatusDate>2015-04-06 00:00:00</StatusDate><StatusSortCode>1</StatusSortCode><TherapyArea id="142">Hematological disease</TherapyArea></Row><Row><Action id="7220">Neoplasm diagnostic agent</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Third Party</CompanyOwnershipRelationship><Country id="US">US</Country><Drug id="8747">palivizumab</Drug><DrugRelationship>General interest</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Priority</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PRI</HighestPatStatusIdForCnty><Indication id="725">Solid tumor</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA8994514">WO-2016164308</Patent><Status id="PRI">First Priority</Status><StatusDate>2015-04-06 00:00:00</StatusDate><StatusSortCode>1</StatusSortCode><TherapyArea id="230">Neoplasm</TherapyArea></Row><Row><Action id="7761">T-lymphocyte stimulator</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Third Party</CompanyOwnershipRelationship><Country id="US">US</Country><Drug id="8747">palivizumab</Drug><DrugRelationship>General interest</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Priority</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PRI</HighestPatStatusIdForCnty><Indication id="1731">Acute myelogenous leukemia</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA8994514">WO-2016164308</Patent><Status id="PRI">First Priority</Status><StatusDate>2015-04-06 00:00:00</StatusDate><StatusSortCode>1</StatusSortCode><TherapyArea id="9099">Rare disease</TherapyArea></Row><Row><Action id="7761">T-lymphocyte stimulator</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Third Party</CompanyOwnershipRelationship><Country id="US">US</Country><Drug id="8747">palivizumab</Drug><DrugRelationship>General interest</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Priority</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PRI</HighestPatStatusIdForCnty><Indication id="1735">Chronic myelocytic leukemia</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA8994514">WO-2016164308</Patent><Status id="PRI">First Priority</Status><StatusDate>2015-04-06 00:00:00</StatusDate><StatusSortCode>1</StatusSortCode><TherapyArea id="142">Hematological disease</TherapyArea></Row><Row><Action id="7761">T-lymphocyte stimulator</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Third Party</CompanyOwnershipRelationship><Country id="US">US</Country><Drug id="8747">palivizumab</Drug><DrugRelationship>General interest</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Priority</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PRI</HighestPatStatusIdForCnty><Indication id="2054">Hematological neoplasm</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA8994514">WO-2016164308</Patent><Status id="PRI">First Priority</Status><StatusDate>2015-04-06 00:00:00</StatusDate><StatusSortCode>1</StatusSortCode><TherapyArea id="142">Hematological disease</TherapyArea></Row><Row><Action id="7761">T-lymphocyte stimulator</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Third Party</CompanyOwnershipRelationship><Country id="US">US</Country><Drug id="8747">palivizumab</Drug><DrugRelationship>General interest</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Priority</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PRI</HighestPatStatusIdForCnty><Indication id="725">Solid tumor</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA8994514">WO-2016164308</Patent><Status id="PRI">First Priority</Status><StatusDate>2015-04-06 00:00:00</StatusDate><StatusSortCode>1</StatusSortCode><TherapyArea id="230">Neoplasm</TherapyArea></Row><Row><Action id="12521">VEGF ligand inhibitor</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="WO">World</Country><Drug id="71794">adalimumab + anti-Ang2 Zybody (inflammatory disease), Zyngenia</Drug><DrugRelationship>General interest</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Publication</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PUB</HighestPatStatusIdForCnty><Indication id="188">Inflammatory disease</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA7191557">WO-2012162561</Patent><Status id="PUB">First Publication</Status><StatusDate>2012-11-29 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="188">Inflammatory disease</TherapyArea></Row><Row><Action id="12521">VEGF ligand inhibitor</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="WO">World</Country><Drug id="71794">adalimumab + anti-Ang2 Zybody (inflammatory disease), Zyngenia</Drug><DrugRelationship>General interest</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Publication</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PUB</HighestPatStatusIdForCnty><Indication id="189">Inflammatory bowel disease</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA7191557">WO-2012162561</Patent><Status id="PUB">First Publication</Status><StatusDate>2012-11-29 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="188">Inflammatory disease</TherapyArea></Row><Row><Action id="12521">VEGF ligand inhibitor</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="WO">World</Country><Drug id="71794">adalimumab + anti-Ang2 Zybody (inflammatory disease), Zyngenia</Drug><DrugRelationship>General interest</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Publication</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PUB</HighestPatStatusIdForCnty><Indication id="213">Multiple sclerosis</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA7191557">WO-2012162561</Patent><Status id="PUB">First Publication</Status><StatusDate>2012-11-29 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="185">Immune disorder</TherapyArea></Row><Row><Action id="12521">VEGF ligand inhibitor</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="WO">World</Country><Drug id="71794">adalimumab + anti-Ang2 Zybody (inflammatory disease), Zyngenia</Drug><DrugRelationship>General interest</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Publication</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PUB</HighestPatStatusIdForCnty><Indication id="281">Psoriasis</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA7191557">WO-2012162561</Patent><Status id="PUB">First Publication</Status><StatusDate>2012-11-29 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="95">Dermatological disease</TherapyArea></Row><Row><Action id="12521">VEGF ligand inhibitor</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="WO">World</Country><Drug id="71794">adalimumab + anti-Ang2 Zybody (inflammatory disease), Zyngenia</Drug><DrugRelationship>General interest</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Publication</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PUB</HighestPatStatusIdForCnty><Indication id="291">Rheumatoid arthritis</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA7191557">WO-2012162561</Patent><Status id="PUB">First Publication</Status><StatusDate>2012-11-29 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="185">Immune disorder</TherapyArea></Row><Row><Action id="12521">VEGF ligand inhibitor</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="WO">World</Country><Drug id="71794">adalimumab + anti-Ang2 Zybody (inflammatory disease), Zyngenia</Drug><DrugRelationship>General interest</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Publication</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PUB</HighestPatStatusIdForCnty><Indication id="318">Systemic lupus erythematosus</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA7191557">WO-2012162561</Patent><Status id="PUB">First Publication</Status><StatusDate>2012-11-29 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="95">Dermatological disease</TherapyArea></Row><Row><Action id="12521">VEGF ligand inhibitor</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="WO">World</Country><Drug id="71794">adalimumab + anti-Ang2 Zybody (inflammatory disease), Zyngenia</Drug><DrugRelationship>General interest</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Publication</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PUB</HighestPatStatusIdForCnty><Indication id="337">Ulcerative colitis</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA7191557">WO-2012162561</Patent><Status id="PUB">First Publication</Status><StatusDate>2012-11-29 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="185">Immune disorder</TherapyArea></Row><Row><Action id="12521">VEGF ligand inhibitor</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="WO">World</Country><Drug id="71794">adalimumab + anti-Ang2 Zybody (inflammatory disease), Zyngenia</Drug><DrugRelationship>General interest</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Publication</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PUB</HighestPatStatusIdForCnty><Indication id="651">Cancer</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA7191557">WO-2012162561</Patent><Status id="PUB">First Publication</Status><StatusDate>2012-11-29 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="230">Neoplasm</TherapyArea></Row><Row><Action id="12521">VEGF ligand inhibitor</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="WO">World</Country><Drug id="71794">adalimumab + anti-Ang2 Zybody (inflammatory disease), Zyngenia</Drug><DrugRelationship>General interest</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Publication</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PUB</HighestPatStatusIdForCnty><Indication id="746">Infectious disease</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA7191557">WO-2012162561</Patent><Status id="PUB">First Publication</Status><StatusDate>2012-11-29 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="746">Infectious disease</TherapyArea></Row><Row><Action id="12521">VEGF ligand inhibitor</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="WO">World</Country><Drug id="71794">adalimumab + anti-Ang2 Zybody (inflammatory disease), Zyngenia</Drug><DrugRelationship>General interest</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Publication</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PUB</HighestPatStatusIdForCnty><Indication id="84">Crohns disease</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA7191557">WO-2012162561</Patent><Status id="PUB">First Publication</Status><StatusDate>2012-11-29 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="185">Immune disorder</TherapyArea></Row><Row><Action id="12521">VEGF ligand inhibitor</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="WO">World</Country><Drug id="71794">adalimumab + anti-Ang2 Zybody (inflammatory disease), Zyngenia</Drug><DrugRelationship>General interest</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Publication</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PUB</HighestPatStatusIdForCnty><Indication id="97">Diabetes mellitus</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA7191557">WO-2012162561</Patent><Status id="PUB">First Publication</Status><StatusDate>2012-11-29 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="112">Endocrine disease</TherapyArea></Row><Row><Action id="3252">Insulin-like growth factor 1 receptor antagonist</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="WO">World</Country><Drug id="71794">adalimumab + anti-Ang2 Zybody (inflammatory disease), Zyngenia</Drug><DrugRelationship>General interest</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Publication</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PUB</HighestPatStatusIdForCnty><Indication id="188">Inflammatory disease</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA7191557">WO-2012162561</Patent><Status id="PUB">First Publication</Status><StatusDate>2012-11-29 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="188">Inflammatory disease</TherapyArea></Row><Row><Action id="3252">Insulin-like growth factor 1 receptor antagonist</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="WO">World</Country><Drug id="71794">adalimumab + anti-Ang2 Zybody (inflammatory disease), Zyngenia</Drug><DrugRelationship>General interest</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Publication</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PUB</HighestPatStatusIdForCnty><Indication id="189">Inflammatory bowel disease</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA7191557">WO-2012162561</Patent><Status id="PUB">First Publication</Status><StatusDate>2012-11-29 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="188">Inflammatory disease</TherapyArea></Row><Row><Action id="3252">Insulin-like growth factor 1 receptor antagonist</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="WO">World</Country><Drug id="71794">adalimumab + anti-Ang2 Zybody (inflammatory disease), Zyngenia</Drug><DrugRelationship>General interest</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Publication</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PUB</HighestPatStatusIdForCnty><Indication id="213">Multiple sclerosis</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA7191557">WO-2012162561</Patent><Status id="PUB">First Publication</Status><StatusDate>2012-11-29 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="185">Immune disorder</TherapyArea></Row><Row><Action id="3252">Insulin-like growth factor 1 receptor antagonist</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="WO">World</Country><Drug id="71794">adalimumab + anti-Ang2 Zybody (inflammatory disease), Zyngenia</Drug><DrugRelationship>General interest</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Publication</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PUB</HighestPatStatusIdForCnty><Indication id="281">Psoriasis</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA7191557">WO-2012162561</Patent><Status id="PUB">First Publication</Status><StatusDate>2012-11-29 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="95">Dermatological disease</TherapyArea></Row><Row><Action id="3252">Insulin-like growth factor 1 receptor antagonist</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="WO">World</Country><Drug id="71794">adalimumab + anti-Ang2 Zybody (inflammatory disease), Zyngenia</Drug><DrugRelationship>General interest</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Publication</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PUB</HighestPatStatusIdForCnty><Indication id="291">Rheumatoid arthritis</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA7191557">WO-2012162561</Patent><Status id="PUB">First Publication</Status><StatusDate>2012-11-29 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="185">Immune disorder</TherapyArea></Row><Row><Action id="3252">Insulin-like growth factor 1 receptor antagonist</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="WO">World</Country><Drug id="71794">adalimumab + anti-Ang2 Zybody (inflammatory disease), Zyngenia</Drug><DrugRelationship>General interest</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Publication</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PUB</HighestPatStatusIdForCnty><Indication id="318">Systemic lupus erythematosus</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA7191557">WO-2012162561</Patent><Status id="PUB">First Publication</Status><StatusDate>2012-11-29 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="95">Dermatological disease</TherapyArea></Row><Row><Action id="3252">Insulin-like growth factor 1 receptor antagonist</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="WO">World</Country><Drug id="71794">adalimumab + anti-Ang2 Zybody (inflammatory disease), Zyngenia</Drug><DrugRelationship>General interest</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Publication</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PUB</HighestPatStatusIdForCnty><Indication id="337">Ulcerative colitis</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA7191557">WO-2012162561</Patent><Status id="PUB">First Publication</Status><StatusDate>2012-11-29 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="185">Immune disorder</TherapyArea></Row><Row><Action id="3252">Insulin-like growth factor 1 receptor antagonist</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="WO">World</Country><Drug id="71794">adalimumab + anti-Ang2 Zybody (inflammatory disease), Zyngenia</Drug><DrugRelationship>General interest</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Publication</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PUB</HighestPatStatusIdForCnty><Indication id="651">Cancer</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA7191557">WO-2012162561</Patent><Status id="PUB">First Publication</Status><StatusDate>2012-11-29 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="230">Neoplasm</TherapyArea></Row><Row><Action id="3252">Insulin-like growth factor 1 receptor antagonist</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="WO">World</Country><Drug id="71794">adalimumab + anti-Ang2 Zybody (inflammatory disease), Zyngenia</Drug><DrugRelationship>General interest</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Publication</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PUB</HighestPatStatusIdForCnty><Indication id="746">Infectious disease</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA7191557">WO-2012162561</Patent><Status id="PUB">First Publication</Status><StatusDate>2012-11-29 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="746">Infectious disease</TherapyArea></Row><Row><Action id="3252">Insulin-like growth factor 1 receptor antagonist</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="WO">World</Country><Drug id="71794">adalimumab + anti-Ang2 Zybody (inflammatory disease), Zyngenia</Drug><DrugRelationship>General interest</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Publication</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PUB</HighestPatStatusIdForCnty><Indication id="84">Crohns disease</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA7191557">WO-2012162561</Patent><Status id="PUB">First Publication</Status><StatusDate>2012-11-29 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="185">Immune disorder</TherapyArea></Row><Row><Action id="3252">Insulin-like growth factor 1 receptor antagonist</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="WO">World</Country><Drug id="71794">adalimumab + anti-Ang2 Zybody (inflammatory disease), Zyngenia</Drug><DrugRelationship>General interest</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Publication</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PUB</HighestPatStatusIdForCnty><Indication id="97">Diabetes mellitus</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA7191557">WO-2012162561</Patent><Status id="PUB">First Publication</Status><StatusDate>2012-11-29 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="112">Endocrine disease</TherapyArea></Row><Row><Action id="3682">FGF1 receptor antagonist</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="WO">World</Country><Drug id="71794">adalimumab + anti-Ang2 Zybody (inflammatory disease), Zyngenia</Drug><DrugRelationship>General interest</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Publication</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PUB</HighestPatStatusIdForCnty><Indication id="188">Inflammatory disease</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA7191557">WO-2012162561</Patent><Status id="PUB">First Publication</Status><StatusDate>2012-11-29 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="188">Inflammatory disease</TherapyArea></Row><Row><Action id="3682">FGF1 receptor antagonist</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="WO">World</Country><Drug id="71794">adalimumab + anti-Ang2 Zybody (inflammatory disease), Zyngenia</Drug><DrugRelationship>General interest</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Publication</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PUB</HighestPatStatusIdForCnty><Indication id="189">Inflammatory bowel disease</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA7191557">WO-2012162561</Patent><Status id="PUB">First Publication</Status><StatusDate>2012-11-29 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="188">Inflammatory disease</TherapyArea></Row><Row><Action id="3682">FGF1 receptor antagonist</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="WO">World</Country><Drug id="71794">adalimumab + anti-Ang2 Zybody (inflammatory disease), Zyngenia</Drug><DrugRelationship>General interest</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Publication</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PUB</HighestPatStatusIdForCnty><Indication id="213">Multiple sclerosis</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA7191557">WO-2012162561</Patent><Status id="PUB">First Publication</Status><StatusDate>2012-11-29 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="185">Immune disorder</TherapyArea></Row><Row><Action id="3682">FGF1 receptor antagonist</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="WO">World</Country><Drug id="71794">adalimumab + anti-Ang2 Zybody (inflammatory disease), Zyngenia</Drug><DrugRelationship>General interest</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Publication</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PUB</HighestPatStatusIdForCnty><Indication id="281">Psoriasis</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA7191557">WO-2012162561</Patent><Status id="PUB">First Publication</Status><StatusDate>2012-11-29 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="95">Dermatological disease</TherapyArea></Row><Row><Action id="3682">FGF1 receptor antagonist</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="WO">World</Country><Drug id="71794">adalimumab + anti-Ang2 Zybody (inflammatory disease), Zyngenia</Drug><DrugRelationship>General interest</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Publication</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PUB</HighestPatStatusIdForCnty><Indication id="291">Rheumatoid arthritis</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA7191557">WO-2012162561</Patent><Status id="PUB">First Publication</Status><StatusDate>2012-11-29 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="185">Immune disorder</TherapyArea></Row><Row><Action id="3682">FGF1 receptor antagonist</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="WO">World</Country><Drug id="71794">adalimumab + anti-Ang2 Zybody (inflammatory disease), Zyngenia</Drug><DrugRelationship>General interest</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Publication</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PUB</HighestPatStatusIdForCnty><Indication id="318">Systemic lupus erythematosus</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA7191557">WO-2012162561</Patent><Status id="PUB">First Publication</Status><StatusDate>2012-11-29 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="95">Dermatological disease</TherapyArea></Row><Row><Action id="3682">FGF1 receptor antagonist</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="WO">World</Country><Drug id="71794">adalimumab + anti-Ang2 Zybody (inflammatory disease), Zyngenia</Drug><DrugRelationship>General interest</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Publication</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PUB</HighestPatStatusIdForCnty><Indication id="337">Ulcerative colitis</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA7191557">WO-2012162561</Patent><Status id="PUB">First Publication</Status><StatusDate>2012-11-29 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="185">Immune disorder</TherapyArea></Row><Row><Action id="3682">FGF1 receptor antagonist</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="WO">World</Country><Drug id="71794">adalimumab + anti-Ang2 Zybody (inflammatory disease), Zyngenia</Drug><DrugRelationship>General interest</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Publication</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PUB</HighestPatStatusIdForCnty><Indication id="651">Cancer</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA7191557">WO-2012162561</Patent><Status id="PUB">First Publication</Status><StatusDate>2012-11-29 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="230">Neoplasm</TherapyArea></Row><Row><Action id="3682">FGF1 receptor antagonist</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="WO">World</Country><Drug id="71794">adalimumab + anti-Ang2 Zybody (inflammatory disease), Zyngenia</Drug><DrugRelationship>General interest</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Publication</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PUB</HighestPatStatusIdForCnty><Indication id="746">Infectious disease</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA7191557">WO-2012162561</Patent><Status id="PUB">First Publication</Status><StatusDate>2012-11-29 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="746">Infectious disease</TherapyArea></Row><Row><Action id="3682">FGF1 receptor antagonist</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="WO">World</Country><Drug id="71794">adalimumab + anti-Ang2 Zybody (inflammatory disease), Zyngenia</Drug><DrugRelationship>General interest</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Publication</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PUB</HighestPatStatusIdForCnty><Indication id="84">Crohns disease</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA7191557">WO-2012162561</Patent><Status id="PUB">First Publication</Status><StatusDate>2012-11-29 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="185">Immune disorder</TherapyArea></Row><Row><Action id="3682">FGF1 receptor antagonist</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="WO">World</Country><Drug id="71794">adalimumab + anti-Ang2 Zybody (inflammatory disease), Zyngenia</Drug><DrugRelationship>General interest</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Publication</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PUB</HighestPatStatusIdForCnty><Indication id="97">Diabetes mellitus</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA7191557">WO-2012162561</Patent><Status id="PUB">First Publication</Status><StatusDate>2012-11-29 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="112">Endocrine disease</TherapyArea></Row><Row><Action id="3685">FGF2 receptor antagonist</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="WO">World</Country><Drug id="71794">adalimumab + anti-Ang2 Zybody (inflammatory disease), Zyngenia</Drug><DrugRelationship>General interest</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Publication</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PUB</HighestPatStatusIdForCnty><Indication id="188">Inflammatory disease</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA7191557">WO-2012162561</Patent><Status id="PUB">First Publication</Status><StatusDate>2012-11-29 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="188">Inflammatory disease</TherapyArea></Row><Row><Action id="3685">FGF2 receptor antagonist</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="WO">World</Country><Drug id="71794">adalimumab + anti-Ang2 Zybody (inflammatory disease), Zyngenia</Drug><DrugRelationship>General interest</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Publication</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PUB</HighestPatStatusIdForCnty><Indication id="189">Inflammatory bowel disease</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA7191557">WO-2012162561</Patent><Status id="PUB">First Publication</Status><StatusDate>2012-11-29 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="188">Inflammatory disease</TherapyArea></Row><Row><Action id="3685">FGF2 receptor antagonist</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="WO">World</Country><Drug id="71794">adalimumab + anti-Ang2 Zybody (inflammatory disease), Zyngenia</Drug><DrugRelationship>General interest</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Publication</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PUB</HighestPatStatusIdForCnty><Indication id="213">Multiple sclerosis</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA7191557">WO-2012162561</Patent><Status id="PUB">First Publication</Status><StatusDate>2012-11-29 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="185">Immune disorder</TherapyArea></Row><Row><Action id="3685">FGF2 receptor antagonist</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="WO">World</Country><Drug id="71794">adalimumab + anti-Ang2 Zybody (inflammatory disease), Zyngenia</Drug><DrugRelationship>General interest</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Publication</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PUB</HighestPatStatusIdForCnty><Indication id="281">Psoriasis</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA7191557">WO-2012162561</Patent><Status id="PUB">First Publication</Status><StatusDate>2012-11-29 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="95">Dermatological disease</TherapyArea></Row><Row><Action id="3685">FGF2 receptor antagonist</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="WO">World</Country><Drug id="71794">adalimumab + anti-Ang2 Zybody (inflammatory disease), Zyngenia</Drug><DrugRelationship>General interest</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Publication</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PUB</HighestPatStatusIdForCnty><Indication id="291">Rheumatoid arthritis</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA7191557">WO-2012162561</Patent><Status id="PUB">First Publication</Status><StatusDate>2012-11-29 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="185">Immune disorder</TherapyArea></Row><Row><Action id="3685">FGF2 receptor antagonist</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="WO">World</Country><Drug id="71794">adalimumab + anti-Ang2 Zybody (inflammatory disease), Zyngenia</Drug><DrugRelationship>General interest</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Publication</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PUB</HighestPatStatusIdForCnty><Indication id="318">Systemic lupus erythematosus</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA7191557">WO-2012162561</Patent><Status id="PUB">First Publication</Status><StatusDate>2012-11-29 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="95">Dermatological disease</TherapyArea></Row><Row><Action id="3685">FGF2 receptor antagonist</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="WO">World</Country><Drug id="71794">adalimumab + anti-Ang2 Zybody (inflammatory disease), Zyngenia</Drug><DrugRelationship>General interest</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Publication</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PUB</HighestPatStatusIdForCnty><Indication id="337">Ulcerative colitis</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA7191557">WO-2012162561</Patent><Status id="PUB">First Publication</Status><StatusDate>2012-11-29 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="185">Immune disorder</TherapyArea></Row><Row><Action id="3685">FGF2 receptor antagonist</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="WO">World</Country><Drug id="71794">adalimumab + anti-Ang2 Zybody (inflammatory disease), Zyngenia</Drug><DrugRelationship>General interest</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Publication</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PUB</HighestPatStatusIdForCnty><Indication id="651">Cancer</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA7191557">WO-2012162561</Patent><Status id="PUB">First Publication</Status><StatusDate>2012-11-29 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="230">Neoplasm</TherapyArea></Row><Row><Action id="3685">FGF2 receptor antagonist</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="WO">World</Country><Drug id="71794">adalimumab + anti-Ang2 Zybody (inflammatory disease), Zyngenia</Drug><DrugRelationship>General interest</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Publication</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PUB</HighestPatStatusIdForCnty><Indication id="746">Infectious disease</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA7191557">WO-2012162561</Patent><Status id="PUB">First Publication</Status><StatusDate>2012-11-29 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="746">Infectious disease</TherapyArea></Row><Row><Action id="3685">FGF2 receptor antagonist</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="WO">World</Country><Drug id="71794">adalimumab + anti-Ang2 Zybody (inflammatory disease), Zyngenia</Drug><DrugRelationship>General interest</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Publication</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PUB</HighestPatStatusIdForCnty><Indication id="84">Crohns disease</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA7191557">WO-2012162561</Patent><Status id="PUB">First Publication</Status><StatusDate>2012-11-29 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="185">Immune disorder</TherapyArea></Row><Row><Action id="3685">FGF2 receptor antagonist</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="WO">World</Country><Drug id="71794">adalimumab + anti-Ang2 Zybody (inflammatory disease), Zyngenia</Drug><DrugRelationship>General interest</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Publication</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PUB</HighestPatStatusIdForCnty><Indication id="97">Diabetes mellitus</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA7191557">WO-2012162561</Patent><Status id="PUB">First Publication</Status><StatusDate>2012-11-29 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="112">Endocrine disease</TherapyArea></Row><Row><Action id="3756">Erbb2 tyrosine kinase receptor inhibitor</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="WO">World</Country><Drug id="71794">adalimumab + anti-Ang2 Zybody (inflammatory disease), Zyngenia</Drug><DrugRelationship>General interest</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Publication</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PUB</HighestPatStatusIdForCnty><Indication id="188">Inflammatory disease</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA7191557">WO-2012162561</Patent><Status id="PUB">First Publication</Status><StatusDate>2012-11-29 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="188">Inflammatory disease</TherapyArea></Row><Row><Action id="3756">Erbb2 tyrosine kinase receptor inhibitor</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="WO">World</Country><Drug id="71794">adalimumab + anti-Ang2 Zybody (inflammatory disease), Zyngenia</Drug><DrugRelationship>General interest</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Publication</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PUB</HighestPatStatusIdForCnty><Indication id="189">Inflammatory bowel disease</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA7191557">WO-2012162561</Patent><Status id="PUB">First Publication</Status><StatusDate>2012-11-29 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="188">Inflammatory disease</TherapyArea></Row><Row><Action id="3756">Erbb2 tyrosine kinase receptor inhibitor</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="WO">World</Country><Drug id="71794">adalimumab + anti-Ang2 Zybody (inflammatory disease), Zyngenia</Drug><DrugRelationship>General interest</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Publication</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PUB</HighestPatStatusIdForCnty><Indication id="213">Multiple sclerosis</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA7191557">WO-2012162561</Patent><Status id="PUB">First Publication</Status><StatusDate>2012-11-29 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="185">Immune disorder</TherapyArea></Row><Row><Action id="3756">Erbb2 tyrosine kinase receptor inhibitor</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="WO">World</Country><Drug id="71794">adalimumab + anti-Ang2 Zybody (inflammatory disease), Zyngenia</Drug><DrugRelationship>General interest</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Publication</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PUB</HighestPatStatusIdForCnty><Indication id="281">Psoriasis</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA7191557">WO-2012162561</Patent><Status id="PUB">First Publication</Status><StatusDate>2012-11-29 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="95">Dermatological disease</TherapyArea></Row><Row><Action id="3756">Erbb2 tyrosine kinase receptor inhibitor</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="WO">World</Country><Drug id="71794">adalimumab + anti-Ang2 Zybody (inflammatory disease), Zyngenia</Drug><DrugRelationship>General interest</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Publication</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PUB</HighestPatStatusIdForCnty><Indication id="291">Rheumatoid arthritis</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA7191557">WO-2012162561</Patent><Status id="PUB">First Publication</Status><StatusDate>2012-11-29 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="185">Immune disorder</TherapyArea></Row><Row><Action id="3756">Erbb2 tyrosine kinase receptor inhibitor</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="WO">World</Country><Drug id="71794">adalimumab + anti-Ang2 Zybody (inflammatory disease), Zyngenia</Drug><DrugRelationship>General interest</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Publication</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PUB</HighestPatStatusIdForCnty><Indication id="318">Systemic lupus erythematosus</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA7191557">WO-2012162561</Patent><Status id="PUB">First Publication</Status><StatusDate>2012-11-29 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="95">Dermatological disease</TherapyArea></Row><Row><Action id="3756">Erbb2 tyrosine kinase receptor inhibitor</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="WO">World</Country><Drug id="71794">adalimumab + anti-Ang2 Zybody (inflammatory disease), Zyngenia</Drug><DrugRelationship>General interest</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Publication</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PUB</HighestPatStatusIdForCnty><Indication id="337">Ulcerative colitis</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA7191557">WO-2012162561</Patent><Status id="PUB">First Publication</Status><StatusDate>2012-11-29 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="185">Immune disorder</TherapyArea></Row><Row><Action id="3756">Erbb2 tyrosine kinase receptor inhibitor</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="WO">World</Country><Drug id="71794">adalimumab + anti-Ang2 Zybody (inflammatory disease), Zyngenia</Drug><DrugRelationship>General interest</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Publication</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PUB</HighestPatStatusIdForCnty><Indication id="651">Cancer</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA7191557">WO-2012162561</Patent><Status id="PUB">First Publication</Status><StatusDate>2012-11-29 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="230">Neoplasm</TherapyArea></Row><Row><Action id="3756">Erbb2 tyrosine kinase receptor inhibitor</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="WO">World</Country><Drug id="71794">adalimumab + anti-Ang2 Zybody (inflammatory disease), Zyngenia</Drug><DrugRelationship>General interest</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Publication</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PUB</HighestPatStatusIdForCnty><Indication id="746">Infectious disease</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA7191557">WO-2012162561</Patent><Status id="PUB">First Publication</Status><StatusDate>2012-11-29 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="746">Infectious disease</TherapyArea></Row><Row><Action id="3756">Erbb2 tyrosine kinase receptor inhibitor</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="WO">World</Country><Drug id="71794">adalimumab + anti-Ang2 Zybody (inflammatory disease), Zyngenia</Drug><DrugRelationship>General interest</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Publication</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PUB</HighestPatStatusIdForCnty><Indication id="84">Crohns disease</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA7191557">WO-2012162561</Patent><Status id="PUB">First Publication</Status><StatusDate>2012-11-29 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="185">Immune disorder</TherapyArea></Row><Row><Action id="3756">Erbb2 tyrosine kinase receptor inhibitor</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="WO">World</Country><Drug id="71794">adalimumab + anti-Ang2 Zybody (inflammatory disease), Zyngenia</Drug><DrugRelationship>General interest</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Publication</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PUB</HighestPatStatusIdForCnty><Indication id="97">Diabetes mellitus</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA7191557">WO-2012162561</Patent><Status id="PUB">First Publication</Status><StatusDate>2012-11-29 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="112">Endocrine disease</TherapyArea></Row><Row><Action id="3846">VEGF-1 receptor antagonist</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="WO">World</Country><Drug id="71794">adalimumab + anti-Ang2 Zybody (inflammatory disease), Zyngenia</Drug><DrugRelationship>General interest</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Publication</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PUB</HighestPatStatusIdForCnty><Indication id="188">Inflammatory disease</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA7191557">WO-2012162561</Patent><Status id="PUB">First Publication</Status><StatusDate>2012-11-29 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="188">Inflammatory disease</TherapyArea></Row><Row><Action id="3846">VEGF-1 receptor antagonist</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="WO">World</Country><Drug id="71794">adalimumab + anti-Ang2 Zybody (inflammatory disease), Zyngenia</Drug><DrugRelationship>General interest</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Publication</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PUB</HighestPatStatusIdForCnty><Indication id="189">Inflammatory bowel disease</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA7191557">WO-2012162561</Patent><Status id="PUB">First Publication</Status><StatusDate>2012-11-29 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="188">Inflammatory disease</TherapyArea></Row><Row><Action id="3846">VEGF-1 receptor antagonist</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="WO">World</Country><Drug id="71794">adalimumab + anti-Ang2 Zybody (inflammatory disease), Zyngenia</Drug><DrugRelationship>General interest</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Publication</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PUB</HighestPatStatusIdForCnty><Indication id="213">Multiple sclerosis</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA7191557">WO-2012162561</Patent><Status id="PUB">First Publication</Status><StatusDate>2012-11-29 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="185">Immune disorder</TherapyArea></Row><Row><Action id="3846">VEGF-1 receptor antagonist</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="WO">World</Country><Drug id="71794">adalimumab + anti-Ang2 Zybody (inflammatory disease), Zyngenia</Drug><DrugRelationship>General interest</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Publication</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PUB</HighestPatStatusIdForCnty><Indication id="281">Psoriasis</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA7191557">WO-2012162561</Patent><Status id="PUB">First Publication</Status><StatusDate>2012-11-29 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="95">Dermatological disease</TherapyArea></Row><Row><Action id="3846">VEGF-1 receptor antagonist</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="WO">World</Country><Drug id="71794">adalimumab + anti-Ang2 Zybody (inflammatory disease), Zyngenia</Drug><DrugRelationship>General interest</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Publication</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PUB</HighestPatStatusIdForCnty><Indication id="291">Rheumatoid arthritis</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA7191557">WO-2012162561</Patent><Status id="PUB">First Publication</Status><StatusDate>2012-11-29 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="185">Immune disorder</TherapyArea></Row><Row><Action id="3846">VEGF-1 receptor antagonist</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="WO">World</Country><Drug id="71794">adalimumab + anti-Ang2 Zybody (inflammatory disease), Zyngenia</Drug><DrugRelationship>General interest</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Publication</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PUB</HighestPatStatusIdForCnty><Indication id="318">Systemic lupus erythematosus</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA7191557">WO-2012162561</Patent><Status id="PUB">First Publication</Status><StatusDate>2012-11-29 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="95">Dermatological disease</TherapyArea></Row><Row><Action id="3846">VEGF-1 receptor antagonist</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="WO">World</Country><Drug id="71794">adalimumab + anti-Ang2 Zybody (inflammatory disease), Zyngenia</Drug><DrugRelationship>General interest</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Publication</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PUB</HighestPatStatusIdForCnty><Indication id="337">Ulcerative colitis</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA7191557">WO-2012162561</Patent><Status id="PUB">First Publication</Status><StatusDate>2012-11-29 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="185">Immune disorder</TherapyArea></Row><Row><Action id="3846">VEGF-1 receptor antagonist</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="WO">World</Country><Drug id="71794">adalimumab + anti-Ang2 Zybody (inflammatory disease), Zyngenia</Drug><DrugRelationship>General interest</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Publication</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PUB</HighestPatStatusIdForCnty><Indication id="651">Cancer</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA7191557">WO-2012162561</Patent><Status id="PUB">First Publication</Status><StatusDate>2012-11-29 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="230">Neoplasm</TherapyArea></Row><Row><Action id="3846">VEGF-1 receptor antagonist</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="WO">World</Country><Drug id="71794">adalimumab + anti-Ang2 Zybody (inflammatory disease), Zyngenia</Drug><DrugRelationship>General interest</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Publication</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PUB</HighestPatStatusIdForCnty><Indication id="746">Infectious disease</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA7191557">WO-2012162561</Patent><Status id="PUB">First Publication</Status><StatusDate>2012-11-29 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="746">Infectious disease</TherapyArea></Row><Row><Action id="3846">VEGF-1 receptor antagonist</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="WO">World</Country><Drug id="71794">adalimumab + anti-Ang2 Zybody (inflammatory disease), Zyngenia</Drug><DrugRelationship>General interest</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Publication</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PUB</HighestPatStatusIdForCnty><Indication id="84">Crohns disease</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA7191557">WO-2012162561</Patent><Status id="PUB">First Publication</Status><StatusDate>2012-11-29 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="185">Immune disorder</TherapyArea></Row><Row><Action id="3846">VEGF-1 receptor antagonist</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="WO">World</Country><Drug id="71794">adalimumab + anti-Ang2 Zybody (inflammatory disease), Zyngenia</Drug><DrugRelationship>General interest</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Publication</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PUB</HighestPatStatusIdForCnty><Indication id="97">Diabetes mellitus</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA7191557">WO-2012162561</Patent><Status id="PUB">First Publication</Status><StatusDate>2012-11-29 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="112">Endocrine disease</TherapyArea></Row><Row><Action id="5025">CD3 antagonist</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="WO">World</Country><Drug id="71794">adalimumab + anti-Ang2 Zybody (inflammatory disease), Zyngenia</Drug><DrugRelationship>General interest</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Publication</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PUB</HighestPatStatusIdForCnty><Indication id="188">Inflammatory disease</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA7191557">WO-2012162561</Patent><Status id="PUB">First Publication</Status><StatusDate>2012-11-29 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="188">Inflammatory disease</TherapyArea></Row><Row><Action id="5025">CD3 antagonist</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="WO">World</Country><Drug id="71794">adalimumab + anti-Ang2 Zybody (inflammatory disease), Zyngenia</Drug><DrugRelationship>General interest</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Publication</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PUB</HighestPatStatusIdForCnty><Indication id="189">Inflammatory bowel disease</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA7191557">WO-2012162561</Patent><Status id="PUB">First Publication</Status><StatusDate>2012-11-29 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="188">Inflammatory disease</TherapyArea></Row><Row><Action id="5025">CD3 antagonist</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="WO">World</Country><Drug id="71794">adalimumab + anti-Ang2 Zybody (inflammatory disease), Zyngenia</Drug><DrugRelationship>General interest</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Publication</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PUB</HighestPatStatusIdForCnty><Indication id="213">Multiple sclerosis</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA7191557">WO-2012162561</Patent><Status id="PUB">First Publication</Status><StatusDate>2012-11-29 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="185">Immune disorder</TherapyArea></Row><Row><Action id="5025">CD3 antagonist</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="WO">World</Country><Drug id="71794">adalimumab + anti-Ang2 Zybody (inflammatory disease), Zyngenia</Drug><DrugRelationship>General interest</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Publication</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PUB</HighestPatStatusIdForCnty><Indication id="281">Psoriasis</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA7191557">WO-2012162561</Patent><Status id="PUB">First Publication</Status><StatusDate>2012-11-29 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="95">Dermatological disease</TherapyArea></Row><Row><Action id="5025">CD3 antagonist</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="WO">World</Country><Drug id="71794">adalimumab + anti-Ang2 Zybody (inflammatory disease), Zyngenia</Drug><DrugRelationship>General interest</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Publication</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PUB</HighestPatStatusIdForCnty><Indication id="291">Rheumatoid arthritis</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA7191557">WO-2012162561</Patent><Status id="PUB">First Publication</Status><StatusDate>2012-11-29 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="185">Immune disorder</TherapyArea></Row><Row><Action id="5025">CD3 antagonist</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="WO">World</Country><Drug id="71794">adalimumab + anti-Ang2 Zybody (inflammatory disease), Zyngenia</Drug><DrugRelationship>General interest</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Publication</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PUB</HighestPatStatusIdForCnty><Indication id="318">Systemic lupus erythematosus</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA7191557">WO-2012162561</Patent><Status id="PUB">First Publication</Status><StatusDate>2012-11-29 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="95">Dermatological disease</TherapyArea></Row><Row><Action id="5025">CD3 antagonist</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="WO">World</Country><Drug id="71794">adalimumab + anti-Ang2 Zybody (inflammatory disease), Zyngenia</Drug><DrugRelationship>General interest</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Publication</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PUB</HighestPatStatusIdForCnty><Indication id="337">Ulcerative colitis</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA7191557">WO-2012162561</Patent><Status id="PUB">First Publication</Status><StatusDate>2012-11-29 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="185">Immune disorder</TherapyArea></Row><Row><Action id="5025">CD3 antagonist</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="WO">World</Country><Drug id="71794">adalimumab + anti-Ang2 Zybody (inflammatory disease), Zyngenia</Drug><DrugRelationship>General interest</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Publication</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PUB</HighestPatStatusIdForCnty><Indication id="651">Cancer</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA7191557">WO-2012162561</Patent><Status id="PUB">First Publication</Status><StatusDate>2012-11-29 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="230">Neoplasm</TherapyArea></Row><Row><Action id="5025">CD3 antagonist</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="WO">World</Country><Drug id="71794">adalimumab + anti-Ang2 Zybody (inflammatory disease), Zyngenia</Drug><DrugRelationship>General interest</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Publication</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PUB</HighestPatStatusIdForCnty><Indication id="746">Infectious disease</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA7191557">WO-2012162561</Patent><Status id="PUB">First Publication</Status><StatusDate>2012-11-29 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="746">Infectious disease</TherapyArea></Row><Row><Action id="5025">CD3 antagonist</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="WO">World</Country><Drug id="71794">adalimumab + anti-Ang2 Zybody (inflammatory disease), Zyngenia</Drug><DrugRelationship>General interest</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Publication</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PUB</HighestPatStatusIdForCnty><Indication id="84">Crohns disease</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA7191557">WO-2012162561</Patent><Status id="PUB">First Publication</Status><StatusDate>2012-11-29 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="185">Immune disorder</TherapyArea></Row><Row><Action id="5025">CD3 antagonist</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="WO">World</Country><Drug id="71794">adalimumab + anti-Ang2 Zybody (inflammatory disease), Zyngenia</Drug><DrugRelationship>General interest</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Publication</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PUB</HighestPatStatusIdForCnty><Indication id="97">Diabetes mellitus</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA7191557">WO-2012162561</Patent><Status id="PUB">First Publication</Status><StatusDate>2012-11-29 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="112">Endocrine disease</TherapyArea></Row><Row><Action id="5082">B-lymphocyte antigen CD19 inhibitor</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="WO">World</Country><Drug id="71794">adalimumab + anti-Ang2 Zybody (inflammatory disease), Zyngenia</Drug><DrugRelationship>General interest</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Publication</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PUB</HighestPatStatusIdForCnty><Indication id="188">Inflammatory disease</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA7191557">WO-2012162561</Patent><Status id="PUB">First Publication</Status><StatusDate>2012-11-29 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="188">Inflammatory disease</TherapyArea></Row><Row><Action id="5082">B-lymphocyte antigen CD19 inhibitor</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="WO">World</Country><Drug id="71794">adalimumab + anti-Ang2 Zybody (inflammatory disease), Zyngenia</Drug><DrugRelationship>General interest</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Publication</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PUB</HighestPatStatusIdForCnty><Indication id="189">Inflammatory bowel disease</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA7191557">WO-2012162561</Patent><Status id="PUB">First Publication</Status><StatusDate>2012-11-29 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="188">Inflammatory disease</TherapyArea></Row><Row><Action id="5082">B-lymphocyte antigen CD19 inhibitor</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="WO">World</Country><Drug id="71794">adalimumab + anti-Ang2 Zybody (inflammatory disease), Zyngenia</Drug><DrugRelationship>General interest</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Publication</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PUB</HighestPatStatusIdForCnty><Indication id="213">Multiple sclerosis</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA7191557">WO-2012162561</Patent><Status id="PUB">First Publication</Status><StatusDate>2012-11-29 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="185">Immune disorder</TherapyArea></Row><Row><Action id="5082">B-lymphocyte antigen CD19 inhibitor</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="WO">World</Country><Drug id="71794">adalimumab + anti-Ang2 Zybody (inflammatory disease), Zyngenia</Drug><DrugRelationship>General interest</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Publication</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PUB</HighestPatStatusIdForCnty><Indication id="281">Psoriasis</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA7191557">WO-2012162561</Patent><Status id="PUB">First Publication</Status><StatusDate>2012-11-29 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="95">Dermatological disease</TherapyArea></Row><Row><Action id="5082">B-lymphocyte antigen CD19 inhibitor</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="WO">World</Country><Drug id="71794">adalimumab + anti-Ang2 Zybody (inflammatory disease), Zyngenia</Drug><DrugRelationship>General interest</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Publication</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PUB</HighestPatStatusIdForCnty><Indication id="291">Rheumatoid arthritis</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA7191557">WO-2012162561</Patent><Status id="PUB">First Publication</Status><StatusDate>2012-11-29 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="185">Immune disorder</TherapyArea></Row><Row><Action id="5082">B-lymphocyte antigen CD19 inhibitor</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="WO">World</Country><Drug id="71794">adalimumab + anti-Ang2 Zybody (inflammatory disease), Zyngenia</Drug><DrugRelationship>General interest</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Publication</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PUB</HighestPatStatusIdForCnty><Indication id="318">Systemic lupus erythematosus</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA7191557">WO-2012162561</Patent><Status id="PUB">First Publication</Status><StatusDate>2012-11-29 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="95">Dermatological disease</TherapyArea></Row><Row><Action id="5082">B-lymphocyte antigen CD19 inhibitor</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="WO">World</Country><Drug id="71794">adalimumab + anti-Ang2 Zybody (inflammatory disease), Zyngenia</Drug><DrugRelationship>General interest</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Publication</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PUB</HighestPatStatusIdForCnty><Indication id="337">Ulcerative colitis</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA7191557">WO-2012162561</Patent><Status id="PUB">First Publication</Status><StatusDate>2012-11-29 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="185">Immune disorder</TherapyArea></Row><Row><Action id="5082">B-lymphocyte antigen CD19 inhibitor</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="WO">World</Country><Drug id="71794">adalimumab + anti-Ang2 Zybody (inflammatory disease), Zyngenia</Drug><DrugRelationship>General interest</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Publication</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PUB</HighestPatStatusIdForCnty><Indication id="651">Cancer</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA7191557">WO-2012162561</Patent><Status id="PUB">First Publication</Status><StatusDate>2012-11-29 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="230">Neoplasm</TherapyArea></Row><Row><Action id="5082">B-lymphocyte antigen CD19 inhibitor</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="WO">World</Country><Drug id="71794">adalimumab + anti-Ang2 Zybody (inflammatory disease), Zyngenia</Drug><DrugRelationship>General interest</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Publication</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PUB</HighestPatStatusIdForCnty><Indication id="746">Infectious disease</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA7191557">WO-2012162561</Patent><Status id="PUB">First Publication</Status><StatusDate>2012-11-29 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="746">Infectious disease</TherapyArea></Row><Row><Action id="5082">B-lymphocyte antigen CD19 inhibitor</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="WO">World</Country><Drug id="71794">adalimumab + anti-Ang2 Zybody (inflammatory disease), Zyngenia</Drug><DrugRelationship>General interest</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Publication</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PUB</HighestPatStatusIdForCnty><Indication id="84">Crohns disease</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA7191557">WO-2012162561</Patent><Status id="PUB">First Publication</Status><StatusDate>2012-11-29 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="185">Immune disorder</TherapyArea></Row><Row><Action id="5082">B-lymphocyte antigen CD19 inhibitor</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="WO">World</Country><Drug id="71794">adalimumab + anti-Ang2 Zybody (inflammatory disease), Zyngenia</Drug><DrugRelationship>General interest</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Publication</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PUB</HighestPatStatusIdForCnty><Indication id="97">Diabetes mellitus</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA7191557">WO-2012162561</Patent><Status id="PUB">First Publication</Status><StatusDate>2012-11-29 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="112">Endocrine disease</TherapyArea></Row><Row><Action id="5085">B-lymphocyte antigen CD20 inhibitor</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="WO">World</Country><Drug id="71794">adalimumab + anti-Ang2 Zybody (inflammatory disease), Zyngenia</Drug><DrugRelationship>General interest</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Publication</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PUB</HighestPatStatusIdForCnty><Indication id="188">Inflammatory disease</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA7191557">WO-2012162561</Patent><Status id="PUB">First Publication</Status><StatusDate>2012-11-29 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="188">Inflammatory disease</TherapyArea></Row><Row><Action id="5085">B-lymphocyte antigen CD20 inhibitor</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="WO">World</Country><Drug id="71794">adalimumab + anti-Ang2 Zybody (inflammatory disease), Zyngenia</Drug><DrugRelationship>General interest</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Publication</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PUB</HighestPatStatusIdForCnty><Indication id="189">Inflammatory bowel disease</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA7191557">WO-2012162561</Patent><Status id="PUB">First Publication</Status><StatusDate>2012-11-29 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="188">Inflammatory disease</TherapyArea></Row><Row><Action id="5085">B-lymphocyte antigen CD20 inhibitor</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="WO">World</Country><Drug id="71794">adalimumab + anti-Ang2 Zybody (inflammatory disease), Zyngenia</Drug><DrugRelationship>General interest</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Publication</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PUB</HighestPatStatusIdForCnty><Indication id="213">Multiple sclerosis</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA7191557">WO-2012162561</Patent><Status id="PUB">First Publication</Status><StatusDate>2012-11-29 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="185">Immune disorder</TherapyArea></Row><Row><Action id="5085">B-lymphocyte antigen CD20 inhibitor</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="WO">World</Country><Drug id="71794">adalimumab + anti-Ang2 Zybody (inflammatory disease), Zyngenia</Drug><DrugRelationship>General interest</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Publication</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PUB</HighestPatStatusIdForCnty><Indication id="281">Psoriasis</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA7191557">WO-2012162561</Patent><Status id="PUB">First Publication</Status><StatusDate>2012-11-29 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="95">Dermatological disease</TherapyArea></Row><Row><Action id="5085">B-lymphocyte antigen CD20 inhibitor</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="WO">World</Country><Drug id="71794">adalimumab + anti-Ang2 Zybody (inflammatory disease), Zyngenia</Drug><DrugRelationship>General interest</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Publication</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PUB</HighestPatStatusIdForCnty><Indication id="291">Rheumatoid arthritis</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA7191557">WO-2012162561</Patent><Status id="PUB">First Publication</Status><StatusDate>2012-11-29 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="185">Immune disorder</TherapyArea></Row><Row><Action id="5085">B-lymphocyte antigen CD20 inhibitor</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="WO">World</Country><Drug id="71794">adalimumab + anti-Ang2 Zybody (inflammatory disease), Zyngenia</Drug><DrugRelationship>General interest</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Publication</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PUB</HighestPatStatusIdForCnty><Indication id="318">Systemic lupus erythematosus</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA7191557">WO-2012162561</Patent><Status id="PUB">First Publication</Status><StatusDate>2012-11-29 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="95">Dermatological disease</TherapyArea></Row><Row><Action id="5085">B-lymphocyte antigen CD20 inhibitor</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="WO">World</Country><Drug id="71794">adalimumab + anti-Ang2 Zybody (inflammatory disease), Zyngenia</Drug><DrugRelationship>General interest</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Publication</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PUB</HighestPatStatusIdForCnty><Indication id="337">Ulcerative colitis</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA7191557">WO-2012162561</Patent><Status id="PUB">First Publication</Status><StatusDate>2012-11-29 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="185">Immune disorder</TherapyArea></Row><Row><Action id="5085">B-lymphocyte antigen CD20 inhibitor</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="WO">World</Country><Drug id="71794">adalimumab + anti-Ang2 Zybody (inflammatory disease), Zyngenia</Drug><DrugRelationship>General interest</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Publication</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PUB</HighestPatStatusIdForCnty><Indication id="651">Cancer</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA7191557">WO-2012162561</Patent><Status id="PUB">First Publication</Status><StatusDate>2012-11-29 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="230">Neoplasm</TherapyArea></Row><Row><Action id="5085">B-lymphocyte antigen CD20 inhibitor</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="WO">World</Country><Drug id="71794">adalimumab + anti-Ang2 Zybody (inflammatory disease), Zyngenia</Drug><DrugRelationship>General interest</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Publication</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PUB</HighestPatStatusIdForCnty><Indication id="746">Infectious disease</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA7191557">WO-2012162561</Patent><Status id="PUB">First Publication</Status><StatusDate>2012-11-29 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="746">Infectious disease</TherapyArea></Row><Row><Action id="5085">B-lymphocyte antigen CD20 inhibitor</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="WO">World</Country><Drug id="71794">adalimumab + anti-Ang2 Zybody (inflammatory disease), Zyngenia</Drug><DrugRelationship>General interest</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Publication</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PUB</HighestPatStatusIdForCnty><Indication id="84">Crohns disease</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA7191557">WO-2012162561</Patent><Status id="PUB">First Publication</Status><StatusDate>2012-11-29 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="185">Immune disorder</TherapyArea></Row><Row><Action id="5085">B-lymphocyte antigen CD20 inhibitor</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="WO">World</Country><Drug id="71794">adalimumab + anti-Ang2 Zybody (inflammatory disease), Zyngenia</Drug><DrugRelationship>General interest</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Publication</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PUB</HighestPatStatusIdForCnty><Indication id="97">Diabetes mellitus</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA7191557">WO-2012162561</Patent><Status id="PUB">First Publication</Status><StatusDate>2012-11-29 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="112">Endocrine disease</TherapyArea></Row><Row><Action id="511">TNF antagonist</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="WO">World</Country><Drug id="71794">adalimumab + anti-Ang2 Zybody (inflammatory disease), Zyngenia</Drug><DrugRelationship>General interest</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Publication</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PUB</HighestPatStatusIdForCnty><Indication id="188">Inflammatory disease</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA7191557">WO-2012162561</Patent><Status id="PUB">First Publication</Status><StatusDate>2012-11-29 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="188">Inflammatory disease</TherapyArea></Row><Row><Action id="511">TNF antagonist</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="WO">World</Country><Drug id="71794">adalimumab + anti-Ang2 Zybody (inflammatory disease), Zyngenia</Drug><DrugRelationship>General interest</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Publication</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PUB</HighestPatStatusIdForCnty><Indication id="189">Inflammatory bowel disease</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA7191557">WO-2012162561</Patent><Status id="PUB">First Publication</Status><StatusDate>2012-11-29 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="188">Inflammatory disease</TherapyArea></Row><Row><Action id="511">TNF antagonist</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="WO">World</Country><Drug id="71794">adalimumab + anti-Ang2 Zybody (inflammatory disease), Zyngenia</Drug><DrugRelationship>General interest</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Publication</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PUB</HighestPatStatusIdForCnty><Indication id="213">Multiple sclerosis</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA7191557">WO-2012162561</Patent><Status id="PUB">First Publication</Status><StatusDate>2012-11-29 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="185">Immune disorder</TherapyArea></Row><Row><Action id="511">TNF antagonist</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="WO">World</Country><Drug id="71794">adalimumab + anti-Ang2 Zybody (inflammatory disease), Zyngenia</Drug><DrugRelationship>General interest</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Publication</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PUB</HighestPatStatusIdForCnty><Indication id="281">Psoriasis</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA7191557">WO-2012162561</Patent><Status id="PUB">First Publication</Status><StatusDate>2012-11-29 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="95">Dermatological disease</TherapyArea></Row><Row><Action id="511">TNF antagonist</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="WO">World</Country><Drug id="71794">adalimumab + anti-Ang2 Zybody (inflammatory disease), Zyngenia</Drug><DrugRelationship>General interest</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Publication</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PUB</HighestPatStatusIdForCnty><Indication id="291">Rheumatoid arthritis</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA7191557">WO-2012162561</Patent><Status id="PUB">First Publication</Status><StatusDate>2012-11-29 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="185">Immune disorder</TherapyArea></Row><Row><Action id="511">TNF antagonist</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="WO">World</Country><Drug id="71794">adalimumab + anti-Ang2 Zybody (inflammatory disease), Zyngenia</Drug><DrugRelationship>General interest</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Publication</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PUB</HighestPatStatusIdForCnty><Indication id="318">Systemic lupus erythematosus</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA7191557">WO-2012162561</Patent><Status id="PUB">First Publication</Status><StatusDate>2012-11-29 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="95">Dermatological disease</TherapyArea></Row><Row><Action id="511">TNF antagonist</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="WO">World</Country><Drug id="71794">adalimumab + anti-Ang2 Zybody (inflammatory disease), Zyngenia</Drug><DrugRelationship>General interest</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Publication</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PUB</HighestPatStatusIdForCnty><Indication id="337">Ulcerative colitis</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA7191557">WO-2012162561</Patent><Status id="PUB">First Publication</Status><StatusDate>2012-11-29 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="185">Immune disorder</TherapyArea></Row><Row><Action id="511">TNF antagonist</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="WO">World</Country><Drug id="71794">adalimumab + anti-Ang2 Zybody (inflammatory disease), Zyngenia</Drug><DrugRelationship>General interest</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Publication</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PUB</HighestPatStatusIdForCnty><Indication id="651">Cancer</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA7191557">WO-2012162561</Patent><Status id="PUB">First Publication</Status><StatusDate>2012-11-29 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="230">Neoplasm</TherapyArea></Row><Row><Action id="511">TNF antagonist</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="WO">World</Country><Drug id="71794">adalimumab + anti-Ang2 Zybody (inflammatory disease), Zyngenia</Drug><DrugRelationship>General interest</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Publication</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PUB</HighestPatStatusIdForCnty><Indication id="746">Infectious disease</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA7191557">WO-2012162561</Patent><Status id="PUB">First Publication</Status><StatusDate>2012-11-29 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="746">Infectious disease</TherapyArea></Row><Row><Action id="511">TNF antagonist</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="WO">World</Country><Drug id="71794">adalimumab + anti-Ang2 Zybody (inflammatory disease), Zyngenia</Drug><DrugRelationship>General interest</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Publication</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PUB</HighestPatStatusIdForCnty><Indication id="84">Crohns disease</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA7191557">WO-2012162561</Patent><Status id="PUB">First Publication</Status><StatusDate>2012-11-29 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="185">Immune disorder</TherapyArea></Row><Row><Action id="511">TNF antagonist</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="WO">World</Country><Drug id="71794">adalimumab + anti-Ang2 Zybody (inflammatory disease), Zyngenia</Drug><DrugRelationship>General interest</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Publication</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PUB</HighestPatStatusIdForCnty><Indication id="97">Diabetes mellitus</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA7191557">WO-2012162561</Patent><Status id="PUB">First Publication</Status><StatusDate>2012-11-29 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="112">Endocrine disease</TherapyArea></Row><Row><Action id="675">Hepatocyte growth factor receptor antagonist</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="WO">World</Country><Drug id="71794">adalimumab + anti-Ang2 Zybody (inflammatory disease), Zyngenia</Drug><DrugRelationship>General interest</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Publication</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PUB</HighestPatStatusIdForCnty><Indication id="188">Inflammatory disease</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA7191557">WO-2012162561</Patent><Status id="PUB">First Publication</Status><StatusDate>2012-11-29 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="188">Inflammatory disease</TherapyArea></Row><Row><Action id="675">Hepatocyte growth factor receptor antagonist</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="WO">World</Country><Drug id="71794">adalimumab + anti-Ang2 Zybody (inflammatory disease), Zyngenia</Drug><DrugRelationship>General interest</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Publication</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PUB</HighestPatStatusIdForCnty><Indication id="189">Inflammatory bowel disease</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA7191557">WO-2012162561</Patent><Status id="PUB">First Publication</Status><StatusDate>2012-11-29 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="188">Inflammatory disease</TherapyArea></Row><Row><Action id="675">Hepatocyte growth factor receptor antagonist</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="WO">World</Country><Drug id="71794">adalimumab + anti-Ang2 Zybody (inflammatory disease), Zyngenia</Drug><DrugRelationship>General interest</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Publication</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PUB</HighestPatStatusIdForCnty><Indication id="213">Multiple sclerosis</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA7191557">WO-2012162561</Patent><Status id="PUB">First Publication</Status><StatusDate>2012-11-29 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="185">Immune disorder</TherapyArea></Row><Row><Action id="675">Hepatocyte growth factor receptor antagonist</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="WO">World</Country><Drug id="71794">adalimumab + anti-Ang2 Zybody (inflammatory disease), Zyngenia</Drug><DrugRelationship>General interest</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Publication</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PUB</HighestPatStatusIdForCnty><Indication id="281">Psoriasis</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA7191557">WO-2012162561</Patent><Status id="PUB">First Publication</Status><StatusDate>2012-11-29 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="95">Dermatological disease</TherapyArea></Row><Row><Action id="675">Hepatocyte growth factor receptor antagonist</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="WO">World</Country><Drug id="71794">adalimumab + anti-Ang2 Zybody (inflammatory disease), Zyngenia</Drug><DrugRelationship>General interest</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Publication</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PUB</HighestPatStatusIdForCnty><Indication id="291">Rheumatoid arthritis</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA7191557">WO-2012162561</Patent><Status id="PUB">First Publication</Status><StatusDate>2012-11-29 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="185">Immune disorder</TherapyArea></Row><Row><Action id="675">Hepatocyte growth factor receptor antagonist</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="WO">World</Country><Drug id="71794">adalimumab + anti-Ang2 Zybody (inflammatory disease), Zyngenia</Drug><DrugRelationship>General interest</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Publication</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PUB</HighestPatStatusIdForCnty><Indication id="318">Systemic lupus erythematosus</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA7191557">WO-2012162561</Patent><Status id="PUB">First Publication</Status><StatusDate>2012-11-29 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="95">Dermatological disease</TherapyArea></Row><Row><Action id="675">Hepatocyte growth factor receptor antagonist</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="WO">World</Country><Drug id="71794">adalimumab + anti-Ang2 Zybody (inflammatory disease), Zyngenia</Drug><DrugRelationship>General interest</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Publication</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PUB</HighestPatStatusIdForCnty><Indication id="337">Ulcerative colitis</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA7191557">WO-2012162561</Patent><Status id="PUB">First Publication</Status><StatusDate>2012-11-29 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="185">Immune disorder</TherapyArea></Row><Row><Action id="675">Hepatocyte growth factor receptor antagonist</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="WO">World</Country><Drug id="71794">adalimumab + anti-Ang2 Zybody (inflammatory disease), Zyngenia</Drug><DrugRelationship>General interest</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Publication</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PUB</HighestPatStatusIdForCnty><Indication id="651">Cancer</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA7191557">WO-2012162561</Patent><Status id="PUB">First Publication</Status><StatusDate>2012-11-29 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="230">Neoplasm</TherapyArea></Row><Row><Action id="675">Hepatocyte growth factor receptor antagonist</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="WO">World</Country><Drug id="71794">adalimumab + anti-Ang2 Zybody (inflammatory disease), Zyngenia</Drug><DrugRelationship>General interest</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Publication</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PUB</HighestPatStatusIdForCnty><Indication id="746">Infectious disease</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA7191557">WO-2012162561</Patent><Status id="PUB">First Publication</Status><StatusDate>2012-11-29 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="746">Infectious disease</TherapyArea></Row><Row><Action id="675">Hepatocyte growth factor receptor antagonist</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="WO">World</Country><Drug id="71794">adalimumab + anti-Ang2 Zybody (inflammatory disease), Zyngenia</Drug><DrugRelationship>General interest</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Publication</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PUB</HighestPatStatusIdForCnty><Indication id="84">Crohns disease</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA7191557">WO-2012162561</Patent><Status id="PUB">First Publication</Status><StatusDate>2012-11-29 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="185">Immune disorder</TherapyArea></Row><Row><Action id="675">Hepatocyte growth factor receptor antagonist</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="WO">World</Country><Drug id="71794">adalimumab + anti-Ang2 Zybody (inflammatory disease), Zyngenia</Drug><DrugRelationship>General interest</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Publication</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PUB</HighestPatStatusIdForCnty><Indication id="97">Diabetes mellitus</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA7191557">WO-2012162561</Patent><Status id="PUB">First Publication</Status><StatusDate>2012-11-29 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="112">Endocrine disease</TherapyArea></Row><Row><Action id="740">Epidermal growth factor receptor antagonist</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="WO">World</Country><Drug id="71794">adalimumab + anti-Ang2 Zybody (inflammatory disease), Zyngenia</Drug><DrugRelationship>General interest</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Publication</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PUB</HighestPatStatusIdForCnty><Indication id="188">Inflammatory disease</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA7191557">WO-2012162561</Patent><Status id="PUB">First Publication</Status><StatusDate>2012-11-29 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="188">Inflammatory disease</TherapyArea></Row><Row><Action id="740">Epidermal growth factor receptor antagonist</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="WO">World</Country><Drug id="71794">adalimumab + anti-Ang2 Zybody (inflammatory disease), Zyngenia</Drug><DrugRelationship>General interest</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Publication</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PUB</HighestPatStatusIdForCnty><Indication id="189">Inflammatory bowel disease</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA7191557">WO-2012162561</Patent><Status id="PUB">First Publication</Status><StatusDate>2012-11-29 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="188">Inflammatory disease</TherapyArea></Row><Row><Action id="740">Epidermal growth factor receptor antagonist</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="WO">World</Country><Drug id="71794">adalimumab + anti-Ang2 Zybody (inflammatory disease), Zyngenia</Drug><DrugRelationship>General interest</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Publication</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PUB</HighestPatStatusIdForCnty><Indication id="213">Multiple sclerosis</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA7191557">WO-2012162561</Patent><Status id="PUB">First Publication</Status><StatusDate>2012-11-29 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="185">Immune disorder</TherapyArea></Row><Row><Action id="740">Epidermal growth factor receptor antagonist</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="WO">World</Country><Drug id="71794">adalimumab + anti-Ang2 Zybody (inflammatory disease), Zyngenia</Drug><DrugRelationship>General interest</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Publication</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PUB</HighestPatStatusIdForCnty><Indication id="281">Psoriasis</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA7191557">WO-2012162561</Patent><Status id="PUB">First Publication</Status><StatusDate>2012-11-29 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="95">Dermatological disease</TherapyArea></Row><Row><Action id="740">Epidermal growth factor receptor antagonist</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="WO">World</Country><Drug id="71794">adalimumab + anti-Ang2 Zybody (inflammatory disease), Zyngenia</Drug><DrugRelationship>General interest</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Publication</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PUB</HighestPatStatusIdForCnty><Indication id="291">Rheumatoid arthritis</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA7191557">WO-2012162561</Patent><Status id="PUB">First Publication</Status><StatusDate>2012-11-29 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="185">Immune disorder</TherapyArea></Row><Row><Action id="740">Epidermal growth factor receptor antagonist</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="WO">World</Country><Drug id="71794">adalimumab + anti-Ang2 Zybody (inflammatory disease), Zyngenia</Drug><DrugRelationship>General interest</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Publication</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PUB</HighestPatStatusIdForCnty><Indication id="318">Systemic lupus erythematosus</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA7191557">WO-2012162561</Patent><Status id="PUB">First Publication</Status><StatusDate>2012-11-29 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="95">Dermatological disease</TherapyArea></Row><Row><Action id="740">Epidermal growth factor receptor antagonist</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="WO">World</Country><Drug id="71794">adalimumab + anti-Ang2 Zybody (inflammatory disease), Zyngenia</Drug><DrugRelationship>General interest</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Publication</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PUB</HighestPatStatusIdForCnty><Indication id="337">Ulcerative colitis</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA7191557">WO-2012162561</Patent><Status id="PUB">First Publication</Status><StatusDate>2012-11-29 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="185">Immune disorder</TherapyArea></Row><Row><Action id="740">Epidermal growth factor receptor antagonist</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="WO">World</Country><Drug id="71794">adalimumab + anti-Ang2 Zybody (inflammatory disease), Zyngenia</Drug><DrugRelationship>General interest</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Publication</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PUB</HighestPatStatusIdForCnty><Indication id="651">Cancer</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA7191557">WO-2012162561</Patent><Status id="PUB">First Publication</Status><StatusDate>2012-11-29 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="230">Neoplasm</TherapyArea></Row><Row><Action id="740">Epidermal growth factor receptor antagonist</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="WO">World</Country><Drug id="71794">adalimumab + anti-Ang2 Zybody (inflammatory disease), Zyngenia</Drug><DrugRelationship>General interest</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Publication</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PUB</HighestPatStatusIdForCnty><Indication id="746">Infectious disease</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA7191557">WO-2012162561</Patent><Status id="PUB">First Publication</Status><StatusDate>2012-11-29 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="746">Infectious disease</TherapyArea></Row><Row><Action id="740">Epidermal growth factor receptor antagonist</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="WO">World</Country><Drug id="71794">adalimumab + anti-Ang2 Zybody (inflammatory disease), Zyngenia</Drug><DrugRelationship>General interest</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Publication</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PUB</HighestPatStatusIdForCnty><Indication id="84">Crohns disease</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA7191557">WO-2012162561</Patent><Status id="PUB">First Publication</Status><StatusDate>2012-11-29 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="185">Immune disorder</TherapyArea></Row><Row><Action id="740">Epidermal growth factor receptor antagonist</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="WO">World</Country><Drug id="71794">adalimumab + anti-Ang2 Zybody (inflammatory disease), Zyngenia</Drug><DrugRelationship>General interest</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Publication</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PUB</HighestPatStatusIdForCnty><Indication id="97">Diabetes mellitus</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA7191557">WO-2012162561</Patent><Status id="PUB">First Publication</Status><StatusDate>2012-11-29 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="112">Endocrine disease</TherapyArea></Row><Row><Action id="12521">VEGF ligand inhibitor</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="WO">World</Country><Drug id="71795">anti-Her-2/anti-Ang2 mAb (cancer), Zyngenia</Drug><DrugRelationship>General interest</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Publication</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PUB</HighestPatStatusIdForCnty><Indication id="188">Inflammatory disease</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA7191557">WO-2012162561</Patent><Status id="PUB">First Publication</Status><StatusDate>2012-11-29 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="188">Inflammatory disease</TherapyArea></Row><Row><Action id="12521">VEGF ligand inhibitor</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="WO">World</Country><Drug id="71795">anti-Her-2/anti-Ang2 mAb (cancer), Zyngenia</Drug><DrugRelationship>General interest</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Publication</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PUB</HighestPatStatusIdForCnty><Indication id="189">Inflammatory bowel disease</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA7191557">WO-2012162561</Patent><Status id="PUB">First Publication</Status><StatusDate>2012-11-29 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="188">Inflammatory disease</TherapyArea></Row><Row><Action id="12521">VEGF ligand inhibitor</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="WO">World</Country><Drug id="71795">anti-Her-2/anti-Ang2 mAb (cancer), Zyngenia</Drug><DrugRelationship>General interest</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Publication</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PUB</HighestPatStatusIdForCnty><Indication id="213">Multiple sclerosis</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA7191557">WO-2012162561</Patent><Status id="PUB">First Publication</Status><StatusDate>2012-11-29 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="185">Immune disorder</TherapyArea></Row><Row><Action id="12521">VEGF ligand inhibitor</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="WO">World</Country><Drug id="71795">anti-Her-2/anti-Ang2 mAb (cancer), Zyngenia</Drug><DrugRelationship>General interest</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Publication</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PUB</HighestPatStatusIdForCnty><Indication id="281">Psoriasis</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA7191557">WO-2012162561</Patent><Status id="PUB">First Publication</Status><StatusDate>2012-11-29 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="95">Dermatological disease</TherapyArea></Row><Row><Action id="12521">VEGF ligand inhibitor</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="WO">World</Country><Drug id="71795">anti-Her-2/anti-Ang2 mAb (cancer), Zyngenia</Drug><DrugRelationship>General interest</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Publication</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PUB</HighestPatStatusIdForCnty><Indication id="291">Rheumatoid arthritis</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA7191557">WO-2012162561</Patent><Status id="PUB">First Publication</Status><StatusDate>2012-11-29 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="185">Immune disorder</TherapyArea></Row><Row><Action id="12521">VEGF ligand inhibitor</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="WO">World</Country><Drug id="71795">anti-Her-2/anti-Ang2 mAb (cancer), Zyngenia</Drug><DrugRelationship>General interest</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Publication</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PUB</HighestPatStatusIdForCnty><Indication id="318">Systemic lupus erythematosus</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA7191557">WO-2012162561</Patent><Status id="PUB">First Publication</Status><StatusDate>2012-11-29 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="95">Dermatological disease</TherapyArea></Row><Row><Action id="12521">VEGF ligand inhibitor</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="WO">World</Country><Drug id="71795">anti-Her-2/anti-Ang2 mAb (cancer), Zyngenia</Drug><DrugRelationship>General interest</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Publication</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PUB</HighestPatStatusIdForCnty><Indication id="337">Ulcerative colitis</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA7191557">WO-2012162561</Patent><Status id="PUB">First Publication</Status><StatusDate>2012-11-29 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="185">Immune disorder</TherapyArea></Row><Row><Action id="12521">VEGF ligand inhibitor</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="WO">World</Country><Drug id="71795">anti-Her-2/anti-Ang2 mAb (cancer), Zyngenia</Drug><DrugRelationship>General interest</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Publication</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PUB</HighestPatStatusIdForCnty><Indication id="651">Cancer</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA7191557">WO-2012162561</Patent><Status id="PUB">First Publication</Status><StatusDate>2012-11-29 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="230">Neoplasm</TherapyArea></Row><Row><Action id="12521">VEGF ligand inhibitor</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="WO">World</Country><Drug id="71795">anti-Her-2/anti-Ang2 mAb (cancer), Zyngenia</Drug><DrugRelationship>General interest</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Publication</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PUB</HighestPatStatusIdForCnty><Indication id="746">Infectious disease</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA7191557">WO-2012162561</Patent><Status id="PUB">First Publication</Status><StatusDate>2012-11-29 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="746">Infectious disease</TherapyArea></Row><Row><Action id="12521">VEGF ligand inhibitor</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="WO">World</Country><Drug id="71795">anti-Her-2/anti-Ang2 mAb (cancer), Zyngenia</Drug><DrugRelationship>General interest</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Publication</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PUB</HighestPatStatusIdForCnty><Indication id="84">Crohns disease</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA7191557">WO-2012162561</Patent><Status id="PUB">First Publication</Status><StatusDate>2012-11-29 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="185">Immune disorder</TherapyArea></Row><Row><Action id="12521">VEGF ligand inhibitor</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="WO">World</Country><Drug id="71795">anti-Her-2/anti-Ang2 mAb (cancer), Zyngenia</Drug><DrugRelationship>General interest</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Publication</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PUB</HighestPatStatusIdForCnty><Indication id="97">Diabetes mellitus</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA7191557">WO-2012162561</Patent><Status id="PUB">First Publication</Status><StatusDate>2012-11-29 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="112">Endocrine disease</TherapyArea></Row><Row><Action id="3252">Insulin-like growth factor 1 receptor antagonist</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="WO">World</Country><Drug id="71795">anti-Her-2/anti-Ang2 mAb (cancer), Zyngenia</Drug><DrugRelationship>General interest</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Publication</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PUB</HighestPatStatusIdForCnty><Indication id="188">Inflammatory disease</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA7191557">WO-2012162561</Patent><Status id="PUB">First Publication</Status><StatusDate>2012-11-29 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="188">Inflammatory disease</TherapyArea></Row><Row><Action id="3252">Insulin-like growth factor 1 receptor antagonist</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="WO">World</Country><Drug id="71795">anti-Her-2/anti-Ang2 mAb (cancer), Zyngenia</Drug><DrugRelationship>General interest</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Publication</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PUB</HighestPatStatusIdForCnty><Indication id="189">Inflammatory bowel disease</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA7191557">WO-2012162561</Patent><Status id="PUB">First Publication</Status><StatusDate>2012-11-29 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="188">Inflammatory disease</TherapyArea></Row><Row><Action id="3252">Insulin-like growth factor 1 receptor antagonist</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="WO">World</Country><Drug id="71795">anti-Her-2/anti-Ang2 mAb (cancer), Zyngenia</Drug><DrugRelationship>General interest</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Publication</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PUB</HighestPatStatusIdForCnty><Indication id="213">Multiple sclerosis</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA7191557">WO-2012162561</Patent><Status id="PUB">First Publication</Status><StatusDate>2012-11-29 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="185">Immune disorder</TherapyArea></Row><Row><Action id="3252">Insulin-like growth factor 1 receptor antagonist</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="WO">World</Country><Drug id="71795">anti-Her-2/anti-Ang2 mAb (cancer), Zyngenia</Drug><DrugRelationship>General interest</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Publication</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PUB</HighestPatStatusIdForCnty><Indication id="281">Psoriasis</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA7191557">WO-2012162561</Patent><Status id="PUB">First Publication</Status><StatusDate>2012-11-29 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="95">Dermatological disease</TherapyArea></Row><Row><Action id="3252">Insulin-like growth factor 1 receptor antagonist</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="WO">World</Country><Drug id="71795">anti-Her-2/anti-Ang2 mAb (cancer), Zyngenia</Drug><DrugRelationship>General interest</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Publication</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PUB</HighestPatStatusIdForCnty><Indication id="291">Rheumatoid arthritis</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA7191557">WO-2012162561</Patent><Status id="PUB">First Publication</Status><StatusDate>2012-11-29 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="185">Immune disorder</TherapyArea></Row><Row><Action id="3252">Insulin-like growth factor 1 receptor antagonist</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="WO">World</Country><Drug id="71795">anti-Her-2/anti-Ang2 mAb (cancer), Zyngenia</Drug><DrugRelationship>General interest</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Publication</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PUB</HighestPatStatusIdForCnty><Indication id="318">Systemic lupus erythematosus</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA7191557">WO-2012162561</Patent><Status id="PUB">First Publication</Status><StatusDate>2012-11-29 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="95">Dermatological disease</TherapyArea></Row><Row><Action id="3252">Insulin-like growth factor 1 receptor antagonist</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="WO">World</Country><Drug id="71795">anti-Her-2/anti-Ang2 mAb (cancer), Zyngenia</Drug><DrugRelationship>General interest</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Publication</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PUB</HighestPatStatusIdForCnty><Indication id="337">Ulcerative colitis</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA7191557">WO-2012162561</Patent><Status id="PUB">First Publication</Status><StatusDate>2012-11-29 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="185">Immune disorder</TherapyArea></Row><Row><Action id="3252">Insulin-like growth factor 1 receptor antagonist</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="WO">World</Country><Drug id="71795">anti-Her-2/anti-Ang2 mAb (cancer), Zyngenia</Drug><DrugRelationship>General interest</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Publication</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PUB</HighestPatStatusIdForCnty><Indication id="651">Cancer</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA7191557">WO-2012162561</Patent><Status id="PUB">First Publication</Status><StatusDate>2012-11-29 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="230">Neoplasm</TherapyArea></Row><Row><Action id="3252">Insulin-like growth factor 1 receptor antagonist</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="WO">World</Country><Drug id="71795">anti-Her-2/anti-Ang2 mAb (cancer), Zyngenia</Drug><DrugRelationship>General interest</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Publication</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PUB</HighestPatStatusIdForCnty><Indication id="746">Infectious disease</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA7191557">WO-2012162561</Patent><Status id="PUB">First Publication</Status><StatusDate>2012-11-29 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="746">Infectious disease</TherapyArea></Row><Row><Action id="3252">Insulin-like growth factor 1 receptor antagonist</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="WO">World</Country><Drug id="71795">anti-Her-2/anti-Ang2 mAb (cancer), Zyngenia</Drug><DrugRelationship>General interest</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Publication</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PUB</HighestPatStatusIdForCnty><Indication id="84">Crohns disease</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA7191557">WO-2012162561</Patent><Status id="PUB">First Publication</Status><StatusDate>2012-11-29 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="185">Immune disorder</TherapyArea></Row><Row><Action id="3252">Insulin-like growth factor 1 receptor antagonist</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="WO">World</Country><Drug id="71795">anti-Her-2/anti-Ang2 mAb (cancer), Zyngenia</Drug><DrugRelationship>General interest</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Publication</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PUB</HighestPatStatusIdForCnty><Indication id="97">Diabetes mellitus</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA7191557">WO-2012162561</Patent><Status id="PUB">First Publication</Status><StatusDate>2012-11-29 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="112">Endocrine disease</TherapyArea></Row><Row><Action id="3682">FGF1 receptor antagonist</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="WO">World</Country><Drug id="71795">anti-Her-2/anti-Ang2 mAb (cancer), Zyngenia</Drug><DrugRelationship>General interest</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Publication</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PUB</HighestPatStatusIdForCnty><Indication id="188">Inflammatory disease</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA7191557">WO-2012162561</Patent><Status id="PUB">First Publication</Status><StatusDate>2012-11-29 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="188">Inflammatory disease</TherapyArea></Row><Row><Action id="3682">FGF1 receptor antagonist</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="WO">World</Country><Drug id="71795">anti-Her-2/anti-Ang2 mAb (cancer), Zyngenia</Drug><DrugRelationship>General interest</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Publication</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PUB</HighestPatStatusIdForCnty><Indication id="189">Inflammatory bowel disease</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA7191557">WO-2012162561</Patent><Status id="PUB">First Publication</Status><StatusDate>2012-11-29 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="188">Inflammatory disease</TherapyArea></Row><Row><Action id="3682">FGF1 receptor antagonist</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="WO">World</Country><Drug id="71795">anti-Her-2/anti-Ang2 mAb (cancer), Zyngenia</Drug><DrugRelationship>General interest</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Publication</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PUB</HighestPatStatusIdForCnty><Indication id="213">Multiple sclerosis</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA7191557">WO-2012162561</Patent><Status id="PUB">First Publication</Status><StatusDate>2012-11-29 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="185">Immune disorder</TherapyArea></Row><Row><Action id="3682">FGF1 receptor antagonist</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="WO">World</Country><Drug id="71795">anti-Her-2/anti-Ang2 mAb (cancer), Zyngenia</Drug><DrugRelationship>General interest</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Publication</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PUB</HighestPatStatusIdForCnty><Indication id="281">Psoriasis</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA7191557">WO-2012162561</Patent><Status id="PUB">First Publication</Status><StatusDate>2012-11-29 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="95">Dermatological disease</TherapyArea></Row><Row><Action id="3682">FGF1 receptor antagonist</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="WO">World</Country><Drug id="71795">anti-Her-2/anti-Ang2 mAb (cancer), Zyngenia</Drug><DrugRelationship>General interest</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Publication</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PUB</HighestPatStatusIdForCnty><Indication id="291">Rheumatoid arthritis</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA7191557">WO-2012162561</Patent><Status id="PUB">First Publication</Status><StatusDate>2012-11-29 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="185">Immune disorder</TherapyArea></Row><Row><Action id="3682">FGF1 receptor antagonist</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="WO">World</Country><Drug id="71795">anti-Her-2/anti-Ang2 mAb (cancer), Zyngenia</Drug><DrugRelationship>General interest</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Publication</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PUB</HighestPatStatusIdForCnty><Indication id="318">Systemic lupus erythematosus</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA7191557">WO-2012162561</Patent><Status id="PUB">First Publication</Status><StatusDate>2012-11-29 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="95">Dermatological disease</TherapyArea></Row><Row><Action id="3682">FGF1 receptor antagonist</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="WO">World</Country><Drug id="71795">anti-Her-2/anti-Ang2 mAb (cancer), Zyngenia</Drug><DrugRelationship>General interest</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Publication</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PUB</HighestPatStatusIdForCnty><Indication id="337">Ulcerative colitis</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA7191557">WO-2012162561</Patent><Status id="PUB">First Publication</Status><StatusDate>2012-11-29 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="185">Immune disorder</TherapyArea></Row><Row><Action id="3682">FGF1 receptor antagonist</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="WO">World</Country><Drug id="71795">anti-Her-2/anti-Ang2 mAb (cancer), Zyngenia</Drug><DrugRelationship>General interest</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Publication</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PUB</HighestPatStatusIdForCnty><Indication id="651">Cancer</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA7191557">WO-2012162561</Patent><Status id="PUB">First Publication</Status><StatusDate>2012-11-29 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="230">Neoplasm</TherapyArea></Row><Row><Action id="3682">FGF1 receptor antagonist</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="WO">World</Country><Drug id="71795">anti-Her-2/anti-Ang2 mAb (cancer), Zyngenia</Drug><DrugRelationship>General interest</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Publication</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PUB</HighestPatStatusIdForCnty><Indication id="746">Infectious disease</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA7191557">WO-2012162561</Patent><Status id="PUB">First Publication</Status><StatusDate>2012-11-29 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="746">Infectious disease</TherapyArea></Row><Row><Action id="3682">FGF1 receptor antagonist</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="WO">World</Country><Drug id="71795">anti-Her-2/anti-Ang2 mAb (cancer), Zyngenia</Drug><DrugRelationship>General interest</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Publication</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PUB</HighestPatStatusIdForCnty><Indication id="84">Crohns disease</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA7191557">WO-2012162561</Patent><Status id="PUB">First Publication</Status><StatusDate>2012-11-29 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="185">Immune disorder</TherapyArea></Row><Row><Action id="3682">FGF1 receptor antagonist</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="WO">World</Country><Drug id="71795">anti-Her-2/anti-Ang2 mAb (cancer), Zyngenia</Drug><DrugRelationship>General interest</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Publication</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PUB</HighestPatStatusIdForCnty><Indication id="97">Diabetes mellitus</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA7191557">WO-2012162561</Patent><Status id="PUB">First Publication</Status><StatusDate>2012-11-29 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="112">Endocrine disease</TherapyArea></Row><Row><Action id="3685">FGF2 receptor antagonist</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="WO">World</Country><Drug id="71795">anti-Her-2/anti-Ang2 mAb (cancer), Zyngenia</Drug><DrugRelationship>General interest</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Publication</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PUB</HighestPatStatusIdForCnty><Indication id="188">Inflammatory disease</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA7191557">WO-2012162561</Patent><Status id="PUB">First Publication</Status><StatusDate>2012-11-29 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="188">Inflammatory disease</TherapyArea></Row><Row><Action id="3685">FGF2 receptor antagonist</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="WO">World</Country><Drug id="71795">anti-Her-2/anti-Ang2 mAb (cancer), Zyngenia</Drug><DrugRelationship>General interest</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Publication</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PUB</HighestPatStatusIdForCnty><Indication id="189">Inflammatory bowel disease</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA7191557">WO-2012162561</Patent><Status id="PUB">First Publication</Status><StatusDate>2012-11-29 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="188">Inflammatory disease</TherapyArea></Row><Row><Action id="3685">FGF2 receptor antagonist</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="WO">World</Country><Drug id="71795">anti-Her-2/anti-Ang2 mAb (cancer), Zyngenia</Drug><DrugRelationship>General interest</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Publication</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PUB</HighestPatStatusIdForCnty><Indication id="213">Multiple sclerosis</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA7191557">WO-2012162561</Patent><Status id="PUB">First Publication</Status><StatusDate>2012-11-29 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="185">Immune disorder</TherapyArea></Row><Row><Action id="3685">FGF2 receptor antagonist</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="WO">World</Country><Drug id="71795">anti-Her-2/anti-Ang2 mAb (cancer), Zyngenia</Drug><DrugRelationship>General interest</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Publication</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PUB</HighestPatStatusIdForCnty><Indication id="281">Psoriasis</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA7191557">WO-2012162561</Patent><Status id="PUB">First Publication</Status><StatusDate>2012-11-29 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="95">Dermatological disease</TherapyArea></Row><Row><Action id="3685">FGF2 receptor antagonist</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="WO">World</Country><Drug id="71795">anti-Her-2/anti-Ang2 mAb (cancer), Zyngenia</Drug><DrugRelationship>General interest</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Publication</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PUB</HighestPatStatusIdForCnty><Indication id="291">Rheumatoid arthritis</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA7191557">WO-2012162561</Patent><Status id="PUB">First Publication</Status><StatusDate>2012-11-29 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="185">Immune disorder</TherapyArea></Row><Row><Action id="3685">FGF2 receptor antagonist</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="WO">World</Country><Drug id="71795">anti-Her-2/anti-Ang2 mAb (cancer), Zyngenia</Drug><DrugRelationship>General interest</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Publication</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PUB</HighestPatStatusIdForCnty><Indication id="318">Systemic lupus erythematosus</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA7191557">WO-2012162561</Patent><Status id="PUB">First Publication</Status><StatusDate>2012-11-29 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="95">Dermatological disease</TherapyArea></Row><Row><Action id="3685">FGF2 receptor antagonist</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="WO">World</Country><Drug id="71795">anti-Her-2/anti-Ang2 mAb (cancer), Zyngenia</Drug><DrugRelationship>General interest</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Publication</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PUB</HighestPatStatusIdForCnty><Indication id="337">Ulcerative colitis</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA7191557">WO-2012162561</Patent><Status id="PUB">First Publication</Status><StatusDate>2012-11-29 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="185">Immune disorder</TherapyArea></Row><Row><Action id="3685">FGF2 receptor antagonist</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="WO">World</Country><Drug id="71795">anti-Her-2/anti-Ang2 mAb (cancer), Zyngenia</Drug><DrugRelationship>General interest</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Publication</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PUB</HighestPatStatusIdForCnty><Indication id="651">Cancer</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA7191557">WO-2012162561</Patent><Status id="PUB">First Publication</Status><StatusDate>2012-11-29 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="230">Neoplasm</TherapyArea></Row><Row><Action id="3685">FGF2 receptor antagonist</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="WO">World</Country><Drug id="71795">anti-Her-2/anti-Ang2 mAb (cancer), Zyngenia</Drug><DrugRelationship>General interest</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Publication</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PUB</HighestPatStatusIdForCnty><Indication id="746">Infectious disease</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA7191557">WO-2012162561</Patent><Status id="PUB">First Publication</Status><StatusDate>2012-11-29 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="746">Infectious disease</TherapyArea></Row><Row><Action id="3685">FGF2 receptor antagonist</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="WO">World</Country><Drug id="71795">anti-Her-2/anti-Ang2 mAb (cancer), Zyngenia</Drug><DrugRelationship>General interest</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Publication</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PUB</HighestPatStatusIdForCnty><Indication id="84">Crohns disease</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA7191557">WO-2012162561</Patent><Status id="PUB">First Publication</Status><StatusDate>2012-11-29 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="185">Immune disorder</TherapyArea></Row><Row><Action id="3685">FGF2 receptor antagonist</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="WO">World</Country><Drug id="71795">anti-Her-2/anti-Ang2 mAb (cancer), Zyngenia</Drug><DrugRelationship>General interest</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Publication</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PUB</HighestPatStatusIdForCnty><Indication id="97">Diabetes mellitus</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA7191557">WO-2012162561</Patent><Status id="PUB">First Publication</Status><StatusDate>2012-11-29 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="112">Endocrine disease</TherapyArea></Row><Row><Action id="3756">Erbb2 tyrosine kinase receptor inhibitor</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="WO">World</Country><Drug id="71795">anti-Her-2/anti-Ang2 mAb (cancer), Zyngenia</Drug><DrugRelationship>General interest</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Publication</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PUB</HighestPatStatusIdForCnty><Indication id="188">Inflammatory disease</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA7191557">WO-2012162561</Patent><Status id="PUB">First Publication</Status><StatusDate>2012-11-29 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="188">Inflammatory disease</TherapyArea></Row><Row><Action id="3756">Erbb2 tyrosine kinase receptor inhibitor</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="WO">World</Country><Drug id="71795">anti-Her-2/anti-Ang2 mAb (cancer), Zyngenia</Drug><DrugRelationship>General interest</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Publication</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PUB</HighestPatStatusIdForCnty><Indication id="189">Inflammatory bowel disease</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA7191557">WO-2012162561</Patent><Status id="PUB">First Publication</Status><StatusDate>2012-11-29 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="188">Inflammatory disease</TherapyArea></Row><Row><Action id="3756">Erbb2 tyrosine kinase receptor inhibitor</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="WO">World</Country><Drug id="71795">anti-Her-2/anti-Ang2 mAb (cancer), Zyngenia</Drug><DrugRelationship>General interest</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Publication</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PUB</HighestPatStatusIdForCnty><Indication id="213">Multiple sclerosis</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA7191557">WO-2012162561</Patent><Status id="PUB">First Publication</Status><StatusDate>2012-11-29 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="185">Immune disorder</TherapyArea></Row><Row><Action id="3756">Erbb2 tyrosine kinase receptor inhibitor</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="WO">World</Country><Drug id="71795">anti-Her-2/anti-Ang2 mAb (cancer), Zyngenia</Drug><DrugRelationship>General interest</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Publication</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PUB</HighestPatStatusIdForCnty><Indication id="281">Psoriasis</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA7191557">WO-2012162561</Patent><Status id="PUB">First Publication</Status><StatusDate>2012-11-29 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="95">Dermatological disease</TherapyArea></Row><Row><Action id="3756">Erbb2 tyrosine kinase receptor inhibitor</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="WO">World</Country><Drug id="71795">anti-Her-2/anti-Ang2 mAb (cancer), Zyngenia</Drug><DrugRelationship>General interest</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Publication</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PUB</HighestPatStatusIdForCnty><Indication id="291">Rheumatoid arthritis</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA7191557">WO-2012162561</Patent><Status id="PUB">First Publication</Status><StatusDate>2012-11-29 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="185">Immune disorder</TherapyArea></Row><Row><Action id="3756">Erbb2 tyrosine kinase receptor inhibitor</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="WO">World</Country><Drug id="71795">anti-Her-2/anti-Ang2 mAb (cancer), Zyngenia</Drug><DrugRelationship>General interest</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Publication</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PUB</HighestPatStatusIdForCnty><Indication id="318">Systemic lupus erythematosus</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA7191557">WO-2012162561</Patent><Status id="PUB">First Publication</Status><StatusDate>2012-11-29 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="95">Dermatological disease</TherapyArea></Row><Row><Action id="3756">Erbb2 tyrosine kinase receptor inhibitor</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="WO">World</Country><Drug id="71795">anti-Her-2/anti-Ang2 mAb (cancer), Zyngenia</Drug><DrugRelationship>General interest</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Publication</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PUB</HighestPatStatusIdForCnty><Indication id="337">Ulcerative colitis</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA7191557">WO-2012162561</Patent><Status id="PUB">First Publication</Status><StatusDate>2012-11-29 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="185">Immune disorder</TherapyArea></Row><Row><Action id="3756">Erbb2 tyrosine kinase receptor inhibitor</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="WO">World</Country><Drug id="71795">anti-Her-2/anti-Ang2 mAb (cancer), Zyngenia</Drug><DrugRelationship>General interest</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Publication</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PUB</HighestPatStatusIdForCnty><Indication id="651">Cancer</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA7191557">WO-2012162561</Patent><Status id="PUB">First Publication</Status><StatusDate>2012-11-29 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="230">Neoplasm</TherapyArea></Row><Row><Action id="3756">Erbb2 tyrosine kinase receptor inhibitor</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="WO">World</Country><Drug id="71795">anti-Her-2/anti-Ang2 mAb (cancer), Zyngenia</Drug><DrugRelationship>General interest</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Publication</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PUB</HighestPatStatusIdForCnty><Indication id="746">Infectious disease</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA7191557">WO-2012162561</Patent><Status id="PUB">First Publication</Status><StatusDate>2012-11-29 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="746">Infectious disease</TherapyArea></Row><Row><Action id="3756">Erbb2 tyrosine kinase receptor inhibitor</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="WO">World</Country><Drug id="71795">anti-Her-2/anti-Ang2 mAb (cancer), Zyngenia</Drug><DrugRelationship>General interest</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Publication</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PUB</HighestPatStatusIdForCnty><Indication id="84">Crohns disease</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA7191557">WO-2012162561</Patent><Status id="PUB">First Publication</Status><StatusDate>2012-11-29 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="185">Immune disorder</TherapyArea></Row><Row><Action id="3756">Erbb2 tyrosine kinase receptor inhibitor</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="WO">World</Country><Drug id="71795">anti-Her-2/anti-Ang2 mAb (cancer), Zyngenia</Drug><DrugRelationship>General interest</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Publication</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PUB</HighestPatStatusIdForCnty><Indication id="97">Diabetes mellitus</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA7191557">WO-2012162561</Patent><Status id="PUB">First Publication</Status><StatusDate>2012-11-29 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="112">Endocrine disease</TherapyArea></Row><Row><Action id="3846">VEGF-1 receptor antagonist</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="WO">World</Country><Drug id="71795">anti-Her-2/anti-Ang2 mAb (cancer), Zyngenia</Drug><DrugRelationship>General interest</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Publication</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PUB</HighestPatStatusIdForCnty><Indication id="188">Inflammatory disease</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA7191557">WO-2012162561</Patent><Status id="PUB">First Publication</Status><StatusDate>2012-11-29 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="188">Inflammatory disease</TherapyArea></Row><Row><Action id="3846">VEGF-1 receptor antagonist</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="WO">World</Country><Drug id="71795">anti-Her-2/anti-Ang2 mAb (cancer), Zyngenia</Drug><DrugRelationship>General interest</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Publication</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PUB</HighestPatStatusIdForCnty><Indication id="189">Inflammatory bowel disease</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA7191557">WO-2012162561</Patent><Status id="PUB">First Publication</Status><StatusDate>2012-11-29 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="188">Inflammatory disease</TherapyArea></Row><Row><Action id="3846">VEGF-1 receptor antagonist</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="WO">World</Country><Drug id="71795">anti-Her-2/anti-Ang2 mAb (cancer), Zyngenia</Drug><DrugRelationship>General interest</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Publication</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PUB</HighestPatStatusIdForCnty><Indication id="213">Multiple sclerosis</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA7191557">WO-2012162561</Patent><Status id="PUB">First Publication</Status><StatusDate>2012-11-29 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="185">Immune disorder</TherapyArea></Row><Row><Action id="3846">VEGF-1 receptor antagonist</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="WO">World</Country><Drug id="71795">anti-Her-2/anti-Ang2 mAb (cancer), Zyngenia</Drug><DrugRelationship>General interest</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Publication</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PUB</HighestPatStatusIdForCnty><Indication id="281">Psoriasis</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA7191557">WO-2012162561</Patent><Status id="PUB">First Publication</Status><StatusDate>2012-11-29 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="95">Dermatological disease</TherapyArea></Row><Row><Action id="3846">VEGF-1 receptor antagonist</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="WO">World</Country><Drug id="71795">anti-Her-2/anti-Ang2 mAb (cancer), Zyngenia</Drug><DrugRelationship>General interest</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Publication</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PUB</HighestPatStatusIdForCnty><Indication id="291">Rheumatoid arthritis</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA7191557">WO-2012162561</Patent><Status id="PUB">First Publication</Status><StatusDate>2012-11-29 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="185">Immune disorder</TherapyArea></Row><Row><Action id="3846">VEGF-1 receptor antagonist</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="WO">World</Country><Drug id="71795">anti-Her-2/anti-Ang2 mAb (cancer), Zyngenia</Drug><DrugRelationship>General interest</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Publication</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PUB</HighestPatStatusIdForCnty><Indication id="318">Systemic lupus erythematosus</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA7191557">WO-2012162561</Patent><Status id="PUB">First Publication</Status><StatusDate>2012-11-29 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="95">Dermatological disease</TherapyArea></Row><Row><Action id="3846">VEGF-1 receptor antagonist</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="WO">World</Country><Drug id="71795">anti-Her-2/anti-Ang2 mAb (cancer), Zyngenia</Drug><DrugRelationship>General interest</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Publication</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PUB</HighestPatStatusIdForCnty><Indication id="337">Ulcerative colitis</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA7191557">WO-2012162561</Patent><Status id="PUB">First Publication</Status><StatusDate>2012-11-29 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="185">Immune disorder</TherapyArea></Row><Row><Action id="3846">VEGF-1 receptor antagonist</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="WO">World</Country><Drug id="71795">anti-Her-2/anti-Ang2 mAb (cancer), Zyngenia</Drug><DrugRelationship>General interest</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Publication</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PUB</HighestPatStatusIdForCnty><Indication id="651">Cancer</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA7191557">WO-2012162561</Patent><Status id="PUB">First Publication</Status><StatusDate>2012-11-29 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="230">Neoplasm</TherapyArea></Row><Row><Action id="3846">VEGF-1 receptor antagonist</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="WO">World</Country><Drug id="71795">anti-Her-2/anti-Ang2 mAb (cancer), Zyngenia</Drug><DrugRelationship>General interest</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Publication</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PUB</HighestPatStatusIdForCnty><Indication id="746">Infectious disease</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA7191557">WO-2012162561</Patent><Status id="PUB">First Publication</Status><StatusDate>2012-11-29 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="746">Infectious disease</TherapyArea></Row><Row><Action id="3846">VEGF-1 receptor antagonist</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="WO">World</Country><Drug id="71795">anti-Her-2/anti-Ang2 mAb (cancer), Zyngenia</Drug><DrugRelationship>General interest</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Publication</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PUB</HighestPatStatusIdForCnty><Indication id="84">Crohns disease</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA7191557">WO-2012162561</Patent><Status id="PUB">First Publication</Status><StatusDate>2012-11-29 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="185">Immune disorder</TherapyArea></Row><Row><Action id="3846">VEGF-1 receptor antagonist</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="WO">World</Country><Drug id="71795">anti-Her-2/anti-Ang2 mAb (cancer), Zyngenia</Drug><DrugRelationship>General interest</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Publication</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PUB</HighestPatStatusIdForCnty><Indication id="97">Diabetes mellitus</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA7191557">WO-2012162561</Patent><Status id="PUB">First Publication</Status><StatusDate>2012-11-29 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="112">Endocrine disease</TherapyArea></Row><Row><Action id="5025">CD3 antagonist</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="WO">World</Country><Drug id="71795">anti-Her-2/anti-Ang2 mAb (cancer), Zyngenia</Drug><DrugRelationship>General interest</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Publication</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PUB</HighestPatStatusIdForCnty><Indication id="188">Inflammatory disease</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA7191557">WO-2012162561</Patent><Status id="PUB">First Publication</Status><StatusDate>2012-11-29 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="188">Inflammatory disease</TherapyArea></Row><Row><Action id="5025">CD3 antagonist</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="WO">World</Country><Drug id="71795">anti-Her-2/anti-Ang2 mAb (cancer), Zyngenia</Drug><DrugRelationship>General interest</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Publication</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PUB</HighestPatStatusIdForCnty><Indication id="189">Inflammatory bowel disease</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA7191557">WO-2012162561</Patent><Status id="PUB">First Publication</Status><StatusDate>2012-11-29 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="188">Inflammatory disease</TherapyArea></Row><Row><Action id="5025">CD3 antagonist</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="WO">World</Country><Drug id="71795">anti-Her-2/anti-Ang2 mAb (cancer), Zyngenia</Drug><DrugRelationship>General interest</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Publication</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PUB</HighestPatStatusIdForCnty><Indication id="213">Multiple sclerosis</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA7191557">WO-2012162561</Patent><Status id="PUB">First Publication</Status><StatusDate>2012-11-29 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="185">Immune disorder</TherapyArea></Row><Row><Action id="5025">CD3 antagonist</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="WO">World</Country><Drug id="71795">anti-Her-2/anti-Ang2 mAb (cancer), Zyngenia</Drug><DrugRelationship>General interest</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Publication</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PUB</HighestPatStatusIdForCnty><Indication id="281">Psoriasis</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA7191557">WO-2012162561</Patent><Status id="PUB">First Publication</Status><StatusDate>2012-11-29 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="95">Dermatological disease</TherapyArea></Row><Row><Action id="5025">CD3 antagonist</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="WO">World</Country><Drug id="71795">anti-Her-2/anti-Ang2 mAb (cancer), Zyngenia</Drug><DrugRelationship>General interest</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Publication</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PUB</HighestPatStatusIdForCnty><Indication id="291">Rheumatoid arthritis</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA7191557">WO-2012162561</Patent><Status id="PUB">First Publication</Status><StatusDate>2012-11-29 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="185">Immune disorder</TherapyArea></Row><Row><Action id="5025">CD3 antagonist</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="WO">World</Country><Drug id="71795">anti-Her-2/anti-Ang2 mAb (cancer), Zyngenia</Drug><DrugRelationship>General interest</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Publication</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PUB</HighestPatStatusIdForCnty><Indication id="318">Systemic lupus erythematosus</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA7191557">WO-2012162561</Patent><Status id="PUB">First Publication</Status><StatusDate>2012-11-29 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="95">Dermatological disease</TherapyArea></Row><Row><Action id="5025">CD3 antagonist</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="WO">World</Country><Drug id="71795">anti-Her-2/anti-Ang2 mAb (cancer), Zyngenia</Drug><DrugRelationship>General interest</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Publication</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PUB</HighestPatStatusIdForCnty><Indication id="337">Ulcerative colitis</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA7191557">WO-2012162561</Patent><Status id="PUB">First Publication</Status><StatusDate>2012-11-29 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="185">Immune disorder</TherapyArea></Row><Row><Action id="5025">CD3 antagonist</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="WO">World</Country><Drug id="71795">anti-Her-2/anti-Ang2 mAb (cancer), Zyngenia</Drug><DrugRelationship>General interest</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Publication</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PUB</HighestPatStatusIdForCnty><Indication id="651">Cancer</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA7191557">WO-2012162561</Patent><Status id="PUB">First Publication</Status><StatusDate>2012-11-29 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="230">Neoplasm</TherapyArea></Row><Row><Action id="5025">CD3 antagonist</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="WO">World</Country><Drug id="71795">anti-Her-2/anti-Ang2 mAb (cancer), Zyngenia</Drug><DrugRelationship>General interest</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Publication</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PUB</HighestPatStatusIdForCnty><Indication id="746">Infectious disease</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA7191557">WO-2012162561</Patent><Status id="PUB">First Publication</Status><StatusDate>2012-11-29 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="746">Infectious disease</TherapyArea></Row><Row><Action id="5025">CD3 antagonist</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="WO">World</Country><Drug id="71795">anti-Her-2/anti-Ang2 mAb (cancer), Zyngenia</Drug><DrugRelationship>General interest</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Publication</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PUB</HighestPatStatusIdForCnty><Indication id="84">Crohns disease</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA7191557">WO-2012162561</Patent><Status id="PUB">First Publication</Status><StatusDate>2012-11-29 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="185">Immune disorder</TherapyArea></Row><Row><Action id="5025">CD3 antagonist</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="WO">World</Country><Drug id="71795">anti-Her-2/anti-Ang2 mAb (cancer), Zyngenia</Drug><DrugRelationship>General interest</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Publication</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PUB</HighestPatStatusIdForCnty><Indication id="97">Diabetes mellitus</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA7191557">WO-2012162561</Patent><Status id="PUB">First Publication</Status><StatusDate>2012-11-29 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="112">Endocrine disease</TherapyArea></Row><Row><Action id="5082">B-lymphocyte antigen CD19 inhibitor</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="WO">World</Country><Drug id="71795">anti-Her-2/anti-Ang2 mAb (cancer), Zyngenia</Drug><DrugRelationship>General interest</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Publication</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PUB</HighestPatStatusIdForCnty><Indication id="188">Inflammatory disease</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA7191557">WO-2012162561</Patent><Status id="PUB">First Publication</Status><StatusDate>2012-11-29 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="188">Inflammatory disease</TherapyArea></Row><Row><Action id="5082">B-lymphocyte antigen CD19 inhibitor</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="WO">World</Country><Drug id="71795">anti-Her-2/anti-Ang2 mAb (cancer), Zyngenia</Drug><DrugRelationship>General interest</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Publication</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PUB</HighestPatStatusIdForCnty><Indication id="189">Inflammatory bowel disease</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA7191557">WO-2012162561</Patent><Status id="PUB">First Publication</Status><StatusDate>2012-11-29 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="188">Inflammatory disease</TherapyArea></Row><Row><Action id="5082">B-lymphocyte antigen CD19 inhibitor</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="WO">World</Country><Drug id="71795">anti-Her-2/anti-Ang2 mAb (cancer), Zyngenia</Drug><DrugRelationship>General interest</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Publication</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PUB</HighestPatStatusIdForCnty><Indication id="213">Multiple sclerosis</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA7191557">WO-2012162561</Patent><Status id="PUB">First Publication</Status><StatusDate>2012-11-29 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="185">Immune disorder</TherapyArea></Row><Row><Action id="5082">B-lymphocyte antigen CD19 inhibitor</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="WO">World</Country><Drug id="71795">anti-Her-2/anti-Ang2 mAb (cancer), Zyngenia</Drug><DrugRelationship>General interest</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Publication</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PUB</HighestPatStatusIdForCnty><Indication id="281">Psoriasis</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA7191557">WO-2012162561</Patent><Status id="PUB">First Publication</Status><StatusDate>2012-11-29 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="95">Dermatological disease</TherapyArea></Row><Row><Action id="5082">B-lymphocyte antigen CD19 inhibitor</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="WO">World</Country><Drug id="71795">anti-Her-2/anti-Ang2 mAb (cancer), Zyngenia</Drug><DrugRelationship>General interest</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Publication</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PUB</HighestPatStatusIdForCnty><Indication id="291">Rheumatoid arthritis</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA7191557">WO-2012162561</Patent><Status id="PUB">First Publication</Status><StatusDate>2012-11-29 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="185">Immune disorder</TherapyArea></Row><Row><Action id="5082">B-lymphocyte antigen CD19 inhibitor</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="WO">World</Country><Drug id="71795">anti-Her-2/anti-Ang2 mAb (cancer), Zyngenia</Drug><DrugRelationship>General interest</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Publication</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PUB</HighestPatStatusIdForCnty><Indication id="318">Systemic lupus erythematosus</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA7191557">WO-2012162561</Patent><Status id="PUB">First Publication</Status><StatusDate>2012-11-29 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="95">Dermatological disease</TherapyArea></Row><Row><Action id="5082">B-lymphocyte antigen CD19 inhibitor</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="WO">World</Country><Drug id="71795">anti-Her-2/anti-Ang2 mAb (cancer), Zyngenia</Drug><DrugRelationship>General interest</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Publication</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PUB</HighestPatStatusIdForCnty><Indication id="337">Ulcerative colitis</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA7191557">WO-2012162561</Patent><Status id="PUB">First Publication</Status><StatusDate>2012-11-29 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="185">Immune disorder</TherapyArea></Row><Row><Action id="5082">B-lymphocyte antigen CD19 inhibitor</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="WO">World</Country><Drug id="71795">anti-Her-2/anti-Ang2 mAb (cancer), Zyngenia</Drug><DrugRelationship>General interest</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Publication</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PUB</HighestPatStatusIdForCnty><Indication id="651">Cancer</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA7191557">WO-2012162561</Patent><Status id="PUB">First Publication</Status><StatusDate>2012-11-29 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="230">Neoplasm</TherapyArea></Row><Row><Action id="5082">B-lymphocyte antigen CD19 inhibitor</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="WO">World</Country><Drug id="71795">anti-Her-2/anti-Ang2 mAb (cancer), Zyngenia</Drug><DrugRelationship>General interest</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Publication</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PUB</HighestPatStatusIdForCnty><Indication id="746">Infectious disease</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA7191557">WO-2012162561</Patent><Status id="PUB">First Publication</Status><StatusDate>2012-11-29 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="746">Infectious disease</TherapyArea></Row><Row><Action id="5082">B-lymphocyte antigen CD19 inhibitor</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="WO">World</Country><Drug id="71795">anti-Her-2/anti-Ang2 mAb (cancer), Zyngenia</Drug><DrugRelationship>General interest</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Publication</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PUB</HighestPatStatusIdForCnty><Indication id="84">Crohns disease</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA7191557">WO-2012162561</Patent><Status id="PUB">First Publication</Status><StatusDate>2012-11-29 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="185">Immune disorder</TherapyArea></Row><Row><Action id="5082">B-lymphocyte antigen CD19 inhibitor</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="WO">World</Country><Drug id="71795">anti-Her-2/anti-Ang2 mAb (cancer), Zyngenia</Drug><DrugRelationship>General interest</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Publication</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PUB</HighestPatStatusIdForCnty><Indication id="97">Diabetes mellitus</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA7191557">WO-2012162561</Patent><Status id="PUB">First Publication</Status><StatusDate>2012-11-29 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="112">Endocrine disease</TherapyArea></Row><Row><Action id="5085">B-lymphocyte antigen CD20 inhibitor</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="WO">World</Country><Drug id="71795">anti-Her-2/anti-Ang2 mAb (cancer), Zyngenia</Drug><DrugRelationship>General interest</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Publication</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PUB</HighestPatStatusIdForCnty><Indication id="188">Inflammatory disease</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA7191557">WO-2012162561</Patent><Status id="PUB">First Publication</Status><StatusDate>2012-11-29 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="188">Inflammatory disease</TherapyArea></Row><Row><Action id="5085">B-lymphocyte antigen CD20 inhibitor</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="WO">World</Country><Drug id="71795">anti-Her-2/anti-Ang2 mAb (cancer), Zyngenia</Drug><DrugRelationship>General interest</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Publication</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PUB</HighestPatStatusIdForCnty><Indication id="189">Inflammatory bowel disease</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA7191557">WO-2012162561</Patent><Status id="PUB">First Publication</Status><StatusDate>2012-11-29 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="188">Inflammatory disease</TherapyArea></Row><Row><Action id="5085">B-lymphocyte antigen CD20 inhibitor</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="WO">World</Country><Drug id="71795">anti-Her-2/anti-Ang2 mAb (cancer), Zyngenia</Drug><DrugRelationship>General interest</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Publication</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PUB</HighestPatStatusIdForCnty><Indication id="213">Multiple sclerosis</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA7191557">WO-2012162561</Patent><Status id="PUB">First Publication</Status><StatusDate>2012-11-29 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="185">Immune disorder</TherapyArea></Row><Row><Action id="5085">B-lymphocyte antigen CD20 inhibitor</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="WO">World</Country><Drug id="71795">anti-Her-2/anti-Ang2 mAb (cancer), Zyngenia</Drug><DrugRelationship>General interest</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Publication</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PUB</HighestPatStatusIdForCnty><Indication id="281">Psoriasis</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA7191557">WO-2012162561</Patent><Status id="PUB">First Publication</Status><StatusDate>2012-11-29 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="95">Dermatological disease</TherapyArea></Row><Row><Action id="5085">B-lymphocyte antigen CD20 inhibitor</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="WO">World</Country><Drug id="71795">anti-Her-2/anti-Ang2 mAb (cancer), Zyngenia</Drug><DrugRelationship>General interest</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Publication</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PUB</HighestPatStatusIdForCnty><Indication id="291">Rheumatoid arthritis</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA7191557">WO-2012162561</Patent><Status id="PUB">First Publication</Status><StatusDate>2012-11-29 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="185">Immune disorder</TherapyArea></Row><Row><Action id="5085">B-lymphocyte antigen CD20 inhibitor</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="WO">World</Country><Drug id="71795">anti-Her-2/anti-Ang2 mAb (cancer), Zyngenia</Drug><DrugRelationship>General interest</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Publication</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PUB</HighestPatStatusIdForCnty><Indication id="318">Systemic lupus erythematosus</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA7191557">WO-2012162561</Patent><Status id="PUB">First Publication</Status><StatusDate>2012-11-29 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="95">Dermatological disease</TherapyArea></Row><Row><Action id="5085">B-lymphocyte antigen CD20 inhibitor</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="WO">World</Country><Drug id="71795">anti-Her-2/anti-Ang2 mAb (cancer), Zyngenia</Drug><DrugRelationship>General interest</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Publication</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PUB</HighestPatStatusIdForCnty><Indication id="337">Ulcerative colitis</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA7191557">WO-2012162561</Patent><Status id="PUB">First Publication</Status><StatusDate>2012-11-29 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="185">Immune disorder</TherapyArea></Row><Row><Action id="5085">B-lymphocyte antigen CD20 inhibitor</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="WO">World</Country><Drug id="71795">anti-Her-2/anti-Ang2 mAb (cancer), Zyngenia</Drug><DrugRelationship>General interest</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Publication</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PUB</HighestPatStatusIdForCnty><Indication id="651">Cancer</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA7191557">WO-2012162561</Patent><Status id="PUB">First Publication</Status><StatusDate>2012-11-29 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="230">Neoplasm</TherapyArea></Row><Row><Action id="5085">B-lymphocyte antigen CD20 inhibitor</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="WO">World</Country><Drug id="71795">anti-Her-2/anti-Ang2 mAb (cancer), Zyngenia</Drug><DrugRelationship>General interest</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Publication</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PUB</HighestPatStatusIdForCnty><Indication id="746">Infectious disease</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA7191557">WO-2012162561</Patent><Status id="PUB">First Publication</Status><StatusDate>2012-11-29 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="746">Infectious disease</TherapyArea></Row><Row><Action id="5085">B-lymphocyte antigen CD20 inhibitor</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="WO">World</Country><Drug id="71795">anti-Her-2/anti-Ang2 mAb (cancer), Zyngenia</Drug><DrugRelationship>General interest</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Publication</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PUB</HighestPatStatusIdForCnty><Indication id="84">Crohns disease</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA7191557">WO-2012162561</Patent><Status id="PUB">First Publication</Status><StatusDate>2012-11-29 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="185">Immune disorder</TherapyArea></Row><Row><Action id="5085">B-lymphocyte antigen CD20 inhibitor</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="WO">World</Country><Drug id="71795">anti-Her-2/anti-Ang2 mAb (cancer), Zyngenia</Drug><DrugRelationship>General interest</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Publication</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PUB</HighestPatStatusIdForCnty><Indication id="97">Diabetes mellitus</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA7191557">WO-2012162561</Patent><Status id="PUB">First Publication</Status><StatusDate>2012-11-29 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="112">Endocrine disease</TherapyArea></Row><Row><Action id="511">TNF antagonist</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="WO">World</Country><Drug id="71795">anti-Her-2/anti-Ang2 mAb (cancer), Zyngenia</Drug><DrugRelationship>General interest</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Publication</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PUB</HighestPatStatusIdForCnty><Indication id="188">Inflammatory disease</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA7191557">WO-2012162561</Patent><Status id="PUB">First Publication</Status><StatusDate>2012-11-29 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="188">Inflammatory disease</TherapyArea></Row><Row><Action id="511">TNF antagonist</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="WO">World</Country><Drug id="71795">anti-Her-2/anti-Ang2 mAb (cancer), Zyngenia</Drug><DrugRelationship>General interest</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Publication</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PUB</HighestPatStatusIdForCnty><Indication id="189">Inflammatory bowel disease</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA7191557">WO-2012162561</Patent><Status id="PUB">First Publication</Status><StatusDate>2012-11-29 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="188">Inflammatory disease</TherapyArea></Row><Row><Action id="511">TNF antagonist</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="WO">World</Country><Drug id="71795">anti-Her-2/anti-Ang2 mAb (cancer), Zyngenia</Drug><DrugRelationship>General interest</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Publication</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PUB</HighestPatStatusIdForCnty><Indication id="213">Multiple sclerosis</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA7191557">WO-2012162561</Patent><Status id="PUB">First Publication</Status><StatusDate>2012-11-29 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="185">Immune disorder</TherapyArea></Row><Row><Action id="511">TNF antagonist</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="WO">World</Country><Drug id="71795">anti-Her-2/anti-Ang2 mAb (cancer), Zyngenia</Drug><DrugRelationship>General interest</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Publication</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PUB</HighestPatStatusIdForCnty><Indication id="281">Psoriasis</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA7191557">WO-2012162561</Patent><Status id="PUB">First Publication</Status><StatusDate>2012-11-29 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="95">Dermatological disease</TherapyArea></Row><Row><Action id="511">TNF antagonist</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="WO">World</Country><Drug id="71795">anti-Her-2/anti-Ang2 mAb (cancer), Zyngenia</Drug><DrugRelationship>General interest</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Publication</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PUB</HighestPatStatusIdForCnty><Indication id="291">Rheumatoid arthritis</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA7191557">WO-2012162561</Patent><Status id="PUB">First Publication</Status><StatusDate>2012-11-29 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="185">Immune disorder</TherapyArea></Row><Row><Action id="511">TNF antagonist</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="WO">World</Country><Drug id="71795">anti-Her-2/anti-Ang2 mAb (cancer), Zyngenia</Drug><DrugRelationship>General interest</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Publication</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PUB</HighestPatStatusIdForCnty><Indication id="318">Systemic lupus erythematosus</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA7191557">WO-2012162561</Patent><Status id="PUB">First Publication</Status><StatusDate>2012-11-29 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="95">Dermatological disease</TherapyArea></Row><Row><Action id="511">TNF antagonist</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="WO">World</Country><Drug id="71795">anti-Her-2/anti-Ang2 mAb (cancer), Zyngenia</Drug><DrugRelationship>General interest</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Publication</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PUB</HighestPatStatusIdForCnty><Indication id="337">Ulcerative colitis</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA7191557">WO-2012162561</Patent><Status id="PUB">First Publication</Status><StatusDate>2012-11-29 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="185">Immune disorder</TherapyArea></Row><Row><Action id="511">TNF antagonist</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="WO">World</Country><Drug id="71795">anti-Her-2/anti-Ang2 mAb (cancer), Zyngenia</Drug><DrugRelationship>General interest</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Publication</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PUB</HighestPatStatusIdForCnty><Indication id="651">Cancer</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA7191557">WO-2012162561</Patent><Status id="PUB">First Publication</Status><StatusDate>2012-11-29 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="230">Neoplasm</TherapyArea></Row><Row><Action id="511">TNF antagonist</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="WO">World</Country><Drug id="71795">anti-Her-2/anti-Ang2 mAb (cancer), Zyngenia</Drug><DrugRelationship>General interest</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Publication</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PUB</HighestPatStatusIdForCnty><Indication id="746">Infectious disease</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA7191557">WO-2012162561</Patent><Status id="PUB">First Publication</Status><StatusDate>2012-11-29 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="746">Infectious disease</TherapyArea></Row><Row><Action id="511">TNF antagonist</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="WO">World</Country><Drug id="71795">anti-Her-2/anti-Ang2 mAb (cancer), Zyngenia</Drug><DrugRelationship>General interest</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Publication</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PUB</HighestPatStatusIdForCnty><Indication id="84">Crohns disease</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA7191557">WO-2012162561</Patent><Status id="PUB">First Publication</Status><StatusDate>2012-11-29 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="185">Immune disorder</TherapyArea></Row><Row><Action id="511">TNF antagonist</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="WO">World</Country><Drug id="71795">anti-Her-2/anti-Ang2 mAb (cancer), Zyngenia</Drug><DrugRelationship>General interest</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Publication</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PUB</HighestPatStatusIdForCnty><Indication id="97">Diabetes mellitus</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA7191557">WO-2012162561</Patent><Status id="PUB">First Publication</Status><StatusDate>2012-11-29 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="112">Endocrine disease</TherapyArea></Row><Row><Action id="675">Hepatocyte growth factor receptor antagonist</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="WO">World</Country><Drug id="71795">anti-Her-2/anti-Ang2 mAb (cancer), Zyngenia</Drug><DrugRelationship>General interest</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Publication</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PUB</HighestPatStatusIdForCnty><Indication id="188">Inflammatory disease</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA7191557">WO-2012162561</Patent><Status id="PUB">First Publication</Status><StatusDate>2012-11-29 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="188">Inflammatory disease</TherapyArea></Row><Row><Action id="675">Hepatocyte growth factor receptor antagonist</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="WO">World</Country><Drug id="71795">anti-Her-2/anti-Ang2 mAb (cancer), Zyngenia</Drug><DrugRelationship>General interest</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Publication</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PUB</HighestPatStatusIdForCnty><Indication id="189">Inflammatory bowel disease</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA7191557">WO-2012162561</Patent><Status id="PUB">First Publication</Status><StatusDate>2012-11-29 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="188">Inflammatory disease</TherapyArea></Row><Row><Action id="675">Hepatocyte growth factor receptor antagonist</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="WO">World</Country><Drug id="71795">anti-Her-2/anti-Ang2 mAb (cancer), Zyngenia</Drug><DrugRelationship>General interest</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Publication</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PUB</HighestPatStatusIdForCnty><Indication id="213">Multiple sclerosis</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA7191557">WO-2012162561</Patent><Status id="PUB">First Publication</Status><StatusDate>2012-11-29 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="185">Immune disorder</TherapyArea></Row><Row><Action id="675">Hepatocyte growth factor receptor antagonist</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="WO">World</Country><Drug id="71795">anti-Her-2/anti-Ang2 mAb (cancer), Zyngenia</Drug><DrugRelationship>General interest</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Publication</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PUB</HighestPatStatusIdForCnty><Indication id="281">Psoriasis</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA7191557">WO-2012162561</Patent><Status id="PUB">First Publication</Status><StatusDate>2012-11-29 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="95">Dermatological disease</TherapyArea></Row><Row><Action id="675">Hepatocyte growth factor receptor antagonist</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="WO">World</Country><Drug id="71795">anti-Her-2/anti-Ang2 mAb (cancer), Zyngenia</Drug><DrugRelationship>General interest</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Publication</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PUB</HighestPatStatusIdForCnty><Indication id="291">Rheumatoid arthritis</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA7191557">WO-2012162561</Patent><Status id="PUB">First Publication</Status><StatusDate>2012-11-29 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="185">Immune disorder</TherapyArea></Row><Row><Action id="675">Hepatocyte growth factor receptor antagonist</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="WO">World</Country><Drug id="71795">anti-Her-2/anti-Ang2 mAb (cancer), Zyngenia</Drug><DrugRelationship>General interest</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Publication</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PUB</HighestPatStatusIdForCnty><Indication id="318">Systemic lupus erythematosus</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA7191557">WO-2012162561</Patent><Status id="PUB">First Publication</Status><StatusDate>2012-11-29 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="95">Dermatological disease</TherapyArea></Row><Row><Action id="675">Hepatocyte growth factor receptor antagonist</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="WO">World</Country><Drug id="71795">anti-Her-2/anti-Ang2 mAb (cancer), Zyngenia</Drug><DrugRelationship>General interest</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Publication</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PUB</HighestPatStatusIdForCnty><Indication id="337">Ulcerative colitis</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA7191557">WO-2012162561</Patent><Status id="PUB">First Publication</Status><StatusDate>2012-11-29 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="185">Immune disorder</TherapyArea></Row><Row><Action id="675">Hepatocyte growth factor receptor antagonist</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="WO">World</Country><Drug id="71795">anti-Her-2/anti-Ang2 mAb (cancer), Zyngenia</Drug><DrugRelationship>General interest</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Publication</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PUB</HighestPatStatusIdForCnty><Indication id="651">Cancer</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA7191557">WO-2012162561</Patent><Status id="PUB">First Publication</Status><StatusDate>2012-11-29 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="230">Neoplasm</TherapyArea></Row><Row><Action id="675">Hepatocyte growth factor receptor antagonist</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="WO">World</Country><Drug id="71795">anti-Her-2/anti-Ang2 mAb (cancer), Zyngenia</Drug><DrugRelationship>General interest</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Publication</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PUB</HighestPatStatusIdForCnty><Indication id="746">Infectious disease</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA7191557">WO-2012162561</Patent><Status id="PUB">First Publication</Status><StatusDate>2012-11-29 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="746">Infectious disease</TherapyArea></Row><Row><Action id="675">Hepatocyte growth factor receptor antagonist</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="WO">World</Country><Drug id="71795">anti-Her-2/anti-Ang2 mAb (cancer), Zyngenia</Drug><DrugRelationship>General interest</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Publication</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PUB</HighestPatStatusIdForCnty><Indication id="84">Crohns disease</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA7191557">WO-2012162561</Patent><Status id="PUB">First Publication</Status><StatusDate>2012-11-29 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="185">Immune disorder</TherapyArea></Row><Row><Action id="675">Hepatocyte growth factor receptor antagonist</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="WO">World</Country><Drug id="71795">anti-Her-2/anti-Ang2 mAb (cancer), Zyngenia</Drug><DrugRelationship>General interest</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Publication</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PUB</HighestPatStatusIdForCnty><Indication id="97">Diabetes mellitus</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA7191557">WO-2012162561</Patent><Status id="PUB">First Publication</Status><StatusDate>2012-11-29 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="112">Endocrine disease</TherapyArea></Row><Row><Action id="740">Epidermal growth factor receptor antagonist</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="WO">World</Country><Drug id="71795">anti-Her-2/anti-Ang2 mAb (cancer), Zyngenia</Drug><DrugRelationship>General interest</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Publication</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PUB</HighestPatStatusIdForCnty><Indication id="188">Inflammatory disease</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA7191557">WO-2012162561</Patent><Status id="PUB">First Publication</Status><StatusDate>2012-11-29 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="188">Inflammatory disease</TherapyArea></Row><Row><Action id="740">Epidermal growth factor receptor antagonist</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="WO">World</Country><Drug id="71795">anti-Her-2/anti-Ang2 mAb (cancer), Zyngenia</Drug><DrugRelationship>General interest</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Publication</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PUB</HighestPatStatusIdForCnty><Indication id="189">Inflammatory bowel disease</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA7191557">WO-2012162561</Patent><Status id="PUB">First Publication</Status><StatusDate>2012-11-29 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="188">Inflammatory disease</TherapyArea></Row><Row><Action id="740">Epidermal growth factor receptor antagonist</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="WO">World</Country><Drug id="71795">anti-Her-2/anti-Ang2 mAb (cancer), Zyngenia</Drug><DrugRelationship>General interest</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Publication</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PUB</HighestPatStatusIdForCnty><Indication id="213">Multiple sclerosis</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA7191557">WO-2012162561</Patent><Status id="PUB">First Publication</Status><StatusDate>2012-11-29 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="185">Immune disorder</TherapyArea></Row><Row><Action id="740">Epidermal growth factor receptor antagonist</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="WO">World</Country><Drug id="71795">anti-Her-2/anti-Ang2 mAb (cancer), Zyngenia</Drug><DrugRelationship>General interest</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Publication</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PUB</HighestPatStatusIdForCnty><Indication id="281">Psoriasis</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA7191557">WO-2012162561</Patent><Status id="PUB">First Publication</Status><StatusDate>2012-11-29 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="95">Dermatological disease</TherapyArea></Row><Row><Action id="740">Epidermal growth factor receptor antagonist</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="WO">World</Country><Drug id="71795">anti-Her-2/anti-Ang2 mAb (cancer), Zyngenia</Drug><DrugRelationship>General interest</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Publication</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PUB</HighestPatStatusIdForCnty><Indication id="291">Rheumatoid arthritis</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA7191557">WO-2012162561</Patent><Status id="PUB">First Publication</Status><StatusDate>2012-11-29 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="185">Immune disorder</TherapyArea></Row><Row><Action id="740">Epidermal growth factor receptor antagonist</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="WO">World</Country><Drug id="71795">anti-Her-2/anti-Ang2 mAb (cancer), Zyngenia</Drug><DrugRelationship>General interest</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Publication</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PUB</HighestPatStatusIdForCnty><Indication id="318">Systemic lupus erythematosus</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA7191557">WO-2012162561</Patent><Status id="PUB">First Publication</Status><StatusDate>2012-11-29 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="95">Dermatological disease</TherapyArea></Row><Row><Action id="740">Epidermal growth factor receptor antagonist</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="WO">World</Country><Drug id="71795">anti-Her-2/anti-Ang2 mAb (cancer), Zyngenia</Drug><DrugRelationship>General interest</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Publication</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PUB</HighestPatStatusIdForCnty><Indication id="337">Ulcerative colitis</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA7191557">WO-2012162561</Patent><Status id="PUB">First Publication</Status><StatusDate>2012-11-29 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="185">Immune disorder</TherapyArea></Row><Row><Action id="740">Epidermal growth factor receptor antagonist</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="WO">World</Country><Drug id="71795">anti-Her-2/anti-Ang2 mAb (cancer), Zyngenia</Drug><DrugRelationship>General interest</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Publication</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PUB</HighestPatStatusIdForCnty><Indication id="651">Cancer</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA7191557">WO-2012162561</Patent><Status id="PUB">First Publication</Status><StatusDate>2012-11-29 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="230">Neoplasm</TherapyArea></Row><Row><Action id="740">Epidermal growth factor receptor antagonist</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="WO">World</Country><Drug id="71795">anti-Her-2/anti-Ang2 mAb (cancer), Zyngenia</Drug><DrugRelationship>General interest</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Publication</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PUB</HighestPatStatusIdForCnty><Indication id="746">Infectious disease</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA7191557">WO-2012162561</Patent><Status id="PUB">First Publication</Status><StatusDate>2012-11-29 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="746">Infectious disease</TherapyArea></Row><Row><Action id="740">Epidermal growth factor receptor antagonist</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="WO">World</Country><Drug id="71795">anti-Her-2/anti-Ang2 mAb (cancer), Zyngenia</Drug><DrugRelationship>General interest</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Publication</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PUB</HighestPatStatusIdForCnty><Indication id="84">Crohns disease</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA7191557">WO-2012162561</Patent><Status id="PUB">First Publication</Status><StatusDate>2012-11-29 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="185">Immune disorder</TherapyArea></Row><Row><Action id="740">Epidermal growth factor receptor antagonist</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="WO">World</Country><Drug id="71795">anti-Her-2/anti-Ang2 mAb (cancer), Zyngenia</Drug><DrugRelationship>General interest</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Publication</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PUB</HighestPatStatusIdForCnty><Indication id="97">Diabetes mellitus</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA7191557">WO-2012162561</Patent><Status id="PUB">First Publication</Status><StatusDate>2012-11-29 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="112">Endocrine disease</TherapyArea></Row><Row><Action id="12521">VEGF ligand inhibitor</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="WO">World</Country><Drug id="77135">tri-specific anti-Her1/Her3 Zybody (cancer), Zyngenia</Drug><DrugRelationship>General interest</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Publication</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PUB</HighestPatStatusIdForCnty><Indication id="188">Inflammatory disease</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA7191557">WO-2012162561</Patent><Status id="PUB">First Publication</Status><StatusDate>2012-11-29 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="188">Inflammatory disease</TherapyArea></Row><Row><Action id="12521">VEGF ligand inhibitor</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="WO">World</Country><Drug id="77135">tri-specific anti-Her1/Her3 Zybody (cancer), Zyngenia</Drug><DrugRelationship>General interest</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Publication</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PUB</HighestPatStatusIdForCnty><Indication id="189">Inflammatory bowel disease</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA7191557">WO-2012162561</Patent><Status id="PUB">First Publication</Status><StatusDate>2012-11-29 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="188">Inflammatory disease</TherapyArea></Row><Row><Action id="12521">VEGF ligand inhibitor</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="WO">World</Country><Drug id="77135">tri-specific anti-Her1/Her3 Zybody (cancer), Zyngenia</Drug><DrugRelationship>General interest</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Publication</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PUB</HighestPatStatusIdForCnty><Indication id="213">Multiple sclerosis</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA7191557">WO-2012162561</Patent><Status id="PUB">First Publication</Status><StatusDate>2012-11-29 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="185">Immune disorder</TherapyArea></Row><Row><Action id="12521">VEGF ligand inhibitor</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="WO">World</Country><Drug id="77135">tri-specific anti-Her1/Her3 Zybody (cancer), Zyngenia</Drug><DrugRelationship>General interest</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Publication</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PUB</HighestPatStatusIdForCnty><Indication id="281">Psoriasis</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA7191557">WO-2012162561</Patent><Status id="PUB">First Publication</Status><StatusDate>2012-11-29 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="95">Dermatological disease</TherapyArea></Row><Row><Action id="12521">VEGF ligand inhibitor</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="WO">World</Country><Drug id="77135">tri-specific anti-Her1/Her3 Zybody (cancer), Zyngenia</Drug><DrugRelationship>General interest</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Publication</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PUB</HighestPatStatusIdForCnty><Indication id="291">Rheumatoid arthritis</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA7191557">WO-2012162561</Patent><Status id="PUB">First Publication</Status><StatusDate>2012-11-29 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="185">Immune disorder</TherapyArea></Row><Row><Action id="12521">VEGF ligand inhibitor</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="WO">World</Country><Drug id="77135">tri-specific anti-Her1/Her3 Zybody (cancer), Zyngenia</Drug><DrugRelationship>General interest</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Publication</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PUB</HighestPatStatusIdForCnty><Indication id="318">Systemic lupus erythematosus</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA7191557">WO-2012162561</Patent><Status id="PUB">First Publication</Status><StatusDate>2012-11-29 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="95">Dermatological disease</TherapyArea></Row><Row><Action id="12521">VEGF ligand inhibitor</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="WO">World</Country><Drug id="77135">tri-specific anti-Her1/Her3 Zybody (cancer), Zyngenia</Drug><DrugRelationship>General interest</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Publication</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PUB</HighestPatStatusIdForCnty><Indication id="337">Ulcerative colitis</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA7191557">WO-2012162561</Patent><Status id="PUB">First Publication</Status><StatusDate>2012-11-29 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="185">Immune disorder</TherapyArea></Row><Row><Action id="12521">VEGF ligand inhibitor</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="WO">World</Country><Drug id="77135">tri-specific anti-Her1/Her3 Zybody (cancer), Zyngenia</Drug><DrugRelationship>General interest</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Publication</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PUB</HighestPatStatusIdForCnty><Indication id="651">Cancer</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA7191557">WO-2012162561</Patent><Status id="PUB">First Publication</Status><StatusDate>2012-11-29 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="230">Neoplasm</TherapyArea></Row><Row><Action id="12521">VEGF ligand inhibitor</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="WO">World</Country><Drug id="77135">tri-specific anti-Her1/Her3 Zybody (cancer), Zyngenia</Drug><DrugRelationship>General interest</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Publication</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PUB</HighestPatStatusIdForCnty><Indication id="746">Infectious disease</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA7191557">WO-2012162561</Patent><Status id="PUB">First Publication</Status><StatusDate>2012-11-29 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="746">Infectious disease</TherapyArea></Row><Row><Action id="12521">VEGF ligand inhibitor</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="WO">World</Country><Drug id="77135">tri-specific anti-Her1/Her3 Zybody (cancer), Zyngenia</Drug><DrugRelationship>General interest</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Publication</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PUB</HighestPatStatusIdForCnty><Indication id="84">Crohns disease</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA7191557">WO-2012162561</Patent><Status id="PUB">First Publication</Status><StatusDate>2012-11-29 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="185">Immune disorder</TherapyArea></Row><Row><Action id="12521">VEGF ligand inhibitor</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="WO">World</Country><Drug id="77135">tri-specific anti-Her1/Her3 Zybody (cancer), Zyngenia</Drug><DrugRelationship>General interest</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Publication</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PUB</HighestPatStatusIdForCnty><Indication id="97">Diabetes mellitus</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA7191557">WO-2012162561</Patent><Status id="PUB">First Publication</Status><StatusDate>2012-11-29 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="112">Endocrine disease</TherapyArea></Row><Row><Action id="3252">Insulin-like growth factor 1 receptor antagonist</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="WO">World</Country><Drug id="77135">tri-specific anti-Her1/Her3 Zybody (cancer), Zyngenia</Drug><DrugRelationship>General interest</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Publication</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PUB</HighestPatStatusIdForCnty><Indication id="188">Inflammatory disease</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA7191557">WO-2012162561</Patent><Status id="PUB">First Publication</Status><StatusDate>2012-11-29 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="188">Inflammatory disease</TherapyArea></Row><Row><Action id="3252">Insulin-like growth factor 1 receptor antagonist</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="WO">World</Country><Drug id="77135">tri-specific anti-Her1/Her3 Zybody (cancer), Zyngenia</Drug><DrugRelationship>General interest</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Publication</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PUB</HighestPatStatusIdForCnty><Indication id="189">Inflammatory bowel disease</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA7191557">WO-2012162561</Patent><Status id="PUB">First Publication</Status><StatusDate>2012-11-29 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="188">Inflammatory disease</TherapyArea></Row><Row><Action id="3252">Insulin-like growth factor 1 receptor antagonist</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="WO">World</Country><Drug id="77135">tri-specific anti-Her1/Her3 Zybody (cancer), Zyngenia</Drug><DrugRelationship>General interest</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Publication</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PUB</HighestPatStatusIdForCnty><Indication id="213">Multiple sclerosis</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA7191557">WO-2012162561</Patent><Status id="PUB">First Publication</Status><StatusDate>2012-11-29 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="185">Immune disorder</TherapyArea></Row><Row><Action id="3252">Insulin-like growth factor 1 receptor antagonist</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="WO">World</Country><Drug id="77135">tri-specific anti-Her1/Her3 Zybody (cancer), Zyngenia</Drug><DrugRelationship>General interest</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Publication</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PUB</HighestPatStatusIdForCnty><Indication id="281">Psoriasis</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA7191557">WO-2012162561</Patent><Status id="PUB">First Publication</Status><StatusDate>2012-11-29 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="95">Dermatological disease</TherapyArea></Row><Row><Action id="3252">Insulin-like growth factor 1 receptor antagonist</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="WO">World</Country><Drug id="77135">tri-specific anti-Her1/Her3 Zybody (cancer), Zyngenia</Drug><DrugRelationship>General interest</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Publication</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PUB</HighestPatStatusIdForCnty><Indication id="291">Rheumatoid arthritis</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA7191557">WO-2012162561</Patent><Status id="PUB">First Publication</Status><StatusDate>2012-11-29 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="185">Immune disorder</TherapyArea></Row><Row><Action id="3252">Insulin-like growth factor 1 receptor antagonist</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="WO">World</Country><Drug id="77135">tri-specific anti-Her1/Her3 Zybody (cancer), Zyngenia</Drug><DrugRelationship>General interest</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Publication</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PUB</HighestPatStatusIdForCnty><Indication id="318">Systemic lupus erythematosus</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA7191557">WO-2012162561</Patent><Status id="PUB">First Publication</Status><StatusDate>2012-11-29 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="95">Dermatological disease</TherapyArea></Row><Row><Action id="3252">Insulin-like growth factor 1 receptor antagonist</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="WO">World</Country><Drug id="77135">tri-specific anti-Her1/Her3 Zybody (cancer), Zyngenia</Drug><DrugRelationship>General interest</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Publication</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PUB</HighestPatStatusIdForCnty><Indication id="337">Ulcerative colitis</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA7191557">WO-2012162561</Patent><Status id="PUB">First Publication</Status><StatusDate>2012-11-29 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="185">Immune disorder</TherapyArea></Row><Row><Action id="3252">Insulin-like growth factor 1 receptor antagonist</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="WO">World</Country><Drug id="77135">tri-specific anti-Her1/Her3 Zybody (cancer), Zyngenia</Drug><DrugRelationship>General interest</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Publication</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PUB</HighestPatStatusIdForCnty><Indication id="651">Cancer</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA7191557">WO-2012162561</Patent><Status id="PUB">First Publication</Status><StatusDate>2012-11-29 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="230">Neoplasm</TherapyArea></Row><Row><Action id="3252">Insulin-like growth factor 1 receptor antagonist</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="WO">World</Country><Drug id="77135">tri-specific anti-Her1/Her3 Zybody (cancer), Zyngenia</Drug><DrugRelationship>General interest</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Publication</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PUB</HighestPatStatusIdForCnty><Indication id="746">Infectious disease</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA7191557">WO-2012162561</Patent><Status id="PUB">First Publication</Status><StatusDate>2012-11-29 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="746">Infectious disease</TherapyArea></Row><Row><Action id="3252">Insulin-like growth factor 1 receptor antagonist</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="WO">World</Country><Drug id="77135">tri-specific anti-Her1/Her3 Zybody (cancer), Zyngenia</Drug><DrugRelationship>General interest</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Publication</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PUB</HighestPatStatusIdForCnty><Indication id="84">Crohns disease</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA7191557">WO-2012162561</Patent><Status id="PUB">First Publication</Status><StatusDate>2012-11-29 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="185">Immune disorder</TherapyArea></Row><Row><Action id="3252">Insulin-like growth factor 1 receptor antagonist</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="WO">World</Country><Drug id="77135">tri-specific anti-Her1/Her3 Zybody (cancer), Zyngenia</Drug><DrugRelationship>General interest</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Publication</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PUB</HighestPatStatusIdForCnty><Indication id="97">Diabetes mellitus</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA7191557">WO-2012162561</Patent><Status id="PUB">First Publication</Status><StatusDate>2012-11-29 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="112">Endocrine disease</TherapyArea></Row><Row><Action id="3682">FGF1 receptor antagonist</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="WO">World</Country><Drug id="77135">tri-specific anti-Her1/Her3 Zybody (cancer), Zyngenia</Drug><DrugRelationship>General interest</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Publication</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PUB</HighestPatStatusIdForCnty><Indication id="188">Inflammatory disease</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA7191557">WO-2012162561</Patent><Status id="PUB">First Publication</Status><StatusDate>2012-11-29 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="188">Inflammatory disease</TherapyArea></Row><Row><Action id="3682">FGF1 receptor antagonist</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="WO">World</Country><Drug id="77135">tri-specific anti-Her1/Her3 Zybody (cancer), Zyngenia</Drug><DrugRelationship>General interest</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Publication</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PUB</HighestPatStatusIdForCnty><Indication id="189">Inflammatory bowel disease</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA7191557">WO-2012162561</Patent><Status id="PUB">First Publication</Status><StatusDate>2012-11-29 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="188">Inflammatory disease</TherapyArea></Row><Row><Action id="3682">FGF1 receptor antagonist</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="WO">World</Country><Drug id="77135">tri-specific anti-Her1/Her3 Zybody (cancer), Zyngenia</Drug><DrugRelationship>General interest</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Publication</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PUB</HighestPatStatusIdForCnty><Indication id="213">Multiple sclerosis</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA7191557">WO-2012162561</Patent><Status id="PUB">First Publication</Status><StatusDate>2012-11-29 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="185">Immune disorder</TherapyArea></Row><Row><Action id="3682">FGF1 receptor antagonist</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="WO">World</Country><Drug id="77135">tri-specific anti-Her1/Her3 Zybody (cancer), Zyngenia</Drug><DrugRelationship>General interest</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Publication</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PUB</HighestPatStatusIdForCnty><Indication id="281">Psoriasis</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA7191557">WO-2012162561</Patent><Status id="PUB">First Publication</Status><StatusDate>2012-11-29 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="95">Dermatological disease</TherapyArea></Row><Row><Action id="3682">FGF1 receptor antagonist</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="WO">World</Country><Drug id="77135">tri-specific anti-Her1/Her3 Zybody (cancer), Zyngenia</Drug><DrugRelationship>General interest</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Publication</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PUB</HighestPatStatusIdForCnty><Indication id="291">Rheumatoid arthritis</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA7191557">WO-2012162561</Patent><Status id="PUB">First Publication</Status><StatusDate>2012-11-29 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="185">Immune disorder</TherapyArea></Row><Row><Action id="3682">FGF1 receptor antagonist</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="WO">World</Country><Drug id="77135">tri-specific anti-Her1/Her3 Zybody (cancer), Zyngenia</Drug><DrugRelationship>General interest</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Publication</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PUB</HighestPatStatusIdForCnty><Indication id="318">Systemic lupus erythematosus</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA7191557">WO-2012162561</Patent><Status id="PUB">First Publication</Status><StatusDate>2012-11-29 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="95">Dermatological disease</TherapyArea></Row><Row><Action id="3682">FGF1 receptor antagonist</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="WO">World</Country><Drug id="77135">tri-specific anti-Her1/Her3 Zybody (cancer), Zyngenia</Drug><DrugRelationship>General interest</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Publication</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PUB</HighestPatStatusIdForCnty><Indication id="337">Ulcerative colitis</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA7191557">WO-2012162561</Patent><Status id="PUB">First Publication</Status><StatusDate>2012-11-29 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="185">Immune disorder</TherapyArea></Row><Row><Action id="3682">FGF1 receptor antagonist</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="WO">World</Country><Drug id="77135">tri-specific anti-Her1/Her3 Zybody (cancer), Zyngenia</Drug><DrugRelationship>General interest</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Publication</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PUB</HighestPatStatusIdForCnty><Indication id="651">Cancer</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA7191557">WO-2012162561</Patent><Status id="PUB">First Publication</Status><StatusDate>2012-11-29 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="230">Neoplasm</TherapyArea></Row><Row><Action id="3682">FGF1 receptor antagonist</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="WO">World</Country><Drug id="77135">tri-specific anti-Her1/Her3 Zybody (cancer), Zyngenia</Drug><DrugRelationship>General interest</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Publication</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PUB</HighestPatStatusIdForCnty><Indication id="746">Infectious disease</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA7191557">WO-2012162561</Patent><Status id="PUB">First Publication</Status><StatusDate>2012-11-29 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="746">Infectious disease</TherapyArea></Row><Row><Action id="3682">FGF1 receptor antagonist</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="WO">World</Country><Drug id="77135">tri-specific anti-Her1/Her3 Zybody (cancer), Zyngenia</Drug><DrugRelationship>General interest</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Publication</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PUB</HighestPatStatusIdForCnty><Indication id="84">Crohns disease</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA7191557">WO-2012162561</Patent><Status id="PUB">First Publication</Status><StatusDate>2012-11-29 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="185">Immune disorder</TherapyArea></Row><Row><Action id="3682">FGF1 receptor antagonist</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="WO">World</Country><Drug id="77135">tri-specific anti-Her1/Her3 Zybody (cancer), Zyngenia</Drug><DrugRelationship>General interest</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Publication</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PUB</HighestPatStatusIdForCnty><Indication id="97">Diabetes mellitus</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA7191557">WO-2012162561</Patent><Status id="PUB">First Publication</Status><StatusDate>2012-11-29 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="112">Endocrine disease</TherapyArea></Row><Row><Action id="3685">FGF2 receptor antagonist</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="WO">World</Country><Drug id="77135">tri-specific anti-Her1/Her3 Zybody (cancer), Zyngenia</Drug><DrugRelationship>General interest</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Publication</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PUB</HighestPatStatusIdForCnty><Indication id="188">Inflammatory disease</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA7191557">WO-2012162561</Patent><Status id="PUB">First Publication</Status><StatusDate>2012-11-29 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="188">Inflammatory disease</TherapyArea></Row><Row><Action id="3685">FGF2 receptor antagonist</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="WO">World</Country><Drug id="77135">tri-specific anti-Her1/Her3 Zybody (cancer), Zyngenia</Drug><DrugRelationship>General interest</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Publication</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PUB</HighestPatStatusIdForCnty><Indication id="189">Inflammatory bowel disease</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA7191557">WO-2012162561</Patent><Status id="PUB">First Publication</Status><StatusDate>2012-11-29 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="188">Inflammatory disease</TherapyArea></Row><Row><Action id="3685">FGF2 receptor antagonist</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="WO">World</Country><Drug id="77135">tri-specific anti-Her1/Her3 Zybody (cancer), Zyngenia</Drug><DrugRelationship>General interest</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Publication</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PUB</HighestPatStatusIdForCnty><Indication id="213">Multiple sclerosis</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA7191557">WO-2012162561</Patent><Status id="PUB">First Publication</Status><StatusDate>2012-11-29 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="185">Immune disorder</TherapyArea></Row><Row><Action id="3685">FGF2 receptor antagonist</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="WO">World</Country><Drug id="77135">tri-specific anti-Her1/Her3 Zybody (cancer), Zyngenia</Drug><DrugRelationship>General interest</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Publication</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PUB</HighestPatStatusIdForCnty><Indication id="281">Psoriasis</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA7191557">WO-2012162561</Patent><Status id="PUB">First Publication</Status><StatusDate>2012-11-29 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="95">Dermatological disease</TherapyArea></Row><Row><Action id="3685">FGF2 receptor antagonist</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="WO">World</Country><Drug id="77135">tri-specific anti-Her1/Her3 Zybody (cancer), Zyngenia</Drug><DrugRelationship>General interest</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Publication</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PUB</HighestPatStatusIdForCnty><Indication id="291">Rheumatoid arthritis</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA7191557">WO-2012162561</Patent><Status id="PUB">First Publication</Status><StatusDate>2012-11-29 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="185">Immune disorder</TherapyArea></Row><Row><Action id="3685">FGF2 receptor antagonist</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="WO">World</Country><Drug id="77135">tri-specific anti-Her1/Her3 Zybody (cancer), Zyngenia</Drug><DrugRelationship>General interest</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Publication</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PUB</HighestPatStatusIdForCnty><Indication id="318">Systemic lupus erythematosus</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA7191557">WO-2012162561</Patent><Status id="PUB">First Publication</Status><StatusDate>2012-11-29 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="95">Dermatological disease</TherapyArea></Row><Row><Action id="3685">FGF2 receptor antagonist</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="WO">World</Country><Drug id="77135">tri-specific anti-Her1/Her3 Zybody (cancer), Zyngenia</Drug><DrugRelationship>General interest</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Publication</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PUB</HighestPatStatusIdForCnty><Indication id="337">Ulcerative colitis</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA7191557">WO-2012162561</Patent><Status id="PUB">First Publication</Status><StatusDate>2012-11-29 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="185">Immune disorder</TherapyArea></Row><Row><Action id="3685">FGF2 receptor antagonist</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="WO">World</Country><Drug id="77135">tri-specific anti-Her1/Her3 Zybody (cancer), Zyngenia</Drug><DrugRelationship>General interest</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Publication</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PUB</HighestPatStatusIdForCnty><Indication id="651">Cancer</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA7191557">WO-2012162561</Patent><Status id="PUB">First Publication</Status><StatusDate>2012-11-29 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="230">Neoplasm</TherapyArea></Row><Row><Action id="3685">FGF2 receptor antagonist</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="WO">World</Country><Drug id="77135">tri-specific anti-Her1/Her3 Zybody (cancer), Zyngenia</Drug><DrugRelationship>General interest</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Publication</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PUB</HighestPatStatusIdForCnty><Indication id="746">Infectious disease</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA7191557">WO-2012162561</Patent><Status id="PUB">First Publication</Status><StatusDate>2012-11-29 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="746">Infectious disease</TherapyArea></Row><Row><Action id="3685">FGF2 receptor antagonist</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="WO">World</Country><Drug id="77135">tri-specific anti-Her1/Her3 Zybody (cancer), Zyngenia</Drug><DrugRelationship>General interest</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Publication</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PUB</HighestPatStatusIdForCnty><Indication id="84">Crohns disease</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA7191557">WO-2012162561</Patent><Status id="PUB">First Publication</Status><StatusDate>2012-11-29 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="185">Immune disorder</TherapyArea></Row><Row><Action id="3685">FGF2 receptor antagonist</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="WO">World</Country><Drug id="77135">tri-specific anti-Her1/Her3 Zybody (cancer), Zyngenia</Drug><DrugRelationship>General interest</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Publication</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PUB</HighestPatStatusIdForCnty><Indication id="97">Diabetes mellitus</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA7191557">WO-2012162561</Patent><Status id="PUB">First Publication</Status><StatusDate>2012-11-29 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="112">Endocrine disease</TherapyArea></Row><Row><Action id="3756">Erbb2 tyrosine kinase receptor inhibitor</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="WO">World</Country><Drug id="77135">tri-specific anti-Her1/Her3 Zybody (cancer), Zyngenia</Drug><DrugRelationship>General interest</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Publication</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PUB</HighestPatStatusIdForCnty><Indication id="188">Inflammatory disease</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA7191557">WO-2012162561</Patent><Status id="PUB">First Publication</Status><StatusDate>2012-11-29 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="188">Inflammatory disease</TherapyArea></Row><Row><Action id="3756">Erbb2 tyrosine kinase receptor inhibitor</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="WO">World</Country><Drug id="77135">tri-specific anti-Her1/Her3 Zybody (cancer), Zyngenia</Drug><DrugRelationship>General interest</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Publication</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PUB</HighestPatStatusIdForCnty><Indication id="189">Inflammatory bowel disease</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA7191557">WO-2012162561</Patent><Status id="PUB">First Publication</Status><StatusDate>2012-11-29 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="188">Inflammatory disease</TherapyArea></Row><Row><Action id="3756">Erbb2 tyrosine kinase receptor inhibitor</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="WO">World</Country><Drug id="77135">tri-specific anti-Her1/Her3 Zybody (cancer), Zyngenia</Drug><DrugRelationship>General interest</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Publication</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PUB</HighestPatStatusIdForCnty><Indication id="213">Multiple sclerosis</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA7191557">WO-2012162561</Patent><Status id="PUB">First Publication</Status><StatusDate>2012-11-29 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="185">Immune disorder</TherapyArea></Row><Row><Action id="3756">Erbb2 tyrosine kinase receptor inhibitor</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="WO">World</Country><Drug id="77135">tri-specific anti-Her1/Her3 Zybody (cancer), Zyngenia</Drug><DrugRelationship>General interest</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Publication</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PUB</HighestPatStatusIdForCnty><Indication id="281">Psoriasis</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA7191557">WO-2012162561</Patent><Status id="PUB">First Publication</Status><StatusDate>2012-11-29 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="95">Dermatological disease</TherapyArea></Row><Row><Action id="3756">Erbb2 tyrosine kinase receptor inhibitor</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="WO">World</Country><Drug id="77135">tri-specific anti-Her1/Her3 Zybody (cancer), Zyngenia</Drug><DrugRelationship>General interest</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Publication</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PUB</HighestPatStatusIdForCnty><Indication id="291">Rheumatoid arthritis</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA7191557">WO-2012162561</Patent><Status id="PUB">First Publication</Status><StatusDate>2012-11-29 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="185">Immune disorder</TherapyArea></Row><Row><Action id="3756">Erbb2 tyrosine kinase receptor inhibitor</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="WO">World</Country><Drug id="77135">tri-specific anti-Her1/Her3 Zybody (cancer), Zyngenia</Drug><DrugRelationship>General interest</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Publication</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PUB</HighestPatStatusIdForCnty><Indication id="318">Systemic lupus erythematosus</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA7191557">WO-2012162561</Patent><Status id="PUB">First Publication</Status><StatusDate>2012-11-29 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="95">Dermatological disease</TherapyArea></Row><Row><Action id="3756">Erbb2 tyrosine kinase receptor inhibitor</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="WO">World</Country><Drug id="77135">tri-specific anti-Her1/Her3 Zybody (cancer), Zyngenia</Drug><DrugRelationship>General interest</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Publication</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PUB</HighestPatStatusIdForCnty><Indication id="337">Ulcerative colitis</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA7191557">WO-2012162561</Patent><Status id="PUB">First Publication</Status><StatusDate>2012-11-29 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="185">Immune disorder</TherapyArea></Row><Row><Action id="3756">Erbb2 tyrosine kinase receptor inhibitor</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="WO">World</Country><Drug id="77135">tri-specific anti-Her1/Her3 Zybody (cancer), Zyngenia</Drug><DrugRelationship>General interest</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Publication</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PUB</HighestPatStatusIdForCnty><Indication id="651">Cancer</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA7191557">WO-2012162561</Patent><Status id="PUB">First Publication</Status><StatusDate>2012-11-29 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="230">Neoplasm</TherapyArea></Row><Row><Action id="3756">Erbb2 tyrosine kinase receptor inhibitor</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="WO">World</Country><Drug id="77135">tri-specific anti-Her1/Her3 Zybody (cancer), Zyngenia</Drug><DrugRelationship>General interest</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Publication</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PUB</HighestPatStatusIdForCnty><Indication id="746">Infectious disease</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA7191557">WO-2012162561</Patent><Status id="PUB">First Publication</Status><StatusDate>2012-11-29 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="746">Infectious disease</TherapyArea></Row><Row><Action id="3756">Erbb2 tyrosine kinase receptor inhibitor</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="WO">World</Country><Drug id="77135">tri-specific anti-Her1/Her3 Zybody (cancer), Zyngenia</Drug><DrugRelationship>General interest</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Publication</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PUB</HighestPatStatusIdForCnty><Indication id="84">Crohns disease</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA7191557">WO-2012162561</Patent><Status id="PUB">First Publication</Status><StatusDate>2012-11-29 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="185">Immune disorder</TherapyArea></Row><Row><Action id="3756">Erbb2 tyrosine kinase receptor inhibitor</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="WO">World</Country><Drug id="77135">tri-specific anti-Her1/Her3 Zybody (cancer), Zyngenia</Drug><DrugRelationship>General interest</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Publication</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PUB</HighestPatStatusIdForCnty><Indication id="97">Diabetes mellitus</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA7191557">WO-2012162561</Patent><Status id="PUB">First Publication</Status><StatusDate>2012-11-29 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="112">Endocrine disease</TherapyArea></Row><Row><Action id="3846">VEGF-1 receptor antagonist</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="WO">World</Country><Drug id="77135">tri-specific anti-Her1/Her3 Zybody (cancer), Zyngenia</Drug><DrugRelationship>General interest</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Publication</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PUB</HighestPatStatusIdForCnty><Indication id="188">Inflammatory disease</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA7191557">WO-2012162561</Patent><Status id="PUB">First Publication</Status><StatusDate>2012-11-29 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="188">Inflammatory disease</TherapyArea></Row><Row><Action id="3846">VEGF-1 receptor antagonist</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="WO">World</Country><Drug id="77135">tri-specific anti-Her1/Her3 Zybody (cancer), Zyngenia</Drug><DrugRelationship>General interest</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Publication</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PUB</HighestPatStatusIdForCnty><Indication id="189">Inflammatory bowel disease</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA7191557">WO-2012162561</Patent><Status id="PUB">First Publication</Status><StatusDate>2012-11-29 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="188">Inflammatory disease</TherapyArea></Row><Row><Action id="3846">VEGF-1 receptor antagonist</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="WO">World</Country><Drug id="77135">tri-specific anti-Her1/Her3 Zybody (cancer), Zyngenia</Drug><DrugRelationship>General interest</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Publication</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PUB</HighestPatStatusIdForCnty><Indication id="213">Multiple sclerosis</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA7191557">WO-2012162561</Patent><Status id="PUB">First Publication</Status><StatusDate>2012-11-29 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="185">Immune disorder</TherapyArea></Row><Row><Action id="3846">VEGF-1 receptor antagonist</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="WO">World</Country><Drug id="77135">tri-specific anti-Her1/Her3 Zybody (cancer), Zyngenia</Drug><DrugRelationship>General interest</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Publication</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PUB</HighestPatStatusIdForCnty><Indication id="281">Psoriasis</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA7191557">WO-2012162561</Patent><Status id="PUB">First Publication</Status><StatusDate>2012-11-29 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="95">Dermatological disease</TherapyArea></Row><Row><Action id="3846">VEGF-1 receptor antagonist</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="WO">World</Country><Drug id="77135">tri-specific anti-Her1/Her3 Zybody (cancer), Zyngenia</Drug><DrugRelationship>General interest</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Publication</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PUB</HighestPatStatusIdForCnty><Indication id="291">Rheumatoid arthritis</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA7191557">WO-2012162561</Patent><Status id="PUB">First Publication</Status><StatusDate>2012-11-29 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="185">Immune disorder</TherapyArea></Row><Row><Action id="3846">VEGF-1 receptor antagonist</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="WO">World</Country><Drug id="77135">tri-specific anti-Her1/Her3 Zybody (cancer), Zyngenia</Drug><DrugRelationship>General interest</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Publication</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PUB</HighestPatStatusIdForCnty><Indication id="318">Systemic lupus erythematosus</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA7191557">WO-2012162561</Patent><Status id="PUB">First Publication</Status><StatusDate>2012-11-29 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="95">Dermatological disease</TherapyArea></Row><Row><Action id="3846">VEGF-1 receptor antagonist</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="WO">World</Country><Drug id="77135">tri-specific anti-Her1/Her3 Zybody (cancer), Zyngenia</Drug><DrugRelationship>General interest</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Publication</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PUB</HighestPatStatusIdForCnty><Indication id="337">Ulcerative colitis</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA7191557">WO-2012162561</Patent><Status id="PUB">First Publication</Status><StatusDate>2012-11-29 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="185">Immune disorder</TherapyArea></Row><Row><Action id="3846">VEGF-1 receptor antagonist</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="WO">World</Country><Drug id="77135">tri-specific anti-Her1/Her3 Zybody (cancer), Zyngenia</Drug><DrugRelationship>General interest</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Publication</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PUB</HighestPatStatusIdForCnty><Indication id="651">Cancer</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA7191557">WO-2012162561</Patent><Status id="PUB">First Publication</Status><StatusDate>2012-11-29 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="230">Neoplasm</TherapyArea></Row><Row><Action id="3846">VEGF-1 receptor antagonist</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="WO">World</Country><Drug id="77135">tri-specific anti-Her1/Her3 Zybody (cancer), Zyngenia</Drug><DrugRelationship>General interest</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Publication</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PUB</HighestPatStatusIdForCnty><Indication id="746">Infectious disease</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA7191557">WO-2012162561</Patent><Status id="PUB">First Publication</Status><StatusDate>2012-11-29 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="746">Infectious disease</TherapyArea></Row><Row><Action id="3846">VEGF-1 receptor antagonist</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="WO">World</Country><Drug id="77135">tri-specific anti-Her1/Her3 Zybody (cancer), Zyngenia</Drug><DrugRelationship>General interest</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Publication</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PUB</HighestPatStatusIdForCnty><Indication id="84">Crohns disease</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA7191557">WO-2012162561</Patent><Status id="PUB">First Publication</Status><StatusDate>2012-11-29 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="185">Immune disorder</TherapyArea></Row><Row><Action id="3846">VEGF-1 receptor antagonist</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="WO">World</Country><Drug id="77135">tri-specific anti-Her1/Her3 Zybody (cancer), Zyngenia</Drug><DrugRelationship>General interest</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Publication</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PUB</HighestPatStatusIdForCnty><Indication id="97">Diabetes mellitus</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA7191557">WO-2012162561</Patent><Status id="PUB">First Publication</Status><StatusDate>2012-11-29 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="112">Endocrine disease</TherapyArea></Row><Row><Action id="5025">CD3 antagonist</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="WO">World</Country><Drug id="77135">tri-specific anti-Her1/Her3 Zybody (cancer), Zyngenia</Drug><DrugRelationship>General interest</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Publication</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PUB</HighestPatStatusIdForCnty><Indication id="188">Inflammatory disease</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA7191557">WO-2012162561</Patent><Status id="PUB">First Publication</Status><StatusDate>2012-11-29 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="188">Inflammatory disease</TherapyArea></Row><Row><Action id="5025">CD3 antagonist</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="WO">World</Country><Drug id="77135">tri-specific anti-Her1/Her3 Zybody (cancer), Zyngenia</Drug><DrugRelationship>General interest</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Publication</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PUB</HighestPatStatusIdForCnty><Indication id="189">Inflammatory bowel disease</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA7191557">WO-2012162561</Patent><Status id="PUB">First Publication</Status><StatusDate>2012-11-29 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="188">Inflammatory disease</TherapyArea></Row><Row><Action id="5025">CD3 antagonist</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="WO">World</Country><Drug id="77135">tri-specific anti-Her1/Her3 Zybody (cancer), Zyngenia</Drug><DrugRelationship>General interest</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Publication</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PUB</HighestPatStatusIdForCnty><Indication id="213">Multiple sclerosis</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA7191557">WO-2012162561</Patent><Status id="PUB">First Publication</Status><StatusDate>2012-11-29 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="185">Immune disorder</TherapyArea></Row><Row><Action id="5025">CD3 antagonist</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="WO">World</Country><Drug id="77135">tri-specific anti-Her1/Her3 Zybody (cancer), Zyngenia</Drug><DrugRelationship>General interest</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Publication</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PUB</HighestPatStatusIdForCnty><Indication id="281">Psoriasis</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA7191557">WO-2012162561</Patent><Status id="PUB">First Publication</Status><StatusDate>2012-11-29 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="95">Dermatological disease</TherapyArea></Row><Row><Action id="5025">CD3 antagonist</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="WO">World</Country><Drug id="77135">tri-specific anti-Her1/Her3 Zybody (cancer), Zyngenia</Drug><DrugRelationship>General interest</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Publication</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PUB</HighestPatStatusIdForCnty><Indication id="291">Rheumatoid arthritis</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA7191557">WO-2012162561</Patent><Status id="PUB">First Publication</Status><StatusDate>2012-11-29 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="185">Immune disorder</TherapyArea></Row><Row><Action id="5025">CD3 antagonist</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="WO">World</Country><Drug id="77135">tri-specific anti-Her1/Her3 Zybody (cancer), Zyngenia</Drug><DrugRelationship>General interest</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Publication</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PUB</HighestPatStatusIdForCnty><Indication id="318">Systemic lupus erythematosus</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA7191557">WO-2012162561</Patent><Status id="PUB">First Publication</Status><StatusDate>2012-11-29 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="95">Dermatological disease</TherapyArea></Row><Row><Action id="5025">CD3 antagonist</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="WO">World</Country><Drug id="77135">tri-specific anti-Her1/Her3 Zybody (cancer), Zyngenia</Drug><DrugRelationship>General interest</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Publication</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PUB</HighestPatStatusIdForCnty><Indication id="337">Ulcerative colitis</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA7191557">WO-2012162561</Patent><Status id="PUB">First Publication</Status><StatusDate>2012-11-29 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="185">Immune disorder</TherapyArea></Row><Row><Action id="5025">CD3 antagonist</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="WO">World</Country><Drug id="77135">tri-specific anti-Her1/Her3 Zybody (cancer), Zyngenia</Drug><DrugRelationship>General interest</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Publication</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PUB</HighestPatStatusIdForCnty><Indication id="651">Cancer</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA7191557">WO-2012162561</Patent><Status id="PUB">First Publication</Status><StatusDate>2012-11-29 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="230">Neoplasm</TherapyArea></Row><Row><Action id="5025">CD3 antagonist</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="WO">World</Country><Drug id="77135">tri-specific anti-Her1/Her3 Zybody (cancer), Zyngenia</Drug><DrugRelationship>General interest</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Publication</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PUB</HighestPatStatusIdForCnty><Indication id="746">Infectious disease</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA7191557">WO-2012162561</Patent><Status id="PUB">First Publication</Status><StatusDate>2012-11-29 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="746">Infectious disease</TherapyArea></Row><Row><Action id="5025">CD3 antagonist</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="WO">World</Country><Drug id="77135">tri-specific anti-Her1/Her3 Zybody (cancer), Zyngenia</Drug><DrugRelationship>General interest</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Publication</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PUB</HighestPatStatusIdForCnty><Indication id="84">Crohns disease</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA7191557">WO-2012162561</Patent><Status id="PUB">First Publication</Status><StatusDate>2012-11-29 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="185">Immune disorder</TherapyArea></Row><Row><Action id="5025">CD3 antagonist</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="WO">World</Country><Drug id="77135">tri-specific anti-Her1/Her3 Zybody (cancer), Zyngenia</Drug><DrugRelationship>General interest</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Publication</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PUB</HighestPatStatusIdForCnty><Indication id="97">Diabetes mellitus</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA7191557">WO-2012162561</Patent><Status id="PUB">First Publication</Status><StatusDate>2012-11-29 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="112">Endocrine disease</TherapyArea></Row><Row><Action id="5082">B-lymphocyte antigen CD19 inhibitor</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="WO">World</Country><Drug id="77135">tri-specific anti-Her1/Her3 Zybody (cancer), Zyngenia</Drug><DrugRelationship>General interest</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Publication</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PUB</HighestPatStatusIdForCnty><Indication id="188">Inflammatory disease</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA7191557">WO-2012162561</Patent><Status id="PUB">First Publication</Status><StatusDate>2012-11-29 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="188">Inflammatory disease</TherapyArea></Row><Row><Action id="5082">B-lymphocyte antigen CD19 inhibitor</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="WO">World</Country><Drug id="77135">tri-specific anti-Her1/Her3 Zybody (cancer), Zyngenia</Drug><DrugRelationship>General interest</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Publication</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PUB</HighestPatStatusIdForCnty><Indication id="189">Inflammatory bowel disease</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA7191557">WO-2012162561</Patent><Status id="PUB">First Publication</Status><StatusDate>2012-11-29 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="188">Inflammatory disease</TherapyArea></Row><Row><Action id="5082">B-lymphocyte antigen CD19 inhibitor</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="WO">World</Country><Drug id="77135">tri-specific anti-Her1/Her3 Zybody (cancer), Zyngenia</Drug><DrugRelationship>General interest</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Publication</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PUB</HighestPatStatusIdForCnty><Indication id="213">Multiple sclerosis</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA7191557">WO-2012162561</Patent><Status id="PUB">First Publication</Status><StatusDate>2012-11-29 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="185">Immune disorder</TherapyArea></Row><Row><Action id="5082">B-lymphocyte antigen CD19 inhibitor</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="WO">World</Country><Drug id="77135">tri-specific anti-Her1/Her3 Zybody (cancer), Zyngenia</Drug><DrugRelationship>General interest</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Publication</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PUB</HighestPatStatusIdForCnty><Indication id="281">Psoriasis</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA7191557">WO-2012162561</Patent><Status id="PUB">First Publication</Status><StatusDate>2012-11-29 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="95">Dermatological disease</TherapyArea></Row><Row><Action id="5082">B-lymphocyte antigen CD19 inhibitor</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="WO">World</Country><Drug id="77135">tri-specific anti-Her1/Her3 Zybody (cancer), Zyngenia</Drug><DrugRelationship>General interest</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Publication</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PUB</HighestPatStatusIdForCnty><Indication id="291">Rheumatoid arthritis</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA7191557">WO-2012162561</Patent><Status id="PUB">First Publication</Status><StatusDate>2012-11-29 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="185">Immune disorder</TherapyArea></Row><Row><Action id="5082">B-lymphocyte antigen CD19 inhibitor</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="WO">World</Country><Drug id="77135">tri-specific anti-Her1/Her3 Zybody (cancer), Zyngenia</Drug><DrugRelationship>General interest</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Publication</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PUB</HighestPatStatusIdForCnty><Indication id="318">Systemic lupus erythematosus</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA7191557">WO-2012162561</Patent><Status id="PUB">First Publication</Status><StatusDate>2012-11-29 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="95">Dermatological disease</TherapyArea></Row><Row><Action id="5082">B-lymphocyte antigen CD19 inhibitor</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="WO">World</Country><Drug id="77135">tri-specific anti-Her1/Her3 Zybody (cancer), Zyngenia</Drug><DrugRelationship>General interest</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Publication</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PUB</HighestPatStatusIdForCnty><Indication id="337">Ulcerative colitis</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA7191557">WO-2012162561</Patent><Status id="PUB">First Publication</Status><StatusDate>2012-11-29 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="185">Immune disorder</TherapyArea></Row><Row><Action id="5082">B-lymphocyte antigen CD19 inhibitor</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="WO">World</Country><Drug id="77135">tri-specific anti-Her1/Her3 Zybody (cancer), Zyngenia</Drug><DrugRelationship>General interest</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Publication</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PUB</HighestPatStatusIdForCnty><Indication id="651">Cancer</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA7191557">WO-2012162561</Patent><Status id="PUB">First Publication</Status><StatusDate>2012-11-29 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="230">Neoplasm</TherapyArea></Row><Row><Action id="5082">B-lymphocyte antigen CD19 inhibitor</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="WO">World</Country><Drug id="77135">tri-specific anti-Her1/Her3 Zybody (cancer), Zyngenia</Drug><DrugRelationship>General interest</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Publication</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PUB</HighestPatStatusIdForCnty><Indication id="746">Infectious disease</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA7191557">WO-2012162561</Patent><Status id="PUB">First Publication</Status><StatusDate>2012-11-29 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="746">Infectious disease</TherapyArea></Row><Row><Action id="5082">B-lymphocyte antigen CD19 inhibitor</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="WO">World</Country><Drug id="77135">tri-specific anti-Her1/Her3 Zybody (cancer), Zyngenia</Drug><DrugRelationship>General interest</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Publication</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PUB</HighestPatStatusIdForCnty><Indication id="84">Crohns disease</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA7191557">WO-2012162561</Patent><Status id="PUB">First Publication</Status><StatusDate>2012-11-29 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="185">Immune disorder</TherapyArea></Row><Row><Action id="5082">B-lymphocyte antigen CD19 inhibitor</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="WO">World</Country><Drug id="77135">tri-specific anti-Her1/Her3 Zybody (cancer), Zyngenia</Drug><DrugRelationship>General interest</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Publication</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PUB</HighestPatStatusIdForCnty><Indication id="97">Diabetes mellitus</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA7191557">WO-2012162561</Patent><Status id="PUB">First Publication</Status><StatusDate>2012-11-29 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="112">Endocrine disease</TherapyArea></Row><Row><Action id="5085">B-lymphocyte antigen CD20 inhibitor</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="WO">World</Country><Drug id="77135">tri-specific anti-Her1/Her3 Zybody (cancer), Zyngenia</Drug><DrugRelationship>General interest</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Publication</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PUB</HighestPatStatusIdForCnty><Indication id="188">Inflammatory disease</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA7191557">WO-2012162561</Patent><Status id="PUB">First Publication</Status><StatusDate>2012-11-29 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="188">Inflammatory disease</TherapyArea></Row><Row><Action id="5085">B-lymphocyte antigen CD20 inhibitor</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="WO">World</Country><Drug id="77135">tri-specific anti-Her1/Her3 Zybody (cancer), Zyngenia</Drug><DrugRelationship>General interest</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Publication</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PUB</HighestPatStatusIdForCnty><Indication id="189">Inflammatory bowel disease</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA7191557">WO-2012162561</Patent><Status id="PUB">First Publication</Status><StatusDate>2012-11-29 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="188">Inflammatory disease</TherapyArea></Row><Row><Action id="5085">B-lymphocyte antigen CD20 inhibitor</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="WO">World</Country><Drug id="77135">tri-specific anti-Her1/Her3 Zybody (cancer), Zyngenia</Drug><DrugRelationship>General interest</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Publication</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PUB</HighestPatStatusIdForCnty><Indication id="213">Multiple sclerosis</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA7191557">WO-2012162561</Patent><Status id="PUB">First Publication</Status><StatusDate>2012-11-29 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="185">Immune disorder</TherapyArea></Row><Row><Action id="5085">B-lymphocyte antigen CD20 inhibitor</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="WO">World</Country><Drug id="77135">tri-specific anti-Her1/Her3 Zybody (cancer), Zyngenia</Drug><DrugRelationship>General interest</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Publication</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PUB</HighestPatStatusIdForCnty><Indication id="281">Psoriasis</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA7191557">WO-2012162561</Patent><Status id="PUB">First Publication</Status><StatusDate>2012-11-29 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="95">Dermatological disease</TherapyArea></Row><Row><Action id="5085">B-lymphocyte antigen CD20 inhibitor</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="WO">World</Country><Drug id="77135">tri-specific anti-Her1/Her3 Zybody (cancer), Zyngenia</Drug><DrugRelationship>General interest</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Publication</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PUB</HighestPatStatusIdForCnty><Indication id="291">Rheumatoid arthritis</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA7191557">WO-2012162561</Patent><Status id="PUB">First Publication</Status><StatusDate>2012-11-29 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="185">Immune disorder</TherapyArea></Row><Row><Action id="5085">B-lymphocyte antigen CD20 inhibitor</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="WO">World</Country><Drug id="77135">tri-specific anti-Her1/Her3 Zybody (cancer), Zyngenia</Drug><DrugRelationship>General interest</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Publication</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PUB</HighestPatStatusIdForCnty><Indication id="318">Systemic lupus erythematosus</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA7191557">WO-2012162561</Patent><Status id="PUB">First Publication</Status><StatusDate>2012-11-29 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="95">Dermatological disease</TherapyArea></Row><Row><Action id="5085">B-lymphocyte antigen CD20 inhibitor</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="WO">World</Country><Drug id="77135">tri-specific anti-Her1/Her3 Zybody (cancer), Zyngenia</Drug><DrugRelationship>General interest</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Publication</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PUB</HighestPatStatusIdForCnty><Indication id="337">Ulcerative colitis</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA7191557">WO-2012162561</Patent><Status id="PUB">First Publication</Status><StatusDate>2012-11-29 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="185">Immune disorder</TherapyArea></Row><Row><Action id="5085">B-lymphocyte antigen CD20 inhibitor</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="WO">World</Country><Drug id="77135">tri-specific anti-Her1/Her3 Zybody (cancer), Zyngenia</Drug><DrugRelationship>General interest</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Publication</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PUB</HighestPatStatusIdForCnty><Indication id="651">Cancer</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA7191557">WO-2012162561</Patent><Status id="PUB">First Publication</Status><StatusDate>2012-11-29 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="230">Neoplasm</TherapyArea></Row><Row><Action id="5085">B-lymphocyte antigen CD20 inhibitor</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="WO">World</Country><Drug id="77135">tri-specific anti-Her1/Her3 Zybody (cancer), Zyngenia</Drug><DrugRelationship>General interest</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Publication</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PUB</HighestPatStatusIdForCnty><Indication id="746">Infectious disease</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA7191557">WO-2012162561</Patent><Status id="PUB">First Publication</Status><StatusDate>2012-11-29 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="746">Infectious disease</TherapyArea></Row><Row><Action id="5085">B-lymphocyte antigen CD20 inhibitor</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="WO">World</Country><Drug id="77135">tri-specific anti-Her1/Her3 Zybody (cancer), Zyngenia</Drug><DrugRelationship>General interest</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Publication</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PUB</HighestPatStatusIdForCnty><Indication id="84">Crohns disease</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA7191557">WO-2012162561</Patent><Status id="PUB">First Publication</Status><StatusDate>2012-11-29 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="185">Immune disorder</TherapyArea></Row><Row><Action id="5085">B-lymphocyte antigen CD20 inhibitor</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="WO">World</Country><Drug id="77135">tri-specific anti-Her1/Her3 Zybody (cancer), Zyngenia</Drug><DrugRelationship>General interest</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Publication</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PUB</HighestPatStatusIdForCnty><Indication id="97">Diabetes mellitus</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA7191557">WO-2012162561</Patent><Status id="PUB">First Publication</Status><StatusDate>2012-11-29 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="112">Endocrine disease</TherapyArea></Row><Row><Action id="511">TNF antagonist</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="WO">World</Country><Drug id="77135">tri-specific anti-Her1/Her3 Zybody (cancer), Zyngenia</Drug><DrugRelationship>General interest</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Publication</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PUB</HighestPatStatusIdForCnty><Indication id="188">Inflammatory disease</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA7191557">WO-2012162561</Patent><Status id="PUB">First Publication</Status><StatusDate>2012-11-29 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="188">Inflammatory disease</TherapyArea></Row><Row><Action id="511">TNF antagonist</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="WO">World</Country><Drug id="77135">tri-specific anti-Her1/Her3 Zybody (cancer), Zyngenia</Drug><DrugRelationship>General interest</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Publication</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PUB</HighestPatStatusIdForCnty><Indication id="189">Inflammatory bowel disease</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA7191557">WO-2012162561</Patent><Status id="PUB">First Publication</Status><StatusDate>2012-11-29 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="188">Inflammatory disease</TherapyArea></Row><Row><Action id="511">TNF antagonist</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="WO">World</Country><Drug id="77135">tri-specific anti-Her1/Her3 Zybody (cancer), Zyngenia</Drug><DrugRelationship>General interest</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Publication</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PUB</HighestPatStatusIdForCnty><Indication id="213">Multiple sclerosis</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA7191557">WO-2012162561</Patent><Status id="PUB">First Publication</Status><StatusDate>2012-11-29 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="185">Immune disorder</TherapyArea></Row><Row><Action id="511">TNF antagonist</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="WO">World</Country><Drug id="77135">tri-specific anti-Her1/Her3 Zybody (cancer), Zyngenia</Drug><DrugRelationship>General interest</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Publication</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PUB</HighestPatStatusIdForCnty><Indication id="281">Psoriasis</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA7191557">WO-2012162561</Patent><Status id="PUB">First Publication</Status><StatusDate>2012-11-29 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="95">Dermatological disease</TherapyArea></Row><Row><Action id="511">TNF antagonist</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="WO">World</Country><Drug id="77135">tri-specific anti-Her1/Her3 Zybody (cancer), Zyngenia</Drug><DrugRelationship>General interest</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Publication</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PUB</HighestPatStatusIdForCnty><Indication id="291">Rheumatoid arthritis</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA7191557">WO-2012162561</Patent><Status id="PUB">First Publication</Status><StatusDate>2012-11-29 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="185">Immune disorder</TherapyArea></Row><Row><Action id="511">TNF antagonist</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="WO">World</Country><Drug id="77135">tri-specific anti-Her1/Her3 Zybody (cancer), Zyngenia</Drug><DrugRelationship>General interest</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Publication</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PUB</HighestPatStatusIdForCnty><Indication id="318">Systemic lupus erythematosus</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA7191557">WO-2012162561</Patent><Status id="PUB">First Publication</Status><StatusDate>2012-11-29 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="95">Dermatological disease</TherapyArea></Row><Row><Action id="511">TNF antagonist</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="WO">World</Country><Drug id="77135">tri-specific anti-Her1/Her3 Zybody (cancer), Zyngenia</Drug><DrugRelationship>General interest</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Publication</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PUB</HighestPatStatusIdForCnty><Indication id="337">Ulcerative colitis</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA7191557">WO-2012162561</Patent><Status id="PUB">First Publication</Status><StatusDate>2012-11-29 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="185">Immune disorder</TherapyArea></Row><Row><Action id="511">TNF antagonist</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="WO">World</Country><Drug id="77135">tri-specific anti-Her1/Her3 Zybody (cancer), Zyngenia</Drug><DrugRelationship>General interest</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Publication</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PUB</HighestPatStatusIdForCnty><Indication id="651">Cancer</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA7191557">WO-2012162561</Patent><Status id="PUB">First Publication</Status><StatusDate>2012-11-29 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="230">Neoplasm</TherapyArea></Row><Row><Action id="511">TNF antagonist</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="WO">World</Country><Drug id="77135">tri-specific anti-Her1/Her3 Zybody (cancer), Zyngenia</Drug><DrugRelationship>General interest</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Publication</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PUB</HighestPatStatusIdForCnty><Indication id="746">Infectious disease</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA7191557">WO-2012162561</Patent><Status id="PUB">First Publication</Status><StatusDate>2012-11-29 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="746">Infectious disease</TherapyArea></Row><Row><Action id="511">TNF antagonist</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="WO">World</Country><Drug id="77135">tri-specific anti-Her1/Her3 Zybody (cancer), Zyngenia</Drug><DrugRelationship>General interest</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Publication</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PUB</HighestPatStatusIdForCnty><Indication id="84">Crohns disease</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA7191557">WO-2012162561</Patent><Status id="PUB">First Publication</Status><StatusDate>2012-11-29 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="185">Immune disorder</TherapyArea></Row><Row><Action id="511">TNF antagonist</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="WO">World</Country><Drug id="77135">tri-specific anti-Her1/Her3 Zybody (cancer), Zyngenia</Drug><DrugRelationship>General interest</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Publication</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PUB</HighestPatStatusIdForCnty><Indication id="97">Diabetes mellitus</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA7191557">WO-2012162561</Patent><Status id="PUB">First Publication</Status><StatusDate>2012-11-29 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="112">Endocrine disease</TherapyArea></Row><Row><Action id="675">Hepatocyte growth factor receptor antagonist</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="WO">World</Country><Drug id="77135">tri-specific anti-Her1/Her3 Zybody (cancer), Zyngenia</Drug><DrugRelationship>General interest</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Publication</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PUB</HighestPatStatusIdForCnty><Indication id="188">Inflammatory disease</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA7191557">WO-2012162561</Patent><Status id="PUB">First Publication</Status><StatusDate>2012-11-29 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="188">Inflammatory disease</TherapyArea></Row><Row><Action id="675">Hepatocyte growth factor receptor antagonist</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="WO">World</Country><Drug id="77135">tri-specific anti-Her1/Her3 Zybody (cancer), Zyngenia</Drug><DrugRelationship>General interest</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Publication</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PUB</HighestPatStatusIdForCnty><Indication id="189">Inflammatory bowel disease</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA7191557">WO-2012162561</Patent><Status id="PUB">First Publication</Status><StatusDate>2012-11-29 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="188">Inflammatory disease</TherapyArea></Row><Row><Action id="675">Hepatocyte growth factor receptor antagonist</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="WO">World</Country><Drug id="77135">tri-specific anti-Her1/Her3 Zybody (cancer), Zyngenia</Drug><DrugRelationship>General interest</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Publication</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PUB</HighestPatStatusIdForCnty><Indication id="213">Multiple sclerosis</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA7191557">WO-2012162561</Patent><Status id="PUB">First Publication</Status><StatusDate>2012-11-29 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="185">Immune disorder</TherapyArea></Row><Row><Action id="675">Hepatocyte growth factor receptor antagonist</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="WO">World</Country><Drug id="77135">tri-specific anti-Her1/Her3 Zybody (cancer), Zyngenia</Drug><DrugRelationship>General interest</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Publication</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PUB</HighestPatStatusIdForCnty><Indication id="281">Psoriasis</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA7191557">WO-2012162561</Patent><Status id="PUB">First Publication</Status><StatusDate>2012-11-29 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="95">Dermatological disease</TherapyArea></Row><Row><Action id="675">Hepatocyte growth factor receptor antagonist</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="WO">World</Country><Drug id="77135">tri-specific anti-Her1/Her3 Zybody (cancer), Zyngenia</Drug><DrugRelationship>General interest</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Publication</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PUB</HighestPatStatusIdForCnty><Indication id="291">Rheumatoid arthritis</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA7191557">WO-2012162561</Patent><Status id="PUB">First Publication</Status><StatusDate>2012-11-29 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="185">Immune disorder</TherapyArea></Row><Row><Action id="675">Hepatocyte growth factor receptor antagonist</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="WO">World</Country><Drug id="77135">tri-specific anti-Her1/Her3 Zybody (cancer), Zyngenia</Drug><DrugRelationship>General interest</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Publication</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PUB</HighestPatStatusIdForCnty><Indication id="318">Systemic lupus erythematosus</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA7191557">WO-2012162561</Patent><Status id="PUB">First Publication</Status><StatusDate>2012-11-29 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="95">Dermatological disease</TherapyArea></Row><Row><Action id="675">Hepatocyte growth factor receptor antagonist</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="WO">World</Country><Drug id="77135">tri-specific anti-Her1/Her3 Zybody (cancer), Zyngenia</Drug><DrugRelationship>General interest</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Publication</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PUB</HighestPatStatusIdForCnty><Indication id="337">Ulcerative colitis</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA7191557">WO-2012162561</Patent><Status id="PUB">First Publication</Status><StatusDate>2012-11-29 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="185">Immune disorder</TherapyArea></Row><Row><Action id="675">Hepatocyte growth factor receptor antagonist</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="WO">World</Country><Drug id="77135">tri-specific anti-Her1/Her3 Zybody (cancer), Zyngenia</Drug><DrugRelationship>General interest</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Publication</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PUB</HighestPatStatusIdForCnty><Indication id="651">Cancer</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA7191557">WO-2012162561</Patent><Status id="PUB">First Publication</Status><StatusDate>2012-11-29 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="230">Neoplasm</TherapyArea></Row><Row><Action id="675">Hepatocyte growth factor receptor antagonist</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="WO">World</Country><Drug id="77135">tri-specific anti-Her1/Her3 Zybody (cancer), Zyngenia</Drug><DrugRelationship>General interest</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Publication</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PUB</HighestPatStatusIdForCnty><Indication id="746">Infectious disease</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA7191557">WO-2012162561</Patent><Status id="PUB">First Publication</Status><StatusDate>2012-11-29 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="746">Infectious disease</TherapyArea></Row><Row><Action id="675">Hepatocyte growth factor receptor antagonist</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="WO">World</Country><Drug id="77135">tri-specific anti-Her1/Her3 Zybody (cancer), Zyngenia</Drug><DrugRelationship>General interest</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Publication</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PUB</HighestPatStatusIdForCnty><Indication id="84">Crohns disease</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA7191557">WO-2012162561</Patent><Status id="PUB">First Publication</Status><StatusDate>2012-11-29 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="185">Immune disorder</TherapyArea></Row><Row><Action id="675">Hepatocyte growth factor receptor antagonist</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="WO">World</Country><Drug id="77135">tri-specific anti-Her1/Her3 Zybody (cancer), Zyngenia</Drug><DrugRelationship>General interest</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Publication</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PUB</HighestPatStatusIdForCnty><Indication id="97">Diabetes mellitus</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA7191557">WO-2012162561</Patent><Status id="PUB">First Publication</Status><StatusDate>2012-11-29 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="112">Endocrine disease</TherapyArea></Row><Row><Action id="740">Epidermal growth factor receptor antagonist</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="WO">World</Country><Drug id="77135">tri-specific anti-Her1/Her3 Zybody (cancer), Zyngenia</Drug><DrugRelationship>General interest</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Publication</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PUB</HighestPatStatusIdForCnty><Indication id="188">Inflammatory disease</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA7191557">WO-2012162561</Patent><Status id="PUB">First Publication</Status><StatusDate>2012-11-29 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="188">Inflammatory disease</TherapyArea></Row><Row><Action id="740">Epidermal growth factor receptor antagonist</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="WO">World</Country><Drug id="77135">tri-specific anti-Her1/Her3 Zybody (cancer), Zyngenia</Drug><DrugRelationship>General interest</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Publication</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PUB</HighestPatStatusIdForCnty><Indication id="189">Inflammatory bowel disease</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA7191557">WO-2012162561</Patent><Status id="PUB">First Publication</Status><StatusDate>2012-11-29 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="188">Inflammatory disease</TherapyArea></Row><Row><Action id="740">Epidermal growth factor receptor antagonist</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="WO">World</Country><Drug id="77135">tri-specific anti-Her1/Her3 Zybody (cancer), Zyngenia</Drug><DrugRelationship>General interest</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Publication</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PUB</HighestPatStatusIdForCnty><Indication id="213">Multiple sclerosis</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA7191557">WO-2012162561</Patent><Status id="PUB">First Publication</Status><StatusDate>2012-11-29 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="185">Immune disorder</TherapyArea></Row><Row><Action id="740">Epidermal growth factor receptor antagonist</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="WO">World</Country><Drug id="77135">tri-specific anti-Her1/Her3 Zybody (cancer), Zyngenia</Drug><DrugRelationship>General interest</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Publication</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PUB</HighestPatStatusIdForCnty><Indication id="281">Psoriasis</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA7191557">WO-2012162561</Patent><Status id="PUB">First Publication</Status><StatusDate>2012-11-29 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="95">Dermatological disease</TherapyArea></Row><Row><Action id="740">Epidermal growth factor receptor antagonist</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="WO">World</Country><Drug id="77135">tri-specific anti-Her1/Her3 Zybody (cancer), Zyngenia</Drug><DrugRelationship>General interest</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Publication</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PUB</HighestPatStatusIdForCnty><Indication id="291">Rheumatoid arthritis</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA7191557">WO-2012162561</Patent><Status id="PUB">First Publication</Status><StatusDate>2012-11-29 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="185">Immune disorder</TherapyArea></Row><Row><Action id="740">Epidermal growth factor receptor antagonist</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="WO">World</Country><Drug id="77135">tri-specific anti-Her1/Her3 Zybody (cancer), Zyngenia</Drug><DrugRelationship>General interest</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Publication</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PUB</HighestPatStatusIdForCnty><Indication id="318">Systemic lupus erythematosus</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA7191557">WO-2012162561</Patent><Status id="PUB">First Publication</Status><StatusDate>2012-11-29 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="95">Dermatological disease</TherapyArea></Row><Row><Action id="740">Epidermal growth factor receptor antagonist</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="WO">World</Country><Drug id="77135">tri-specific anti-Her1/Her3 Zybody (cancer), Zyngenia</Drug><DrugRelationship>General interest</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Publication</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PUB</HighestPatStatusIdForCnty><Indication id="337">Ulcerative colitis</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA7191557">WO-2012162561</Patent><Status id="PUB">First Publication</Status><StatusDate>2012-11-29 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="185">Immune disorder</TherapyArea></Row><Row><Action id="740">Epidermal growth factor receptor antagonist</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="WO">World</Country><Drug id="77135">tri-specific anti-Her1/Her3 Zybody (cancer), Zyngenia</Drug><DrugRelationship>General interest</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Publication</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PUB</HighestPatStatusIdForCnty><Indication id="651">Cancer</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA7191557">WO-2012162561</Patent><Status id="PUB">First Publication</Status><StatusDate>2012-11-29 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="230">Neoplasm</TherapyArea></Row><Row><Action id="740">Epidermal growth factor receptor antagonist</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="WO">World</Country><Drug id="77135">tri-specific anti-Her1/Her3 Zybody (cancer), Zyngenia</Drug><DrugRelationship>General interest</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Publication</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PUB</HighestPatStatusIdForCnty><Indication id="746">Infectious disease</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA7191557">WO-2012162561</Patent><Status id="PUB">First Publication</Status><StatusDate>2012-11-29 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="746">Infectious disease</TherapyArea></Row><Row><Action id="740">Epidermal growth factor receptor antagonist</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="WO">World</Country><Drug id="77135">tri-specific anti-Her1/Her3 Zybody (cancer), Zyngenia</Drug><DrugRelationship>General interest</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Publication</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PUB</HighestPatStatusIdForCnty><Indication id="84">Crohns disease</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA7191557">WO-2012162561</Patent><Status id="PUB">First Publication</Status><StatusDate>2012-11-29 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="185">Immune disorder</TherapyArea></Row><Row><Action id="740">Epidermal growth factor receptor antagonist</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="WO">World</Country><Drug id="77135">tri-specific anti-Her1/Her3 Zybody (cancer), Zyngenia</Drug><DrugRelationship>General interest</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Publication</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PUB</HighestPatStatusIdForCnty><Indication id="97">Diabetes mellitus</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA7191557">WO-2012162561</Patent><Status id="PUB">First Publication</Status><StatusDate>2012-11-29 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="112">Endocrine disease</TherapyArea></Row><Row><Action id="14007">Programmed cell death ligand 1 inhibitor</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Third Party</CompanyOwnershipRelationship><Country id="WO">World</Country><Drug id="23886">urelumab</Drug><DrugRelationship>General interest</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Publication</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PUB</HighestPatStatusIdForCnty><Indication id="1731">Acute myelogenous leukemia</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA8994513">WO-2016164305</Patent><Status id="PUB">First Publication</Status><StatusDate>2016-10-13 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="9099">Rare disease</TherapyArea></Row><Row><Action id="14007">Programmed cell death ligand 1 inhibitor</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Third Party</CompanyOwnershipRelationship><Country id="WO">World</Country><Drug id="23886">urelumab</Drug><DrugRelationship>General interest</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Publication</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PUB</HighestPatStatusIdForCnty><Indication id="1735">Chronic myelocytic leukemia</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA8994513">WO-2016164305</Patent><Status id="PUB">First Publication</Status><StatusDate>2016-10-13 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="142">Hematological disease</TherapyArea></Row><Row><Action id="14007">Programmed cell death ligand 1 inhibitor</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Third Party</CompanyOwnershipRelationship><Country id="WO">World</Country><Drug id="23886">urelumab</Drug><DrugRelationship>General interest</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Publication</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PUB</HighestPatStatusIdForCnty><Indication id="2054">Hematological neoplasm</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA8994513">WO-2016164305</Patent><Status id="PUB">First Publication</Status><StatusDate>2016-10-13 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="142">Hematological disease</TherapyArea></Row><Row><Action id="14007">Programmed cell death ligand 1 inhibitor</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Third Party</CompanyOwnershipRelationship><Country id="WO">World</Country><Drug id="23886">urelumab</Drug><DrugRelationship>General interest</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Publication</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PUB</HighestPatStatusIdForCnty><Indication id="651">Cancer</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA8994513">WO-2016164305</Patent><Status id="PUB">First Publication</Status><StatusDate>2016-10-13 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="230">Neoplasm</TherapyArea></Row><Row><Action id="14007">Programmed cell death ligand 1 inhibitor</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Third Party</CompanyOwnershipRelationship><Country id="WO">World</Country><Drug id="23886">urelumab</Drug><DrugRelationship>General interest</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Publication</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PUB</HighestPatStatusIdForCnty><Indication id="725">Solid tumor</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA8994513">WO-2016164305</Patent><Status id="PUB">First Publication</Status><StatusDate>2016-10-13 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="230">Neoplasm</TherapyArea></Row><Row><Action id="5429">CDw123 antagonist</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Third Party</CompanyOwnershipRelationship><Country id="WO">World</Country><Drug id="23886">urelumab</Drug><DrugRelationship>General interest</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Publication</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PUB</HighestPatStatusIdForCnty><Indication id="1731">Acute myelogenous leukemia</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA8994513">WO-2016164305</Patent><Status id="PUB">First Publication</Status><StatusDate>2016-10-13 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="9099">Rare disease</TherapyArea></Row><Row><Action id="5429">CDw123 antagonist</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Third Party</CompanyOwnershipRelationship><Country id="WO">World</Country><Drug id="23886">urelumab</Drug><DrugRelationship>General interest</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Publication</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PUB</HighestPatStatusIdForCnty><Indication id="1735">Chronic myelocytic leukemia</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA8994513">WO-2016164305</Patent><Status id="PUB">First Publication</Status><StatusDate>2016-10-13 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="142">Hematological disease</TherapyArea></Row><Row><Action id="5429">CDw123 antagonist</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Third Party</CompanyOwnershipRelationship><Country id="WO">World</Country><Drug id="23886">urelumab</Drug><DrugRelationship>General interest</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Publication</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PUB</HighestPatStatusIdForCnty><Indication id="2054">Hematological neoplasm</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA8994513">WO-2016164305</Patent><Status id="PUB">First Publication</Status><StatusDate>2016-10-13 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="142">Hematological disease</TherapyArea></Row><Row><Action id="5429">CDw123 antagonist</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Third Party</CompanyOwnershipRelationship><Country id="WO">World</Country><Drug id="23886">urelumab</Drug><DrugRelationship>General interest</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Publication</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PUB</HighestPatStatusIdForCnty><Indication id="651">Cancer</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA8994513">WO-2016164305</Patent><Status id="PUB">First Publication</Status><StatusDate>2016-10-13 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="230">Neoplasm</TherapyArea></Row><Row><Action id="5429">CDw123 antagonist</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Third Party</CompanyOwnershipRelationship><Country id="WO">World</Country><Drug id="23886">urelumab</Drug><DrugRelationship>General interest</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Publication</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PUB</HighestPatStatusIdForCnty><Indication id="725">Solid tumor</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA8994513">WO-2016164305</Patent><Status id="PUB">First Publication</Status><StatusDate>2016-10-13 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="230">Neoplasm</TherapyArea></Row><Row><Action id="7761">T-lymphocyte stimulator</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Third Party</CompanyOwnershipRelationship><Country id="WO">World</Country><Drug id="23886">urelumab</Drug><DrugRelationship>General interest</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Publication</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PUB</HighestPatStatusIdForCnty><Indication id="1731">Acute myelogenous leukemia</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA8994513">WO-2016164305</Patent><Status id="PUB">First Publication</Status><StatusDate>2016-10-13 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="9099">Rare disease</TherapyArea></Row><Row><Action id="7761">T-lymphocyte stimulator</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Third Party</CompanyOwnershipRelationship><Country id="WO">World</Country><Drug id="23886">urelumab</Drug><DrugRelationship>General interest</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Publication</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PUB</HighestPatStatusIdForCnty><Indication id="1735">Chronic myelocytic leukemia</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA8994513">WO-2016164305</Patent><Status id="PUB">First Publication</Status><StatusDate>2016-10-13 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="142">Hematological disease</TherapyArea></Row><Row><Action id="7761">T-lymphocyte stimulator</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Third Party</CompanyOwnershipRelationship><Country id="WO">World</Country><Drug id="23886">urelumab</Drug><DrugRelationship>General interest</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Publication</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PUB</HighestPatStatusIdForCnty><Indication id="2054">Hematological neoplasm</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA8994513">WO-2016164305</Patent><Status id="PUB">First Publication</Status><StatusDate>2016-10-13 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="142">Hematological disease</TherapyArea></Row><Row><Action id="7761">T-lymphocyte stimulator</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Third Party</CompanyOwnershipRelationship><Country id="WO">World</Country><Drug id="23886">urelumab</Drug><DrugRelationship>General interest</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Publication</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PUB</HighestPatStatusIdForCnty><Indication id="651">Cancer</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA8994513">WO-2016164305</Patent><Status id="PUB">First Publication</Status><StatusDate>2016-10-13 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="230">Neoplasm</TherapyArea></Row><Row><Action id="7761">T-lymphocyte stimulator</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Third Party</CompanyOwnershipRelationship><Country id="WO">World</Country><Drug id="23886">urelumab</Drug><DrugRelationship>General interest</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Publication</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PUB</HighestPatStatusIdForCnty><Indication id="725">Solid tumor</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA8994513">WO-2016164305</Patent><Status id="PUB">First Publication</Status><StatusDate>2016-10-13 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="230">Neoplasm</TherapyArea></Row><Row><Action id="14007">Programmed cell death ligand 1 inhibitor</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Third Party</CompanyOwnershipRelationship><Country id="WO">World</Country><Drug id="8747">palivizumab</Drug><DrugRelationship>General interest</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Publication</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PUB</HighestPatStatusIdForCnty><Indication id="1731">Acute myelogenous leukemia</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA8994513">WO-2016164305</Patent><Status id="PUB">First Publication</Status><StatusDate>2016-10-13 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="9099">Rare disease</TherapyArea></Row><Row><Action id="14007">Programmed cell death ligand 1 inhibitor</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Third Party</CompanyOwnershipRelationship><Country id="WO">World</Country><Drug id="8747">palivizumab</Drug><DrugRelationship>General interest</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Publication</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PUB</HighestPatStatusIdForCnty><Indication id="1735">Chronic myelocytic leukemia</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA8994513">WO-2016164305</Patent><Status id="PUB">First Publication</Status><StatusDate>2016-10-13 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="142">Hematological disease</TherapyArea></Row><Row><Action id="14007">Programmed cell death ligand 1 inhibitor</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Third Party</CompanyOwnershipRelationship><Country id="WO">World</Country><Drug id="8747">palivizumab</Drug><DrugRelationship>General interest</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Publication</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PUB</HighestPatStatusIdForCnty><Indication id="2054">Hematological neoplasm</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA8994513">WO-2016164305</Patent><Status id="PUB">First Publication</Status><StatusDate>2016-10-13 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="142">Hematological disease</TherapyArea></Row><Row><Action id="14007">Programmed cell death ligand 1 inhibitor</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Third Party</CompanyOwnershipRelationship><Country id="WO">World</Country><Drug id="8747">palivizumab</Drug><DrugRelationship>General interest</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Publication</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PUB</HighestPatStatusIdForCnty><Indication id="651">Cancer</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA8994513">WO-2016164305</Patent><Status id="PUB">First Publication</Status><StatusDate>2016-10-13 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="230">Neoplasm</TherapyArea></Row><Row><Action id="14007">Programmed cell death ligand 1 inhibitor</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Third Party</CompanyOwnershipRelationship><Country id="WO">World</Country><Drug id="8747">palivizumab</Drug><DrugRelationship>General interest</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Publication</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PUB</HighestPatStatusIdForCnty><Indication id="725">Solid tumor</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA8994513">WO-2016164305</Patent><Status id="PUB">First Publication</Status><StatusDate>2016-10-13 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="230">Neoplasm</TherapyArea></Row><Row><Action id="5429">CDw123 antagonist</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Third Party</CompanyOwnershipRelationship><Country id="WO">World</Country><Drug id="8747">palivizumab</Drug><DrugRelationship>General interest</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Publication</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PUB</HighestPatStatusIdForCnty><Indication id="1731">Acute myelogenous leukemia</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA8994513">WO-2016164305</Patent><Status id="PUB">First Publication</Status><StatusDate>2016-10-13 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="9099">Rare disease</TherapyArea></Row><Row><Action id="5429">CDw123 antagonist</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Third Party</CompanyOwnershipRelationship><Country id="WO">World</Country><Drug id="8747">palivizumab</Drug><DrugRelationship>General interest</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Publication</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PUB</HighestPatStatusIdForCnty><Indication id="1735">Chronic myelocytic leukemia</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA8994513">WO-2016164305</Patent><Status id="PUB">First Publication</Status><StatusDate>2016-10-13 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="142">Hematological disease</TherapyArea></Row><Row><Action id="5429">CDw123 antagonist</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Third Party</CompanyOwnershipRelationship><Country id="WO">World</Country><Drug id="8747">palivizumab</Drug><DrugRelationship>General interest</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Publication</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PUB</HighestPatStatusIdForCnty><Indication id="2054">Hematological neoplasm</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA8994513">WO-2016164305</Patent><Status id="PUB">First Publication</Status><StatusDate>2016-10-13 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="142">Hematological disease</TherapyArea></Row><Row><Action id="5429">CDw123 antagonist</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Third Party</CompanyOwnershipRelationship><Country id="WO">World</Country><Drug id="8747">palivizumab</Drug><DrugRelationship>General interest</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Publication</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PUB</HighestPatStatusIdForCnty><Indication id="651">Cancer</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA8994513">WO-2016164305</Patent><Status id="PUB">First Publication</Status><StatusDate>2016-10-13 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="230">Neoplasm</TherapyArea></Row><Row><Action id="5429">CDw123 antagonist</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Third Party</CompanyOwnershipRelationship><Country id="WO">World</Country><Drug id="8747">palivizumab</Drug><DrugRelationship>General interest</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Publication</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PUB</HighestPatStatusIdForCnty><Indication id="725">Solid tumor</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA8994513">WO-2016164305</Patent><Status id="PUB">First Publication</Status><StatusDate>2016-10-13 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="230">Neoplasm</TherapyArea></Row><Row><Action id="7761">T-lymphocyte stimulator</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Third Party</CompanyOwnershipRelationship><Country id="WO">World</Country><Drug id="8747">palivizumab</Drug><DrugRelationship>General interest</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Publication</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PUB</HighestPatStatusIdForCnty><Indication id="1731">Acute myelogenous leukemia</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA8994513">WO-2016164305</Patent><Status id="PUB">First Publication</Status><StatusDate>2016-10-13 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="9099">Rare disease</TherapyArea></Row><Row><Action id="7761">T-lymphocyte stimulator</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Third Party</CompanyOwnershipRelationship><Country id="WO">World</Country><Drug id="8747">palivizumab</Drug><DrugRelationship>General interest</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Publication</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PUB</HighestPatStatusIdForCnty><Indication id="1735">Chronic myelocytic leukemia</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA8994513">WO-2016164305</Patent><Status id="PUB">First Publication</Status><StatusDate>2016-10-13 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="142">Hematological disease</TherapyArea></Row><Row><Action id="7761">T-lymphocyte stimulator</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Third Party</CompanyOwnershipRelationship><Country id="WO">World</Country><Drug id="8747">palivizumab</Drug><DrugRelationship>General interest</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Publication</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PUB</HighestPatStatusIdForCnty><Indication id="2054">Hematological neoplasm</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA8994513">WO-2016164305</Patent><Status id="PUB">First Publication</Status><StatusDate>2016-10-13 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="142">Hematological disease</TherapyArea></Row><Row><Action id="7761">T-lymphocyte stimulator</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Third Party</CompanyOwnershipRelationship><Country id="WO">World</Country><Drug id="8747">palivizumab</Drug><DrugRelationship>General interest</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Publication</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PUB</HighestPatStatusIdForCnty><Indication id="651">Cancer</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA8994513">WO-2016164305</Patent><Status id="PUB">First Publication</Status><StatusDate>2016-10-13 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="230">Neoplasm</TherapyArea></Row><Row><Action id="7761">T-lymphocyte stimulator</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Third Party</CompanyOwnershipRelationship><Country id="WO">World</Country><Drug id="8747">palivizumab</Drug><DrugRelationship>General interest</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Publication</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PUB</HighestPatStatusIdForCnty><Indication id="725">Solid tumor</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA8994513">WO-2016164305</Patent><Status id="PUB">First Publication</Status><StatusDate>2016-10-13 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="230">Neoplasm</TherapyArea></Row><Row><Action id="14007">Programmed cell death ligand 1 inhibitor</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Third Party</CompanyOwnershipRelationship><Country id="WO">World</Country><Drug id="23886">urelumab</Drug><DrugRelationship>General interest</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Publication</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PUB</HighestPatStatusIdForCnty><Indication id="1731">Acute myelogenous leukemia</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA8994514">WO-2016164308</Patent><Status id="PUB">First Publication</Status><StatusDate>2016-10-13 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="9099">Rare disease</TherapyArea></Row><Row><Action id="14007">Programmed cell death ligand 1 inhibitor</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Third Party</CompanyOwnershipRelationship><Country id="WO">World</Country><Drug id="23886">urelumab</Drug><DrugRelationship>General interest</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Publication</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PUB</HighestPatStatusIdForCnty><Indication id="1735">Chronic myelocytic leukemia</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA8994514">WO-2016164308</Patent><Status id="PUB">First Publication</Status><StatusDate>2016-10-13 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="142">Hematological disease</TherapyArea></Row><Row><Action id="14007">Programmed cell death ligand 1 inhibitor</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Third Party</CompanyOwnershipRelationship><Country id="WO">World</Country><Drug id="23886">urelumab</Drug><DrugRelationship>General interest</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Publication</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PUB</HighestPatStatusIdForCnty><Indication id="2054">Hematological neoplasm</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA8994514">WO-2016164308</Patent><Status id="PUB">First Publication</Status><StatusDate>2016-10-13 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="142">Hematological disease</TherapyArea></Row><Row><Action id="14007">Programmed cell death ligand 1 inhibitor</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Third Party</CompanyOwnershipRelationship><Country id="WO">World</Country><Drug id="23886">urelumab</Drug><DrugRelationship>General interest</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Publication</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PUB</HighestPatStatusIdForCnty><Indication id="725">Solid tumor</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA8994514">WO-2016164308</Patent><Status id="PUB">First Publication</Status><StatusDate>2016-10-13 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="230">Neoplasm</TherapyArea></Row><Row><Action id="5451">CDw137 antagonist</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Third Party</CompanyOwnershipRelationship><Country id="WO">World</Country><Drug id="23886">urelumab</Drug><DrugRelationship>General interest</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Publication</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PUB</HighestPatStatusIdForCnty><Indication id="1731">Acute myelogenous leukemia</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA8994514">WO-2016164308</Patent><Status id="PUB">First Publication</Status><StatusDate>2016-10-13 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="9099">Rare disease</TherapyArea></Row><Row><Action id="5451">CDw137 antagonist</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Third Party</CompanyOwnershipRelationship><Country id="WO">World</Country><Drug id="23886">urelumab</Drug><DrugRelationship>General interest</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Publication</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PUB</HighestPatStatusIdForCnty><Indication id="1735">Chronic myelocytic leukemia</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA8994514">WO-2016164308</Patent><Status id="PUB">First Publication</Status><StatusDate>2016-10-13 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="142">Hematological disease</TherapyArea></Row><Row><Action id="5451">CDw137 antagonist</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Third Party</CompanyOwnershipRelationship><Country id="WO">World</Country><Drug id="23886">urelumab</Drug><DrugRelationship>General interest</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Publication</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PUB</HighestPatStatusIdForCnty><Indication id="2054">Hematological neoplasm</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA8994514">WO-2016164308</Patent><Status id="PUB">First Publication</Status><StatusDate>2016-10-13 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="142">Hematological disease</TherapyArea></Row><Row><Action id="5451">CDw137 antagonist</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Third Party</CompanyOwnershipRelationship><Country id="WO">World</Country><Drug id="23886">urelumab</Drug><DrugRelationship>General interest</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Publication</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PUB</HighestPatStatusIdForCnty><Indication id="725">Solid tumor</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA8994514">WO-2016164308</Patent><Status id="PUB">First Publication</Status><StatusDate>2016-10-13 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="230">Neoplasm</TherapyArea></Row><Row><Action id="7220">Neoplasm diagnostic agent</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Third Party</CompanyOwnershipRelationship><Country id="WO">World</Country><Drug id="23886">urelumab</Drug><DrugRelationship>General interest</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Publication</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PUB</HighestPatStatusIdForCnty><Indication id="1731">Acute myelogenous leukemia</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA8994514">WO-2016164308</Patent><Status id="PUB">First Publication</Status><StatusDate>2016-10-13 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="9099">Rare disease</TherapyArea></Row><Row><Action id="7220">Neoplasm diagnostic agent</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Third Party</CompanyOwnershipRelationship><Country id="WO">World</Country><Drug id="23886">urelumab</Drug><DrugRelationship>General interest</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Publication</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PUB</HighestPatStatusIdForCnty><Indication id="1735">Chronic myelocytic leukemia</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA8994514">WO-2016164308</Patent><Status id="PUB">First Publication</Status><StatusDate>2016-10-13 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="142">Hematological disease</TherapyArea></Row><Row><Action id="7220">Neoplasm diagnostic agent</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Third Party</CompanyOwnershipRelationship><Country id="WO">World</Country><Drug id="23886">urelumab</Drug><DrugRelationship>General interest</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Publication</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PUB</HighestPatStatusIdForCnty><Indication id="2054">Hematological neoplasm</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA8994514">WO-2016164308</Patent><Status id="PUB">First Publication</Status><StatusDate>2016-10-13 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="142">Hematological disease</TherapyArea></Row><Row><Action id="7220">Neoplasm diagnostic agent</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Third Party</CompanyOwnershipRelationship><Country id="WO">World</Country><Drug id="23886">urelumab</Drug><DrugRelationship>General interest</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Publication</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PUB</HighestPatStatusIdForCnty><Indication id="725">Solid tumor</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA8994514">WO-2016164308</Patent><Status id="PUB">First Publication</Status><StatusDate>2016-10-13 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="230">Neoplasm</TherapyArea></Row><Row><Action id="7761">T-lymphocyte stimulator</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Third Party</CompanyOwnershipRelationship><Country id="WO">World</Country><Drug id="23886">urelumab</Drug><DrugRelationship>General interest</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Publication</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PUB</HighestPatStatusIdForCnty><Indication id="1731">Acute myelogenous leukemia</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA8994514">WO-2016164308</Patent><Status id="PUB">First Publication</Status><StatusDate>2016-10-13 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="9099">Rare disease</TherapyArea></Row><Row><Action id="7761">T-lymphocyte stimulator</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Third Party</CompanyOwnershipRelationship><Country id="WO">World</Country><Drug id="23886">urelumab</Drug><DrugRelationship>General interest</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Publication</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PUB</HighestPatStatusIdForCnty><Indication id="1735">Chronic myelocytic leukemia</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA8994514">WO-2016164308</Patent><Status id="PUB">First Publication</Status><StatusDate>2016-10-13 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="142">Hematological disease</TherapyArea></Row><Row><Action id="7761">T-lymphocyte stimulator</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Third Party</CompanyOwnershipRelationship><Country id="WO">World</Country><Drug id="23886">urelumab</Drug><DrugRelationship>General interest</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Publication</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PUB</HighestPatStatusIdForCnty><Indication id="2054">Hematological neoplasm</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA8994514">WO-2016164308</Patent><Status id="PUB">First Publication</Status><StatusDate>2016-10-13 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="142">Hematological disease</TherapyArea></Row><Row><Action id="7761">T-lymphocyte stimulator</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Third Party</CompanyOwnershipRelationship><Country id="WO">World</Country><Drug id="23886">urelumab</Drug><DrugRelationship>General interest</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Publication</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PUB</HighestPatStatusIdForCnty><Indication id="725">Solid tumor</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA8994514">WO-2016164308</Patent><Status id="PUB">First Publication</Status><StatusDate>2016-10-13 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="230">Neoplasm</TherapyArea></Row><Row><Action id="14007">Programmed cell death ligand 1 inhibitor</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Third Party</CompanyOwnershipRelationship><Country id="WO">World</Country><Drug id="8747">palivizumab</Drug><DrugRelationship>General interest</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Publication</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PUB</HighestPatStatusIdForCnty><Indication id="1731">Acute myelogenous leukemia</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA8994514">WO-2016164308</Patent><Status id="PUB">First Publication</Status><StatusDate>2016-10-13 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="9099">Rare disease</TherapyArea></Row><Row><Action id="14007">Programmed cell death ligand 1 inhibitor</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Third Party</CompanyOwnershipRelationship><Country id="WO">World</Country><Drug id="8747">palivizumab</Drug><DrugRelationship>General interest</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Publication</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PUB</HighestPatStatusIdForCnty><Indication id="1735">Chronic myelocytic leukemia</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA8994514">WO-2016164308</Patent><Status id="PUB">First Publication</Status><StatusDate>2016-10-13 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="142">Hematological disease</TherapyArea></Row><Row><Action id="14007">Programmed cell death ligand 1 inhibitor</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Third Party</CompanyOwnershipRelationship><Country id="WO">World</Country><Drug id="8747">palivizumab</Drug><DrugRelationship>General interest</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Publication</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PUB</HighestPatStatusIdForCnty><Indication id="2054">Hematological neoplasm</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA8994514">WO-2016164308</Patent><Status id="PUB">First Publication</Status><StatusDate>2016-10-13 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="142">Hematological disease</TherapyArea></Row><Row><Action id="14007">Programmed cell death ligand 1 inhibitor</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Third Party</CompanyOwnershipRelationship><Country id="WO">World</Country><Drug id="8747">palivizumab</Drug><DrugRelationship>General interest</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Publication</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PUB</HighestPatStatusIdForCnty><Indication id="725">Solid tumor</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA8994514">WO-2016164308</Patent><Status id="PUB">First Publication</Status><StatusDate>2016-10-13 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="230">Neoplasm</TherapyArea></Row><Row><Action id="5451">CDw137 antagonist</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Third Party</CompanyOwnershipRelationship><Country id="WO">World</Country><Drug id="8747">palivizumab</Drug><DrugRelationship>General interest</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Publication</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PUB</HighestPatStatusIdForCnty><Indication id="1731">Acute myelogenous leukemia</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA8994514">WO-2016164308</Patent><Status id="PUB">First Publication</Status><StatusDate>2016-10-13 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="9099">Rare disease</TherapyArea></Row><Row><Action id="5451">CDw137 antagonist</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Third Party</CompanyOwnershipRelationship><Country id="WO">World</Country><Drug id="8747">palivizumab</Drug><DrugRelationship>General interest</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Publication</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PUB</HighestPatStatusIdForCnty><Indication id="1735">Chronic myelocytic leukemia</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA8994514">WO-2016164308</Patent><Status id="PUB">First Publication</Status><StatusDate>2016-10-13 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="142">Hematological disease</TherapyArea></Row><Row><Action id="5451">CDw137 antagonist</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Third Party</CompanyOwnershipRelationship><Country id="WO">World</Country><Drug id="8747">palivizumab</Drug><DrugRelationship>General interest</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Publication</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PUB</HighestPatStatusIdForCnty><Indication id="2054">Hematological neoplasm</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA8994514">WO-2016164308</Patent><Status id="PUB">First Publication</Status><StatusDate>2016-10-13 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="142">Hematological disease</TherapyArea></Row><Row><Action id="5451">CDw137 antagonist</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Third Party</CompanyOwnershipRelationship><Country id="WO">World</Country><Drug id="8747">palivizumab</Drug><DrugRelationship>General interest</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Publication</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PUB</HighestPatStatusIdForCnty><Indication id="725">Solid tumor</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA8994514">WO-2016164308</Patent><Status id="PUB">First Publication</Status><StatusDate>2016-10-13 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="230">Neoplasm</TherapyArea></Row><Row><Action id="7220">Neoplasm diagnostic agent</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Third Party</CompanyOwnershipRelationship><Country id="WO">World</Country><Drug id="8747">palivizumab</Drug><DrugRelationship>General interest</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Publication</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PUB</HighestPatStatusIdForCnty><Indication id="1731">Acute myelogenous leukemia</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA8994514">WO-2016164308</Patent><Status id="PUB">First Publication</Status><StatusDate>2016-10-13 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="9099">Rare disease</TherapyArea></Row><Row><Action id="7220">Neoplasm diagnostic agent</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Third Party</CompanyOwnershipRelationship><Country id="WO">World</Country><Drug id="8747">palivizumab</Drug><DrugRelationship>General interest</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Publication</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PUB</HighestPatStatusIdForCnty><Indication id="1735">Chronic myelocytic leukemia</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA8994514">WO-2016164308</Patent><Status id="PUB">First Publication</Status><StatusDate>2016-10-13 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="142">Hematological disease</TherapyArea></Row><Row><Action id="7220">Neoplasm diagnostic agent</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Third Party</CompanyOwnershipRelationship><Country id="WO">World</Country><Drug id="8747">palivizumab</Drug><DrugRelationship>General interest</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Publication</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PUB</HighestPatStatusIdForCnty><Indication id="2054">Hematological neoplasm</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA8994514">WO-2016164308</Patent><Status id="PUB">First Publication</Status><StatusDate>2016-10-13 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="142">Hematological disease</TherapyArea></Row><Row><Action id="7220">Neoplasm diagnostic agent</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Third Party</CompanyOwnershipRelationship><Country id="WO">World</Country><Drug id="8747">palivizumab</Drug><DrugRelationship>General interest</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Publication</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PUB</HighestPatStatusIdForCnty><Indication id="725">Solid tumor</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA8994514">WO-2016164308</Patent><Status id="PUB">First Publication</Status><StatusDate>2016-10-13 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="230">Neoplasm</TherapyArea></Row><Row><Action id="7761">T-lymphocyte stimulator</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Third Party</CompanyOwnershipRelationship><Country id="WO">World</Country><Drug id="8747">palivizumab</Drug><DrugRelationship>General interest</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Publication</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PUB</HighestPatStatusIdForCnty><Indication id="1731">Acute myelogenous leukemia</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA8994514">WO-2016164308</Patent><Status id="PUB">First Publication</Status><StatusDate>2016-10-13 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="9099">Rare disease</TherapyArea></Row><Row><Action id="7761">T-lymphocyte stimulator</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Third Party</CompanyOwnershipRelationship><Country id="WO">World</Country><Drug id="8747">palivizumab</Drug><DrugRelationship>General interest</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Publication</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PUB</HighestPatStatusIdForCnty><Indication id="1735">Chronic myelocytic leukemia</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA8994514">WO-2016164308</Patent><Status id="PUB">First Publication</Status><StatusDate>2016-10-13 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="142">Hematological disease</TherapyArea></Row><Row><Action id="7761">T-lymphocyte stimulator</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Third Party</CompanyOwnershipRelationship><Country id="WO">World</Country><Drug id="8747">palivizumab</Drug><DrugRelationship>General interest</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Publication</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PUB</HighestPatStatusIdForCnty><Indication id="2054">Hematological neoplasm</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA8994514">WO-2016164308</Patent><Status id="PUB">First Publication</Status><StatusDate>2016-10-13 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="142">Hematological disease</TherapyArea></Row><Row><Action id="7761">T-lymphocyte stimulator</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Third Party</CompanyOwnershipRelationship><Country id="WO">World</Country><Drug id="8747">palivizumab</Drug><DrugRelationship>General interest</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Publication</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PUB</HighestPatStatusIdForCnty><Indication id="725">Solid tumor</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA8994514">WO-2016164308</Patent><Status id="PUB">First Publication</Status><StatusDate>2016-10-13 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="230">Neoplasm</TherapyArea></Row><Row><Action id="14770">ApoB editing catalytic polypeptide stimulator</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Third Party</CompanyOwnershipRelationship><Country id="US">US</Country><Drug/><DrugRelationship/><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Priority</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PRI</HighestPatStatusIdForCnty><Indication id="609">Genetic disorder</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA6253839">WO-2010132092</Patent><Status id="PRI">First Priority</Status><StatusDate>2009-05-12 00:00:00</StatusDate><StatusSortCode>1</StatusSortCode><TherapyArea id="609">Genetic disorder</TherapyArea></Row><Row><Action id="7118">Cytidine deaminase stimulator</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Third Party</CompanyOwnershipRelationship><Country id="US">US</Country><Drug/><DrugRelationship/><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Priority</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PRI</HighestPatStatusIdForCnty><Indication id="609">Genetic disorder</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA6253839">WO-2010132092</Patent><Status id="PRI">First Priority</Status><StatusDate>2009-05-12 00:00:00</StatusDate><StatusSortCode>1</StatusSortCode><TherapyArea id="609">Genetic disorder</TherapyArea></Row><Row><Action id="12479">Interleukin-1 beta ligand inhibitor</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="US">US</Country><Drug/><DrugRelationship/><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Priority</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PRI</HighestPatStatusIdForCnty><Indication id="185">Immune disorder</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA7057914">WO-2012109624</Patent><Status id="PRI">First Priority</Status><StatusDate>2011-02-11 00:00:00</StatusDate><StatusSortCode>1</StatusSortCode><TherapyArea id="185">Immune disorder</TherapyArea></Row><Row><Action id="12479">Interleukin-1 beta ligand inhibitor</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="US">US</Country><Drug/><DrugRelationship/><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Priority</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PRI</HighestPatStatusIdForCnty><Indication id="36">Autoimmune disease</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA7057914">WO-2012109624</Patent><Status id="PRI">First Priority</Status><StatusDate>2011-02-11 00:00:00</StatusDate><StatusSortCode>1</StatusSortCode><TherapyArea id="185">Immune disorder</TherapyArea></Row><Row><Action id="12479">Interleukin-1 beta ligand inhibitor</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="US">US</Country><Drug/><DrugRelationship/><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Priority</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PRI</HighestPatStatusIdForCnty><Indication id="651">Cancer</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA7057914">WO-2012109624</Patent><Status id="PRI">First Priority</Status><StatusDate>2011-02-11 00:00:00</StatusDate><StatusSortCode>1</StatusSortCode><TherapyArea id="230">Neoplasm</TherapyArea></Row><Row><Action id="12479">Interleukin-1 beta ligand inhibitor</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="US">US</Country><Drug/><DrugRelationship/><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Priority</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PRI</HighestPatStatusIdForCnty><Indication id="746">Infectious disease</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA7057914">WO-2012109624</Patent><Status id="PRI">First Priority</Status><StatusDate>2011-02-11 00:00:00</StatusDate><StatusSortCode>1</StatusSortCode><TherapyArea id="746">Infectious disease</TherapyArea></Row><Row><Action id="17067">MIP-3 beta ligand inhibitor</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="US">US</Country><Drug/><DrugRelationship/><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Priority</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PRI</HighestPatStatusIdForCnty><Indication id="185">Immune disorder</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA7057914">WO-2012109624</Patent><Status id="PRI">First Priority</Status><StatusDate>2011-02-11 00:00:00</StatusDate><StatusSortCode>1</StatusSortCode><TherapyArea id="185">Immune disorder</TherapyArea></Row><Row><Action id="17067">MIP-3 beta ligand inhibitor</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="US">US</Country><Drug/><DrugRelationship/><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Priority</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PRI</HighestPatStatusIdForCnty><Indication id="36">Autoimmune disease</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA7057914">WO-2012109624</Patent><Status id="PRI">First Priority</Status><StatusDate>2011-02-11 00:00:00</StatusDate><StatusSortCode>1</StatusSortCode><TherapyArea id="185">Immune disorder</TherapyArea></Row><Row><Action id="17067">MIP-3 beta ligand inhibitor</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="US">US</Country><Drug/><DrugRelationship/><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Priority</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PRI</HighestPatStatusIdForCnty><Indication id="651">Cancer</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA7057914">WO-2012109624</Patent><Status id="PRI">First Priority</Status><StatusDate>2011-02-11 00:00:00</StatusDate><StatusSortCode>1</StatusSortCode><TherapyArea id="230">Neoplasm</TherapyArea></Row><Row><Action id="17067">MIP-3 beta ligand inhibitor</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="US">US</Country><Drug/><DrugRelationship/><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Priority</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PRI</HighestPatStatusIdForCnty><Indication id="746">Infectious disease</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA7057914">WO-2012109624</Patent><Status id="PRI">First Priority</Status><StatusDate>2011-02-11 00:00:00</StatusDate><StatusSortCode>1</StatusSortCode><TherapyArea id="746">Infectious disease</TherapyArea></Row><Row><Action id="1722">VEGF receptor antagonist</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="US">US</Country><Drug/><DrugRelationship/><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Priority</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PRI</HighestPatStatusIdForCnty><Indication id="185">Immune disorder</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA7057914">WO-2012109624</Patent><Status id="PRI">First Priority</Status><StatusDate>2011-02-11 00:00:00</StatusDate><StatusSortCode>1</StatusSortCode><TherapyArea id="185">Immune disorder</TherapyArea></Row><Row><Action id="1722">VEGF receptor antagonist</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="US">US</Country><Drug/><DrugRelationship/><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Priority</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PRI</HighestPatStatusIdForCnty><Indication id="36">Autoimmune disease</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA7057914">WO-2012109624</Patent><Status id="PRI">First Priority</Status><StatusDate>2011-02-11 00:00:00</StatusDate><StatusSortCode>1</StatusSortCode><TherapyArea id="185">Immune disorder</TherapyArea></Row><Row><Action id="1722">VEGF receptor antagonist</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="US">US</Country><Drug/><DrugRelationship/><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Priority</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PRI</HighestPatStatusIdForCnty><Indication id="651">Cancer</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA7057914">WO-2012109624</Patent><Status id="PRI">First Priority</Status><StatusDate>2011-02-11 00:00:00</StatusDate><StatusSortCode>1</StatusSortCode><TherapyArea id="230">Neoplasm</TherapyArea></Row><Row><Action id="1722">VEGF receptor antagonist</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="US">US</Country><Drug/><DrugRelationship/><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Priority</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PRI</HighestPatStatusIdForCnty><Indication id="746">Infectious disease</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA7057914">WO-2012109624</Patent><Status id="PRI">First Priority</Status><StatusDate>2011-02-11 00:00:00</StatusDate><StatusSortCode>1</StatusSortCode><TherapyArea id="746">Infectious disease</TherapyArea></Row><Row><Action id="3107">CCR5 chemokine antagonist</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="US">US</Country><Drug/><DrugRelationship/><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Priority</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PRI</HighestPatStatusIdForCnty><Indication id="185">Immune disorder</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA7057914">WO-2012109624</Patent><Status id="PRI">First Priority</Status><StatusDate>2011-02-11 00:00:00</StatusDate><StatusSortCode>1</StatusSortCode><TherapyArea id="185">Immune disorder</TherapyArea></Row><Row><Action id="3107">CCR5 chemokine antagonist</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="US">US</Country><Drug/><DrugRelationship/><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Priority</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PRI</HighestPatStatusIdForCnty><Indication id="36">Autoimmune disease</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA7057914">WO-2012109624</Patent><Status id="PRI">First Priority</Status><StatusDate>2011-02-11 00:00:00</StatusDate><StatusSortCode>1</StatusSortCode><TherapyArea id="185">Immune disorder</TherapyArea></Row><Row><Action id="3107">CCR5 chemokine antagonist</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="US">US</Country><Drug/><DrugRelationship/><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Priority</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PRI</HighestPatStatusIdForCnty><Indication id="651">Cancer</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA7057914">WO-2012109624</Patent><Status id="PRI">First Priority</Status><StatusDate>2011-02-11 00:00:00</StatusDate><StatusSortCode>1</StatusSortCode><TherapyArea id="230">Neoplasm</TherapyArea></Row><Row><Action id="3107">CCR5 chemokine antagonist</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="US">US</Country><Drug/><DrugRelationship/><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Priority</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PRI</HighestPatStatusIdForCnty><Indication id="746">Infectious disease</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA7057914">WO-2012109624</Patent><Status id="PRI">First Priority</Status><StatusDate>2011-02-11 00:00:00</StatusDate><StatusSortCode>1</StatusSortCode><TherapyArea id="746">Infectious disease</TherapyArea></Row><Row><Action id="3756">Erbb2 tyrosine kinase receptor inhibitor</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="US">US</Country><Drug/><DrugRelationship/><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Priority</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PRI</HighestPatStatusIdForCnty><Indication id="185">Immune disorder</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA7057914">WO-2012109624</Patent><Status id="PRI">First Priority</Status><StatusDate>2011-02-11 00:00:00</StatusDate><StatusSortCode>1</StatusSortCode><TherapyArea id="185">Immune disorder</TherapyArea></Row><Row><Action id="3756">Erbb2 tyrosine kinase receptor inhibitor</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="US">US</Country><Drug/><DrugRelationship/><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Priority</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PRI</HighestPatStatusIdForCnty><Indication id="36">Autoimmune disease</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA7057914">WO-2012109624</Patent><Status id="PRI">First Priority</Status><StatusDate>2011-02-11 00:00:00</StatusDate><StatusSortCode>1</StatusSortCode><TherapyArea id="185">Immune disorder</TherapyArea></Row><Row><Action id="3756">Erbb2 tyrosine kinase receptor inhibitor</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="US">US</Country><Drug/><DrugRelationship/><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Priority</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PRI</HighestPatStatusIdForCnty><Indication id="651">Cancer</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA7057914">WO-2012109624</Patent><Status id="PRI">First Priority</Status><StatusDate>2011-02-11 00:00:00</StatusDate><StatusSortCode>1</StatusSortCode><TherapyArea id="230">Neoplasm</TherapyArea></Row><Row><Action id="3756">Erbb2 tyrosine kinase receptor inhibitor</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="US">US</Country><Drug/><DrugRelationship/><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Priority</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PRI</HighestPatStatusIdForCnty><Indication id="746">Infectious disease</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA7057914">WO-2012109624</Patent><Status id="PRI">First Priority</Status><StatusDate>2011-02-11 00:00:00</StatusDate><StatusSortCode>1</StatusSortCode><TherapyArea id="746">Infectious disease</TherapyArea></Row><Row><Action id="5085">B-lymphocyte antigen CD20 inhibitor</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="US">US</Country><Drug/><DrugRelationship/><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Priority</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PRI</HighestPatStatusIdForCnty><Indication id="185">Immune disorder</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA7057914">WO-2012109624</Patent><Status id="PRI">First Priority</Status><StatusDate>2011-02-11 00:00:00</StatusDate><StatusSortCode>1</StatusSortCode><TherapyArea id="185">Immune disorder</TherapyArea></Row><Row><Action id="5085">B-lymphocyte antigen CD20 inhibitor</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="US">US</Country><Drug/><DrugRelationship/><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Priority</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PRI</HighestPatStatusIdForCnty><Indication id="36">Autoimmune disease</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA7057914">WO-2012109624</Patent><Status id="PRI">First Priority</Status><StatusDate>2011-02-11 00:00:00</StatusDate><StatusSortCode>1</StatusSortCode><TherapyArea id="185">Immune disorder</TherapyArea></Row><Row><Action id="5085">B-lymphocyte antigen CD20 inhibitor</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="US">US</Country><Drug/><DrugRelationship/><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Priority</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PRI</HighestPatStatusIdForCnty><Indication id="651">Cancer</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA7057914">WO-2012109624</Patent><Status id="PRI">First Priority</Status><StatusDate>2011-02-11 00:00:00</StatusDate><StatusSortCode>1</StatusSortCode><TherapyArea id="230">Neoplasm</TherapyArea></Row><Row><Action id="5085">B-lymphocyte antigen CD20 inhibitor</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="US">US</Country><Drug/><DrugRelationship/><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Priority</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PRI</HighestPatStatusIdForCnty><Indication id="746">Infectious disease</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA7057914">WO-2012109624</Patent><Status id="PRI">First Priority</Status><StatusDate>2011-02-11 00:00:00</StatusDate><StatusSortCode>1</StatusSortCode><TherapyArea id="746">Infectious disease</TherapyArea></Row><Row><Action id="75286">Transferrin receptor protein antagonist</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="US">US</Country><Drug/><DrugRelationship/><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Priority</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PRI</HighestPatStatusIdForCnty><Indication id="185">Immune disorder</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA7057914">WO-2012109624</Patent><Status id="PRI">First Priority</Status><StatusDate>2011-02-11 00:00:00</StatusDate><StatusSortCode>1</StatusSortCode><TherapyArea id="185">Immune disorder</TherapyArea></Row><Row><Action id="75286">Transferrin receptor protein antagonist</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="US">US</Country><Drug/><DrugRelationship/><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Priority</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PRI</HighestPatStatusIdForCnty><Indication id="36">Autoimmune disease</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA7057914">WO-2012109624</Patent><Status id="PRI">First Priority</Status><StatusDate>2011-02-11 00:00:00</StatusDate><StatusSortCode>1</StatusSortCode><TherapyArea id="185">Immune disorder</TherapyArea></Row><Row><Action id="75286">Transferrin receptor protein antagonist</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="US">US</Country><Drug/><DrugRelationship/><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Priority</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PRI</HighestPatStatusIdForCnty><Indication id="651">Cancer</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA7057914">WO-2012109624</Patent><Status id="PRI">First Priority</Status><StatusDate>2011-02-11 00:00:00</StatusDate><StatusSortCode>1</StatusSortCode><TherapyArea id="230">Neoplasm</TherapyArea></Row><Row><Action id="75286">Transferrin receptor protein antagonist</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="US">US</Country><Drug/><DrugRelationship/><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Priority</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PRI</HighestPatStatusIdForCnty><Indication id="746">Infectious disease</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA7057914">WO-2012109624</Patent><Status id="PRI">First Priority</Status><StatusDate>2011-02-11 00:00:00</StatusDate><StatusSortCode>1</StatusSortCode><TherapyArea id="746">Infectious disease</TherapyArea></Row><Row><Action id="1320">Factor I modulator</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="US">US</Country><Drug/><DrugRelationship/><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Priority</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PRI</HighestPatStatusIdForCnty><Indication id="2054">Hematological neoplasm</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA7670275">WO-2014028776</Patent><Status id="PRI">First Priority</Status><StatusDate>2012-08-15 00:00:00</StatusDate><StatusSortCode>1</StatusSortCode><TherapyArea id="142">Hematological disease</TherapyArea></Row><Row><Action id="1320">Factor I modulator</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="US">US</Country><Drug/><DrugRelationship/><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Priority</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PRI</HighestPatStatusIdForCnty><Indication id="316">B-cell lymphoma</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA7670275">WO-2014028776</Patent><Status id="PRI">First Priority</Status><StatusDate>2012-08-15 00:00:00</StatusDate><StatusSortCode>1</StatusSortCode><TherapyArea id="142">Hematological disease</TherapyArea></Row><Row><Action id="1320">Factor I modulator</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="US">US</Country><Drug/><DrugRelationship/><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Priority</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PRI</HighestPatStatusIdForCnty><Indication id="36">Autoimmune disease</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA7670275">WO-2014028776</Patent><Status id="PRI">First Priority</Status><StatusDate>2012-08-15 00:00:00</StatusDate><StatusSortCode>1</StatusSortCode><TherapyArea id="185">Immune disorder</TherapyArea></Row><Row><Action id="1320">Factor I modulator</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="US">US</Country><Drug/><DrugRelationship/><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Priority</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PRI</HighestPatStatusIdForCnty><Indication id="746">Infectious disease</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA7670275">WO-2014028776</Patent><Status id="PRI">First Priority</Status><StatusDate>2012-08-15 00:00:00</StatusDate><StatusSortCode>1</StatusSortCode><TherapyArea id="746">Infectious disease</TherapyArea></Row><Row><Action id="1515">Transferrin modulator</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="US">US</Country><Drug/><DrugRelationship/><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Priority</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PRI</HighestPatStatusIdForCnty><Indication id="2054">Hematological neoplasm</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA7670275">WO-2014028776</Patent><Status id="PRI">First Priority</Status><StatusDate>2012-08-15 00:00:00</StatusDate><StatusSortCode>1</StatusSortCode><TherapyArea id="142">Hematological disease</TherapyArea></Row><Row><Action id="1515">Transferrin modulator</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="US">US</Country><Drug/><DrugRelationship/><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Priority</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PRI</HighestPatStatusIdForCnty><Indication id="316">B-cell lymphoma</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA7670275">WO-2014028776</Patent><Status id="PRI">First Priority</Status><StatusDate>2012-08-15 00:00:00</StatusDate><StatusSortCode>1</StatusSortCode><TherapyArea id="142">Hematological disease</TherapyArea></Row><Row><Action id="1515">Transferrin modulator</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="US">US</Country><Drug/><DrugRelationship/><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Priority</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PRI</HighestPatStatusIdForCnty><Indication id="36">Autoimmune disease</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA7670275">WO-2014028776</Patent><Status id="PRI">First Priority</Status><StatusDate>2012-08-15 00:00:00</StatusDate><StatusSortCode>1</StatusSortCode><TherapyArea id="185">Immune disorder</TherapyArea></Row><Row><Action id="1515">Transferrin modulator</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="US">US</Country><Drug/><DrugRelationship/><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Priority</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PRI</HighestPatStatusIdForCnty><Indication id="746">Infectious disease</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA7670275">WO-2014028776</Patent><Status id="PRI">First Priority</Status><StatusDate>2012-08-15 00:00:00</StatusDate><StatusSortCode>1</StatusSortCode><TherapyArea id="746">Infectious disease</TherapyArea></Row><Row><Action id="5023">CD3 modulator</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="US">US</Country><Drug/><DrugRelationship/><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Priority</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PRI</HighestPatStatusIdForCnty><Indication id="2054">Hematological neoplasm</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA7670275">WO-2014028776</Patent><Status id="PRI">First Priority</Status><StatusDate>2012-08-15 00:00:00</StatusDate><StatusSortCode>1</StatusSortCode><TherapyArea id="142">Hematological disease</TherapyArea></Row><Row><Action id="5023">CD3 modulator</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="US">US</Country><Drug/><DrugRelationship/><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Priority</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PRI</HighestPatStatusIdForCnty><Indication id="316">B-cell lymphoma</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA7670275">WO-2014028776</Patent><Status id="PRI">First Priority</Status><StatusDate>2012-08-15 00:00:00</StatusDate><StatusSortCode>1</StatusSortCode><TherapyArea id="142">Hematological disease</TherapyArea></Row><Row><Action id="5023">CD3 modulator</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="US">US</Country><Drug/><DrugRelationship/><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Priority</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PRI</HighestPatStatusIdForCnty><Indication id="36">Autoimmune disease</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA7670275">WO-2014028776</Patent><Status id="PRI">First Priority</Status><StatusDate>2012-08-15 00:00:00</StatusDate><StatusSortCode>1</StatusSortCode><TherapyArea id="185">Immune disorder</TherapyArea></Row><Row><Action id="5023">CD3 modulator</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="US">US</Country><Drug/><DrugRelationship/><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Priority</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PRI</HighestPatStatusIdForCnty><Indication id="746">Infectious disease</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA7670275">WO-2014028776</Patent><Status id="PRI">First Priority</Status><StatusDate>2012-08-15 00:00:00</StatusDate><StatusSortCode>1</StatusSortCode><TherapyArea id="746">Infectious disease</TherapyArea></Row><Row><Action id="5080">B-lymphocyte antigen CD19 modulator</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="US">US</Country><Drug/><DrugRelationship/><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Priority</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PRI</HighestPatStatusIdForCnty><Indication id="2054">Hematological neoplasm</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA7670275">WO-2014028776</Patent><Status id="PRI">First Priority</Status><StatusDate>2012-08-15 00:00:00</StatusDate><StatusSortCode>1</StatusSortCode><TherapyArea id="142">Hematological disease</TherapyArea></Row><Row><Action id="5080">B-lymphocyte antigen CD19 modulator</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="US">US</Country><Drug/><DrugRelationship/><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Priority</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PRI</HighestPatStatusIdForCnty><Indication id="316">B-cell lymphoma</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA7670275">WO-2014028776</Patent><Status id="PRI">First Priority</Status><StatusDate>2012-08-15 00:00:00</StatusDate><StatusSortCode>1</StatusSortCode><TherapyArea id="142">Hematological disease</TherapyArea></Row><Row><Action id="5080">B-lymphocyte antigen CD19 modulator</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="US">US</Country><Drug/><DrugRelationship/><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Priority</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PRI</HighestPatStatusIdForCnty><Indication id="36">Autoimmune disease</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA7670275">WO-2014028776</Patent><Status id="PRI">First Priority</Status><StatusDate>2012-08-15 00:00:00</StatusDate><StatusSortCode>1</StatusSortCode><TherapyArea id="185">Immune disorder</TherapyArea></Row><Row><Action id="5080">B-lymphocyte antigen CD19 modulator</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="US">US</Country><Drug/><DrugRelationship/><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Priority</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PRI</HighestPatStatusIdForCnty><Indication id="746">Infectious disease</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA7670275">WO-2014028776</Patent><Status id="PRI">First Priority</Status><StatusDate>2012-08-15 00:00:00</StatusDate><StatusSortCode>1</StatusSortCode><TherapyArea id="746">Infectious disease</TherapyArea></Row><Row><Action id="51332">Thyroxine binding globulin modulator</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="US">US</Country><Drug/><DrugRelationship/><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Priority</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PRI</HighestPatStatusIdForCnty><Indication id="2054">Hematological neoplasm</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA7670275">WO-2014028776</Patent><Status id="PRI">First Priority</Status><StatusDate>2012-08-15 00:00:00</StatusDate><StatusSortCode>1</StatusSortCode><TherapyArea id="142">Hematological disease</TherapyArea></Row><Row><Action id="51332">Thyroxine binding globulin modulator</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="US">US</Country><Drug/><DrugRelationship/><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Priority</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PRI</HighestPatStatusIdForCnty><Indication id="316">B-cell lymphoma</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA7670275">WO-2014028776</Patent><Status id="PRI">First Priority</Status><StatusDate>2012-08-15 00:00:00</StatusDate><StatusSortCode>1</StatusSortCode><TherapyArea id="142">Hematological disease</TherapyArea></Row><Row><Action id="51332">Thyroxine binding globulin modulator</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="US">US</Country><Drug/><DrugRelationship/><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Priority</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PRI</HighestPatStatusIdForCnty><Indication id="36">Autoimmune disease</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA7670275">WO-2014028776</Patent><Status id="PRI">First Priority</Status><StatusDate>2012-08-15 00:00:00</StatusDate><StatusSortCode>1</StatusSortCode><TherapyArea id="185">Immune disorder</TherapyArea></Row><Row><Action id="51332">Thyroxine binding globulin modulator</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="US">US</Country><Drug/><DrugRelationship/><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Priority</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PRI</HighestPatStatusIdForCnty><Indication id="746">Infectious disease</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA7670275">WO-2014028776</Patent><Status id="PRI">First Priority</Status><StatusDate>2012-08-15 00:00:00</StatusDate><StatusSortCode>1</StatusSortCode><TherapyArea id="746">Infectious disease</TherapyArea></Row><Row><Action id="69528">ELP gene stimulator</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="US">US</Country><Drug/><DrugRelationship/><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Priority</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PRI</HighestPatStatusIdForCnty><Indication id="2054">Hematological neoplasm</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA7670275">WO-2014028776</Patent><Status id="PRI">First Priority</Status><StatusDate>2012-08-15 00:00:00</StatusDate><StatusSortCode>1</StatusSortCode><TherapyArea id="142">Hematological disease</TherapyArea></Row><Row><Action id="69528">ELP gene stimulator</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="US">US</Country><Drug/><DrugRelationship/><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Priority</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PRI</HighestPatStatusIdForCnty><Indication id="316">B-cell lymphoma</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA7670275">WO-2014028776</Patent><Status id="PRI">First Priority</Status><StatusDate>2012-08-15 00:00:00</StatusDate><StatusSortCode>1</StatusSortCode><TherapyArea id="142">Hematological disease</TherapyArea></Row><Row><Action id="69528">ELP gene stimulator</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="US">US</Country><Drug/><DrugRelationship/><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Priority</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PRI</HighestPatStatusIdForCnty><Indication id="36">Autoimmune disease</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA7670275">WO-2014028776</Patent><Status id="PRI">First Priority</Status><StatusDate>2012-08-15 00:00:00</StatusDate><StatusSortCode>1</StatusSortCode><TherapyArea id="185">Immune disorder</TherapyArea></Row><Row><Action id="69528">ELP gene stimulator</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="US">US</Country><Drug/><DrugRelationship/><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Priority</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PRI</HighestPatStatusIdForCnty><Indication id="746">Infectious disease</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA7670275">WO-2014028776</Patent><Status id="PRI">First Priority</Status><StatusDate>2012-08-15 00:00:00</StatusDate><StatusSortCode>1</StatusSortCode><TherapyArea id="746">Infectious disease</TherapyArea></Row><Row><Action id="815">Albumin modulator</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="US">US</Country><Drug/><DrugRelationship/><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Priority</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PRI</HighestPatStatusIdForCnty><Indication id="2054">Hematological neoplasm</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA7670275">WO-2014028776</Patent><Status id="PRI">First Priority</Status><StatusDate>2012-08-15 00:00:00</StatusDate><StatusSortCode>1</StatusSortCode><TherapyArea id="142">Hematological disease</TherapyArea></Row><Row><Action id="815">Albumin modulator</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="US">US</Country><Drug/><DrugRelationship/><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Priority</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PRI</HighestPatStatusIdForCnty><Indication id="316">B-cell lymphoma</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA7670275">WO-2014028776</Patent><Status id="PRI">First Priority</Status><StatusDate>2012-08-15 00:00:00</StatusDate><StatusSortCode>1</StatusSortCode><TherapyArea id="142">Hematological disease</TherapyArea></Row><Row><Action id="815">Albumin modulator</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="US">US</Country><Drug/><DrugRelationship/><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Priority</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PRI</HighestPatStatusIdForCnty><Indication id="36">Autoimmune disease</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA7670275">WO-2014028776</Patent><Status id="PRI">First Priority</Status><StatusDate>2012-08-15 00:00:00</StatusDate><StatusSortCode>1</StatusSortCode><TherapyArea id="185">Immune disorder</TherapyArea></Row><Row><Action id="815">Albumin modulator</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="US">US</Country><Drug/><DrugRelationship/><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Priority</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PRI</HighestPatStatusIdForCnty><Indication id="746">Infectious disease</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA7670275">WO-2014028776</Patent><Status id="PRI">First Priority</Status><StatusDate>2012-08-15 00:00:00</StatusDate><StatusSortCode>1</StatusSortCode><TherapyArea id="746">Infectious disease</TherapyArea></Row><Row><Action id="14007">Programmed cell death ligand 1 inhibitor</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Third Party</CompanyOwnershipRelationship><Country id="US">US</Country><Drug/><DrugRelationship/><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Priority</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PRI</HighestPatStatusIdForCnty><Indication id="651">Cancer</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA8994530">WO-2016164369</Patent><Status id="PRI">First Priority</Status><StatusDate>2015-04-06 00:00:00</StatusDate><StatusSortCode>1</StatusSortCode><TherapyArea id="230">Neoplasm</TherapyArea></Row><Row><Action id="5451">CDw137 antagonist</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Third Party</CompanyOwnershipRelationship><Country id="US">US</Country><Drug/><DrugRelationship/><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Priority</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PRI</HighestPatStatusIdForCnty><Indication id="651">Cancer</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA8994530">WO-2016164369</Patent><Status id="PRI">First Priority</Status><StatusDate>2015-04-06 00:00:00</StatusDate><StatusSortCode>1</StatusSortCode><TherapyArea id="230">Neoplasm</TherapyArea></Row><Row><Action id="7220">Neoplasm diagnostic agent</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Third Party</CompanyOwnershipRelationship><Country id="US">US</Country><Drug/><DrugRelationship/><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Priority</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PRI</HighestPatStatusIdForCnty><Indication id="651">Cancer</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA8994530">WO-2016164369</Patent><Status id="PRI">First Priority</Status><StatusDate>2015-04-06 00:00:00</StatusDate><StatusSortCode>1</StatusSortCode><TherapyArea id="230">Neoplasm</TherapyArea></Row><Row><Action id="14770">ApoB editing catalytic polypeptide stimulator</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Third Party</CompanyOwnershipRelationship><Country id="WO">World</Country><Drug/><DrugRelationship/><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Publication</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PUB</HighestPatStatusIdForCnty><Indication id="609">Genetic disorder</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA6253839">WO-2010132092</Patent><Status id="PUB">First Publication</Status><StatusDate>2010-11-18 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="609">Genetic disorder</TherapyArea></Row><Row><Action id="7118">Cytidine deaminase stimulator</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Third Party</CompanyOwnershipRelationship><Country id="WO">World</Country><Drug/><DrugRelationship/><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Publication</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PUB</HighestPatStatusIdForCnty><Indication id="609">Genetic disorder</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA6253839">WO-2010132092</Patent><Status id="PUB">First Publication</Status><StatusDate>2010-11-18 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="609">Genetic disorder</TherapyArea></Row><Row><Action id="12479">Interleukin-1 beta ligand inhibitor</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="WO">World</Country><Drug/><DrugRelationship/><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Publication</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PUB</HighestPatStatusIdForCnty><Indication id="185">Immune disorder</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA7057914">WO-2012109624</Patent><Status id="PUB">First Publication</Status><StatusDate>2012-08-16 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="185">Immune disorder</TherapyArea></Row><Row><Action id="12479">Interleukin-1 beta ligand inhibitor</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="WO">World</Country><Drug/><DrugRelationship/><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Publication</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PUB</HighestPatStatusIdForCnty><Indication id="36">Autoimmune disease</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA7057914">WO-2012109624</Patent><Status id="PUB">First Publication</Status><StatusDate>2012-08-16 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="185">Immune disorder</TherapyArea></Row><Row><Action id="12479">Interleukin-1 beta ligand inhibitor</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="WO">World</Country><Drug/><DrugRelationship/><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Publication</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PUB</HighestPatStatusIdForCnty><Indication id="651">Cancer</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA7057914">WO-2012109624</Patent><Status id="PUB">First Publication</Status><StatusDate>2012-08-16 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="230">Neoplasm</TherapyArea></Row><Row><Action id="12479">Interleukin-1 beta ligand inhibitor</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="WO">World</Country><Drug/><DrugRelationship/><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Publication</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PUB</HighestPatStatusIdForCnty><Indication id="746">Infectious disease</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA7057914">WO-2012109624</Patent><Status id="PUB">First Publication</Status><StatusDate>2012-08-16 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="746">Infectious disease</TherapyArea></Row><Row><Action id="17067">MIP-3 beta ligand inhibitor</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="WO">World</Country><Drug/><DrugRelationship/><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Publication</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PUB</HighestPatStatusIdForCnty><Indication id="185">Immune disorder</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA7057914">WO-2012109624</Patent><Status id="PUB">First Publication</Status><StatusDate>2012-08-16 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="185">Immune disorder</TherapyArea></Row><Row><Action id="17067">MIP-3 beta ligand inhibitor</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="WO">World</Country><Drug/><DrugRelationship/><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Publication</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PUB</HighestPatStatusIdForCnty><Indication id="36">Autoimmune disease</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA7057914">WO-2012109624</Patent><Status id="PUB">First Publication</Status><StatusDate>2012-08-16 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="185">Immune disorder</TherapyArea></Row><Row><Action id="17067">MIP-3 beta ligand inhibitor</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="WO">World</Country><Drug/><DrugRelationship/><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Publication</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PUB</HighestPatStatusIdForCnty><Indication id="651">Cancer</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA7057914">WO-2012109624</Patent><Status id="PUB">First Publication</Status><StatusDate>2012-08-16 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="230">Neoplasm</TherapyArea></Row><Row><Action id="17067">MIP-3 beta ligand inhibitor</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="WO">World</Country><Drug/><DrugRelationship/><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Publication</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PUB</HighestPatStatusIdForCnty><Indication id="746">Infectious disease</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA7057914">WO-2012109624</Patent><Status id="PUB">First Publication</Status><StatusDate>2012-08-16 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="746">Infectious disease</TherapyArea></Row><Row><Action id="1722">VEGF receptor antagonist</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="WO">World</Country><Drug/><DrugRelationship/><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Publication</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PUB</HighestPatStatusIdForCnty><Indication id="185">Immune disorder</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA7057914">WO-2012109624</Patent><Status id="PUB">First Publication</Status><StatusDate>2012-08-16 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="185">Immune disorder</TherapyArea></Row><Row><Action id="1722">VEGF receptor antagonist</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="WO">World</Country><Drug/><DrugRelationship/><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Publication</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PUB</HighestPatStatusIdForCnty><Indication id="36">Autoimmune disease</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA7057914">WO-2012109624</Patent><Status id="PUB">First Publication</Status><StatusDate>2012-08-16 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="185">Immune disorder</TherapyArea></Row><Row><Action id="1722">VEGF receptor antagonist</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="WO">World</Country><Drug/><DrugRelationship/><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Publication</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PUB</HighestPatStatusIdForCnty><Indication id="651">Cancer</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA7057914">WO-2012109624</Patent><Status id="PUB">First Publication</Status><StatusDate>2012-08-16 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="230">Neoplasm</TherapyArea></Row><Row><Action id="1722">VEGF receptor antagonist</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="WO">World</Country><Drug/><DrugRelationship/><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Publication</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PUB</HighestPatStatusIdForCnty><Indication id="746">Infectious disease</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA7057914">WO-2012109624</Patent><Status id="PUB">First Publication</Status><StatusDate>2012-08-16 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="746">Infectious disease</TherapyArea></Row><Row><Action id="3107">CCR5 chemokine antagonist</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="WO">World</Country><Drug/><DrugRelationship/><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Publication</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PUB</HighestPatStatusIdForCnty><Indication id="185">Immune disorder</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA7057914">WO-2012109624</Patent><Status id="PUB">First Publication</Status><StatusDate>2012-08-16 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="185">Immune disorder</TherapyArea></Row><Row><Action id="3107">CCR5 chemokine antagonist</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="WO">World</Country><Drug/><DrugRelationship/><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Publication</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PUB</HighestPatStatusIdForCnty><Indication id="36">Autoimmune disease</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA7057914">WO-2012109624</Patent><Status id="PUB">First Publication</Status><StatusDate>2012-08-16 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="185">Immune disorder</TherapyArea></Row><Row><Action id="3107">CCR5 chemokine antagonist</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="WO">World</Country><Drug/><DrugRelationship/><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Publication</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PUB</HighestPatStatusIdForCnty><Indication id="651">Cancer</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA7057914">WO-2012109624</Patent><Status id="PUB">First Publication</Status><StatusDate>2012-08-16 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="230">Neoplasm</TherapyArea></Row><Row><Action id="3107">CCR5 chemokine antagonist</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="WO">World</Country><Drug/><DrugRelationship/><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Publication</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PUB</HighestPatStatusIdForCnty><Indication id="746">Infectious disease</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA7057914">WO-2012109624</Patent><Status id="PUB">First Publication</Status><StatusDate>2012-08-16 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="746">Infectious disease</TherapyArea></Row><Row><Action id="3756">Erbb2 tyrosine kinase receptor inhibitor</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="WO">World</Country><Drug/><DrugRelationship/><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Publication</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PUB</HighestPatStatusIdForCnty><Indication id="185">Immune disorder</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA7057914">WO-2012109624</Patent><Status id="PUB">First Publication</Status><StatusDate>2012-08-16 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="185">Immune disorder</TherapyArea></Row><Row><Action id="3756">Erbb2 tyrosine kinase receptor inhibitor</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="WO">World</Country><Drug/><DrugRelationship/><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Publication</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PUB</HighestPatStatusIdForCnty><Indication id="36">Autoimmune disease</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA7057914">WO-2012109624</Patent><Status id="PUB">First Publication</Status><StatusDate>2012-08-16 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="185">Immune disorder</TherapyArea></Row><Row><Action id="3756">Erbb2 tyrosine kinase receptor inhibitor</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="WO">World</Country><Drug/><DrugRelationship/><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Publication</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PUB</HighestPatStatusIdForCnty><Indication id="651">Cancer</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA7057914">WO-2012109624</Patent><Status id="PUB">First Publication</Status><StatusDate>2012-08-16 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="230">Neoplasm</TherapyArea></Row><Row><Action id="3756">Erbb2 tyrosine kinase receptor inhibitor</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="WO">World</Country><Drug/><DrugRelationship/><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Publication</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PUB</HighestPatStatusIdForCnty><Indication id="746">Infectious disease</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA7057914">WO-2012109624</Patent><Status id="PUB">First Publication</Status><StatusDate>2012-08-16 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="746">Infectious disease</TherapyArea></Row><Row><Action id="5085">B-lymphocyte antigen CD20 inhibitor</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="WO">World</Country><Drug/><DrugRelationship/><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Publication</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PUB</HighestPatStatusIdForCnty><Indication id="185">Immune disorder</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA7057914">WO-2012109624</Patent><Status id="PUB">First Publication</Status><StatusDate>2012-08-16 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="185">Immune disorder</TherapyArea></Row><Row><Action id="5085">B-lymphocyte antigen CD20 inhibitor</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="WO">World</Country><Drug/><DrugRelationship/><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Publication</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PUB</HighestPatStatusIdForCnty><Indication id="36">Autoimmune disease</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA7057914">WO-2012109624</Patent><Status id="PUB">First Publication</Status><StatusDate>2012-08-16 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="185">Immune disorder</TherapyArea></Row><Row><Action id="5085">B-lymphocyte antigen CD20 inhibitor</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="WO">World</Country><Drug/><DrugRelationship/><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Publication</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PUB</HighestPatStatusIdForCnty><Indication id="651">Cancer</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA7057914">WO-2012109624</Patent><Status id="PUB">First Publication</Status><StatusDate>2012-08-16 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="230">Neoplasm</TherapyArea></Row><Row><Action id="5085">B-lymphocyte antigen CD20 inhibitor</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="WO">World</Country><Drug/><DrugRelationship/><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Publication</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PUB</HighestPatStatusIdForCnty><Indication id="746">Infectious disease</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA7057914">WO-2012109624</Patent><Status id="PUB">First Publication</Status><StatusDate>2012-08-16 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="746">Infectious disease</TherapyArea></Row><Row><Action id="75286">Transferrin receptor protein antagonist</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="WO">World</Country><Drug/><DrugRelationship/><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Publication</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PUB</HighestPatStatusIdForCnty><Indication id="185">Immune disorder</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA7057914">WO-2012109624</Patent><Status id="PUB">First Publication</Status><StatusDate>2012-08-16 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="185">Immune disorder</TherapyArea></Row><Row><Action id="75286">Transferrin receptor protein antagonist</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="WO">World</Country><Drug/><DrugRelationship/><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Publication</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PUB</HighestPatStatusIdForCnty><Indication id="36">Autoimmune disease</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA7057914">WO-2012109624</Patent><Status id="PUB">First Publication</Status><StatusDate>2012-08-16 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="185">Immune disorder</TherapyArea></Row><Row><Action id="75286">Transferrin receptor protein antagonist</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="WO">World</Country><Drug/><DrugRelationship/><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Publication</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PUB</HighestPatStatusIdForCnty><Indication id="651">Cancer</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA7057914">WO-2012109624</Patent><Status id="PUB">First Publication</Status><StatusDate>2012-08-16 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="230">Neoplasm</TherapyArea></Row><Row><Action id="75286">Transferrin receptor protein antagonist</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="WO">World</Country><Drug/><DrugRelationship/><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Publication</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PUB</HighestPatStatusIdForCnty><Indication id="746">Infectious disease</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA7057914">WO-2012109624</Patent><Status id="PUB">First Publication</Status><StatusDate>2012-08-16 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="746">Infectious disease</TherapyArea></Row><Row><Action id="1320">Factor I modulator</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="WO">World</Country><Drug/><DrugRelationship/><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Publication</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PUB</HighestPatStatusIdForCnty><Indication id="2054">Hematological neoplasm</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA7670275">WO-2014028776</Patent><Status id="PUB">First Publication</Status><StatusDate>2014-02-20 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="142">Hematological disease</TherapyArea></Row><Row><Action id="1320">Factor I modulator</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="WO">World</Country><Drug/><DrugRelationship/><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Publication</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PUB</HighestPatStatusIdForCnty><Indication id="316">B-cell lymphoma</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA7670275">WO-2014028776</Patent><Status id="PUB">First Publication</Status><StatusDate>2014-02-20 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="142">Hematological disease</TherapyArea></Row><Row><Action id="1320">Factor I modulator</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="WO">World</Country><Drug/><DrugRelationship/><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Publication</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PUB</HighestPatStatusIdForCnty><Indication id="36">Autoimmune disease</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA7670275">WO-2014028776</Patent><Status id="PUB">First Publication</Status><StatusDate>2014-02-20 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="185">Immune disorder</TherapyArea></Row><Row><Action id="1320">Factor I modulator</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="WO">World</Country><Drug/><DrugRelationship/><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Publication</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PUB</HighestPatStatusIdForCnty><Indication id="746">Infectious disease</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA7670275">WO-2014028776</Patent><Status id="PUB">First Publication</Status><StatusDate>2014-02-20 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="746">Infectious disease</TherapyArea></Row><Row><Action id="1515">Transferrin modulator</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="WO">World</Country><Drug/><DrugRelationship/><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Publication</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PUB</HighestPatStatusIdForCnty><Indication id="2054">Hematological neoplasm</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA7670275">WO-2014028776</Patent><Status id="PUB">First Publication</Status><StatusDate>2014-02-20 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="142">Hematological disease</TherapyArea></Row><Row><Action id="1515">Transferrin modulator</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="WO">World</Country><Drug/><DrugRelationship/><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Publication</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PUB</HighestPatStatusIdForCnty><Indication id="316">B-cell lymphoma</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA7670275">WO-2014028776</Patent><Status id="PUB">First Publication</Status><StatusDate>2014-02-20 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="142">Hematological disease</TherapyArea></Row><Row><Action id="1515">Transferrin modulator</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="WO">World</Country><Drug/><DrugRelationship/><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Publication</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PUB</HighestPatStatusIdForCnty><Indication id="36">Autoimmune disease</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA7670275">WO-2014028776</Patent><Status id="PUB">First Publication</Status><StatusDate>2014-02-20 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="185">Immune disorder</TherapyArea></Row><Row><Action id="1515">Transferrin modulator</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="WO">World</Country><Drug/><DrugRelationship/><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Publication</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PUB</HighestPatStatusIdForCnty><Indication id="746">Infectious disease</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA7670275">WO-2014028776</Patent><Status id="PUB">First Publication</Status><StatusDate>2014-02-20 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="746">Infectious disease</TherapyArea></Row><Row><Action id="5023">CD3 modulator</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="WO">World</Country><Drug/><DrugRelationship/><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Publication</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PUB</HighestPatStatusIdForCnty><Indication id="2054">Hematological neoplasm</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA7670275">WO-2014028776</Patent><Status id="PUB">First Publication</Status><StatusDate>2014-02-20 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="142">Hematological disease</TherapyArea></Row><Row><Action id="5023">CD3 modulator</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="WO">World</Country><Drug/><DrugRelationship/><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Publication</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PUB</HighestPatStatusIdForCnty><Indication id="316">B-cell lymphoma</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA7670275">WO-2014028776</Patent><Status id="PUB">First Publication</Status><StatusDate>2014-02-20 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="142">Hematological disease</TherapyArea></Row><Row><Action id="5023">CD3 modulator</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="WO">World</Country><Drug/><DrugRelationship/><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Publication</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PUB</HighestPatStatusIdForCnty><Indication id="36">Autoimmune disease</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA7670275">WO-2014028776</Patent><Status id="PUB">First Publication</Status><StatusDate>2014-02-20 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="185">Immune disorder</TherapyArea></Row><Row><Action id="5023">CD3 modulator</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="WO">World</Country><Drug/><DrugRelationship/><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Publication</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PUB</HighestPatStatusIdForCnty><Indication id="746">Infectious disease</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA7670275">WO-2014028776</Patent><Status id="PUB">First Publication</Status><StatusDate>2014-02-20 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="746">Infectious disease</TherapyArea></Row><Row><Action id="5080">B-lymphocyte antigen CD19 modulator</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="WO">World</Country><Drug/><DrugRelationship/><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Publication</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PUB</HighestPatStatusIdForCnty><Indication id="2054">Hematological neoplasm</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA7670275">WO-2014028776</Patent><Status id="PUB">First Publication</Status><StatusDate>2014-02-20 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="142">Hematological disease</TherapyArea></Row><Row><Action id="5080">B-lymphocyte antigen CD19 modulator</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="WO">World</Country><Drug/><DrugRelationship/><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Publication</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PUB</HighestPatStatusIdForCnty><Indication id="316">B-cell lymphoma</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA7670275">WO-2014028776</Patent><Status id="PUB">First Publication</Status><StatusDate>2014-02-20 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="142">Hematological disease</TherapyArea></Row><Row><Action id="5080">B-lymphocyte antigen CD19 modulator</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="WO">World</Country><Drug/><DrugRelationship/><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Publication</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PUB</HighestPatStatusIdForCnty><Indication id="36">Autoimmune disease</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA7670275">WO-2014028776</Patent><Status id="PUB">First Publication</Status><StatusDate>2014-02-20 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="185">Immune disorder</TherapyArea></Row><Row><Action id="5080">B-lymphocyte antigen CD19 modulator</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="WO">World</Country><Drug/><DrugRelationship/><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Publication</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PUB</HighestPatStatusIdForCnty><Indication id="746">Infectious disease</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA7670275">WO-2014028776</Patent><Status id="PUB">First Publication</Status><StatusDate>2014-02-20 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="746">Infectious disease</TherapyArea></Row><Row><Action id="51332">Thyroxine binding globulin modulator</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="WO">World</Country><Drug/><DrugRelationship/><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Publication</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PUB</HighestPatStatusIdForCnty><Indication id="2054">Hematological neoplasm</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA7670275">WO-2014028776</Patent><Status id="PUB">First Publication</Status><StatusDate>2014-02-20 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="142">Hematological disease</TherapyArea></Row><Row><Action id="51332">Thyroxine binding globulin modulator</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="WO">World</Country><Drug/><DrugRelationship/><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Publication</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PUB</HighestPatStatusIdForCnty><Indication id="316">B-cell lymphoma</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA7670275">WO-2014028776</Patent><Status id="PUB">First Publication</Status><StatusDate>2014-02-20 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="142">Hematological disease</TherapyArea></Row><Row><Action id="51332">Thyroxine binding globulin modulator</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="WO">World</Country><Drug/><DrugRelationship/><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Publication</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PUB</HighestPatStatusIdForCnty><Indication id="36">Autoimmune disease</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA7670275">WO-2014028776</Patent><Status id="PUB">First Publication</Status><StatusDate>2014-02-20 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="185">Immune disorder</TherapyArea></Row><Row><Action id="51332">Thyroxine binding globulin modulator</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="WO">World</Country><Drug/><DrugRelationship/><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Publication</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PUB</HighestPatStatusIdForCnty><Indication id="746">Infectious disease</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA7670275">WO-2014028776</Patent><Status id="PUB">First Publication</Status><StatusDate>2014-02-20 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="746">Infectious disease</TherapyArea></Row><Row><Action id="69528">ELP gene stimulator</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="WO">World</Country><Drug/><DrugRelationship/><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Publication</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PUB</HighestPatStatusIdForCnty><Indication id="2054">Hematological neoplasm</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA7670275">WO-2014028776</Patent><Status id="PUB">First Publication</Status><StatusDate>2014-02-20 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="142">Hematological disease</TherapyArea></Row><Row><Action id="69528">ELP gene stimulator</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="WO">World</Country><Drug/><DrugRelationship/><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Publication</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PUB</HighestPatStatusIdForCnty><Indication id="316">B-cell lymphoma</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA7670275">WO-2014028776</Patent><Status id="PUB">First Publication</Status><StatusDate>2014-02-20 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="142">Hematological disease</TherapyArea></Row><Row><Action id="69528">ELP gene stimulator</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="WO">World</Country><Drug/><DrugRelationship/><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Publication</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PUB</HighestPatStatusIdForCnty><Indication id="36">Autoimmune disease</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA7670275">WO-2014028776</Patent><Status id="PUB">First Publication</Status><StatusDate>2014-02-20 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="185">Immune disorder</TherapyArea></Row><Row><Action id="69528">ELP gene stimulator</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="WO">World</Country><Drug/><DrugRelationship/><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Publication</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PUB</HighestPatStatusIdForCnty><Indication id="746">Infectious disease</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA7670275">WO-2014028776</Patent><Status id="PUB">First Publication</Status><StatusDate>2014-02-20 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="746">Infectious disease</TherapyArea></Row><Row><Action id="815">Albumin modulator</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="WO">World</Country><Drug/><DrugRelationship/><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Publication</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PUB</HighestPatStatusIdForCnty><Indication id="2054">Hematological neoplasm</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA7670275">WO-2014028776</Patent><Status id="PUB">First Publication</Status><StatusDate>2014-02-20 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="142">Hematological disease</TherapyArea></Row><Row><Action id="815">Albumin modulator</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="WO">World</Country><Drug/><DrugRelationship/><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Publication</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PUB</HighestPatStatusIdForCnty><Indication id="316">B-cell lymphoma</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA7670275">WO-2014028776</Patent><Status id="PUB">First Publication</Status><StatusDate>2014-02-20 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="142">Hematological disease</TherapyArea></Row><Row><Action id="815">Albumin modulator</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="WO">World</Country><Drug/><DrugRelationship/><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Publication</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PUB</HighestPatStatusIdForCnty><Indication id="36">Autoimmune disease</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA7670275">WO-2014028776</Patent><Status id="PUB">First Publication</Status><StatusDate>2014-02-20 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="185">Immune disorder</TherapyArea></Row><Row><Action id="815">Albumin modulator</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="WO">World</Country><Drug/><DrugRelationship/><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Publication</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PUB</HighestPatStatusIdForCnty><Indication id="746">Infectious disease</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA7670275">WO-2014028776</Patent><Status id="PUB">First Publication</Status><StatusDate>2014-02-20 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="746">Infectious disease</TherapyArea></Row><Row><Action id="14007">Programmed cell death ligand 1 inhibitor</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Third Party</CompanyOwnershipRelationship><Country id="WO">World</Country><Drug/><DrugRelationship/><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Publication</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PUB</HighestPatStatusIdForCnty><Indication id="651">Cancer</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA8994530">WO-2016164369</Patent><Status id="PUB">First Publication</Status><StatusDate>2016-10-13 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="230">Neoplasm</TherapyArea></Row><Row><Action id="5451">CDw137 antagonist</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Third Party</CompanyOwnershipRelationship><Country id="WO">World</Country><Drug/><DrugRelationship/><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Publication</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PUB</HighestPatStatusIdForCnty><Indication id="651">Cancer</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA8994530">WO-2016164369</Patent><Status id="PUB">First Publication</Status><StatusDate>2016-10-13 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="230">Neoplasm</TherapyArea></Row><Row><Action id="7220">Neoplasm diagnostic agent</Action><AuthorityGroup/><Company id="1050617">Zyngenia Inc</Company><CompanyOwnershipRelationship>Third Party</CompanyOwnershipRelationship><Country id="WO">World</Country><Drug/><DrugRelationship/><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Publication</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PUB</HighestPatStatusIdForCnty><Indication id="651">Cancer</Indication><LatestChange/><ParentCompany id="1050617">Zyngenia Inc</ParentCompany><Patent id="PA8994530">WO-2016164369</Patent><Status id="PUB">First Publication</Status><StatusDate>2016-10-13 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="230">Neoplasm</TherapyArea></Row></Rowset>